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Abstract 
Background & aims: Patients with type 2 diabetes have chronic kidney disease (CKD) and 
cardiovascular disease (CVD) event rates far in excess of the non-diabetic population. Traditional 
key risk factors for diabetic kidney disease (DKD) are hypertension, hyperlipidemia, and 
hyperglycaemia. In the last decade, some genetic and lifestyle factors predisposing to DKD, and 
possible mechanisms underlying the progression to DKD have been postulated. ADIPOQ genetic 
variants are associated with albuminuria, but findings are limited to Western populations using 
case-control study designs. To dates, it remains unclear how diet and weight change affect the 
development of DKD. Our preliminary cross-sectional study suggests that a healthy diet rich in fish 
and vegetables is associated with better renal function in type 2 diabetes. Very few studies have 
used dietary pattern and nutrient biomarker analysis to study the relationship between diet and DKD. 
Mechanistically, inflammatory adipocytokines seem to play important roles linking these factors 
with kidney disease. Thus, four specific factors are investigated in this research: 1) ADIPOQ 
polymorphisms, 2) dietary patterns, 3) erythrocyte fatty acids, and 4) obesity and weight change. 
This thesis aimed to investigate the effect of these factors on the risk of DKD, and to explore 
possible inflammatory mechanisms underlying the associations. Four studies were conducted, each 
of which addressed a particular aim. 
Methods: A cohort of 1199 Taiwanese adults with type 2 diabetes who were participating in the 
Diabetes Management through an Integrated Delivery System (DMIDS) program were followed 
from baseline (2003-2005) to 2012. ADIPOQ genotypes, fatty acids, and concentrations of 
inflammatory biomarkers (adiponectin, IL-6, and CRP) were determined using blood samples 
collected in 2008. Dietary intake was first assessed in 2008 using a food frequency questionnaire, 
and then subsequently at 12-month intervals. Major dietary patterns were identified using factor 
analysis. Overweight and obesity were defined using Asian BMI cut-off points (23 and 27.5 kg/m
2
, 
respectively). Relative changes in weight (%) were also calculated. Kidney disease was defined by 
albuminuria (albumin-to-creatinine ratio, ACR ≥30 mg/g) and kidney dysfunction (decreased 
estimated glomerular filtration rate, eGFR <60 ml/min/1.73m
2
). Cox proportional hazard models 
were used to examine the association between ADIPOQ polymorphisms and progression to 
albuminuria. Generalized estimating equation models using repeated measures data were used to 
examine how diet and obesity affect the risk of DKD. Finally, logistic regression was used to 
examine the association of weight change, fatty acids, and inflammatory biomarkers with DKD.   
Results: Major findings for each study are as follows: Study 1: male patients carrying ADIPOQ 
polymorphisms rs2241766 (+45T/G) TT and rs1063537 CC recessive homozygotes had an 
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increased hazard of albuminuria, but no association was found in females. Patients with albuminuria 
tended to have higher concentrations of adiponectin, but circulating adiponectin did not appear to be 
regulated by ADIPOQ genetic variants. Study 2: adherence to a fish-vegetable pattern was 
associated with a reduced risk of kidney dysfunction. Patients who consumed more fish, and 
adhered more strongly to a fish-vegetable pattern, had greater concentrations of erythrocyte n-3 
polyunsaturated fatty acids (PUFAs), which suggest that erythrocyte fatty acids may serve as a 
dietary biomarker to reflect dietary exposure. Study 3: higher concentrations of erythrocyte n-3 
PUFAs were associated with a lower risk of kidney function decline over time, while pro-
inflammatory IL-6 was independently associated with a higher risk of decline. Higher levels of n-3 
PUFAs attenuated the pro-inflammatory effect of IL-6 on kidney dysfunction. Study 4: obesity and 
weight gain over time were associated with an increased risk of kidney dysfunction. Conversely, a 
modest weight loss of 5 to 10% of initial body weight reduced the risk of kidney dysfunction; a 
larger weight loss >10% did not have significant benefits, which indicates a J-shaped association. A 
similar J-shaped association was observed with IL-6 such that a large weight loss >10% was 
associated with increased, rather than decreased, concentrations of IL-6. We did not find any 
association between diet, obesity, and albuminuria in this diabetic cohort.      
Conclusions and future studies: ADIPOQ polymorphisms are associated with the progression to 
albuminuria in Taiwanese male patients with type 2 diabetes. Diet and obesity/weight change are 
modifiable lifestyle factors that affect the development of kidney dysfunction. IL-6 is an important 
inflammatory mediator that links diet, obesity, and kidney dysfunction in diabetes. Our findings 
provide empirical evidence in support of the current clinical guidelines for the prevention or 
management of DKD for Asian diabetic patients. We suggest Asian patients include more fish and 
vegetables in their diet, maintain a normal BMI of 18.5-23 kg/m
2
, and lose 5-10% of initial body 
weight if they are overweight or obese. Larger prospective cohort studies are needed to investigate 
gene-gender specific effects and gene-environment interactions with DKD in different racial 
groups. A future priority is to integrate genetics, dietary intake, dietary biomarkers, and new 
statistical methods in order to explore gene-diet-lifestyle-disease associations.    
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Chapter 1: General introduction  
1.1 Context of the research  
The prevalence of chronic kidney disease (CKD) is projected to increase dramatically worldwide 
over the next two decades with an aging population and increasing prevalence of obesity, type 2 
diabetes, and hypertension in middle-aged adults.
1
 Diabetic kidney disease (DKD), also termed 
diabetic nephropathy (DN), is the single greatest contributor to end stage renal disease (ESRD)
2,3
 
and cardiovascular mortality
4
 and contributes to high health care costs and poor treatment 
outcomes.
5
 Patients with type 2 diabetes have a faster rate of renal function decline than subjects 
without diabetes, even when albuminuria is not present.
6
 A global prospective study has reported 
that Asian and Hispanic type 2 diabetic patients have the highest prevalence of albuminuria (55%), 
while Caucasians have the lowest (40.6%),
7
 which indicates that ethnic differences exist in the 
prevalence of DN. Taiwan in particular has the highest incidence and prevalence of ESRD 
worldwide. According to the United States Renal Data System (USRDS) 2009 report, over 40% of 
incident ESRD cases are due to diabetes.
8
 DKD is a complex disease caused by genetic and 
environmental factors. Consequently, identifying genetic risks in different ethnic backgrounds, and 
reducing modifiable lifestyle risk factors that may prevent or delay the progression of CKD, has 
become vital public health priorities, particularly among Asian patients with type 2 diabetes.  
 
It is of interest to note that many traditional cardiovascular risk factors commonly coexist in 
patients with kidney disease because these two diseases share common upstream pathways of 
vascular dysfunction.
9
 The major risk factors for DKD are hypertension, hyperlipidemia, and 
hyperglycaemia.
10
 In the last decade, genome-wide scan (GWS) studies have been increasingly 
carried out to identify the genetic susceptibility loci for DN. The genetic variants (single nucleotide 
polymorphisms, SNPs) in the adiponectin gene (ADIPOQ) on chromosome 3q, encoding circulating 
adiponectin,
11-13
 were found to interact with diet (especially dietary fats),
14-16
 and be associated with 
obesity, insulin resistance, type 2 diabetes,
17
 and DN.
18
 However, studies of the effects of these 
polymorphisms on the risk of DN have been predominantly carried out among western populations 
using case-control study designs.
19-22
  
 
Because diabetic patients may modify their lifestyle behaviours after diagnosis, longitudinal studies 
are essential to understand how dietary intake and weight change affect the progression of DKD. 
Furthermore, as Asians have different dietary habits and different BMI cut-off points for obesity 
compared to Caucasians, it is important that studies targeting Asian patients with type 2 diabetes are 
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carried out. Results from our preliminary cross-sectional studies of type 2 diabetic patients (Fig 1.1) 
suggest that an unhealthy diet high in fats and meats is associated with hyperferritinemia (iron 
overload), which is an independent risk factor for insulin resistance
23
 and microalbuminuria.
24
 
However, a healthy diet high in fish and vegetables is associated with better renal function 
(increased estimated glomerular filtration rate, eGFR).
25
 Further studies using longitudinal data to 
confirm this association are needed. Moreover, very few studies have been concerned with 
incorporating dietary patterns and dietary biomarkers in efforts to study the relationship between 
diet and kidney disease among diabetic patients. Obesity is an additional lifestyle factor, closely 
linked with unhealthy diet and physical inactivity, that is associated with progression to kidney 
disease (e.g. obesity-related glomerulopathy) in the general population.
26
 Weight loss interventions 
have found improvements in proteinuria and blood pressure, and appear to prevent or delay decline 
in renal function.
27
 Paradoxically, excess weight is associated with lower mortality in hemodialysis 
populations
28-30
 and in diabetic patients as well.
31
 Weight changes may occur after being diagnosed 
with type 2 diabetes as a consequence of lifestyle modifications.
32
 The association of obesity and 
weight change with the development of kidney disease is still uncertain in type 2 diabetes.  
  
Inflammation, oxidative stress, endothelial dysfunction, and hormonal factors have been identified 
as pathogenic mechanisms underlying the onset of kidney disease.
33
 Inflammation has been shown 
to affect multiple facets of hypertension,
34
 kidney
35,36
 and cardiovascular risks.
37
 Dietary 
modulation
38
 and weight control
39
 appear to  regulate inflammatory adipokines, cytokines, and 
endothelial function involved in the pathogenesis of kidney and cardiovascular disease (CVD). 
However, most of these findings are from basic science studies or observational population studies.  
 
The Diabetes Management through Integrated Delivery System (DMIDS) study, which was 
succeeded by a second five-year project (the DN study), is a large multi-centre diabetic cohort study 
in Taiwan funded by the Taiwan National Health Research Institutes (NHRI) with long-term follow 
up from 2003 to 2012. This study recruited a cohort of 1209 type 2 diabetic patients at baseline 
(2003-2005). Using this cohort of Taiwanese patients with type 2 diabetes, the research described in 
this thesis will attempt to clarify the association of ADIPOQ genetic variations and lifestyle factors 
with the risk of kidney disease, and to explore possible inflammatory mechanisms (Fig. 1.1). It is 
anticipated that the findings presented in this thesis will be used to develop more effective 
behaviour change or lifestyle management programs to prevent or delay the progression of DKD in 
Asian diabetic populations.   
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1.2 Thesis aims and hypotheses   
The overall aim of this thesis is to investigate ADIPOQ genetic variations and modifiable lifestyle 
factors (diet and obesity) associated with the development of kidney disease in a cohort of 
Taiwanese patients with type 2 diabetes. We further examined whether inflammatory 
adipocytokines play a critical role in linking these factors to the development of DKD. Dietary 
pattern analysis has been introduced as an alternative and complementary approach to study the 
association between diet and the risk of chronic disease.
40
 Erythrocyte fatty acids have emerged as 
nutrient biomarkers to reflect long-term intake of dietary fats.
41
 Also, fatty acids can regulate 
adipose tissue metabolism and adipokine production,
42
 thereby affecting inflammatory status. Thus, 
four specific factors were investigated in this research: 1) ADIPOQ polymorphisms, 2) dietary 
patterns, 3) erythrocyte fatty acids, and 4) obesity and weight change (Fig. 1.1).  
 
Each factor was the focus of a study aim, which leads to original research and four individual 
publications. These publications are incorporated in the thesis as Chapters 4-7. Subjects and follow 
up durations for each study were based on the study design and availability of data sets. Specific 
objectives and hypotheses for each study are described in full below.  
 
Aim 1 (Chapter 4): To investigate the association between ADIPOQ polymorphisms and 
albuminuria 
Primary objectives  
1. To determinate 18 ADIPOQ polymorphisms in the Taiwanese population 
2. To examine ADIPOQ genetic effects on the progression of albuminuria in Taiwanese adults 
with type 2 diabetes using a prospective study design     
Secondary objectives 
3. To examine whether the ADIPOQ genetic effect is gender specific  
4. To examine whether ADIPOQ polymorphisms regulate circulating adiponectin  
 
Hypotheses 
1. The frequencies of 18 ADIPOQ genotypes are comparable with the reference Chinese 
population. 
2. For Taiwanese adults with type 2 diabetes who also carry risk alleles and genotypes of 
ADIPOQ, the hazard of progression to albuminuria is greater.     
3. There are gender-specific genetic effects of ADIPOQ in the Taiwanese population.  
4. The ADIPOQ genetic variants regulate the production of circulating adiponectin. 
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Aim 2 (Chapter 5): To investigate the association of dietary patterns with albuminuria and 
kidney dysfunction  
Primary objectives 
1. To generate major dietary patterns in Taiwanese patients with type 2 diabetes at each time 
point 
2. To examine the association of dietary patterns with albuminuria and kidney dysfunction in 
Taiwanese patients with type 2 diabetes using repeated measure data 
Secondary objectives 
3. To evaluate the identified dietary patterns with nutrient biomarkers (erythrocyte fatty acids) 
using cross-sectional data  
4. To examine the correlations between dietary patterns and plasma inflammatory biomarkers 
using cross-sectional data  
 
Hypotheses 
1. Dietary patterns identified in this diabetic cohort are generally consistent over time.  
2. Unhealthy dietary patterns (e.g. high fat and meat) increase the risk of kidney disease in type 
2 diabetes, whereas healthy dietary patterns (e.g. high fish and vegetable) reduce the risk.  
3. Unhealthy patterns are positively associated with concentrations of erythrocyte saturated 
fatty acids (SFAs), while healthy patterns are positively associated with n-3 polyunsaturated 
fatty acids (PUFAs).  
4. Unhealthy dietary patterns correlate positively with C-reactive protein (CRP) and pro-
inflammatory interleukin-6 (IL-6) but negatively with anti-inflammatory adiponectin; while 
healthy dietary patterns demonstrate the inverse relationship.     
 
 
Aim 3 (Chapter 6): To investigate the association of fatty acids and inflammatory biomarkers 
with albuminuria and kidney dysfunction 
Primary objectives 
1. To examine the association of fatty acids with albuminuria and kidney dysfunction in 
patients with type 2 diabetes  
2. To examine the association of inflammatory biomarkers with albuminuria and kidney 
dysfunction in patients with type 2 diabetes  
Secondary objective 
3. To examine whether anti-inflammatory PUFAs modify the effect of pro-inflammatory 
biomarkers on the risk of kidney disease   
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Hypotheses 
1. SFAs increase the risk of kidney disease in type 2 diabetes, while PUFAs, particularly n-3 
PUFAs, attenuate the risk. 
2. CRP and pro-inflammatory IL-6 are associated positively with kidney disease in type 2 
diabetes, while anti-inflammatory adiponectin is associated negatively with kidney disease.  
3. High anti-inflammatory n-3 PUFAs can attenuate the effect of pro-inflammatory IL-6 on the 
risk of kidney disease. 
 
 
Aim 4 (Chapter 7): To investigate the association of obesity and weight change with 
albuminuria and kidney dysfunction 
Primary objectives 
1. To examine the association of body mass index (BMI) with albuminuria and kidney 
dysfunction in Taiwanese patients with type 2 diabetes using repeated measure data 
2. To examine the association of weight and BMI change over time with albuminuria and 
kidney dysfunction in Taiwanese patients with type 2 diabetes  
Secondary objectives 
3. To examine whether the obesity effect is gender specific  
4. To examine the association of baseline BMI and weight change with inflammatory 
adipocytokines 
 
Hypotheses  
1. Having a higher BMI increases the risk of kidney disease in type 2 diabetes.  
2. Both large weight loss and large weight gain increase the risk of kidney disease among 
patients with type 2 diabetes (J-shape association). 
3. There are gender-specific effects of obesity on the risk of kidney disease in the Taiwanese 
population. 
4. Among diabetic patients, a higher baseline BMI and large weight gains are associated with 
higher concentrations of CRP and pro-inflammatory IL-6 and lower concentrations of anti-
inflammatory adiponectin.  
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Preliminary data: cross-sectional study 23-25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Present study: cohort study  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 The preliminary data and aims of the present study  
Abbreviations: HOMA-IR, homeostasis model assessment for insulin resistance; ACR, albumin-to-
creatinine ratio; eGFR, estimated glomerular filtration rate; SFAs, saturated fatty acids; PUFAs, 
polyunsaturated fatty acids; BMI, body mass index; CRP, C-reactive protein; SNP, single 
nucleotide polymorphism.  
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1.3 Outline of thesis  
There are eight chapters in this thesis. Chapter 1 provides a general introduction to the research 
with study aims and outline of thesis chapters. The literature review (Chapter 2) includes the 
background of DKD and reviews the role of the four factors in the development of kidney disease. 
Chapter 3 then introduces the general study methodology and laboratory experiments conducted in 
this study.  
 
Results are then presented in four chapters. Chapter 4 (ADIPOQ polymorphisms), Chapter 5 
(dietary patterns), Chapter 6 (fatty acids), and Chapter 7 (obesity and weight change) all consist of 
journal articles (published or submitted) investigating the genetic and lifestyle factors for the 
development of kidney disease in a cohort of Taiwanese adults with type 2 diabetes. Each chapter 
includes a chapter introduction, published article or submitted manuscript (including abstract, 
introduction, materials and methods, results, discussion, and references) accompanied by 
supplementary materials for online publication and some additional analyses, and then a chapter 
conclusion.   
 
The findings are summarised and discussed in Chapter 8, followed by implications and future 
research. All relevant References (publication references excluded) and Appendices are listed at 
the end of the thesis.         
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Chapter 2: Literature review  
2.1 Diabetic kidney disease 
Several different terms are used to refer to conditions associated with kidney disease, including 
chronic kidney disease (CKD), diabetic nephropathy (DN), and diabetic kidney disease (DKD) (Fig. 
2.1).
43
 CKD is a nonspecific term referring to a long-term decline in renal function (kidney 
dysfunction) that could be attributable to several different disease processes. DN is a more specific 
term referring to a clinical syndrome of albuminuria (including microalbuminuria and 
macroalbuminuria/proteinuria) that is primarily the result of poor glycemic control. DKD is an all-
encompassing term that captures DN and CKD among patients with diabetes; it is often associated 
with hypertension or renovascular disease.
43
 DKD and DN have sometimes been used 
interchangeably in the literature. In this thesis, DN refers to albuminuria.  
 
 
Figure 2.1 Different terms associated with kidney disease 43 
 
 
2.1.1 Epidemiology of diabetic kidney disease 
According to the World Health Organisation (WHO) 2013 fact sheet, 347 million people worldwide 
have diabetes, and WHO projects that diabetes will be the 7
th
 leading cause of death in 2030.
44
 
Diabetes is the primary cause of end-stage renal disease (ESRD),
2,3
 and results in dialysis and 
increased cardiovascular mortality (Fig. 2.2).
3
 A higher incidence and more rapid progression to DN 
were found among patients with type 2 diabetes compared to type 1 diabetes.
2,45,46
. Approximately 
15–25% of type 1, and 30–40% of type 2 diabetic patients, will progress to DN,45-48 so the majority 
of diabetic patients with advanced nephropathy have type 2 diabetes. The pathogenesis of renal 
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impairment in type 1 and type 2 diabetes is generally similar, but more heterogeneous and complex 
in type 2 diabetes.
49
 In type 2 diabetes, the time to progress to overt nephropathy or ESRD has been 
estimated at 15-20 years after the onset of diabetes.
50
  
 
 
Figure 2.2 The link between diabetes, CKD, and ESRD 51 
 
 
Long-term diabetic complications, particularly renal disease and cardiovascular disease (CVD), 
have added substantially to the medical costs associated with type 2 diabetes.
52-54
 In the USA, the 
greatest fiscal impact for type 2 diabetes is associated with patients who also have heart failure, 
renal disease, and myocardial infarction (14%, 11%, and 7.2%, respectively) due to the high costs 
associated with these comorbidities.
53
 The 12-month mean allowed expenditure (the health plan has 
contracted for a particular service) for renal disease was $US 13,876 per person (year 2007 values), 
and 12-month mean charged expenditure (charged by provider for a particular service) was $US 
34,987.
53
 Thus, greater prevention programs are needed to reduce the substantial economic burden 
of DKD.  
  
Racial differences  
The prevalence of DN varies according to ethnicity. Microalbuminuria develops at a rate of 2-3% 
per year in Caucasian type 2 diabetic patients, while at a rate of ~4% per year in non-Caucasian 
patients.
2
 A study following a large cohort of 429,918 diabetic patients reported that early DN was 
more likely to be present in African Americans and Native Americans than Caucasians.
55
 Diabetic 
ESRD were more prevalent in African Americans, Native Americans, Asians, and Hispanics 
compared to Caucasians.
55
 Another cross-sectional study that recruited 6,801 hypertensive type 2 
diabetic patients in 103 centres in 10 Asian countries reported that an alarmingly high prevalence 
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(about 60%) of albuminuria has been observed, implying an impending pandemic of diabetic renal 
disease and CVD in Asia with its substantial economic impacts
56
 (albuminuria is indicative of 
CVD). Figure 2.3 shows the prevalence of microalbuminuria and macroalbuminuria in selected 
Asian countries. In these Asian populations, the average prevalence of microalbuminuria was 
39.8% and macroalbuminuria was 18.8%.
56
 Similarly, in the Pima Indian population, over 50% of 
type 2 diabetics progressed to albuminuria within 10-15 years of diabetes duration.
57
 In contrast, the 
prevalence of albuminuria is much lower in the UK population. Approximately 25% type 2 
diabetics had microalbuminuria and 5.3% had macroalbuminuria after 10 years of diabetes.
58
 The 
racial differences in the prevalence or incidence of diabetic complications may be explained by 
variations in genetic or environmental factors
55,56,59
 such as access to health care, socioeconomic 
status, education, control of glycemic status, hypertension, hyperlipidemia, and salt intake.
56,60
  
 
 
Figure 2.3 The prevalence of microalbuminuria and macroalbuminuria in selected Asian countries56  
The dotted line indicates the average prevalence of microalbuminuria (39.8%) (White bar: 
normoalbuminuria; grey bar: macroalbuminuria; dotted bar: microalbuminuria).  
 
  
Gender differences  
In addition to racial differences, gender differences were observed in DN
61
 and ESRD.
62-64
 
Evidence showed that men developed DN earlier than women.
61
 Women seem to have a lower risk 
of developing ESRD.
62
 In community-based screenings, the cumulative incidence of ESRD 
remained low during the reproductive ages and started to increase 10 years later in women than in 
men (Fig. 2.4).
64
 In the general population, men tend to have higher systolic blood pressure than 
women.
65
 Because hypertension is a key determinant of developing atherosclerosis and ESRD, this 
Page | 11  
  
gender difference may contribute to the faster decline in kidney function in men.
62
 Other possible 
reasons to explain the gender disparity in kidney disease include the direct cellular effects of sex 
hormones, differences in nephron number or renal mass, systemic or glomerular hemodynamics, 
and lifestyle factors such as dietary protein intake, phosphorus and salt intake, smoking, and alcohol 
consumption.
62,66
  
 
 
Figure 2.4 The cumulative incidence of ESRD per 100,000 people screened according to age at 
screening in men and women 62 
 
 
Sex hormones and aging play important roles in renal morphology and hemodynamics, which can 
lead to kidney injury (Fig. 2.5). Estrogen inhibits synthesis of collagen induced by angiotensin II 
(ANG II) and transforming growth factor-β (TGF-β) and supresses reactive oxygen species (ROS) 
generation, all of which participate in the pathophysiology of progressive renal injury.
49,54
 In 
addition, estrogen, a potent antioxidant, stimulates nitric oxide (NO) production and bioavailability 
by reducing production of free radicals.
63,67,68
 These actions of estrogen may favourably alter renal 
hemodynamics and impact glomerulosclerosis and kidney injury, contributing to the protective 
effect of female gender. In contrast, testosterone may accelerate the tubular apoptotic process and 
the progression of kidney disease in men.
63
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Figure 2.5 The roles of estrogen, testosterone, and aging in kidney injury 63  
Abbreviations: ANG II, angiotensin II; ROS, reactive oxygen species; NO, nitric oxide; RVR, renal 
vascular resistance; RBF, renal blood flow. The dashed arrow indicates an inhibitory effect, and the 
continuous arrows indicate a stimulatory effect.  
 
 
2.1.2 Kidney disease in Taiwan  
As a country with a rapidly increasing age profile, and increasing prevalence of diabetes, 
hypertension, and hyperlipidemia, Taiwan has the highest incidence and prevalence of ESRD 
worldwide.
8,69
 The high prevalence of ESRD can be partially explained by the implementation of 
the Taiwan National Health Insurance (NHI) program in 1995, which ensures that patients with 
ESRD receive renal replacement treatment (dialysis) and therefore survive longer.
69
 According to 
the United States Renal Data system (USRDS) 2009 report, the incidence and prevalence of ESRD 
in Taiwan in 2007 was 415 and 2288 per million population, respectively (Fig. 2.6, 2.7).
8
 Over 40% 
of cases of ESRD are due to diabetes.
8
 Figure 2.8 shows that four out of the top five countries with 
the highest incidence of ESRD due to diabetes are Asian countries (Hong Kong, Korea, Japan, and 
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Taiwan).
8
 This indicates that Asian diabetic patients are at highest risk of developing ESRD. 
According to the Nutrition And Health Surveys in Taiwan (NAHSIT 2005-2008), the age-
standardized prevalence of diabetes in the adult population was 9.3% in males and 6.4% in 
females.
70
 Diabetes is currently the fifth leading cause of death in Taiwan, with a mortality rate of 
35.7 per 100,000 people in 2009.
71
  
 
 
 
Figure 2.6 An international comparison of the unadjusted incidence and prevalence of ESRD 
according to the USRDS 2009 report 8 
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Figure 2.7 Top five countries with the highest incidence and prevalence of ESRD in 2007 
according to the USRDS 2009 report 8 
 
 
 
Figure 2.8 Top five countries with the highest percentage of incident ESRD due to diabetes in 2006 
and 2007 according to the USRDS 2009 report 8 
 
 
A large-scale cohort study in Taiwan (n=462,293) reported that the national prevalence of CKD in 
the general population was 11.9% (majority at stage 3; 7.1% for CKD stage 3-5) (Fig. 2.9), but 
patient’s awareness of having CKD was low at 3.5%.72 The prevalence of CKD is higher in 
Taiwanese men than in women (12.9% and 11.0% respectively).
72
 Prevalence in the 60-64 year age 
group was double the prevalence in the 55-59 year age group (26.1% compared to 13.1%), and 
more than one third (37.2%) of elderly adults aged ≥65 years had CKD (Fig. 2.10).72 A high 
prevalence for CKD stage 3-5 (6.9%) and low CKD awareness were also found in another study of 
the Taiwan population.
73
 As a result of the asymptomatic nature of the condition in the  early stages, 
the disease burden of CKD is still widely underestimated,
69
 and unrecognized CKD is common in 
diabetic patients.
74
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Figure 2.9 National prevalence of CKD among adults in Taiwan (2006) 72 
 
 
 
Figure 2.10 National prevalence of CKD by five-year age categories among adults in Taiwan 
(2006) 72 
 
 
2.1.3 Classification of diabetic kidney disease 
DKD is characterised by specific alterations in renal morphology and function.
47
 DN has been 
classically defined as increased albumin excretion rate (AER), also known as albuminuria.
75
 
Recently, albuminuria and glomerular filtration rate (GFR) have been integrated in the assessment 
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of DKD.
49
 In most cases, albuminuria and a decline in GFR occur in parallel,
49,75
 but some patients 
may follow a non-albuminuric pathway to renal impairment.
49
 Albuminuria is a result of abnormal 
transglomerular passage of macromolecules such as protein.
76
 This glomerular damage could be due 
to two mechanisms: 1) increased permeability of the glomerular barrier (membrane) together with 
increased hydrostatic pressure in glomerular capillaries; 2) impaired reabsorption capacity by the 
epithelial cells of the proximal tubuli.
76,77
  
 
Albuminuria  
The natural progression of DN is a process that takes several years. The earliest clinical sign is 
albuminuria, which generally appears within 5-15 years following diabetes onset.
2
 
Microalbuminuria is a marker for kidney and cardiovascular disease risk in type 2 diabetes.
78
 Renal 
microvascular damage may result in macrovascular CVD because of a shared upstream pathway of 
vascular dysfunction.
9
 The process is categorized into two stages: microalbuminuria and 
macroalbuminuria, based on the levels of urinary albumin excretion (UAE).
48
 Diabetic patients 
found to have microalbuminuria or macroalbuminuria are classically defined as having DN. The 
cut-off points for each stage, according to the 2011 diabetes guideline of the American Diabetes 
Association (ADA), are provided in Table 2.1.
48
  
 
Three common methods are used to screen for microalbuminuria; cut-off points depend on the 
screening method
79
 (Table 2.1):  
1. Spot collection (mg/g): albumin-to-creatinine ratio (ACR) in a random spot urine 
2. 24-h collection (mg/24h): 24-h urine collection, allowing the measures of creatinine clearance   
3. Timed collection (μg/min): a 4-h or over-night urine collection  
 
Table 2.1 The classification and definition of DN 
48,79
 
 
Category  
Spot collection 
(μg/mg creatinine) 
24h collection 
(mg/24h) 
Timed collection 
(μg/min) 
Normoalbuminuria  <30 <30 <20 
Microalbuminuria  30-299 30-299 20-199 
Macroalbuminuria ≥300 ≥300 ≥200 
Because of variability in urinary albumin excretion, two of three specimens collected within a three- to six-month 
period should be abnormal before a patient is considered to have crossed one of these diagnostic thresholds. Exercise 
within 24h, infection, fever, congestive heart failure, marked hyperglycemia, marked hypertension, pyuria, and 
hematuria may elevate urinary albumin excretion over baseline values.      
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A spot urine ACR has been recognized by the ADA and Kidney Disease Outcomes Quality 
Initiative (K/DOQI) guidelines as an accurate and easiest method to screen microalbuminuria.
79,80
 
The cut-off point used with this technique is 30-299 mg/g for microalbuminuria and ≥300 mg/g for 
macroalbuminuria. However, due to day-to-day variability in UAE, abnormal albuminuria must be 
confirmed by the presence of abnormal albumin levels in at least two out of three tests collected 
within three to six months.
79
 
 
Kidney dysfunction (decreased eGFR) 
In addition to albuminuria, other clinical definitions of DKD include a progressive rise in blood 
pressure, gradual reduction in GFR leading to ESRD, and increased risk of CVD.
2
 Estimate of GFR 
(eGFR) is a measure of how well the kidney filters blood, and is a better indication of renal function 
than serum creatinine because eGFR takes creatinine and other variables (including age, gender, 
and race) into account.
80
 Until recently, the two most common equations used to calculate eGFR 
were the Cockcroft-Gault equation
80
 and the Modification of Diet in Renal Disease (MDRD) study 
equation.
80
 Recently, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) research 
group, established by the National Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK), developed new equations to estimate GFR more accurately. These equations, which 
include the CKD-EPI creatinine equation (2009),
81
 the CKD-EPI cystatin C equation (2012), and 
the CKD-EPI creatinine-cystatin C equation (2012),
82
 are recommended for use by the National 
Kidney Foundation (NKF).  In 2011, the CKD-EPI 2009 creatinine equation was further developed 
to include a four-level race equation specifically for Black, Asian, Hispanic and Native American, 
and White and other.
83
 These are specified as follows: 
 
• Cockcroft-Gault equation: 80 
CCr (mL/min) = [140-(age × weight)] / [72 × creatinine (mg/dL)] × [0.85 if female]. 
 
• MDRD study equation: 80  
GFR (mL/min/1.73m
2
) = 186 × [serum creatinine (mg/dL)]
-1.154
 × [age]
-0.203
 × [0.742 if female] × 
[1.21 if African-American]. 
 
• CKD-EPI creatinine two-level race equation (2009): 81  
GFR (mL/min/1.73m
2
) = 141 × min(Scr/κ, 1)α × max(Scr/κ, 1)−1.209 × 0.993age [× 1.018 if female] [× 
1.159 if Black], where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is −0.329 
for females and −0.411 for males, min is the minimum of Scr/κ or 1, and max is the maximum of 
Scr/κ or 1. 
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Sex  Serum creatinine (mg/dL) eGFR (ml/min/1.73m
2
) 
Female ≤0.7 144 × (Scr/0.7)-0.329 × 0.993age [× 1.159 if Black] 
 >0.7 144 × (Scr/0.7)
-1.209
 × 0.993
age 
[× 1.159 if Black] 
Male ≤0.9 141 × (Scr/0.9)-0.411 × 0.993age [× 1.159 if Black] 
 >0.9 141 × (Scr/0.9)
-1.209
 × 0.993
age 
[× 1.159 if Black] 
 
 
• CKD-EPI creatinine four-level race equation (2011): 83  
GFR (mL/min/1.73m
2
) = 141 × min(Scr/κ, 1)α × max(Scr/κ, 1)−1.210 × 0.993age × 0.993 [× 0.993 if 
female] [× 1.16 if Black] [× 1.05 if Asian] [× 1.01 if Hispanic and Native American], where Scr is 
serum creatinine, κ is 0.7 for females and 0.9 for males, α is −0.328 for females and −0.412 for 
males, min is the minimum of Scr/κ or 1, and max is the maximum of Scr/κ. 
 
Race Sex  Serum creatinine (mg/dL) eGFR (ml/min/1.73m
2
) 
Asian  Female ≤0.7 151 × (Scr/0.7)-0.328 × 0.993age 
  >0.7 151 × (Scr/0.7)
-1.210
 × 0.993
age
 
 Male ≤0.9 149 × (Scr/0.9)-0.412 × 0.993age 
  >0.9 149 × (Scr/0.9)
-1.210
 × 0.993
age
 
 
 
• CKD-EPI cystatin C equation (2012): 82 
GFR (mL/min/1.73m
2
) = 133 × min(Scys/0.8, 1
)−0.499
 × max(Scys/0.8, 1)
−1.328 
× 0.996
age
 [× 0.932 if 
female], where Scys is serum cystatin C, min is the minimum of Scr/κ or 1, and max is the 
maximum of Scys/κ or 1. 
 
Sex Serum cystatin C (mg/liter) eGFR (ml/min/1.73m
2
) 
Female/Male ≤0.8 133 × (Scys/0.8)-0.499 × 0.996age [× 0.932 if female] 
 >0.8 133 × (Scys/0.8)
-1.328
 × 0.996
age 
[× 0.932 if female] 
 
 
• CKD-EPI creatinine-cystatin C equation (2012): 82 
GFR (mL/min/1.73m
2
) = 135 × min(Scr/κ, 1)α × max(Scr/κ, 1)−0.601 × min(Scys/0.8, 1)−0.375 × 
max(Scys/0.8, 1)
−0.711 
× 0.995
age
 [× 0.969 if female] [× 1.08 if Black], where Scr is serum creatinine, 
Scys is serum cystatin C, κ is 0.7 for females and 0.9 for males, α is −0.248 for females and −0.207 
for males, min is the minimum of Scr/κ or 1, and max is the maximum of Scr/κ or 1. 
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Sex  Creatinine  
(mg/dL) 
cystatin C  
(mg/liter) 
eGFR  
(ml/min/1.73m
2
) [× 1.08 if Black] 
Female ≤0.7 ≤0.8 130 × (Scr/0.7)-0.248 × (Scys/0.8)-0.375 × 0.995age 
  >0.8 130 × (Scr/0.7)
-0.248
 × (Scys/0.8)
-0.711
 × 0.995
age 
 >0.7 ≤0.8 130 × (Scr/0.7)-0.601 × (Scys/0.8)-0.375 × 0.995age 
  >0.8 130 × (Scr/0.7)
-0.601
 × (Scys/0.8)
-0.711
 × 0.995
age 
Male ≤0.9 ≤0.8 135 × (Scr/0.9)-0.207 × (Scys/0.8)-0.375 × 0.995age 
  >0.8 135 × (Scr/0.9)
-0.207
 × (Scys/0.8)
-0.711
 × 0.995
age 
 >0.9 ≤0.8 135 × (Scr/0.9)-0.601 × (Scys/0.8)-0.375 × 0.995age 
  >0.8 135 × (Scr/0.9)
-0.601
 × (Scys/0.8)
-0.711
 × 0.995
age 
 
 
The stage of CKD is based on eGFR and kidney damage (Table 2.2). Patients with eGFR lower 
than 15 mL/min/1.73m
2
, or with signs and symptoms of kidney failure, are classified as being at the 
most advanced stage of CKD, which refers to ESRD.
80
 At this stage, patients need dialysis or 
transplantation due to irreversible damage to kidney function. In the early stage of CKD (stage 1), 
patients have kidney damage but normal or increased GFR. This early glomerular hyperfiltration 
has been found to be a predictor of DN.
84
 Hyperfiltration has been defined using different 
thresholds ranging from 125 to 140 ml/min/1.73m
2
.
49
 In general, when GFR <60 ml/min/1.73m
2
, 
eGFR based on creatinine-based formulas are usually accurate; however, GFR within the range of 
60-89 ml/min/1.73m
2 
needs improved creatinine-based equations or cystatin-C-based equations.
49,85
  
 
Table 2.2 The five stages of CKD 
80
 
Stage Description GFR  Related terms 
1 Kidney damage with normal or ↑ GFR       ≥90 Albuminuria, proteinuria, hematuria  
2 Kidney damage with mild ↓ GFR 60–89 Albuminuria, proteinuria, hematuria 
3 Moderately ↓ GFR 30–59 Early renal insufficiency  
4 Severely ↓ GFR 15–29 Late renal insufficiency, pre-ESRD 
5 Kidney failure <15 (or dialysis) Renal failure, uremia, ESRD 
Kidney damage is defined as pathologic abnormalities, or markers of damage, including abnormalities in blood, urine 
tests, or imaging studies.  
 
 
Integrating albuminuria and eGFR 
In clinical settings, the diagnosis of DN relies largely on the presence of albuminuria. Although 
measuring urinary ACR in a random spot sample to screen for microalbuminuria (ACR >30 mg/g) 
is reliable and practical, abnormal results should be confirmed in two out of three samples collected 
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within a three- to six-month period due to day-to-day variability in UAE.
3
 Additionally, 
microalbuminuria screening is not sufficient to detect critical outcomes such as CKD stage 5, GFR 
loss, or CVD morbidity.
5
 Increases in AER are dynamic (under active control), whilst decreases in 
GFR are usually progressive (more advancing and continuously progressing in severity).
49
 Table 2.3 
shows a comparison of kidney disease stages in diabetes (DN) and CKD classification. Patients 
with diabetes and CKD stage 1 and  5 can generally be staged using either classification, but 
classification of stages 2, 3, and 4 should be based on albuminuria and GFR.
49
  Thus, both AER and 
GFR should be included in the assessment of DKD; their roles are complementary rather than 
competitive.
5,49
  
 
Table 2.3 Comparison of stages of nephropathy in diabetes and in CKD 
49
 
Nephropathy stage 
a
 Stage of DN KDOQI stage of CKD (ml/min/1.73m
2
) 
1 Hyperfiltration  ≥90 b 
2 Normoalbuminuria 60–89 b 
3 Microalbuminuria  30–59 
4 Macroalbuminuria 15–29 
5 ESRD <15 (or dialysis) 
a
 In general, patients with DN and stage 1 and 5 CKD can be staged using either classification.  
b
 Plus “kidney damage”, defined as pathologic abnormalities or markers of damage, including abnormalities in blood, 
urine tests, or imaging studies.  
 
 
2.2 Risk factors for diabetic kidney disease  
CKD and CVD share common upstream pathways of vascular dysfunction, so the presence of CVD 
risk factors in middle age may lead to the development of CKD in later life (Fig. 2.11).
1,9
 Age, 
genetics, and environmental factors affect midlife CVD risk factors and the development of CKD.
1
 
The major risk factors for the progression of kidney disease from diabetes are hyperglycemia, 
hypertension, and hyperlipidemia,
10
 all of which are partly attributable to unhealthy lifestyle 
behaviours such as a diet high in saturated fat and sugar and physical inactivity. The adiponectin 
gene (ADIPOQ) is one of the genes that can interact with diet (especially dietary fats) to affect 
adiponectin concentrations and metabolic disorders.
14-16
 ADIPOQ genetic variations are also 
associated with obesity, insulin resistance, type 2 diabetes,
17
 and albuminuria.
18
 The pathogenesis of 
DKD is complex and multifactorial. Metabolic, hemodynamic, intracellular, growth, biochemical, 
and vasoactive factors are all involved in the progress.
2,47
 Recently, inflammatory molecules and 
pathways in the pathogenesis of DKD have been increasingly studied.
36,86-88
 Current literature has 
concluded that DKD is a complex disease caused by genetic and environmental factors,
89-91
 but the 
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proximal mechanisms leading to DKD remain largely unknown. For the present study, we reviewed 
the literature regarding the role of ADIPOQ genetic variations, dietary patterns, fatty acids, and 
obesity in the development of kidney disease, as well as the underlying inflammatory mechanisms.   
 
 
Figure 2.11 Concept model of factors modifying the prevalence of CKD in late life 1 
 
 
2.2.1 ADIPOQ genetic polymorphisms 
Genome-wide scan and DN (albuminuria) 
Genome-wide scans (GWS) have been increasingly conducted to identify the genetic susceptibility 
loci for DN (albuminuria). Chromosomes 3q, 7q, 7p, 10q, and 18q are the most common regions 
linked to DN.
91-97
 Chromosome 3q has been indicated as a nephropathy susceptibility locus in both 
type 1 (Caucasian population)
22,98,99
 and type 2 diabetes (Pima Indian, African American, and 
Caucasian populations).
92,93,95
 Genetic association analysis is one of the methods used to identify 
specific loci that influence complex disease traits, and it directly links genotype to phenotype.
100
 
 
ADIPOQ genetic variations and DN (albuminuria) 
One review reported that genetic variants (single nucleotide polymorphisms, SNPs) found in the 
ADIPOQ gene on chromosome 3q, the engulfment and cell motility gene (ELMO) on 7p, and the 
carnosinase 1 gene (CNDP1) on 18q are all closely linked with susceptibility to DN.
91
 The 
ADIPOQ gene, located on human chromosome 3q27, encoding circulating adiponectin, has been 
mapped as a genetic susceptibility locus for obesity, insulin resistance, type 2 diabetes and CVD in 
different populations.
17,18,101,102
 Figure 2.12 shows that the ADIPOQ gene contains three exons and 
spans 15,790 bases of genomic sequence, and encodes the protein adiponectin, a polypeptide made 
up of 244 amino acids consisting of a C1q-like globular and collagen-like fibrous domains.
18
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Figure 2.12 ADIPOQ genomic DNA structure, mRNA, and protein 18 
 
 
A number of case-control studies have reported associations between ADIPOQ polymorphisms and 
DN in type 1 and type 2 diabetes.
19-22,103,104
 Some ADIPOQ SNPs, including rs17300539 (-11391 
G/A) and rs266729 (-11377 C/G) in promoter, rs182052 (-10066 G/A) in intron 1, rs2241766 (+45 
T/G) in exon 2, and rs1501299 (+276 G/T) in intron 2, have been demonstrated to be associated 
with DN and circulating adiponectin (Table 2.4).
18
 The -11391 A allele was the most common 
variant associated with nephropathy in both type 1 and type 2 diabetes in Caucasians,
20,22,103,105
 but 
very few Chinese carry this allele. Other ADIPOQ genetic variants associated with DN include -
11377 C/G,
19-21
 -10066 G/A,
104
 and +45 T/G.
105
 These case-control studies were carried out 
predominantly among Europeans with only one being conducted in a Chinese population.
21
 Gender 
also appears to modify the ADIPOQ associated risk for DN,
17,18
 but the biological basis of this 
gene-gender interaction is not very well understood at this point and warrants further investigation 
to elucidate the biological mechanisms.
19,20
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Table 2.4 Common ADIPOQ SNPs associated with DN and circulating adiponectin according to 
diabetes status and ethnicity   
ADIPOQ SNPs  Region Associated/ethnic group   
rs17300539 (-11391 G/A) Promoter • DN  
- T2DM French (A-allele)
105
 
- T1DM European descent
20
  
- T1DM Denmark, Finland, France (A-allele)
22
  
- T1DM Denmark (A-allele)
103
 
• Higher Adiponectin  
- T2DM and obese French (A-allele)
106
 
- T2DM French (A-allele)
105
  
- T1DM Denmark (A-allele)
103
 
- UK (A-allele)
107
 
- Italy non-diabetics
108
  
- Obese French (A-allele)
109
 
rs266729 (-11377 C/G)
 
 Promoter • DN   
- T2DM Taiwanese (C-allele)
21
 
- T1DM European descent (G-allele)
19,20
  
• Higher Adiponectin  
- T2DM and obese French (C-allele)
106
 
- Obese French (C-allele)
109
 
rs182052 (-10066 G/A)  Intron 1 • DN 
- T2DM African American (A-allele)
104
  
• Higher Adiponectin  
- UK (G-allele)
12,108
  
- Caucasian
110
 
rs2241766 (+45 T/G) Exon 2  • DN   
- T2DM French (G-allele)
105
  
• Higher Adiponectin  
- T2DM French (G-allele)
105
 
- T2DM and obese French (G-allele)
106
 
- Caucasian
110
  
rs1501299 (+276 G/T) Intron 2 • Higher Adiponectin  
- T2DM Japanese (T-allele)
111
 
- T2DM and obese French (T-allele)
106
 
- UK (T-allele)
12,107
  
- Caucasian
110
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ADIPOQ genetic variations and circulating adiponectin  
A genome-wide association study clearly detected that ADIPOQ was a major gene to modulate 
plasma adiponectin.
11
 The genetic heritability of circulating adiponectin is high; approximately 30-
50%.
12,13
 An increase in circulating adiponectin was found when patients who carried minor -11391 
allele,
103,106,107,109
 +45 G allele,
106
 or +276 T allele.
12,106,107
 However, carriers of the minor -11377 G 
allele
106,109
 and -10066 A allele
12,108,110
 had reduced circulating adiponectin. ADIPOQ genetic 
variations can also interact with dietary interventions to modulate adiponectin concentrations,
12
 
which may further affect metabolism. Higher serum adiponectin levels were found in subjects who 
carried the +276 T allele, while lower adiponectin levels were found in the presence of the -10066 
A allele. A dietary intervention involving a high intake of monounsaturated fatty acids (MUFAs) 
resulted in a significant increase in serum adiponectin in patients with the -10066 GG and GA+AA 
genotypes. 
12
  
 
ADIPOQ genetic variants may increase incident renal events in type 2 diabetes by leading to higher 
levels of circulating adiponectin.
105
 French type 2 diabetic patients who carry -11391 A and +45 G 
minor alleles may have a higher renal risk as a result of increased adiponectin concentrations (all 
isoforms) (Table 2.4), particularly medium-molecular weight (MMW) and low-molecular weight 
(LMW) isoforms.
105
 Levels of serum adiponectin are determined by the ratio of HMW/ 
(MMW+LMW).
18
 Jaziri et al. (2010) concluded that ADIPOQ genetic variants associated with high 
circulating adiponectin may be the cause of incident renal failure rather than a consequence.
105
 
 
Beneficial effects of circulating adiponectin  
Adipose tissue has been recognized as an endocrine and metabolic organ since this fat tissue 
secretes several hormones/adipokines that regulate systemic metabolism.
18
 Adiponectin is a 30-kDa 
adipocyte-derived hormone,
102
 also referred to as Gbp-28 (gelatin-binding protein 28), Acrp30 
(adipocyte complement–related protein 30), apM1 (adipose most abundant transcript 1), and ACDC 
(adipocyte C1q and collagen domain-containing).
18,112
 Adiponectin is the most abundant product 
secreted predominantly from white adipose tissue.
18
 Its insulin-sensitizing, anti-inflammatory, and 
anti-atherogenic properties have been clearly demonstrated to have protective effects against insulin 
resistance, type 2 diabetes, and CVD (Fig. 2.13).
112
  
 
Patients with metabolic disorders, such as insulin resistance, obesity, metabolic syndrome, and type 
2 diabetes, tend to have lower concentrations of adiponectin due to its insulin-sensitizing 
properties.
18,112-114
 The Health Professionals Follow-Up Study (HPFS) and Nurses’ Health Study 
(NHS) found that plasma adiponectin levels were significantly correlated with glycemic control and 
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blood lipids in type 2 diabetes.
115,116
 Increased adiponectin concentrations were positively 
associated with high density lipoprotein cholesterol (HDL-C) and inversely associated with 
haemoglobin A1c (HbA1c) and triglycerides, but had little or no effect on low-density lipoprotein 
cholesterol (LDL-C).
115,116
 Upon adjusting for many covariates including age, body mass index 
(BMI), lifestyle factors, aspirin and insulin use, disease histories, and fasting status, the correlations 
remained for diabetic men but not diabetic women, with the exception of HbA1c.
115,116
 Other 
studies also showed similar results in lipid profiles where higher levels of adiponectin were 
correlated with higher levels of HDL-C
114
 and lower levels of triglycerides.
113,114
 Overall, diabetic 
patients with higher levels of adiponectin may have better glycemic control due to its insulin-
sensitizing properties, which enhance insulin action. These patients may also have better lipid 
profiles, but the influences of adiponectin on blood lipids remains unclear. Although adiponectin 
plays a role in mediating the association between body fat and lipoproteins, other factors regulate 
lipid production.
116
         
 
Adiponectin has anti-inflammatory benefits,112 so it could suppress the inflammatory response 
involved in the progression from atherogenesis to endothelial dysfunction, which results in vascular 
diseases.
114
 Circulating adiponectin has been found to be negatively correlated with c-reactive 
protein (CRP)
114-116
 and fibrinogen.
115,116
 These results remained unchanged after adjusting for 
HbA1c and HDL-C, both of which were strongly correlated with adiponectin.
115,116
 These findings 
suggest that the effects of glycemic control and lipid metabolism may not mediate the anti-
inflammatory properties of adiponectin.115,116 One study showed no significant association between 
adiponectin and inflammation, but this finding should be confirmed using a larger sample size.
117
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Figure 2.13 The beneficial effects of adiponectin 112 
 
 
Paradoxical elevation of adiponectin  
Patients with kidney diseases,
118-120
 including DN (both type 1 and type 2 diabetes),
121-125
 tend to 
have a higher, rather than lower, concentration of adiponectin. Whether high levels of adiponectin 
are a cause or a consequence of DN remains unclear. Increased circulating adiponectin in overt DN 
and renal failure may be a result of a physiological counter-regulatory response to reduce 
endothelial damage.
122
 Due to the anti-inflammatory and anti-atherogenic properties of adiponectin 
itself, an increase in circulating adiponectin could reduce renal insufficiency and renal tubular 
damage, and so slow down the progression of DN.
125
 This response may also reduce adiponectin 
clearance,
121
 and secondary resistance to adiponectin could develop. However, prospective studies 
indicate that a causal relationship could be plausible; raised adiponectin concentrations precede DN 
in both type 1
126
 and type 2 diabetes.
105
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Increased urinary adiponectin levels were also found in type 2 diabetic patients with overt DN 
(macroalbuminuria), compared to those with early DN (microalbuminuria) and without DN 
(normoalbuminuria).
124,125
 Strongly positive correlations between urinary adiponectin and urinary 
albumin and serum adiponectin were also found in both studies.
124,125
 Raised urinary adiponectin 
levels in advanced DN patients may be attributable to the leakage of circulating adiponectin through 
the damaged kidney (glomerular vascular damage).
124,127
 Urinary adiponectin excretion therefore 
could be recognized as an independent predictor of vascular damage,
127
 and could lead to 
progression to vascular events such as DN.
124,125
 
 
 
2.2.2 Dietary patterns 
Dietary patterns and diabetes 
Diet is a well-known modifiable factor for many chronic diseases, including diabetes and its 
complications. Individuals do not consume isolated nutrients or foods, but instead consume meals 
integrating several food items or food groups.
128
 Efforts to understand the role of dietary intake in 
disease must address the complex and interacting network of nutrients and foods that make up diet 
and also consumption patterns and behaviours. The use of dietary pattern analysis to identify major 
consumption patterns may offer a feasible approach to examine the effects of diet on chronic 
diseases.
40,129,130
 Dietary pattern analysis has become a complementary approach because it can 
generate food intake patterns based on actual foods consumed within a particular population.
40
 
There are three major data-driven (posteriori) approaches commonly used to identify dietary 
patterns: factor analysis, principal component analysis, and cluster analysis.
40,130
   
 
The two most common dietary patterns identified in Western countries are:
131-136
  
• Western dietary pattern: frequent intake of red and processed meats, refined sweets, desserts, 
refined grains, French fries, butter, potatoes, and whole-fat milk. 
• Prudent dietary pattern: frequent intake of whole grains, fruits, vegetables, legumes, fish, poultry, 
and low-fat dairy products.  
 
Many original studies conducted in industrialized countries have demonstrated that a Western 
dietary pattern increases the risk of type 2 diabetes, whereas a prudent dietary pattern has an inverse 
association with this risk.
131-133
 Additionally, a Western dietary pattern, and particularly a high 
intake of dietary fats, may also have a significant association with metabolic disorders such as 
insulin resistance,
137
 metabolic syndrome,
137-139
 and obesity.
140,141
 This association may result from 
the close links between glucose (carbohydrate) metabolism and fatty acids (lipid) metabolism.
142
 In 
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general, saturated fatty acids (SFAs) and trans-fatty acids (TFAs) are found abundantly in a 
Western dietary pattern, while monounsaturated fatty acids (MUFAs) and polyunsaturated fatty 
acids (PUFAs) are found in the prudent diet. MUFAs and PUFAs were found to have beneficial 
effects on insulin sensitivity, whereas SFAs and TFAs were found to have an inverse effect.
142
 
 
Dietary patterns in the Chinese population 
Dietary patterns in the Chinese population may differ from those observed in the Western 
population. According to the Nutrition And Health Survey in Taiwan (NAHSIT) study, a dietary 
pattern characterized by a high intake of lean meats, fish, milk, vegetables, fruit, and some specific 
Chinese food items such as soybeans, mushrooms, and seaweed was protective against metabolic 
syndrome.
143
 In the Singapore-Chinese population, a healthier dietary pattern with higher 
consumption of vegetables, fruits, and soy products had a protective effect on the risk of incident 
type 2 diabetes, whereas an unhealthier pattern with higher intake in dim sum (steamed Cantonese 
foods), meat and processed meats, sweets, sweetened beverages, and fried foods was associated 
with an increased risk.
144
 A large-scale study in China
145
 indicated that a more traditional Chinese 
diet (high consumption of rice and vegetables, and moderate intake of animal products) was 
associated with the lowest prevalence of glucose tolerance abnormalities. However, the prevalence 
of glucose tolerance abnormalities was higher among people who consumed typical Chinese high-
carbohydrate diet (highest staple intake including wheat flour, cereals, and tubers but lower intake 
of vegetables, fruit, and animal products) or a New Affluence cluster diet (higher consumption of 
animal products, soybean products, and alcohol). The effects of traditional Chinese diet on the risk 
of other chronic diseases such as CVD and kidney disease remain unclear at this point.   
 
Dietary patterns and kidney disease 
An association between food groups and dietary patterns and albuminuria and renal function decline 
has been demonstrated in non-diabetic populations.
135,146,147
 The Nurses’ Health Study (NHS) found 
that dietary nutrients
147
 and dietary patterns
135
 were associated with microalbuminuria and kidney 
function decline in older Caucasian women. Greater intake of animal fat and ≥2 servings of red 
meat per week were associated with an increased risk of microalbuminuria, and higher sodium and 
lower β-carotene intake were associated with rapid eGFR decline.147 In general, a higher 
consumption of animal products promotes kidney damage (glomerular injury).
148
 Greater 
consumption of non-dairy animal foods was associated with higher ACR.
146
 In animal experiments, 
a high intake of animal fat (e.g. lard and egg yolk) altered kidney structure and function resulting in 
a reduction in glomerular number and size and an increase in blood pressure.
149
 A review has 
indicated that protein-restricted diets are beneficial for CKD,
150
 while the effect of low-protein diets 
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on the progression of DN remains unclear.
3,151,152
 Evidence shows both quantity and quality of 
dietary protein appear to be important factors.
150
 Dietary salt and kidney disease progression could 
be linked by modulation of transforming growth factor-β1 (TGF-β1).153 Excess salt intake 
contributes to intra-renal overproduction of TGF-β1 which leads to vascular and kidney damage as 
a result of reduced endothelial cell flexibility.
153
 The protective effects of antioxidants (e.g. 
carotene) on kidney function may be attributable to a decrease in intra-renal free-radical damage.
154
 
  
The application of dietary pattern analysis makes the association between diet and kidney disease 
clearer and easier to interpret, but so far, limited studies have been conducted using this approach 
for kidney disease. The NHS study revealed a significant association between two styles of diet and 
microalbuminuria and kidney function: Western dietary pattern (high in red and processed meats, 
saturated fats, and sweets) and DASH-style (Dietary Approach to Stop Hypertension) dietary 
pattern (high in vegetables, fruits, and whole grains).
135
 The highest quartile of Western dietary 
pattern was positively associated with microalbuminuria (OR=2.17, p-trend=0.01) and rapid eGFR 
decline (≥3 ml/min/1.73m2 per year; OR=1.77). In contrast, the DASH-style pattern had protective 
effects against kidney function decline (eGFR decline ≥ 30%; OR=0.55 in the top quartile).135 The 
diabetes sub-study found that the results remained similar after stratifying by diabetic status.
135
 The 
Multi-Ethnic Study of Atherosclerosis (MESA) study, which enrolled 5,042 men and women with 
diverse ethnic backgrounds, reported similar associations.
146
. A dietary pattern with a greater intake 
of whole grains, vegetables, fruit, and low-fat dairy products was inversely correlated with ACR 
(20% difference between quintiles 1 and 5) and the odds of microalbuminuria (40% reduction in the 
top quintile compared to bottom quintile). In contrast, a dietary pattern high in refined grains, high-
fat dairy products, meats, and non-dairy animal products was positively correlated with ACR. The 
authors indicated that the differences in the direction of associations between ACR and dairy and 
non-dairy animal products respectively may be due to differences in the amino acid and fatty acid 
compositions. The impact of dairy foods, which consist of branched-chain amino acids, on renal 
function is lower than non-dairy foods.
155
 In contrast, non-dairy animal foods are a major source of 
saturated fat which has a positive association with ACR,
156
 as well as inflammation and endothelial 
dysfunction.
157,158
 To date, very limited data on the association between dietary patterns and kidney 
disease are available for type 2 diabetic patients, especially for Asian or Chinese populations. 
 
Dietary patterns and inflammation  
Inflammation may be one possible pathophysiologic mechanism that links dietary patterns and 
microalbuminuria.
135
 A Western dietary pattern consisting of high amounts of saturated fat, 
fructose, and salt induces dyslipidemia, oxidative stress, inflammation, hormonal disturbances, and 
Page | 30  
  
fibrosis, all of which play a role in the pathogenesis of CKD.
136
 Independent associations between 
dietary patterns and inflammation and endothelial dysfunction were found in the NHS
134,159
 and 
Health Professionals Follow-Up Study (HPFS).
160
 The NHS conducted a nested case-control study 
and used reduced rank regression (RRR) method to identify a dietary pattern characterized by 
frequent consumption of sugar-sweetened and diet soft drinks, refined grains, and processed meat, 
but low intake of wine, coffee, cruciferous vegetables, and yellow vegetables. This pattern was 
positively correlated with IL-6, sTNFR2, CRR, E-selectin, sICAM-1, and sVCAM-1 in multivariate 
models.
159
 CRP and IL-6 are well known markers of systemic inflammation, and E-selectin, 
sICAM-1, and sVCAM-1 are markers of endothelial dysfunction.
134
 Those biomarkers have been 
found to be predictors of CVD.
161-163
 Another cross-sectional analysis in the NHS also found that 
the Western dietary pattern was positively correlated with CRP, IL-6, E-selectin, sICAM-1, and 
sVCAM-1, whereas the prudent dietary pattern was negatively correlated with CRP and E-
selectin.
134
 In the HPFS, a positive correlation between the Western dietary pattern and CRP was 
also reported. Overall, a dietary intake high in trans-fatty acid sources (Western dietary pattern) 
may lead to endothelial function decline;
164
 in contrast, frequent consumption of antioxidant 
vitamins (from fruit), folic acid (from vegetables), and n-3 fatty acids (from fish) may have 
protective effects on vascular function by decreasing endothelial activation and improving 
endothelium-dependent vasodilatation.
38
 In summary, inflammation has been demonstrated as a 
mediator for the potential pathway between diet and CVD.
134,135,165
 Microalbuminuria is a risk 
factor for kidney disease and CVD in type 2 diabetes.
78
 The strong correlations between dietary 
patterns and inflammation suggest that inflammation might play a role in the relationship between 
diet and kidney disease. 
 
 
2.2.3 Fatty acids  
Fatty acid structure  
Fatty acids are carboxylic acids (R-COOH) that consist of a carbonyl (RR’C=O) and a hydroxyl (R-
OH), where R is a functional group. Fatty acids originate from triglycerides and phospholipids, and 
have important roles in membrane formation, metabolism (as sources of fuel: ATP synthesis, 
storage, and transport of energy), and signal transduction.
166,167
 The classification of fatty acids is 
based on the number of carbon-carbon double bonds. There are three main types of fatty acids (Fig. 
2.14) :
167
  
1. Saturated fatty acids (SFAs): without a double bond 
2. Monounsaturated fatty acids (MUFAs): with one double bond  
3. Polyunsaturated fatty acids (PUFAs): with more than one double bond, including n-3 PUFAs 
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and n-6 PUFAs    
 
 
Figure 2.14 General classification of fatty acids 167 
 
 
Fatty acids and dietary exposure   
Using bloodstream fatty acids as a nutrient biomarker of dietary exposure may provide a useful 
measure that reflects long-term intake of fatty acids and long-term changes in food composition.
41
 
Erythrocytes reflect long-term intake over the past months, while concentrations of plasma or serum 
lipoproteins reflect short-term intake over the past week. This is because the half-life of 
erythrocytes (120 days) is much longer than that of plasma or serum lipoproteins.
41
 A few studies 
have used individual fatty acids as concentration biomarkers to evaluate or validate dietary fish and 
PUFA intakes.
168,169
 Concentration biomarkers are associated with the relevant dietary exposure, 
but the strength of correlations is often low (<0.6) because their concentrations are influenced by 
complex metabolic and genetic factors.
170
 
 
Fatty acids and kidney disease  
There is limited evidence to show a direct association between SFAs and nephropathy. One study 
reported that this association could result from the link with systemic insulin resistance.
171
 
Palmitate, which is a circulating saturated free fatty acid, can block insulin-stimulated glucose 
uptake in human podocytes (insulin-sensitive cells), and also suppress the gene expression that 
correlates with insulin sensitivity.
171
 Insulin resistance is well known as a hallmark of type 2 
diabetes and is associated with kidney disease.
172,173
 The biological mechanisms underlying the 
association between SFAs and kidney disease in diabetic patients are not fully clear yet.      
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Long chain n-3 PUFAs (omega-3, mainly found in fish oil) have antihyperlipidemic, 
antihypertensive, and anti-inflammatory properties,
167
 and confer long-term protection against heart 
disease, 
174
 which is the major cause of death for DN patients. N-6 PUFAs (omega-6) also have 
some protective effects against CVD.
167
 PUFAs,
167
 particularly n-3 PUFAs,
175-178
 have a 
renoprotective effect because they attenuate albuminuria in both type 1 and type 2 DN. A 
retrospective analysis indicated that a higher intake of long chain n-3 PUFAs (EPA and DHA) 
appears to reduce progression to albuminuria among patients with type 1 diabetes but has no effect 
on the incidence of albuminuria.
176
 Another cross-sectional analysis also found that compared to 
lower fish intake (<1 portions/week), a higher intake of fish (>2 portions/week) may reduce the risk 
of macroalbuminuria (OR=0.22) in type 2 diabetes but not microalbuminuria.
177
 A high intake of 
fish protein (>75
th
 percentile) and fish fat (>75
th
 percentile) was associated with a reduced risk of 
microalbuminuria (OR=0.22 and 0.31 respectively).
178
 These results suggest that urine albumin 
excretion (UAE) could be reduced through dietary consumption of long chain n-3 PUFA sources, 
but the benefit may be greater among diabetics with overt nephropathy. The protective effects may 
be due to the anti-inflammatory properties of PUFAs, which would explain why a greater beneficial 
association was found in more advanced/overt nephropathy.
176
  
 
In animal models of DN (Fig. 2.15),
167
 n-3 PUFA supplements can attenuate glomerular blood 
pressure, reduce podocyte and tubule cell damage, and improve proteinuria. N-3 PUFA 
consumption may also attenuate glomerular and tubuleinterstitial inflammatory infiltrate and 
mesangial activation, which inhibits the production of C-C motif chemokine 2 (CCL2), reactive 
oxygen species (ROS), and transforming growth factor β (TGF-β). These effects can, in turn, 
attenuate glomerulosclerosis which is an important cause of eGFR decline. However, there is 
insufficient evidence for such an effect at this point.
167
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Figure 2.15 The important factors involved in the development of DN, and pathways in which they 
might be affected by n-3 PUFA consumption 167 
 
 
Fatty acids and inflammation  
Fatty acids are a class of compounds that can regulate adipose tissue metabolism and adipocytokine 
production, thereby affecting inflammatory status.
179
 Inflammation is one of the major contributors 
to endothelial dysfunction and vascular diseases, leading to CKD and CVD.180,181 Various 
inflammatory molecules have been shown to play critical roles in the development of DN, including 
chemokines, adhesion molecules, and cytokines.
87
 IL-6 is a pro-inflammatory cytokine, whereas 
adiponectin is an anti-inflammatory adipokine, and both are produced and secreted from white 
adipose tissue.
179
 Dysmodulation of these adipokines may lead to low-grade inflammation. 
Understanding the regulatory mechanisms underlying the production of inflammatory molecules, 
and how these mechanisms influence the development of renal vascular dysfunction, is of interest. 
In addition, the use of bloodstream fatty acids as biomarkers of dietary intake may provide a better 
way to measure long-term intake of fatty acids and long-term changes in food composition than 
food questionnaires.
41,182
 Although the molecular mechanisms involved in the regulation of 
adipokines remain unclear, the diet-gene interactions may influence gene transcription and protein 
product of these proteins.
179
 Genetic variants can directly regulate circulating levels of adipokines, 
and can also interact with dietary fats to modulate adipokine secretion.
12,179
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IL-6 is a pro-inflammatory cytokine with 26 kDa, and many different cells regulate its production 
including lymphocytes, monocytes, fibroblasts and endothelial cells.
183
 IL-6 plays a central role in 
the inflammatory response
183
 because it is the only cytokine that can activate the synthesis of all the 
acute phase proteins (e.g. CRP, amyloid A, and fibrinogen) involved in inflammation. The ability of 
SFAs to stimulate adipose tissue inflammation
184
 and the ability of PUFAs to inhibit the 
inflammatory response have been widely recognized. However, these regulatory effects on 
inflammatory adipokines are not fully understood. In animal models, a three-fold increase in IL-6 
expression was found in adipose tissue when mice were fed palmitic acid (C16:0).
185
 However, rats 
fed olive oil (a source of MUFAs) released the lowest amount of IL-6 from adipocytes.
186
 In human 
studies, dietary intakes of long chain n-3 PUFAs and non-fried fish were inversely associated with 
plasma IL-6 and other inflammatory biomarkers.
187
 Similarly, plasma PUFAs (particularly n-3 fatty 
acids) were negatively associated with pro-inflammatory markers (IL-6, TNF-α, and CRP) and 
positively associated with anti-inflammatory markers (soluble IL-6r, IL-10, and TGF-β).188  
   
Adiponectin is an anti-inflammatory adipokine correlated with both dietary and plasma fatty acid 
profiles. Dietary conjugated linoleic acid (CLA, n-6 PUFA), a family of isomers of linoleic acid 
(LA, C18:2n-6), contributed to an increase in plasma adiponectin as a result of the enhancement of 
adiponectin mRNA expression in the white adipose tissue of Zucker diabetic fatty rats.
189
 Another 
animal study showed that dietary n-3 PUFAs (EPA and DHA) activated adiponectin expression in 
adipocytes and released adiponectin from white adipose tissue.
190
 Plasma palmitic acid (C16:0) was 
inversely correlated with circulating adiponectin, whereas plasma DHA (n-3 PUFA) was positively 
correlated with adiponectin in healthy humans.
191
 In addition, linoleic acid (LA, C18:2n-6) was 
found to be associated with reduced CRP and increased adiponectin, while γ-linolenic acid (GLA, 
C18:3n-6) and dihomo-γ-linolenic acid (DGLA, C20:3n-6) were related to increased CRP and 
reduced adiponectin.
192
 An inverse association between γ-linolenic acid (GLA, C18:3n-6) and 
adiponectin has been found in other studies.
191
  
 
In summary, SFAs can activate the expression and production of pro-inflammatory adipokines and 
suppress that of anti-inflammatory adipokines; however, unsaturated fatty acids have inverse effects 
to modulate adipokines. Inflammation could be a possible mediator linking fatty acids and kidney 
disease, although the regulatory mechanisms involved are not fully understood. It is important to 
understand the regulatory mechanisms of fatty acids that underlie the effect of inflammatory 
molecules on renal dysfunction in diabetes. 
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2.2.4 Obesity and weight change  
Obesity and kidney disease  
Obesity increases the risk of kidney disease in the general population, and this association is 
independent of age, gender, ethnicity, lifestyle factors (smoking, alcohol use, and exercise).
26
 It is 
clear that obesity is associated with insulin resistance, metabolic syndrome, type 2 diabetes, and 
hypertension. These metabolic and cardiovascular risk factors are the leading causes of CKD and 
ESRD.
193-195
 The coexistence of hyperglycemia, dyslipidemia, hypertension, insulin resistance, and 
inflammation in obesity leads to further kidney damage and deterioration of kidney function as a 
result of hyperfiltration.
194
 Although obesity is less prevalent in Asian populations than in Western 
populations, Asians are at a greater risk of developing type 2 diabetes and CVD at lower BMI cut-
off points than those established by World Health Organisation (WHO) (overweight: ≥25 kg/m2; 
obesity: ≥30 kg/m2).196 Thus, the WHO recommends using cut-off points of 23 and 27.5 kg/m2 for 
overweight and obesity respectively among Asian populations.
196
   
 
Gender differences in the relationship between obesity and kidney disease were observed in some 
studies.
197-203 
In general, men tend to have a higher risk of ESRD than women.
204
 This could be 
partly explained by the effect of testosterone and other sex-hormones on gender differences in the 
progressive glomerular injury.
205
 However, in Western populations, evidence shows that obese 
women have a higher risk for kidney disease than obese men.
200-203 
In Asian populations, the effect 
of obesity on kidney disease was found in men but not in women.
197-199
 The explanation for this 
gender difference in different ethnic backgrounds remains unclear at this point.  
 
Obesity physically compresses the kidneys, stimulates sodium reabsorption, and causes impaired 
renal-pressure natriuresis, arterial hypertension, and glomerular hyperfiltration, all of which lead to 
kidney dysfunction (glomerulosclerosis) (Fig. 2.16).
193
 Increased sympathetic nervous system (SNS) 
activity, and activation of the renin-angiotensin system (RAS), are two other important mechanisms 
that increase tubular sodium reabsorption and alter renal-pressure natriuresis in obesity.
193,206
 
Visceral obesity also triggers some metabolic derangements including glucose intolerance, 
dyslipidemia, lipotoxicity, and also inflammation, ultimately leading to renal injury.
193
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Figure 2.16 Potential mechanisms by which obesity increases the development of kidney damage 
and kidney dysfunction 193 
 
 
Weight change and kidney disease  
Rapid weight gain over a short period increases renal tubular sodium reabsorption and causes 
compensatory renal vasodilation and glomerular hyperfiltration (increased GFR).
193,207
 The 
increased GFR eventually subsides and is followed by a gradual decrease because kidney damage 
and nephron loss occur in association with prolonged obesity-related diabetes and hypertension.
193
  
These early functional and structural effects of obesity on the kidneys are not fully understood. 
Over a longer period of follow-up, weight gain is an independent risk factor for CKD in healthy 
populations,
208,209
 even when the BMI remains within the normal range.
208
    
 
Non-surgical short-term weight loss interventions (low-calorie and normal-protein diets) lead to 
significant decreases in proteinuria, blood pressure, and cholesterol in general obese patients
210
 and 
also in obese diabetic patients.
211,212
 However, this weight loss did not seem to significantly 
improve GFR or creatinine clearance.
210,213
 Conversely, surgical interventions normalised GFR, and 
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also reduced protein and blood pressure in morbidly obese patients with glomerular 
hyperfiltration.
214-216
 Among overweight and obese patients with type 2 diabetes, a modest weight 
loss of 5 to 10% over one year improved cardiovascular risk factors including blood pressure, 
glycemic control, and blood lipids;
217
 this intensive lifestyle intervention also reduced the risk of 
CKD over an eight-year follow-up.
218
  
 
Obesity paradox  
Morbid obesity and weight gain were paradoxically associated with better cardiovascular survival in 
ESRD,
219
 hemodialysis patients,
28-30
 and also in patients with diabetes
31
 and heart failure.
220,221
 This 
reverse epidemiology of obesity is known as the “obesity paradox.”31 Higher BMI appears to be 
protective against mortality in patients with ESRD or who are undergoing dialysis.
28,219
 Several 
possibilities have been proposed to explain the obesity paradox. One explanation is that obese 
individuals may be presenting earlier with less advanced disease compared with those who are 
underweight.
193
 Being underweight and having unintentional weight loss may reflect a poor health 
condition or greater disease severity, which are closely associated with high risk of mortality.
193
 
Protein-energy malnutrition is less likely to develop in overweight and obese patients than in lean 
patients with critical illness.
219
 Additionally, obese patients may be more hemodynamically 
stable.
221
 
 
In general, obesity is a significant risk factor for the progression of CKD, independent of diabetes 
and hypertension. Weight loss interventions (dietary or physical activity interventions) may 
improve renal and cardiovascular risk factors. However, once patients develop severe CKD (i.e. 
ESRD or dialysis), obesity confers a survival advantage (more favourable prognosis). This is 
possibly due to other more important survival factors, such as nutritional status.
222
  
 
Obesity, inflammation, and kidney disease 
Inflammation, oxidative stress, endothelial dysfunction, and hormonal factors are main pathogenic 
mechanisms of kidney disease in obese patients.
33
 Obesity leads to insulin resistance, diabetes, and 
increased visceral adiposity, and results in altered adipokines and cytokines.
223
 Adipose tissue is 
recognised as an endocrine and secretory organ that increases with obesity and produces 
adipocytokines.
33,224
 Adiposity leads to reduced adiponectin and increased adipokines (including 
leptin, resistin, and visfatin), and also increased pro-inflammatory cytokines including TNF-α, IL-6, 
CRP, and MCP-1 (Fig. 2.17).
223,225
 These adipokines further affect vasoconstriction, podocytopenia, 
mesangial expansion, extracellular matrix deposition, and basement membrane thickening, leading 
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to glomerulopathy.
225
 Thus, alterations in adipocytokine are a link between obesity and kidney 
disease.  
 
Low-grade inflammation occurs in obesity and insulin resistance, and contributes to increased 
infiltration of macrophages into adipose tissue and kidneys.
33
 The macrophage infiltration causes an 
increase in the production of pro-inflammatory cytokines IL- 6 and nuclear factor κB (NF-κB) and 
cellular adhesion molecules. It has been shown that weight loss partially reverses inflammatory 
alteration. Surgical weight loss has been found to be significantly associated with a lower pro-
inflammatory state (including CRP)
214,226
 and a higher level of adiponectin.
226
 A behavioural weight 
loss intervention also reported that weight loss improved adiponectin and IL-6, and these 
improvements persisted at 24 months despite subjects regaining weight.
227
 Thus, both surgical and 
non-surgical weight loss interventions can help prevent a state of chronic inflammation and its 
associated adverse impacts. To date, whether obesity and weight change over time are independent 
risk factors for kidney disease in Asian patients with type 2 diabetes is uncertain, and how these 
factors affect inflammatory adipocytokines in diabetes is unclear.  
 
 
 
Figure 2.17 Inflammatory mechanisms of obesity-related glomerulopathy 225 
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2.2.5 Inflammatory mechanisms  
It is clear that inflammatory cytokines play a critical role as mediators of CKD
36
 and DN.
88,228
 
Inflammatory mechanisms are important in the pathogenesis of DN, and explain how metabolic 
abnormalities (such as hyperglycemia) and renal hemodynamics (such as glomerular hypertension 
and endothelial dysfunction) in diabetic patients progress to functional and structural kidney 
damage (Fig. 2.18).
36,88
  
 
 
Figure 2.18 Inflammation involved in the development of DN 36 
 
 
Inflammatory cytokines, transcription factors (nuclear factor-κB) chemokines and their receptors, 
and adhesion molecules are the main inflammatory molecules involved in the development of DN 
(Fig. 2.19). Pro-inflammatory cytokines (IL-1, IL-6, IL-18 and TNF-α) are the main regulators of 
inflammation and play critical roles in the pathogenesis of DN.
229,230
 TNF-α, IL-6, and  leptin 
contribute to insulin resistance and vascular damage,
33
 and are associated with mortality in CKD 
and ESRD,
33,180,231
 while the relationship between adiponectin and survival is controversial in 
patients with kidney disease.
33
 The role of inflammatory cytokines in patients with DKD is not fully 
clear.  
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Figure 2.19 Overview of inflammatory molecules and signaling pathways in the development of 
DN 88  
 
 
2.3 Summary of literature review   
DKD is a global public health problem leading to an increasing number of people with ESRD and 
CVD. Asian patients with type 2 diabetes are at higher risk of developing DKD compared to 
Caucasians. The pathogenesis of DKD is complex and multifactorial resulting from genetic and 
lifestyle factors, and renal inflammation is one of the major mechanisms (Fig. 2.20). In this thesis, 
we reviewed current literature to appraise the association between ADIPOQ genetic variations and 
two important lifestyle factors (diet and obesity) and the risk of kidney disease. Studies showed that 
ADIPOQ polymorphisms, a Western dietary pattern, SFAs, and obesity/weight gain are associated 
with increased risk of kidney disease, while the DASH-style diet, n-3 PUFAs, and weight loss are 
associated with reduced risk. However, these findings are limited to Caucasian populations or 
healthy (non-diabetic) populations, and genetic association studies are carried out predominantly 
using case-control study designs. Very few studies investigated these associations in a cohort of this 
high-risk DKD population (Asian patients with type 2 diabetes). It is noted that inflammation, 
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including adipokines and cytokines, may be important mediators in the pathogenesis of DKD. It is 
still unclear at this point whether the effects of these genetic and lifestyle factors on inflammatory 
adipocytokines contribute to the progression of kidney damage among patients with type 2 diabetes.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.20 Factors and mechanisms involved in the development of DKD   
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Chapter 3: General materials and methods  
3.1 The Diabetes Management through Integrated Delivery System study  
The Diabetes Management through Integrated Delivery System (DMIDS) study was a five-year 
study (2003-2007) funded by the Taiwan National Health Research Institutes (NHRI) 
(NCT00288678). The primary aim was to evaluate the effects of implementing a system for   
managing glycemic control among type 2 diabetic patients. Patients were a representative sample 
recruited from five medical centres and 36 clinics in five cities of northern, middle, and southern 
Taiwan. The baseline recruitment period was between August 2003 and December 2005. The 
number of original enrolees who had least two interpretable laboratory tests was 1,209. Details of 
diagnosis and exclusion criteria for the original cohort are described below. Figure 3.1 shows the 
timeline for the DMIDS study and provides information on the availability of datasets for this thesis 
project.  
  
Enrolees were diagnosed with type 2 diabetes if they met any of the criteria described in the 1997 
American Diabetes Association (ADA) guidelines:
232
  
 Symptoms of diabetes plus a casual plasma glucose concentration ≥200 mg/dl (11.1 
mmol/l). Casual is defined as any time of day without regard to time since last meal. 
Symptoms of diabetes include polyuria, polydipsia, and unexplained weight loss. 
 Fasting plasma glucose (FPG) ≥ 126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric 
intake for at least eight hours prior to the test. 
 Two hour plasma glucose ≥200 mg/dl during an oral glucose tolerance test (OGTT). The 
test should be performed as described by the World Health Organisation (WHO), using a 
glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.   
 
All type 2 diabetic patients were eligible unless they met any of the following exclusion criteria at 
baseline:  
 Age <30 or >70 years 
 Type 1 diabetes  
 Pregnant  
 Major diabetic complications such as foot amputation or uremia under dialysis 
 Systemic illness such as acute myocardial infarction, cerebrovascular accident (stroke), or 
cancer 
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At baseline (Aug 2003 to Dec 2005), anthropometric and clinical measurements were taken for each 
patient, and information regarding demographic characteristics, lifestyle, medical history, and 
medication was collected using a health questionnaire. After baseline, biochemical parameters 
including glucose, glycated haemoglobin (HbA1C), lipids, and renal indicators were determined in 
blood samples collected every six months until the end of 2007. Patients recruited in 2003 had 
bloods taken for four years, while those recruited in 2005 had bloods taken for two years.  
 
3.2 The Diabetic Nephropathy study  
In 2008, a second five-year project (2008-2012) was initiated to investigate the development of 
diabetic nephropathy (DN) in this diabetic cohort. All participants in the DMIDS study were 
eligible. Between 2008 and 2010, about 80% (n=958) of patients agreed to participate the DN study 
and completed at least one baseline examination. Anthropometric measurements, clinical 
measurements, a health questionnaire, and a food frequency questionnaire (FFQ) were completed 
for each patient at 12-month intervals until the end of 2012 (Fig. 3.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Timeline of the DMIDS and DN studies and available datasets for the thesis project 
 
Baseline recruitment (n=1209) 
 Anthropometric and clinical 
measures 
 Health questionnaire# 
 
2008- 2010 recruitment (n=958) 
 Anthropometric and  
clinical measures  
 Health questionnaire# 
 FFQ 
 
2011-2012 
 Clinical measures 
 
2009 2010 2011 2012 2003-2005  
#
 Health questionnaire  
 Demographic characteristics  
 Lifestyle (e.g. smoking, alcohol, and exercise) 
 Medical history  
 Medication (e.g. glucose-lowering, lipid-lowering, and antihypertensive medication) 
*Laboratory analysis using blood samples from the 2008 examination   
 DNA extraction and ADIPOQ genotyping (18 SNPs) 
 Erythrocyte and plasma fatty acids measurements 
 Plasma adiponectin and IL-6 measurements 
2008*  
The DMIDS study 2003-2007 The DN study 2008-2012 
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These two five-year cohort studies were approved by the ethics committees of the Taiwan National 
Health Research Institutes and Kaohsiung Medical University Hospital (Appendices 1 & 2). Written 
informed consent was obtained from each subject.  
 
The comparison of the baseline characteristics of subjects who participated in the DN study (n=958) 
and those who did not (n=251) are shown in Table 3.1. There were no significant differences in 
gender, duration of diabetes, hypertension, lifestyle factors, and blood lipids between the two 
groups. However, subjects who did not participate in the DN study tended to be older, less 
educated, and have a lower BMI (all p<0.01). As expected, those who did not participate in the DN 
study had poorer glycemic control (higher HbA1C, p=0.029) and worse kidney outcomes (lower 
glomerular filtration rate (GFR) and higher albumin-to-creatinine ratio (ACR), both p<0.01) 
compared to those who participated. This could result in an underestimation of our renal outcomes.       
 
Table 3.1 Baseline characteristics of subjects in the DMIDS study, stratified according to 
participation in the DN study  
 DMIDS study DN study Did not participate  p-value 
n 1209 958 251  
Age (years) 55.9±8.6 55.5±8.5 57.4±8.9 0.002 
Diabetes duration (years) 5.1±5.6 4.9±5.5 5.4±5.8 0.215 
Male (%) 579 (47.9) 448 (46.8) 131 (52.2) 0.125 
Education ≤6 years (%) 687 (56.8) 521 (54.4) 166 (66.1) 0.001 
Hypertension (%) 790 (77.9) 626 (78.3) 164 (76.6) 0.613 
Smoking (%)  Never 823 (68.1) 658 (68.8) 165 (65.7) 0.230 
                    Past 132 (10.9) 108 (11.3) 24 (9.6)  
                        Current 253 (20.9) 191 (20.0) 62 (24.7)  
Drinking (%) 185 (15.3) 139 (14.5) 46 (18.3) 0.137 
BMI (kg/m
2
) 25.9±3.8 26.1±3.8 25.1±3.7 <0.001 
SBP (mm Hg) 130.0±16.6 129.9±16.1 130.2±18.3 0.849 
DBP (mm Hg) 80.7±9.7 80.8±9.7 80.3±9.7 0.441 
HbA1C (%) 8.5±2.0 8.4±1.9 8.7±2.1 0.029 
Triglycerides (mg/dL) 179.8±176.8 177.6±181.0 188.0±159.8 0.408 
Cholesterol (mg/dL) 194.2±43.2 194.7±43.0 192.0±44.1 0.381 
Serum creatinine (mg/dL) 0.81±0.39 0.78±0.28 0.93±0.66 0.001 
eGFR (mL/min/1.73m
2
) 98.7±21.7 100.2±19.7 92.9±27.2 <0.001 
ACR (mg/g) 11.0 [4.0-41.0] 10.0 [4.0-35.0] 22.0 [5.0-100.3] 0.005 
Data are presented as mean ± SD or median [25, 75 percentile]. Abbreviations: BMI, body mass index; SBP, systolic 
blood pressure; DBP, diastolic blood pressure; HbA1C, hemoglobin A1C; eGFR, estimated glomerular filtration rate; 
ACR, urine albumin-to-creatinine ratio.   
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3.3 The accompanying studies for the original cohort 
A three-year accompanying study (2009-2012), funded by the Taiwan Nation Science Council 
(NSC 98-2314-B-037-044-MY3), was initiated to investigate the effects of adiponectin/adiponectin 
receptor genetic polymorphisms/gene expression and dietary fatty acid composition on risks of 
diabetes with or without nephropathy in this diabetic cohort. Another three-year (2013-2016) 
Taiwan NSC-funded study (NSC 102-2628-B-037-008-MY3) investigated the effects of dietary 
patterns and related dietary biomarkers on the progression of diabetic microvascular complications.  
 
3.4 The PhD thesis  
The study conception and design of this PhD thesis was based on the two grants funded by the 
Taiwan NSC, and used the datasets from original diabetic cohort (DMIDS and DN studies). 
Accordingly, data collection relating to risk factors of the ADIPOQ gene, dietary patterns, and 
nutrient biomarker fatty acids have been governed by the availability of funding and also by the 
need for co-ordination with the research aims of other accompanying studies. We additionally 
examined the obesity factor in the present study using the longitudinal data collected from the 
original cohort. This PhD project was approved by the Research Ethics Committee of the School of 
Population Health, University of Queensland (HC010313) (Appendix 3). Figure 3.1 shows the 
available datasets for the studies presented in this thesis. We obtained complete datasets from the 
baseline, 2008, 2009, and 2010 assessments, and only clinical measure data in 2011 and 2012.      
 
Before and during my candidature (from January to July, 2010; January to July, 2011; and January 
to December, 2012), I joined the research team in Taiwan as a part-time research assistant to 
conduct some field work and laboratory work for the original diabetic cohort. I worked with the 
research team to conduct questionnaire interviews and to collect urine and blood specimens. I also 
carried out a number of laboratory experiments for my thesis project in the laboratory of Kaohsiung 
Medical University, Taiwan (from January to December, 2012). Details of clinical indicator 
assessments and laboratory protocols are present in the following paragraphs.  
 
3.5 Assessment of clinical indicators 
Anthropometric measurements 
Trained research nurses measured height, body weight, systolic blood pressure, and diastolic blood 
pressure at every visit while the patients were under fasting conditions. Height was measured to the 
nearest 0.5 cm on standardised, wall-mounted height boards, without shoes. Body weight was 
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measured to the nearest 0.1 kg on standardised digital scales without heavy clothes. Body mass 
index (BMI) was defined as weight (kg)/height (m
2
). Blood pressure was measured to the nearest 1 
mmHg, with each patient measured three times within a one-minute interval. The mean value of 
blood pressure was used for the analysis.  
 
Biochemical measurements  
Fasting venous blood (≥eight hours) and spot urine specimens were collected at each examination. 
All samples were kept on ice (2-8°C), sent to a central laboratory (Union Clinical Laboratory, 
Taipei, Taiwan), and measured within eight hours. Routine biochemical testing included fasting 
glucose, HbA1C, triglycerides, cholesterol, high-density lipoprotein (HDL-C), low-density 
lipoprotein (LDL-C), blood urea nitrogen (BUN), and creatinine. HbA1c was measured by high-
performance liquid chromatography (Variant II, Bio-Rad Laboratories, Hercules, CA, USA; or 
Tosoh G7, Tosoh, Kobe, Japan). Glucose, triglycerides, cholesterol, LDL-C, HDL-C, BUN, and 
creatinine were measured by an automatic analyser (Hitachi 7060, Hitachi High Technologies, 
Tokyo, Japan; or Beckman LX20, Beckman Coulter, Fullerton, CA, USA). Serum creatinine was 
measured by the Jaffe method, with the calibration procedures based on the US National Institute of 
Standards and Technology (NIST) standards.  
 
Urine albumin was measured by immunoturbidimetry (Hitachi 7060, Hitachi High Technologies, 
Tokyo, Japan), and urine creatinine was assayed using the Jaffe reaction on an automatic analyser 
(Beckman LX20, Beckman Coulter, Fullerton, CA, USA). 
 
High-sensitivity C-reactive protein (hsCRP) was analysed using an immunoturbidimetric method 
(Roche Cobas Integra 800, Mannheim, Germany). Insulin was measured by a chemiluminescent 
immunometric assay (Immulite 1000, Diagnostic Products, Los Angeles, CA, USA). Insulin 
resistance was then assessed using the homeostatic model: HOMA-IR = insulin (μU/ml) × fasting 
plasma glucose (mmol/L)/22.5.  
 
Dietary assessment  
Dietary intake of enrolled subjects was first assessed in 2008, and then collected at 12-month 
intervals until the end of 2012. For the present study, data sets were only available from 2008 to 
2010 (Fig. 3.1). Diet was assessed using a semi-quantitative food frequency questionnaire (FFQ). 
This FFQ, which was developed for use with Chinese adults, has 45 questions on the consumption 
of food belonging to various groups, serving sizes, and eating habits. Details of this dietary 
assessment method have been previously reported.
25
 Briefly, we assessed some specific food groups 
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frequently consumed in a Chinese population, including soy products, processed wheat/gluten 
products, pickled vegetables, Chinese staple foods, low-nitrogen staple foods, starchy/thickened 
soup and foods, and low-calorie desserts and snacks. Participants were asked to report the average 
frequency of their consumption of food groups over the previous 12 months, with six frequency 
options ranging from “almost never” to “one or more times per day” for most food groups. Some 
food groups (e.g. eggs, milk and yogurt, fresh fruit, Chinese staple foods, bread, and root vegetables 
etc.) were recorded as usual portion size consumed per day. For the dietary pattern analysis, 
consumption frequency of each food group was converted to weekly equivalent (e.g. times or 
portions per week). Additionally, the average serving sizes of foods belonging to each food group 
were determined, and daily energy intakes were calculated for each patient.    
 
Assessment of covariates 
Age, sex, duration of diabetes, education level, medical history, medication use, and lifestyle factors 
were assessed at baseline with additional assessments carried out again at each follow-up 
examination. Patients were asked to report their education level (illiterate, known few words, 
literate, primary school, junior school, high school, university or more). We categorised education 
level into less than or equal to six years (primary school) and more than six years (higher than 
primary school). Patients also self-reported whether their general physician had diagnosed them 
with hyperglycemia, hypertension, hyperlipidemia, hyperuricemia (gout), kidney disease, 
cardiovascular disease (CVD), or liver disease (yes or no), and whether they took medications to 
treat these diseases (yes or no). Patients were also asked whether they smoked cigarettes (never, try 
a few times, ever, current smoker during last month), drank alcohol at least once a week during the 
previous six months (yes or no), and participated in exercise in the last two weeks (yes or no).  
 
3.6 Laboratory experiments  
In 2008, plasma and erythrocyte samples were isolated from venous whole blood samples collected 
in EDTA and PBI tubes by centrifugation (3000 rpm, 4℃, for 15 minutes) and stored deep frozen at 
-80°C in the laboratory of Kaohsiung Medical University. These samples were used to assess fatty 
acids and inflammatory biomarkers at a later time. DNA was extracted from buffy coat stored at -
20°C until single nucleotide polymorphism (SNP) genotyping. The genetic variations are assumed 
to be an unmodifiable factor, so we performed the genetic association analysis of ADIPOQ 
polymorphisms back to baseline 2003-2005 in an attempt to get a longer follow-up period.    
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There were three major experiments conducted in the present study: (1) ADIPOQ genotype 
determination (2) fatty acids extraction and analysis (3) circulating adiponectin and interleukin 6 
(IL-6) measurements. These three experiments were supervised by Dr. Huang and conducted in the 
laboratory of Kaohsiung Medical University, Taiwan. Two research team members, Chen PS and 
Jhang HR, provided technical assistance in DNA extraction and fatty acids measurements.  
 
3.6.1 ADIPOQ genotype determination  
Genomic DNA was isolated from human leukocytes collected in EDTA tubes using a modification 
of the Puregene
®
 DNA isolation kit method. The extracted DNA was stored in -20℃ in the 
laboratory of Kaohsiung Medical University. Then, the DNA samples were sent to the laboratory at 
The National Taiwan University for primer design and genotyping. Laboratory protocols are present 
in full below:   
 
Isolation of genomic DNA from venous whole blood  
Buffy coat isolation:  
1) Centrifuge EDTA tubes containing whole blood at 3000 revolutions per minute (rpm), 4℃ for 
15 minutes. 
2) Pipet off plasma, place in 1.5 mL eppendorf. 
3) Pipet up buffy coat into a 15 mL tube.  
4) Add red blood cell (RBC) lysis buffer to 14 mL mark, mix well, incubate for 10 minutes at 
room temperature.  
5) Centrifuge at 3000 rpm, 4℃ for 15 minutes. 
6) Add RBC lysis buffer to 14 mL and mix well. 
7) Pipet off supernatant leaving the visible white cell pellet.    
8) Vortex the tube to resuspend the cells in the residual liquid.   
9) Add 3 mL cell lysis solution and pipet up and down to lyse the cells, store at room temperature.   
 
Genomic DNA isolation:  
1) Add 1.5 mL protein precipitation solution to the cell lysate, vortex for 1 minute. 
2) Centrifuge at 3000 relative centrifugal force (rcf), 20℃ for 30 minutes. The precipitated protein 
should form a tight dark brown pellet in the bottom of tube.  
3) Pour the supernatant containing the DNA into a new 15 mL tube. 
4) Add 4 mL isopropanol, mix the sample by inverting gently 50 times. The DNA is visible as a 
small white pellet in the bottom. Carefully pour off supernatant.  
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5) Add 5 mL 70% ethanol and pipet the tube several times to wash the DNA pellet. 
6) Transfer the DNA to a yellow cap 1.5 mL eppendorf, pipet off remaining ethanol. 
7) Invert and drain the tube on clean absorbent paper and leave eppendorf lid open to air dry for 30 
minutes.  
8) Add Tris-EDTA (TE) solution depending on size of DNA pellet, store at 4℃.  
9) Test the ratio of absorptions at 260 nm vs. 280 nm to assess the purity of nucleic acids, store at -
20℃ for genotyping.  
 
SNP selection  
We selected 18 single nucleotide polymorphisms (SNPs) in the ADIPOQ gene according to: 1) tag 
SNP in the Han Chinese population; 2) common SNPs associated with diabetes and DN in previous 
studies; 3) minor allele frequency (MAF) ≥5%. Tag SNPs for the Han Chinese population were 
identified using SNPinfo (http://snpinfo.niehs.nih.gov/). We used the National Centre for 
Biotechnology Information (NCBI) SNP datasets (http://www.ncbi.nlm.nih.gov/snp/) to check the 
allele and genotype frequency. Of 18 selected SNPs, nine were tag SNPs with minor allele 
frequencies (MAF) >5% in the HapMap Han Chinese population (Fig. 3.2), including rs16861194 
(-11426A>G), rs266729 (-11377C>G), rs182052, rs822394, rs12495941, rs7627128, rs1501299 
(+276G>T), rs3774261 and rs1063537. Two common SNPs, rs17300539 (-11391G>A) and 
rs2241766 (+45T>G, also known as +94T>G), were selected based on previous review and meta-
analysis studies.
18,233
 The remaining seven SNPs (rs4632532, rs16861205, rs822396, rs2241767, 
rs3821799, rs6773957 and rs2082940) were genotyped in an attempt to duplicate/reproduce our 
findings, since they were highly correlated with one of the tag SNPs (r
2≥0.8).  
 
SNP genotype determination  
The GenomeLabTM SNPstream ® genotyping platform (Beckman Coulter Inc., Fullerton, CA, 
USA) and its accompanying SNPstream software suite were used to perform multiplex (12-plex) 
polymerase chain reaction (PCR) and SNP genotyping. The PCR primers were designed to amplify 
DNA (Table 3.2), and probes were designed to identify the SNP (Table 3.3). The SNPstream 
genotyping assay was performed according to methods previously described.
234
 All SNPs were 
accurately genotyped with a call rate >95%. 
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Figure 3.2 ADIPOQ tag SNPs in the Han Chinese population. Each tag SNP is highly correlated 
with the representative SNPs.   
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Table 3.2 Characteristics and primer sequences of the 18 ADIPOQ SNPs  
SNP ID Location Position M/m Forward primer (5’→3’) Reverse primer (5’→3’) 
rs4632532 (-19166 T>C)  promoter 186551682 T/C TTATGTACCAATAGATTGTGAAGCA AATCTTTGGTGAGTGTTCTTTCA 
rs16861194 (-11426 A>G) promoter 186559425 A/G TTGTTGAAGTTGGTGCTGG ATCTGAGCCGGTTCTTGC 
rs17300539 (-11391 G>A) promoter 186841671 G/A ATATCTGGGGGGCAGGCA TGGCACGCTCATGTTTTGT 
rs266729 (-11377 C>G) promoter 186559474 C/G TCGTAATTTAATTCATCAGAATGTGT TTAGGTGTTCCTAGAAAGTTTAGGC 
rs182052 (-10066 G>A) intron 1 186560782 G/A AGAGAAAGGGTTATTTCAGACATTC TTAATCGAATTGGACTTCATCTG 
rs16861205 (-9215 G>A) intron 1 186561634 G/A ATTTTCTGACAGAAGAAACTGGAT TAACCTCTAAAATCCCTCCCA 
rs822394 (-4120 C>A) intron 1 186566728 C/A AACTTTCTTTTACAATCAGAGTCCG TTCCATGACAGTGGCACG 
rs822396 (-3971 A>G) intron 1 186566877 A/G GCTGATCGCACCTATTAGTGG AAACTCAGGGGTCTCTGGAG 
rs12495941 (-2668 G>T) intron 1 186568180 G/T AACTGACAACACACAAATGTTTTT GCCAACCAGTAGTACATCATTAGTG 
rs7627128 (-2049 C>A) intron 1 186568799 C/A ATATATATGATAAAGATGAAAGATGAGTTGG AGGGATGGAAGAAAGACCG 
rs2241766 (+45 T>G)  exon 2 186570892 T/G GATGCTGTTGCTGGGAGC AGGGGAAGCAGGACTCCG 
rs1501299 (+276 G>T) intron 2 186571123 G/T TTGCTTATGGTTAACATAAAAAAGC AGGTAAGAATGTTTCTGGCCTC 
rs2241767 (+349 A>G) intron 2 186571196 A/G ACAGGGAGAAAGCAAAGCTT GGCACCATCTACACTCATCC 
rs3821799 (+639 T>C) intron 2 186571486 T/C TGCCTTTGGGGAACTCTT AGTATATTTTCTCTATGCTCCATACTTTG 
rs3774261 (+712 A>G) intron 2 186571559 A/G TCTGTTGGTGGTTACTACAAGAAA AAGCTCTGCCTCCTCCTT 
rs6773957 (+2858 A>G) 3' UTR 186573705 A/G CTTGCAGATCCTTGATAAATGC ATAAAACTGATTACATGCAGAGACTG 
rs1063537 (+3228 C>T) 3' UTR 186574075 C/T TAGTTGATGGTGGTAAACATTCTCT ATATATTGATAGAGAATGCTATTTACTCTGTT 
rs2082940 (+3317 C>T) 3' UTR 186574164 C/T AAAAACAGAGTAAATAGCATTCTCTATCA AATACCTTAATGATTAGCAATACACATATAAG 
Abbreviations: SNP: single nucleotide polymorphism; M/m; major allele/minor allele; UTR: untranslated region. 
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Table 3.3 Probe sequences of the 18 ADIPOQ SNPs 
SNP ID Probe (5’→3’) 
rs4632532 (-19166 T>C)  AGACTCCTTCCCTTCCAAGTATCTTTTACCCGATTGGAACTAGAATATGTC 
rs16861194 (-11426 A>G) ATCCTAAGCCCTTGCTGGGGTCGTATTTTAATTCATCAGAATGTGTGGCTT 
rs17300539 (-11391 G>A) CTTTGTGGAACCAGAGGCACAGAGAAAGTCAACTGAGGCCAAAAGAGGCCT 
rs266729 (-11377 C>G) TTGCAAGAACCGGCTCAGATCCTGCACTTCAAAAACAAAACATGAGCGTGC 
rs182052 (-10066 G>A) GATGCATGGAACCATTCTGAATTTTTCCCAGTTCGCTCTGTAGCAGGATAC 
rs16861205 (-9215 G>A) GCTCGCCCCAGTGAGTGCTGTTTCTTAGGCATCCTGGTTGTTTTGAGCTGT 
rs822394 (-4120 C>A) AACTTCTGAGGCTCCTGTGCTAATCTCACTCTTGTATTTTTGGCACCTCTA 
rs822396 (-3971 A>G) GTAGGAGAAAGAGATCTTTATTTTTTACAAAGGGGGAGGAGCCAGAAAACT 
rs12495941 (-2668 G>T) CCCAAAGCTGATGAGGGTAGTTAAGATATGCCCTTTTATACACACACTAAT 
rs7627128 (-2049 C>A) GCCACGTGAAGAGGGTAGTATAGAATCCCAGGTAATGGGGCATAGGAGTGG 
rs2241766 (+45 T>G)  TTCTACTGCTATTAGCTCTGCCCGGACATGACCAGGAAACCACGACTCAAG 
rs1501299 (+276 G>T) TCTAGGCCTTAGTTAATAATGAATGACTTCATATAGTTTATATCAGTGTAG 
rs2241767 (+349 A>G) TTTATGTTAACCATAAGCAACCTGATGTGATTTGGGGTTGGTCTTCCAAGG 
rs3821799 (+639 T>C) TGTGCAAGGCTCTGTTGGTGGTTACTACAAGAAAGTCTACTCTAAAAATGT 
rs3774261 (+712 A>G) TCAAAGTATGGAGCATAGAGAAAATATACTCACCGTGGACCTGATGAAGAA 
rs6773957 (+2858 A>G) CATGAAGACCAATCTCTTGAATCCCTTATCTACCCAGAATTAACTCCATTC 
rs1063537 (+3228 C>T) AGGAGACAATAACTCCAGTGATGTTTTTCAAAGATTTTAGCAAAAACAGAG 
rs2082940 (+3317 C>T) TATCTTTTTGCTTACAGTTTTAAATACTGAACAATTCTCTCTTATATGTGT 
 
3.6.2 Fatty acid extraction, derivatization, and analysis  
Erythrocyte and plasma fatty acids can partly reflect dietary intakes. Erythrocyte fatty acids are 
commonly used biomarkers of long-term intake of fatty acids.
41
 Erythrocyte and plasma lipids were 
extracted according to a modification of the Bligh and Dyer method,
235
 and they were derivatized to 
fatty acid methyl esters (FAMEs) using boron trifluoride-methanol. The FAMEs were extracted by 
hexane. Laboratory protocols are present in full below:  
 
Fatty acid extraction and derivatization to FAMEs 
1) Add 10 μL C17:0 (2 μg/μL) in a 16 ml glass tube (Kimble Chase Life Science and Research 
Products LLC, Vineland, NJ, USA) as an internal standard.  
2) Add 1.36 mL (for erythrocyte, or 1.30 mL for plasma) ddH2O, vortex 3 seconds.  
3) Pipet off 300 μL erythrocyte or plasma, vortex 10 seconds. 
4) Add 4 mL methanol (MeOH), then 2 mL chloroform (CHCl3) with 0.05% butylated 
hydroxytoluene (BHT), put N2 gas into the tube, vortex 1 minute to mix well.      
5) Centrifuge at 3100 rpm, 4℃, 15 minutes, transfer the up-later to a new 16 mL glass tube. 
6) Add 2 mL CHCl3 (with 0.5% BHT) to make a standard ratio of chloroform: methanol: 
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ddH2O=4: 4: 1.6. 
7) Add 2 mL 0.58% sodium chloride (NaCl), put N2, vortex 1 minute. 
8) Centrifuge at 3100 rpm, 4℃, 15 mins, transfer the lower-layer to a new 16 mL glass tube. 
9) Incubate at 40℃ and dry CHCl3 with N2.  
10)  Add 2 mL 5N sodium hydroxide (NaOH)/MeOH, put N2, vortex 1 minute, then incubate at 
60℃ for 10 minutes. 
11) After cooling, add 2 mL boron trifluoride (BF3)-methanol (20% BF3 + 80% MeOH), put N2, 
vortex 1 minute, incubate at 100℃ for 10 minutes. 
12) After cooling, add 2.5 mL hexane, put N2, vortex 2 minutes, incubate at 100℃ for 10 minutes. 
13) After cooling, transfer up-layer to a new 8 mL glass tube. 
14) Add 2 mL saturated sodium chloride (NaCl), put N2, vortex 2 minutes. 
15) Centrifuge at 2000 rcf, 4℃, 8 minutes, transfer up-layer to a new glass tube. 
16)  Incubate at 40℃ and dry hexane with N2. 
17) Weight FAMEs, add 40-50 μL dichloromethane (DCM) to dissolve the fatty acids, vortex.  
18)  Transfer the sample to a gas chromatography vial, put N2, store at -20℃ for analysis.  
  
FAME analysis by gas chromatography 
The methylated fatty acids were quantified using a gas chromatography-flame ionization detection 
(GC-FID; Agilent Technologies 6890N, CA, USA) equipped with a capillary column (30m × 
0.250mm inner diameter × 0.25μm film) (Agilent J&W GC Column DB-225, CA, USA). Ns was 
employed as a carrier gas (split flow: 25mL/sec, split ratio: 15:1). The oven temperature was 
programmed to start at 60℃, increase by 10℃ per minute to a maximum of 180℃, then hold for 
five minutes. It was then ramped to 220℃ at a rate of 3℃ per minute and run for 29 minutes for a 
total running time of 60 minutes. An equal weight FAME mixture GLC-68A (Nu-Chek-Prep, 
Elysian, MN, USA) was used to generate response factors. Individual fatty acids were identified by 
comparing each peak’s retention time with the retention times of FAME standards including 
Supelco-1891-1AMP (GLC-10), 1893-1AMP GLC-30, 1894-1AMP (GLC-50), 1899-1AMP (GLC-
100), and Supelco 37 component FAME mix (Supelco Inc., Bellefonte, PA, USA). The C17:0 
(Sigma, St Louis, MO, USA) was added as an internal standard to calculate quantitative profiles of 
erythrocyte and plasma fatty acids. The concentration of each fatty acid was calculated as a 
percentage of total area under the peaks, expressed as weight % of total fatty acids. Figures 3.3 and 
3.4 show the peaks and retention times of the GLC-68A standard and an erythrocyte FAME sample.  
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Figure 3.3 The peaks and retention times of GLC-68A standard  
 
 
Figure 3.4 The peaks and retention times of an erythrocyte FAME sample  
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3.6.3 Circulating adiponectin and IL-6 measurements    
Adiponectin  
The concentrations of adiponectin were determined from plasma samples using a commercial 
enzyme-linked immunosorbent assay (ELISA) kit (R&D systems, Minneapolis, MN, USA). This 
assay is designed to measure total human circulating adiponectin in the presence of an adiponectin-
specific antibody using the quantitative sandwich enzyme immunoassay technique. The detection 
range is from 3.9 to 250 ng/mL. Laboratory protocols are present in full below: 
 
Sample and reagent preparation: 
1) Plasma samples require a 100-fold dilution (10 μL sample + 990 μL Calbrator Diulent 
RD6-39). 
2) Bring all reagents to room temperature before use. 
3) Dilute 20 mL of Wash Buffer concentrate into deionized or distilled water to prepare 500 
mL of Wash Buffer. 
4) Prepare Substrate Solution, mix Colour Reagents A and B together in equal volumes within 
15 minutes of use, protect from light. 
 
Adiponectin standard preparation: 
1) Reconstitute the adiponectin standard with 2.0 mL of Calbrator Diulent RD6-39 (for 
serum/plasma samples), produce a stock solution of 250 ng/mL. 
2) Mix the standard to ensure complete reconstitution and allow the standard to sit for a 
minimum of 15 minutes with gentle agitation prior to making dilutions.  
3) Pipet 200 μL of Calbrator Diulent RD6-39 into each tube.  
4) Use the stock solution to produce a dilution series, mix each tube thoroughly before the next 
transfer (Fig. 3.5). 
5) Serve the 250 ng/mL standard as the high standard, serve the appropriate Calbrator Diulent 
as the zero standard (0 ng/mL). 
 
Assay procedure:  
1) Bring all reagents and samples to room temperature before use.  
2) Full protocols are shown full in Figure 3.6. 
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Figure 3.5 The dilution series for the adiponectin standard preparation   
 
 
 
Figure 3.6 The procedure summary for adiponectin immunoassay (R&D systems, USA)  
 
 
RT=room temperature  
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Calculation of results:  
1) Average the duplicate readings for each standard, control, and sample, then subtract the 
average zero standard optical density. 
2) Plot the optical density for the standard vs the concentration of the standards and draw the 
best curve (standard line) (an example is shown in Figure 3.7). 
3) Linearize the data by using regression analysis (four parameters) (Fig 3.7). 
4) Find the absorbance value on the y-axis, extend a horizontal line to the standard curve. 
5) At the point of intersection, extend a vertical line from the x-axis and read the corresponding 
adiponectin concentration.   
6) Multiply by the dilution factor (100-fold). 
 
Curve Formula A B C D R2 
Y = (A-D)/(1+(X/C)^B) + D -0.0054 1 1.28E+04 111 1 
 
Figure 3.7 Example of a standard curve for adiponectin concentrations and its curve formula  
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IL-6 
Plasma interleukin-6 (IL-6) levels were quantitated by a high sensitivity ELISA kit (R&D systems, 
Minneapolis, MN, USA) with a minimal detectable concentration of 0.156 pg/mL to a maximum of 
10 pg/mL. Laboratory protocols are present in full below: 
 
Reagent preparation: 
1) Take precautionary measures (wear a mask and gloves) to protect reagents during 
preparation (because alkaline phosphatase is detectable in saliva). 
2) Bring all reagents to room temperature before use.  
3) Dilute 100 mL of Wash Buffer concentrate into deionized or distilled water to prepare 1000 
mL of Wash Buffer. 
4) Prepare Substrate Solution, reconstitute the lyophilized Substrate with 6.0 mL of Substrate 
Diluent at least 10 minutes before use and mix thoroughly (avoid contamination).  
5) Prepare Amplifier Solution, reconstitute the lyophilized Amplifier with 6.0 mL of Amplifier 
Diluent at least 10 minutes before use and mix thoroughly (avoid contamination).  
6) Prepare 20 mL Calibrator Diluent RD6-11, dilute 10 mL of Calibrator Diluent RD6-11 
concentrate into 10 mL of deionized or distilled water.  
 
IL-6 standard preparation: 
1) Reconstitute the IL-6 standard with 5.0 mL of Calbrator Diulent RD6-11 (for serum/plasma 
samples), produce a stock solution of 10 pg/mL. 
2) Mix the standard to ensure complete reconstitution and allow the standard to sit for a 
minimum of 15 minutes with gentle agitation prior to making dilutions.  
3) Pipet 500 μL of Calbrator Diulent RD6-11 into each tube.  
4) Use the stock solution to produce a dilution series, mix each tube thoroughly before the next 
transfer (Fig. 3.8). 
5) Serve the 10 pg/mL standard as the high standard, serve the appropriate Calbrator Diulent as 
the zero standard (0 pg/mL). 
 
Assay procedure:  
1) Bring all reagents and samples to room temperature before use.  
2) Full protocols are shown full in Figure 3.9 
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Figure 3.8 The dilution series for the IL-6 standard preparation 
 
 
 
 
Figure 3.9 The procedure summary for IL-6 immunoassay (R&D systems, USA) 
 
 
RT=room temperature  
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Calculation of results:  
1) Average the duplicate readings for each standard, control, and sample, then subtract the 
average zero standard optical density. 
2) Plot the optical density for the standard vs the concentration of the standards and draw the 
best curve (standard line) (an example is shown in Figure 3.10). 
3) Linearize the data using regression analysis (four parameters) (Fig 3.10). 
4) Find the absorbance value on the y-axis, extend a horizontal line to the standard curve. 
5) At the point of intersection, extend a vertical line from the x-axis and read the corresponding 
IL-6 concentration.   
 
Curve Formula A B C D R
2
 
Y = (A-D)/(1+(X/C)^B) + D 0.0048 1.15 9.58 5 1 
 
 
Figure 3.10 Example of a standard curve for IL-6 concentrations and its curve formula  
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3.7 Assessment of kidney disease   
In this diabetic cohort, the development of kidney disease was based on albuminuria and decreased 
kidney function. The renal indicators used to assess kidney disease are shown below:   
1) Kidney damage: albuminuria  
Urinary albumin-to-creatinine ratio (ACR) ≥30 mg/g in two consecutive urine tests was 
defined as having albuminuria in our cohort.
236
   
 
2) Decreased kidney function:  
 Increased serum creatinine  
An elevated serum creatinine of ≥1.5 mg/dL for men or ≥1.2 mg/dL for women was defined 
as clinically significant kidney insufficiency or impairment.237,238 These gender-specific cut-
off points for serum creatinine have been described as being equivalent to an insulin 
clearance of <60 mL/min.238  
 
 Decreased eGFR 
A decreased estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73m2 is a widely 
used cut-off point for kidney dysfunction or chronic kidney disease (CKD).9 eGFR was 
calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) four-level race equation based on serum creatinine (Scr), age, sex and a four-level 
variable for race (Black, Asian, Hispanic and Native American, and White and other).83 The 
CKD-EPI formula is more accurate than the Modification of Diet in Renal Disease (MDRD) 
equation, especially when eGFR is ≥ 60ml/min/1.73m2.239 
  
 Renal function (eGFR) decline  
As previously described in other type 2 diabetes studies,245,246 an eGFR decline of ≥25% 
(between assessment in 2008 and follow up in 2012) was defined as significant renal 
function decline.240,241 
 
3.8 Statistical analysis  
Aim 1 (Chapter 4): Association between ADIPOQ polymorphisms and DN (albuminuria)  
- Study design: six-year prospective study (baseline to 2009). 
- Exposures: 18 ADIPOQ polymorphisms (genotypes) at baseline. 
- Outcomes: progression to albuminuria (ACR ≥30 mg/g) events. 
- Method summary: Cox proportional hazard models were used for the prospective study design, 
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and logistic regression analysis was used for the case-control study design (confirmatory 
analysis). We further stratified by gender to examine gender-specific effects. Details are 
presented in the statistical analysis section of the publication in Chapter 4.    
 
Aim 2 (Chapter 5): Association between dietary patterns and diabetic kidney disease (DKD) 
- Study design: three-year cohort study (2008-2010). 
- Exposures: analyses of dietary patterns in 2008, 2009, and 2010.  
- Outcomes: albuminuria (ACR ≥30 mg/g) and kidney dysfunction (serum creatinine of ≥1.5 
mg/dL for men or ≥1.2 mg/dL and eGFR <60 ml/min/1.73m2) in 2008, 2009, and 2010. 
- Method summary: factor analysis was used to identify dietary patterns at each time point. 
Generalized estimating equation models were used for repeated measures of diet and renal 
outcomes. Details are presented in the statistical analysis section of the publication in Chapter 5.  
 
Aim 3 (Chapter 6): Association of fatty acids and inflammatory biomarkers with DKD 
- Study design: four-year cohort study (2008-2012). 
- Exposures: erythrocyte fatty acids and plasma adipocytokines in 2008.  
- Outcomes: albuminuria (ACR ≥30 mg/g) in 2012 and kidney function decline (eGFR decline 
>25%) between 2008 and 2012. 
- Method summary: logistic regression models were used for fatty acids/inflammatory biomarkers 
and renal function decline over time. Fatty acid stratification was used to examine effect 
modification. Details are presented in the statistical analysis section of the publication in 
Chapter 6.   
 
Aim 4 (Chapter 7): Association of obesity and weight change with DKD 
- Study design: seven-year cohort study (baseline to 2010). 
- Exposures: BMI at baseline, 2008, 2009, and 2010, and changes in weight and BMI between 
baseline and 2010.  
- Outcomes: albuminuria (ACR ≥30 mg/g) and kidney dysfunction (eGFR<60 ml/min/1.73m2) at 
baseline, 2008, 2009, and 2010. 
- Method summary: generalized estimating equation models were used for repeated measures of 
BMI and renal outcomes, and logistic regression analysis was used for weight change and renal 
outcomes in 2010. Gender stratification was used to examine gender-specific effects. Details are 
presented in the statistical analysis section of the publication in Chapter 7.   
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Chapter 4: Adiponectin gene (ADIPOQ) polymorphisms correlate with the 
progression of nephropathy in Taiwanese male patients with type 2 diabetes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been published in Diabetes Research and Clinical Practice. 
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MC. Adiponectin gene (ADIPOQ) polymorphisms correlate with the progression of nephropathy in 
Taiwanese male patients with type 2 diabetes. Diabetes Res Clin Pract. 2014;105(2):261-270. 
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4.1 Chapter introduction  
Study objectives 
Primary: 
1. To determinate 18 ADIPOQ polymorphisms in the Taiwanese population 
2. To examine ADIPOQ genetic effects on the progression of diabetic nephropathy (DN; 
albuminuria) in Taiwanese adults with type 2 diabetes using a prospective study design     
Secondary: 
3. To examine whether the ADIPOQ genetic effect is gender specific  
4. To examine whether ADIPOQ polymorphisms regulate circulating adiponectin  
 
Outline of the study 
 
 
 
 
 
 
 
 
 Study design: a six-year follow-up cohort study from baseline to 2009 
1) prospective design, n=566 (excluded 276 patients with albuminuria at baseline) 
2) case-control design, n=842 (replicated the genetic association in a larger sample size, data 
presented in the supplementary materials)  
 Exclusion criteria: specimens not available to perform genotyping (n=367), patient who had 
ACR ≥30 mg/g in at least one of the first two urine tests (n=267) 
 Statistical analysis:  
1) survival analysis (Kaplan–Meier estimate and Cox proportional hazard model)  
2) logistic regression analysis for case-control design  
3) analyses stratified by gender  
 
4.2 Published article  
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Aims: Polymorphisms of the ADIPOQ gene were associated with diabetic nephropathy (DN)
in case–control studies predominantly among European populations. Gender may modify
the ADIPOQ associated risk for DN. We investigated the association of 18 ADIPOQ polymor-
phisms with DN in a prospective Taiwanese cohort of type 2 diabetes (T2D) and explored
whether gender plays a role in this genetic association.
Methods: Selected single nucleotide polymorphisms (SNPs) of ADIPOQ were genotyped in 566
T2D patients with normoalbuminuria at baseline. DN was defined based on urinary albu-
min-to-creatinine ratio (ACR). The Cox proportional hazard model was used to explore the
association of individual SNP to DN events under different genetic models over a 6-year
follow-up period. Analyses were further stratified by gender.
Results: In male patients, the adjusted hazard ratios under the recessive models were 1.81
for rs2241766 TT (vs. GT + GG, 95% CI = 1.10–2.96, p = 0.019) and 1.89 for rs1063537 CC (vs.
CT + TT, 95% CI = 1.15–3.11, p = 0.013). In the Kaplan–Meier survival curve, males carrying
rs2241766 TT (vs. GT + GG, p = 0.050) and rs1063537 CC (vs. CT + TT, p = 0.037) recessive
homozygotes also had a reduced nephropathy-free survival rate. SNPs rs2241767 and
rs2082940, both in strong correlation with tag SNP rs1063537 (r2  0.96), were also associated
with DN progression in males. In females, ADIPOQ polymorphisms were not associated with
the progression of DN.
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Conclusions: ADIPOQ genetic polymorphisms rs2241766 (+45T>G), rs1063537, rs2241767 and
rs2082940 were correlated with the progression of DN in Taiwanese male patients with T2D.
The role of gender in this ADIPOQ genetic association needs to be further investigated in
other populations.
# 2014 Elsevier Ireland Ltd. All rights reserved.
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Diabetic nephropathy (DN) is the leading cause of end-stage
renal disease (ESRD) [1], and affects more patients with type 2
diabetes (T2D) than those with type 1 diabetes (T1D) [2]. A
global study has reported that the overall prevalence of
albuminuria in T2D to be about 50% [3]. Asian and Hispanic
patients have the highest prevalence of albuminuria (55%),
while Caucasians have the lowest (40.6%) [3], indicating
possible ethnic differences. The pathogenesis of DN is
multifactorial, and thought to come about as a result of
environmental and genetic factors [4]. Genetic factors play an
important role in the observed ethnic disparity in the
development of DN [4], and gender may predispose patients
to the development of kidney disease, as both animal and
human studies have reported a higher incidence and a faster
progression rate of the disease among males [5–7].
The adiponectin gene (ADIPOQ), located on human chro-
mosome 3q27, has been mapped as a genetic susceptibility
locus for obesity, insulin resistance, T2D, and cardiovascular
disease (CVD) in different populations [8,9]. Adiponectin,
encoded by ADIPOQ, is lower in patients with T2D and CVD
due to its insulin-sensitizing, anti-inflammatory, and anti-
atherogenic properties [10]. However, an increase in circulat-
ing adiponectin is found in patients with kidney diseases [11–
13]. Polymorphisms in the two small regions of ADIPOQ, one in
the promoter and another in the boundary of exon 2–intron 2,
are the most commonly discussed variants. To date, a small
number of case–control studies have reported an association
between ADIPOQ polymorphisms and DN among T1D and T2D
patients [14–19]. However, these studies were carried out
predominantly among Europeans with only one being con-
ducted in a Chinese population [16]. Zhang et al. have recently
reported an association between promoter polymorphism
rs17300539 (11391A/G) and DN in European female subjects
with T1D, though the biological basis of gender predisposition
is not very well understood [14,15].
In this prospective study, we first genotyped a larger
number of 18 ADIPOQ polymorphisms, and then examined
their genetic effects on the progression of DN in Taiwanese
T2D patients. We further explored whether gender plays a role
in this genetic association.2. Materials and methods
2.1. Study subjects
The study subjects were diagnosed T2D patients enrolled in a
study project involving diabetes management through an
integrated delivery system (DMIDS) (ClinicalTrials.govNCT00288678). Details of the study design and inclusion/
exclusion criteria have been reported elsewhere [20]. Briefly,
1209 T2D patients were recruited at baseline (August 2003 to
December 2005) and followed until the end of 2009. We
excluded 367 patients who did not have available specimens
to perform ADIPOQ genotyping and 276 who had urinary
albumin-to-creatinine ratio (ACR) 30 mg/g in at least one of
the first two urine tests, leaving us with 566 subjects for
genetic association analysis. This study was approved by
the Ethics Committee of the National Health Research
Institutes and Kaohsiung Medical University Hospital,
Taiwan. Written informed consent was obtained from each
subject.
2.2. Clinical assessments and primary end point
Anthropometric data (including height, weight, systolic and
diastolic blood pressure), fasting venous blood (over-
night  8 h), and morning spot urine were collected every 6
months. Glucose, triglyceride, cholesterol, LDL-C, HDL-C and
creatinine were measured by an automatic analyser (Hitachi
7060; Hitachi High Technologies, Tokyo, Japan). HbA1C was
measured by high-performance liquid chromatography (Vari-
ant II; Bio-Rad Laboratories, Hercules, CA, USA) and urinary
albumin by immunoturbidimetry (Hitachi 7060; Hitachi High
Technologies, Tokyo, Japan). All samples were kept in 2–8 8C,
delivered to a central laboratory, and measured within 8 h.
Adiponectin was determined by a commercial enzyme-linked
immunosorbent assay (ELISA) kit (R&D systems, Minneapolis,
MN, USA), using plasma samples cross-sectionally collected in
2008. Duplicate measurements were performed and coeffi-
cient of variation less than 10% were calculated for quality
control.
The end point of this study was progression to DN, which
has been classically defined by the presence of microalbumi-
nuria. In our cohort, microalbuminuria was defined as having
urinary ACR 30 mg/g in two consecutive urine tests [20].
2.3. SNP selection and genotyping
We performed 18 single nucleotide polymorphisms (SNPs) in
the ADIPOQ gene. Nine of these SNPs were tag SNPs with minor
allele frequencies (MAF) >5% in the HapMap Han Chinese
population. Tag SNPs, including rs16861194 (11426A>G),
rs266729 (11377C>G), rs182052, rs822394, rs12495941,
rs7627128, rs1501299 (+276G>T), rs3774261 and rs1063537,
were selected. Two common SNPs, rs17300539 (11391G>A)
and rs2241766 (+45T>G, also known as +94T>G), were
included in the selection based on previous review and
meta-analysis studies [21,22]. The remaining seven SNPs
(rs4632532, rs16861205, rs822396, rs2241767, rs3821799,
rs6773957 and rs2082940) were genotyped in an attempt to
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correlated with one of the tag SNPs (r2  0.8).
Genomic DNA was isolated from human leukocytes using
standard methods and stored at 208C until genotyping. The
GenomeLabTM SNPstream1 genotyping platform (Beckman
Coulter Inc., Fullerton, CA, USA) and its accompanying
SNPstream software suite were used to perform multiplex
polymerase chain reaction (12-plex PCR) and SNP genotyping.
ThePCR primers were designedto amplifyDNA, and probes were
designed to identify the SNP. The SNPstream genotyping assay
was performed according to methods previously described [23].
All SNPs were accurately genotyped with a call rate >95%.
2.4. Statistical analysis
Chi-squared test or Student’s t-test were used to compare
baseline characteristics between nephropathy and non-
nephropathy groups whenever appropriate. One-sample
Kolmogorov–Smirnov test was used to examine the normality
of the continuous variables, and a log transformation to
normalize the skewed distribution. Pairwise jD0j and r2 values
between SNPs were computed using the Haploview version 4.2
(Broad Institute, Cambridge, MA, USA). Frequencies of allele
and genotype between the DN and non-DN groups were
examined by Chi-squared or Fisher’s exact test. Each SNP in
the non-DN control group was tested for deviation from
Hardy–Weinberg equilibrium using X2 goodness-of-fit test. To
examine the gender-specific effect on genetic risk for DN, we
further stratified by gender.
Kaplan–Meier estimates, log-rank tests, and univariate Cox
proportional hazard models were used to explore the
association of individual SNP with time to new DN events
under different specifications of the genetic model, including
allelic, additive, dominant and recessive models. Patient data
were censored at the end of the study or the time of death orTable 1 – Baseline clinical characteristics of 566 patients with 
gender.
Nephropathy 
All Male Female 
Number 144 70 74 42
Age (y) 55.5  9.0 54.7  8.9 56.3  9.1 5
Diabetes duration (y) 5.5  5.6 5.1  5.3 5.9  5.9 
Education 6y (%) 95 (66.0) 39 (55.7) 56 (75.7) 21
Current smoker (%) 28 (19.4) 26 (37.1) 2 (2.7) 6
ACEI or ARB use (%) 102 (70.8) 49 (70.0) 53 (71.6) 26
Body mass index (kg/m2) 26.1  4.0 26.0  3.1 26.2  4.8 2
Systolic BP (mm Hg) 130.6  15.6 131.4  14.9 129.8  16.2 12
Diastolic BP (mm Hg) 81.3  9.7 82.3  9.6 80.3  9.8 8
HbA1C (%) 8.5  1.8 8.5  1.7 8.5  1.8 
Triglyceride (mmol/l) 1.9  1.4 2.1  1.7 1.6  0.9 
Cholesterol (mmol/l) 5.0  1.0 5.1  1.0 5.0  0.9 
LDL cholesterol (mmol/l) 3.3  0.8 3.3  0.9 3.2  0.8 
HDL cholesterol (mmol/l) 1.2  0.3 1.2  0.3 1.3  0.3 
Creatinine (mmol/l) 67.8  23.6 81.2  24.9 55.3  13.2 6
ACR (mg/mmol) 1.2  0.8 1.2  0.9 1.1  0.8 
Adiponectin (ng/ml)a 7.5  7.0 6.3  6.4 8.7  7.3 
Data are presented as mean  SD or n (%). Abbreviation: ACEI: angiotens
ACR: urinary albumin-to-creatinine ratio.
a Plasma adiponectin concentrations were measured cross-sectionally inloss to follow-up. A hazard ratio (HR) in Cox proportional
hazard models refers to the hazard of a (set of) risk genotype
over the other non-risk genotypes of a SNP on developing
nephropathy. Multivariate Cox proportional hazard models
were further adjusted for diabetes duration, education (6, >6
years), blood pressure (140/90, <140/90 mm Hg), HbA1C,
triglyceride, and use of ACEI or ARB (yes, no) at baseline to
determine the independent genetic effects. Analyses of female
patient data were additionally adjusted for menopause status
(pre-, post-menopause). We evaluated proportional hazard
assumptions using log-log survival plots or time interactions
for all covariates, with no violations noted.
Posterior study power was estimated for each SNP
associated with progression of DN separated by gender,
using the genetic power calculator [24]. We also included
267 patients with urinary ACR  30 mg/g at baseline to
perform a case–control analysis in an attempt to investigate
this genetic association in a larger sample size (total n = 842,
males = 396, Supplemental Tables 1 and 2). The independent
association between ADIPOQ polymorphisms and DN
was examined using multivariate logistic regression
models.
ANCOVA analyses were carried out to examine the adjusted
mean plasma concentrations of adiponectin among genotypes
stratified by disease status. All statistical operations were
performed using the SPSS version 21.0 (SPSS Inc., Chicago, IL,
USA). A two-sided p value < 0.05 was considered significant.
3. Results
3.1. Baseline characteristics of study subjects
The baseline characteristics of the 566 selected T2D patients
are shown in Table 1. Of these subjects, 263 (46.5%) were male,type 2 diabetes stratified by nephropathy progression and
Non-Nephropathy p-Values
All Male Female All Male Female
2 193 229
5.1  8.2 53.4  8.4 56.6  7.7 0.621 0.250 0.774
4.3  5.5 3.9  4.1 4.6  6.3 0.021 0.084 0.114
3 (50.5) 60 (31.1) 153 (66.8) 0.001 <0.001 0.152
7 (15.9) 58 (30.1) 9 (3.9) 0.323 0.276 0.624
4 (62.6) 118 (61.1) 146 (63.8) 0.073 0.187 0.215
6.0  3.7 26.1  3.5 26.0  3.9 0.949 0.920 0.990
7.8  15.4 127.3  15.7 128.3  15.1 0.076 0.057 0.519
0.0  10.0 80.8  9.7 79.4  10.1 0.173 0.240 0.480
8.0  1.7 8.0  1.8 8.0  1.7 0.005 0.042 0.049
1.7  1.2 1.7  1.3 1.7  1.1 0.156 0.021 0.639
4.9  1.0 4.9  1.1 5.0  1.0 0.561 0.162 0.586
3.2  0.9 3.2  0.9 3.2  0.9 0.843 0.698 0.912
1.3  0.4 1.1  0.2 1.4  0.4 0.799 0.743 0.726
7.0  18.0 76.0  15.7 59.6  16.4 0.806 0.232 0.024
0.7  0.7 0.7  0.7 0.7  0.6 <0.001 <0.001 <0.001
6.7  5.6 5.0  3.6 8.1  6.6 0.318 0.207 0.662
in-converting-enzyme inhibitor; ARB: angiotensin receptor blockers;
 the year 2008 of this cohort.
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duration was 4.6  5.5 years. Over a follow-up period of 6
years, 144 (25.4%) patients who had normoalbuminuria at
baseline progressed to DN. Patients who progressed to DN
were less educated and had a longer diabetes duration, higher
concentrations of HbA1C and ACR at baseline ( p < 0.05).
Additionally, they also tended to have higher blood pressure
and increased ACEI or ARB medication use, although the
differences only reached marginal significance. In female
patients, we found that females with DN had a lower
creatinine level than females without DN (55.3 vs.
59.6 mmol/l, p = 0.024). Generally, patients with increases in
urinary albumin had increased serum creatinine levels. It is
possible that variations in muscle mass between the two
groups may contribute to lower creatinine level observed in
DN subjects. Assessment of body composition was unavail-
able for this cohort study. In the case–control design (n = 842),
420 patients were defined as cases (DN group) in the end of
2009, who had a high prevalence (about 50%) of DN.
3.2. LD analysis
The G to A polymorphism at rs17300539 (11391G>A) was not
found in our population. We, therefore, performed linkage
disequilibrium (LD) analyses and association analyses based
on the remaining 17 SNPs. As shown in Fig. 1, tag SNP
rs1063537 was in complete LD with rs2241767 (r2 = 1) and in
high LD with rs2082940 (r2 = 0.96). SNP rs2241766 was in strongFig. 1 – Position and linkage disequilibrium (LD) plot generated b
r2 values and color scheme. Pairwise r2 I 0.8 are shown by black
A haplotype block represents a region with a paucity of haploty
hotspots.LD with rs1063537 (r2 = 0.88), as were rs2241767 and rs2082940.
Therefore, only rs2241766 and the 9 tag SNPs were presented
without losing the power of using all SNPs. The allele and
genotype frequencies in this cohort were all comparable to
those in the HapMap Han Chinese population. In the non-DN
group, the genotype distributions were consistent with Hardy–
Weinberg equilibrium ( p > 0.05), except for rs266729, rs822394
and rs822396.
3.3. Distribution and association of ADIPOQ
polymorphisms with DN risk
Overall, the distributions of ADIPOQ alleles and genotypes
were not statistically different between nephropathy and non-
nephropathy groups (Table 2). When analyzed separately by
gender, frequency of rs1063537 C allele was significantly
higher in patients with DN progression compared to those
without that progression in males (75.0% vs. 65.5%, p = 0.040),
but not in females ( p = 0.366) (Table 3). The HR for DN was 1.50
(95% CI: 1.03–2.21, p = 0.037) for C allele in males. We also
found that distribution of rs2241766 T allele was higher in
male subjects with DN progression (74.3% vs. 65.5%), however
only reaching marginal significance ( p = 0.058). Additionally,
frequencies of rs2241766 TT and rs1063537 CC genotype were
slightly higher in male patients with DN progression (chi-
squared p = 0.099–0.133), and those differences became signif-
icant in a larger sample size of case–control analysis (chi-
squared p = 0.002–0.006) (Table 3 and Supplemental Table 1).y the 17 ADIPOQ polymorphisms genotyped, with pairwise
 color, which determined polymorphism pairs in strong LD.
pe diversity (2–4 per block), separated by recombination
Table 2 – Genotype and allele distribution of 18 ADIPOQ polymorphisms in type 2 diabetic patients with and without progression to nephropathy.
SNPs Location M/m Nephropathy (n = 144) Non-Nephropathy (n = 422) HWE
Genotype (MM/Mm/mm) Allele (M/m) Genotype (MM/Mm/mm) Allele (M/m) Pa Pb Pc
rs4632532 (19166 T>C) Promoter T/C 47/70/27 (32.6/48.6/18.8) 164/124 (56.9/43.1) 123/223/76 (29.1/52.8/18.0) 469/375 (55.6/44.4) 0.657 0.685 0.150
rs16861194 (11426 A>G) Promoter A/G 106/32/6 (73.6/22.2/4.2) 244/44 (84.7/15.3) 299/114/9 (70.9/27.0/2.1) 712/132 (84.4/15.6) 0.253 0.884 0.626
rs17300539 (11391 G>A) Promoter G/A 144/0/0 (100.0/0.0/0.0) 288/0 (100.0/0.0) 422/0/0 (100.0/0.0/0.0) 844/0 (100.0/0.0) – – –
rs266729 (11377 C>G) Promoter C/G 98/44/2 (68.1/30.6/1.4) 240/48 (83.3/16.7) 283/133/6 (67.1/31.5/1.4) 699/145 (82.8/17.2) 0.974 0.841 0.027
rs182052 (10066 G>A) Intron 1 G/A 50/71/23 (34.7/49.3/16.0) 171/117 (59.4/40.6) 136/220/66 (32.2/52.1/15.6) 492/352 (58.3/41.7) 0.828 0.748 0.138
rs16861205 (9215 G>A) Intron 1 G/A 107/33/4 (74.3/22.9/2.8) 247/41 (85.8/14.2) 298/113/11 (70.6/26.8/2.6) 709/135 (84.0/16.0) 0.659 0.477 0.941
rs822394 (4120 A>C) Intron 1 C/A 106/36/2 (73.6/25.0/1.4) 248/40 (86.1/13.9) 309/111/2 (73.2/26.3/0.5) 729/115 (86.4/13.6) 0.444 0.911 0.016
rs822396 (3971 G>A) Intron 1 A/G 107/29/2 (77.5/21.0/1.4) 243/33 (88.0/12.0) 311/102/2 (74.9/24.6/0.5) 724/106 (87.2/12.8) 0.287 0.724 0.036
rs12495941 (2668 G>T) Intron 1 G/T 45/78/21 (31.2/54.2/14.6) 168/120 (58.3/41.7) 153/204/65 (36.3/48.3/15.4) 510/334 (60.4/39.6) 0.461 0.531 0.825
rs7627128 (2049 C>A) Intron 1 C/A 90/46/8 (62.5/31.9/5.6) 226/62 (78.5/21.5) 253/154/15 (60.0/36.5/3.6) 660/184 (78.2/21.8) 0.406 0.923 0.149
rs2241766 (+45 T>G) Exon 2 T/G 77/57/10 (53.5/39.6/6.9) 211/77 (73.3/26.7) 206/186/30 (48.8/44.1/7.1) 598/246 (70.9/29.1) 0.614 0.434 0.168
rs1501299 (+276 G>T) Intron 2 G/T 78/57/9 (54.2/39.6/6.2) 213/75 (74.0/26.0) 221/179/22 (52.4/42.4/5.2) 621/223 (73.6/26.4) 0.785 0.899 0.062
rs2241767 (+349 A>G) Intron 2 A/G 78/57/9 (54.2/39.6/6.2) 213/75 (74.0/26.0) 212/180/30 (50.2/42.7/7.1) 604/240 (71.6/28.4) 0.712 0.434 0.324
rs3821799 (+639 T>C) Intron 2 T/C 45/72/27 (31.2/50.0/18.8) 162/126 (56.2/43.8) 139/221/62 (32.9/52.4/14.7) 499/345 (59.1/40.9) 0.513 0.393 0.086
rs3774261 (+712 A>G) Intron 2 A/G 41/72/31 (28.5/50.0/21.5) 154/134 (53.5/46.5) 121/228/73 (28.7/54.0/17.3) 470/374 (55.7/44.3) 0.503 0.514 0.052
rs6773957 (+2858 A>G) 30 UTR A/G 40/73/31 (27.8/50.7/21.5) 153/135 (53.1/46.9) 123/224/75 (29.1/53.1/17.8) 470/374 (55.7/44.3) 0.608 0.450 0.121
rs1063537 (+3228 C>T) 30 UTR C/T 78/57/9 (54.2/39.6/6.2) 213/75 (74.0/26.0) 212/180/30 (50.2/42.7/7.1) 604/240 (71.6/28.4) 0.712 0.434 0.324
rs2082940 (+3317 T>C) 30 UTR C/T 76/59/9 (52.8/41.0/6.2) 211/77 (73.3/26.7) 212/181/29 (50.2/42.9/6.9) 605/239 (71.7/28.3) 0.864 0.605 0.246
Data are presented as n (%). Abbreviation: SNP: single nucleotide polymorphism; M/m: major allele/minor allele; 30 UTR: 30 untranslated region; HWE: Hardy–Weinberg equilibrium.
a Genotype p-value was examined by chi-squared tests.
b Allelic p-value was examined by chi-squared tests.
c Chi-squared test was used to test HWE for genotype frequencies in the non-nephropathy group.
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Table 3 – Gender stratified analysis of genotype and allele distribution of ADIPOQ polymorphisms in type 2 diabetic
patients with and without progression to nephropathy.
Gender SNPs Genotype Nephropathy Non-Nephropathy p-Value HR (95% CI) p-Value
Male rs2241766 GG 3 (4.3) 18 (9.3) 0.133 1.00
GT 30 (42.9) 97 (50.3) 1.64 (0.50–5.38) 0.413
TT 37 (52.9) 78 (40.4) 2.47 (0.76–8.00) 0.132
T allele 104 (74.3) 253 (65.5) 0.058 1.45 (0.99–2.12) 0.053
rs1063537 TT 3 (4.3) 19 (9.8) 0.099 1.00
CT 29 (41.4) 95 (49.2) 1.72 (0.52–5.65) 0.371
CC 38 (54.3) 79 (40.9) 2.65 (0.82–8.57) 0.105
C allele 105 (75.0) 253 (65.5) 0.040 1.50 (1.03–2.21) 0.037
Female rs2241766 GG 7 (9.5) 12 (5.2) 0.446 1.00
GT 27 (36.5) 89 (38.9) 0.63 (0.27–1.45) 0.275
TT 40 (54.1) 128 (55.9) 0.66 (0.30–1.47) 0.306
T allele 107 (72.3) 345 (75.3) 0.462 0.90 (0.63–1.29) 0.575
rs1063537 TT 6 (8.1) 11 (4.8) 0.515 1.00
CT 28 (37.8) 85 (37.1) 0.70 (0.29–1.69) 0.429
CC 40 (54.1) 133 (58.1) 0.66 (0.28–1.55) 0.336
C allele 108 (73.0) 351 (76.6) 0.366 0.87 (0.60–1.25) 0.439
Data are presented as n (%) and HR (95% CI). Abbreviation: SNP: single nucleotide polymorphism.
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for rs2241766 TT genotype and 3.10 (95% CI = 1.33–7.20,
p = 0.009) for rs1063537 CC genotype (Supplemental Table 1).
3.4. Survival analyses under different genetic models
The associations between ADIPOQ SNPs and the risk of DN
progression under different genetic models are shown in
Table 4. In males, based on comparison of genotype effects,
the recessive model was the most appropriate genetic
model in this study, in which the adjusted HRs were 1.81Table 4 – Gender stratified analysis of association between AD
nephropathy under different genetic models.
Gender SNPs Genetic models 
HR
Male rs2241766 Dominant (GT + TT vs. GG) 2.0
Recessive (TT vs. GT + GG) 1.5
Additive (GG/GT/TT) 1.5
Allele (T vs. G) 1.4
rs1063537 Dominant (CT + CC vs. TT) 2.1
Recessive (CC vs. CT + TT) 1.6
Additive (TT/CT/CC) 1.5
Allele (C vs. T) 1.5
Female rs2241766 Dominant (GT + TT vs. GG) 0.6
Recessive (TT vs. GT + GG) 0.9
Additive (GG/GT/TT) 0.9
Allele (T vs. G) 0.9
rs1063537 Dominant (CT + CC vs. TT) 0.6
Recessive (CC vs. CT + TT) 0.8
Additive (TT/CT/CC) 0.8
Allele (C vs. T) 0.8
Data are presented as HR (95% CI). Additive genetic effects were modeled
to genotypes (i.e. rs2241766 was coded as 1 for GG, 2 for GT, and 3 for TT
model was coded as 1 for any genotype that contains disease allele and
disease genotype and 0 otherwise.
a Adjusted model: diabetes duration, education (6, >6 years), blood pres
or ARB (yes, no) at baseline. Female patients were additionally adjusted (95% CI = 1.10–2.96, p = 0.019) for rs2241766 TT (vs. GT + GG) and
1.89 (95% CI = 1.15–3.11, p = 0.013) for rs1063537 CC (vs. CT + TT).
In the additive model, rs2241766 and rs1063537 were also
significantly associated with DN, with respective adjusted HRs
of 1.66 ( p = 0.021) and 1.73 ( p = 0.013), suggesting a dose-additive
manner. In the Kaplan–Meier survival curve estimate under the
recessive model, we also found that male patients carrying
rs2241766 TT (vs. GT + GG, p = 0.050) and rs1063537 CC (vs.
CT + TT, p = 0.037) homozygotes had a reduced nephropathy-
free survival rate compared to the reference group (Fig. 2).
Additionally, two SNPs rs2241767 and rs2082940, both highlyIPOQ polymorphisms and the progression of diabetic
Crude model Adjusted modela
 (95% CI) p-Value HR (95% CI) p-Value
1 (0.63–6.41) 0.235 1.74 (0.55–5.57) 0.348
9 (1.00–2.55) 0.053 1.81 (1.10–2.96) 0.019
3 (1.02–2.29) 0.038 1.66 (1.08–2.56) 0.021
5 (0.99–2.12) 0.053 1.50 (1.02–2.21) 0.041
5 (0.68–6.82) 0.196 1.90 (0.59–6.05) 0.280
4 (1.03–2.63) 0.039 1.89 (1.15–3.11) 0.013
7 (1.05–2.35) 0.027 1.73 (1.12–2.66) 0.013
0 (1.03–2.21) 0.037 1.56 (1.06–2.31) 0.026
5 (0.30–1.41) 0.271 0.84 (0.36–1.98) 0.689
7 (0.61–1.52) 0.878 1.03 (0.65–1.66) 0.890
0 (0.63–1.30) 0.573 0.99 (0.68–1.44) 0.957
0 (0.63–1.29) 0.575 0.99 (0.68–1.44) 0.958
7 (0.29–1.55) 0.354 0.91 (0.36–2.30) 0.842
9 (0.56–1.40) 0.606 0.95 (0.59–1.52) 0.822
6 (0.60–1.25) 0.435 0.95 (0.65–1.39) 0.793
7 (0.60–1.25) 0.439 0.95 (0.65–1.38) 0.796
 by defining continuous variable with levels 1, 2, and 3 corresponding
; rs1063537 was coded as 1 for TT, 2 for CT, and 3 for CC). Dominant
 0 otherwise. Recessive model was coded as 1 for the homozygous
sure (140/90, <140/90mm Hg), HbA1C, triglyceride, and use of ACEI
for baseline menopause status (pre-, post-menopause).
Fig. 2 – Estimates of diabetic nephropathy event-free survival by the Kaplan–Meier method. Survival probabilities were
estimated under recessive model of ADIPOQ polymorphisms (A) rs2241766 and (B) rs1063537, stratified by gender.
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associated with the development of DN under the allelic,
additive and recessive models among males (data not shown).
In females, ADIPOQ SNPs were not associated with DN
progression. We did not find an association between meno-
pause status and DN in either uni- or multi-variate model,
although sex hormone might be one plausible explanation of
the gender difference in the development of DN.
Study power of a genetic association largely relies on the
frequencies of risk allele and the prevalence of disease of
interest. Due to a high frequency of risk allele at approximately
0.7 and a high prevalence of DN in T2D of at least 30%, our
sample size of male patients was calculated to have a power of
85.9–89.7% to detect an HR of 1.81–1.89 for DN under the
recessive model at a level of 0.05. Additionally, the association of
rs2241766 and rs1063537 with the risk of DN found in the
prospective design was replicable in case–control design using
multivariate logistic regression models (Supplemental Table 2).
3.5. Levels of plasma adiponectin
The mean plasma adiponectin concentration in our study was
6.9  6.0 ng/ml. Patients with nephropathy had slightly higher
concentrations than those without nephropathy (7.5  7.0 vs.
6.7  5.6 ng/ml, p = 0.318), but the differences did not reach
statistical significance (Table 1). The adiponectin concentra-
tions in females were significantly higher than in males ineither nephropathy (8.7 vs. 6.3 ng/ml, p < 0.001) or non-
nephropathy groups (8.1 vs. 5.0 ng/ml, p = 0.005). We also
found that post-menopausal women had a higher level of
circulating adiponectin than pre-menopausal women (9.3 vs.
6.3 ng/ml, p < 0.001, data not shown).
4. Discussion
In this cohort of Taiwanese T2D patients, we found the
rs2241766 (+45T>G) TT, rs1063537 CC, rs2241767 AA and
rs2082940 CC recessive homozygotes of the ADIPOQ to be
associated with a greater risk for progression to DN in male
T2D patients but not in females over a 6 year follow-up period.
Males carrying these recessive homozygotes also had a
reduced nephropathy-free survival rate. These four SNPs in
our sample were highly correlated (r2 > 0.8), as they have also
been reported among Europeans [25].
Only two prospective studies to date have found an
association between +45T>G and DN risk in T2D. The +45G
allele was associated with an increased risk of incident renal
event in the French population [26], and the GG genotype of
+45T>G was associated with DN in Korean patients [27]. The
findings of both studies were inconsistent with ours as we
found that +45T allele or TT genotype carriers had a greater
risk for DN progression. This discrepancy may be partially
explained by differences in ethnic backgrounds. The
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 5 ( 2 0 1 4 ) 2 6 1 – 2 7 0268mechanisms underlying the association of +45T>G polymor-
phisms with DN progression in the Taiwanese or Chinese
population remain to be determined. Other case–control
studies carried out among European T1D patients showed
that SNPs in the promoter region, not in the exon region
(+45T>G), may confer susceptibility to the risk of DN [14,15,17].
Among studies of Han-Chinese populations, only one Taiwa-
nese case–control study found that a potential interaction
among ADIPOQ (11377C>G), GHSR and TCF7L2 might contrib-
ute to the risk of DN in T2D, though no single ADIPOQ genetic
effect was found [16]. Most of previous studies [14–19] were
performed using case–control designs and only analyzed a few
common SNPs. The present study represents one of the few
prospective investigations in the Chinese population examin-
ing the association between ADIPOQ genetic variations and the
progression of DN with a wide selection of 18 ADIPOQ SNPs.
In the Chinese population, there has been extensive
investigation of the association of +45T>G polymorphism
with metabolic disease and CVD. A few Taiwanese studies
have associated the mutant G allele at +45T>G with improved
insulin sensitivity [28] and reduced risks of obesity [29] and
coronary artery disease [30]. These findings suggest that +45G
allele may confer a protective effect against metabolic disease
and CVD in the Taiwanese population. On the other hand, in
other regions of China, meta-analysis studies have reported
that the G allele does not consistently show protective effects
on metabolic syndrome [31], T2D [22], or CVD [32]. These
contrasting results in different regions of Chinese might be
explained by regional variations and different study methods
including diagnostic criteria, sample size, and study design.
Gender is another important factor to consider in DN
development since males have a more rapid progression to
this complex disease than females [7]. The ratio is about 1.3:1
[33]. In the present study, the ADIPOQ associated risk for DN
was only found in males, but not in females. However, Zhang
et al. [14,15] reported that European female T1D patients, but
not males, had ADIPOQ genetic risk for DN. One Japanese study
also reported gender differences in the association of ADIPOQ
but with T2D in male subjects [34]. Considering gender factor
into genetic research seems to be more complicated, and the
effects are not universal in different populations. Besides
genetic factor, other factors such as differences in diet,
nephron number or renal mass and the direct/potential
effects of sex hormone may also explain the gender
predisposition in the development of kidney disease [7].
Estrogens may confer protective effect on kidney disease as a
result of its potent antioxidant actions in the mesangial
microenvironment [6]. To date, many studies are still
accumulating evidence to address the questions of gender
and ethnic disparities and to elucidate the biological mecha-
nisms underlying gene–gender interactions in such a complex
disease.
Increased concentrations of circulating adiponectin have
been found in patients with ESRD and DN [11–13]. In the
present study, we did not observe a statistically significant
difference in adiponectin concentrations between DN and
non-DN groups. This could be explained by the finding that
most of our T2D patients were in early stage of kidney disease
(over 90% of patients with a glomerular filtration rate 60 ml/
min/1.73 m2 at baseline). Due to the beneficial effects ofadiponectin, an increase in its concentrations among patients
with kidney disease may result from the physiological counter
regulatory response which is up-regulated to reduce endothe-
lial damage and renal insufficiency, and which could contrib-
ute to the development of secondary resistance to adiponectin
[11,13]. In addition, we found an increased circulating
adiponectin level in post-menopausal females. This could
also be explained by adiponectin resistance or reduction in
adiponectin clearance associated with renal function decline
after menopause [35].
The +45T>G polymorphism, a synonymous mutation
(Gly ! Gly) in the exon region, may affect expression levels
of adiponectin by altering pre-mRNA splicing [36]. One
possible explanation for the absence of an association of
+45T>G or other SNPs with circulating adiponectin in the
current study is that a large variation of adiponectin
concentrations in our DN patients. One Taiwanese study
found that the +45G allele was associated with a reduced risk
of obesity as it led to increased mRNA expressions in omental
adipose tissue [29]. In our study, we also found that patients
carrying +45 GG genotype had higher circulating adiponectin
levels than GT + TT carriers, although the difference did not
reach statistical significance. However, one European study
showed that +45G allele carriers had a greater risk of renal
event resulting from high adiponectin concentrations in this
group [26]. The ADIPOQ genetic mechanisms in the mRNA
expression and adiponectin production remain largely un-
known in patients with kidney disease.
The strength of the present study was its prospective
design. The study is limited in that it had a relatively small
sample size when further stratified by gender. However, the
results found in males did reach 80% of power and were
reproducible in the case–control analysis. Another limitation
is that the genetic association found in this study may not be
generalized to other ethnic groups. Larger ethnically matched
studies might help clarify whether this genetic association can
be found in other Asian and Chinese populations.
In conclusion, this study provides evidence that the
rs2241766 (+45T>G), rs1063537, rs2241767 and rs2082940
polymorphisms in the ADIPOQ are associated with the
progression of DN in Taiwanese male patients with T2D.
Whether gender plays some roles in the association between
ADIPOQ genetic variations and the development of DN
warrants further investigations in different ethnic popula-
tions.
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4.3 Supplementary materials for online publication 
Table 4.1 Gender-stratified analysis of genotype and allele distribution of ADIPOQ polymorphisms 
in type 2 diabetic patients with and without nephropathy (case-control design n=842, males=396) 
Gender SNPs Genotype DN Non-DN P-value OR (95% CI) P-value 
Male rs2241766  GG 10 (4.9) 18 (9.3) 0.006 1.00  
  GT 80 (39.4) 97 (50.3)  1.49 (0.65-3.40) 0.350 
  TT 113 (55.7) 78 (40.4)  2.61 (1.14-5.95) 0.023 
  T allele 306 (75.4) 253 (65.5) 0.002 1.61 (1.18-2.19) 0.003 
 rs1063537  TT 9 (4.4) 19 (9.8) 0.002 1.00  
  CT 78 (38.4) 95 (49.2)  1.73 (0.74-4.05) 0.203 
  CC 116 (57.1) 79 (40.9)  3.10 (1.33-7.20) 0.009 
  C allele 310 (76.4) 253 (65.5) 0.001 1.70 (1.24-2.32) 0.001 
Female rs2241766  GG 16 (7.4) 12 (5.2) 0.552 1.00  
  GT 88 (40.6) 89 (38.9)  0.74 (0.33-1.66) 0.466 
  TT 113 (52.1) 128 (55.9)  0.66 (0.30-1.46) 0.306 
  T allele 314 (72.4) 345 (75.3) 0.312 0.86 (0.64-1.16) 0.312 
 rs1063537  TT 15 (6.9) 11 (4.8) 0.366 1.00  
  CT 89 (41.0) 85 (37.1)  0.77 (0.33-1.77) 0.534 
  CC 113 (52.1) 133 (58.1)  0.62 (0.28-1.41) 0.257 
  C allele 315 (72.6) 351 (76.6) 0.164 0.81 (0.60-1.09) 0.164 
Data are presented as n (%) and OR (95% CI). Abbreviations: SNP, single nucleotide polymorphism; DN, diabetic 
nephropathy. 
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Table 4.2 Gender-stratified analysis of association between ADIPOQ polymorphisms and DN 
under different genetic models (case-control design n=842, males=396) 
Gender SNPs Genetic models Crude model Adjusted model 
1
 
   OR (95% CI) P-value OR (95% CI) P-value 
Male rs2241766  Dominant (GT+TT vs. GG)  1.99 (0.89-4.42) 0.093 1.58 (0.63-3.95) 0.328 
  Recessive (TT vs. GT+GG) 1.85 (1.24-2.76) 0.002 1.83 (1.16-2.90) 0.010 
  Additive (GG/GT/TT) 1.69 (1.22-2.34) 0.002 1.62 (1.11-2.36) 0.013 
  Allele (T vs. G)  1.61 (1.18-2.19) 0.003 1.53 (1.08-2.17) 0.018 
 rs1063537 Dominant (CT+CC vs. TT) 2.35 (1.04-5.34) 0.041 1.99 (0.78-5.08) 0.148 
  Recessive (CC vs. CT+TT) 1.92 (1.29-2.87) 0.001 2.02 (1.27-3.20) 0.003 
  Additive (TT/CT/CC) 1.78 (1.28-2.47) 0.001 1.80 (1.23-2.63) 0.003 
  Allele (C vs. T) 1.70 (1.24-2.32) 0.001 1.68 (1.18-2.39) 0.004 
Female rs2241766  Dominant (GT+TT vs. GG) 0.70 (0.32-1.50) 0.355 0.79 (0.35-1.78) 0.567 
  Recessive (TT vs. GT+GG) 0.86 (0.59-1.25) 0.418 0.93 (0.62-1.38) 0.702 
  Additive (GG/GT/TT) 0.85 (0.63-1.16) 0.305 0.92 (0.66-1.27) 0.591 
  Allele (T vs. G)  0.86 (0.64-1.16) 0.312 0.92 (0.67-1.26) 0.594 
 rs1063537  Dominant (CT+CC vs. TT) 0.68 (0.31-1.51) 0.345 0.79 (0.34-1.83) 0.578 
  Recessive (CC vs. CT+TT) 0.78 (0.54-1.14) 0.203 0.82 (0.55-1.22) 0.327 
  Additive (TT/CT/CC) 0.80 (0.59-1.09) 0.158 0.84 (0.61-1.17) 0.309 
  Allele (C vs. T) 0.81 (0.60-1.09) 0.164 0.85 (0.61-1.17) 0.313 
Data are presented as OR (95% CI). Additive genetic effects were modelled by defining continuous variables with 
levels 1, 2, and 3 corresponding to genotypes (i.e. rs2241766 was coded as 1 for GG, 2 for GT, and 3 for TT; rs1063537 
was coded as 1 for TT, 2 for CT, and 3 for CC). Dominant model was coded as 1 for any genotype that contained the 
disease allele and 0 otherwise. Recessive model was coded as 1 for the homozygous disease genotype and 0 otherwise.  
Abbreviation: SNP, single nucleotide polymorphism. 
1
 Adjusted model: diabetes duration, education (≤6, >6 years), blood pressure (≥140/90, <140/90mmHg), HbA1C, 
triglycerides, and use of ACEI or ARB (yes, no) at baseline. Baseline menopause status (pre-, post-menopause) was 
adjusted for in female patients. 
 
 
4.4 Additional analyses  
Genotype frequencies compared with the reference Chinese population  
We determined the genotype frequencies of the 18 ADIPOQ SNPs in this diabetic cohort (total 
n=842). In our population, the G to A polymorphism of SNP rs17300539 (-11391 G>A) was not 
found, which is comparable to the reference Han Chinese population in the HapMap database. 
However, in the European population, the -11391 variant A allele was found to be associated with 
DN.
18
 Approximately 8% of the European was found to be carrying this variant allele, which 
indicates an ethnic-specific effect. The genotype frequencies of the other 17 remaining SNPs were 
all comparable to the reference Han Chinese population in the HapMap database (Table 4.3). The 
observed genotype frequencies were consistent with Hardy-Weinberg equilibrium in this diabetic 
population (p>0.05), except for rs822394, rs1501299, rs3821799, rs3774261, and rs6773957. 
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Table 4.3 Genotype frequencies of ADIPOQ SNPs in Taiwanese adults with type 2 diabetes 
(n=842) compared with that in the Han Chinese population based on the HapMap database  
SNP Genotype  Frequency  Hardy-Weinberg HapMap reference 
1
 
  N (%) equilibrium HCB/CHB CHD 
rs4632532  TT 250 (29.8) 0.205 - - 
 CT 433 (51.5)  - - 
 CC 157 (18.7)  - - 
rs16861194 AA 590 (70.1) 0.941 0.689 0.671  
 AG 230 (27.3)  0.289  0.306  
 GG 22 (2.6)  0.022  0.024  
rs17300539  GG 842 (100.0) - 1.000  - 
 GA 0 (0.0)  0.000  - 
 AA 0 (0.0)  0.000  - 
rs266729  CC 568 (67.5) 0.050 0.511  - 
 CG 257 (30.5)  0.378  - 
 GG 17 (2.0)  0.111  - 
rs182052  GG 275 (32.7) 0.150 0.244  0.306  
 AG 430 (51.1)  0.578  0.494  
 AA 137 (16.3)  0.178  0.200  
rs16861205  GG 590 (70.1) 0.890 0.644  0.682  
 AG 229 (27.2)  0.333  0.294  
 AA 23 (2.7)  0.022  0.024  
rs822394  CC 625 (74.2) 0.018 0.800  0.762  
 AC 210 (24.9)  0.200  0.238  
 AA 7 (0.8)  0.000  0.000  
rs822396  AA 632 (76.6) 0.094 0.791  0.765  
 AG 186 (22.5)  0.209  0.235  
 GG 7 (0.8)  0.000  0.000  
rs12495941  GG 295 (35.0) 0.258 0.378  - 
 GT 420 (49.9)  0.489  - 
 TT 127 (15.1)  0.133  - 
rs7627128  CC 513 (60.9) 0.377 0.605  0.588  
 AC 294 (34.9)  0.326  0.365  
 AA 35 (4.2)  0.070  0.047  
rs2241766  TT 432 (51.3) 0.144 - - 
 GT 354 (42.0)  - - 
 GG 56 (6.7)  - - 
rs1501299  GG 434 (51.5) 0.033 0.442  0.459  
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 GT 358 (42.5)  0.465  0.400  
 TT 50 (5.9)  0.093  0.141  
rs2241767 AA 441 (52.4) 0.192 0.533  0.518  
 AG 347 (41.2)  0.378  0.388  
 GG 54 (6.4)  0.089  0.094  
rs3821799  TT 276 (32.8) 0.010 0.378  0.376  
 CT 443 (52.6)  0.444  0.518  
 CC 123 (14.6)  0.178  0.106  
rs3774261 AA 241 (28.6) 0.028 0.378 0.376  
 AG 448 (53.2)  0.444 0.506  
 GG 153 (18.2)  0.178 0.118  
rs6773957  AA 242 (28.7) 0.047 0.378  0.376  
 AG 445 (52.9)  0.444  0.506  
 GG 155 (18.4)  0.178  0.118  
rs1063537  CC 441 (52.4) 0.192 0.535  0.500  
 CT 347 (41.2)  0.372  0.405  
 TT 54 (6.4)  0.093  0.095  
rs2082940  CC 439 (52.1) 0.127 0.535 0.518  
 CT 350 (41.6)  0.372 0.388  
 TT 53 (6.3)  0.093 0.094  
1
 National Centre for Biotechnology Information (NCBI) website: http://www.ncbi.nlm.nih.gov/, the data were 
referred to the data in July, 2014. HCB= Han Chinese in Beijing, China, CHD= Chinese in Metropolitan Denver, 
Colorado, USA 
 
 
ADIPOQ polymorphisms and circulating adiponectin  
Figure 4.1 shows the concentrations of plasma adiponectin among genotypes of rs2241766 and 
rs1063537 polymorphism stratified by nephropathy status and gender. Adiponectin levels were 
adjusted for age, diabetes duration, and body mass index (BMI) (using ANCOVA analysis). For 
rs2241766, there were no significant genetic effects or gene-gender interaction to affect circulating 
adiponectin in either nephropathy (p=0.530, p-int=0.279 respectively) or non-nephropathy groups 
(p=0.763, p-int=0.545 respectively). Similarly, no association was found for rs1063537. It is noted 
that females had significantly higher concentrations of adiponectin than men regardless of 
nephropathy status and genotypes (all p<0.01). There is strong evidence that adiponectin levels are 
higher in women than in men regardless of body fat distribution.
242
 This could be explained by the 
fact that androgens decrease circulating adiponectin.
243 
Because the standard deviation of 
adiponectin was quite large and the distribution of adiponectin was skewed in our diabetic patients, 
we also conducted quantile regression analyses to examine whether nephropathy status, ADIPOQ 
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polymorphisms or gender are related to high adiponectin levels (quantile 75). The model also 
adjusted for age, diabetes duration and BMI. Similar results were found where only gender had a 
significant association with adiponectin (p<0.001), while no association was found for nephropathy 
status (p=0.242) or rs2241766 genotype (p=0.347). We have therefore suggested that in this 
diabetic population, ADIPOQ genetic variations may not directly regulate circulating adiponectin. 
 
Inconsistent associations of ADIPOQ genetic variations with adiponectin production and metabolic 
outcomes could be due to environmental interactions, especially dietary factors.
14
 ADIPOQ 
polymorphisms may interact with dietary fat and plasma fatty acids to modulate insulin 
resistance,
15,244
 which is one of the critical predictors of the development of DN.
236
 To date, the 
complex gene-diet or gene-nutrient interactions among type 2 diabetes remain largely unknown.     
 
 
  
Figure 4.1 Plasma adiponectin concentrations among genotypes of rs2241766 and rs1063537 
polymorphisms stratified by DN and gender.  
 
 
Haplotype analysis in males 
Haplotypes are the particular combinations of specific alleles observed in a population.
245
 From 
Gabriel et al (2002),
245
 a haplotype block, based on 95% confidence bounds on r
2
 and D prime 
values,
245
 represents a region with a paucity of haplotype diversity, separated by recombination 
hotspots. Haplotypes with a frequency of >5% were included for association analyses using 
Haploview version 4.2 (Broad Institute, Cambridge, MA, USA). In the prospective study design, 
three haplotype blocks were defined in the male population based on their r
2
 and D prime values 
(n=263) (Fig, 4.3, 4.4).  
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Figure 4.2 Position and linkage disequilibrium (LD) plot generated by the 17 ADIPOQ 
polymorphisms genotyped in males (n=263), with pairwise (A) r2 and (B) D prime values and 
colour scheme. 
(A) Pairwise r2 ≥0.8 are shown by black colour 
(B) Pairwise D prime ≥0.8 are shown by red colour 
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Male subjects carrying haplotype G-G-G-T-A-A-T-T (rs2241766 G- rs1501299 G- rs2241767 G- 
rs3821799 T- rs3774261 A- rs6773957 A- rs1063537 T- rs2082940 T) were less likely to progress 
to DN, although statistical significance was marginal (DN: 25.0% vs. non-DN: 32.9%, p=0.083) 
(Table 4.4). This was consistent with our findings that males carrying rs2241766 G, rs2241767 G, 
rs1063537 T, and rs2082940 T alleles had a lower hazard of DN progression.  
 
Table 4.4 Common haplotypes of ADIPOQ polymorphisms in male subjects (n=263) 
Haplotypes Frequency DN Non-DN p-value 
    Block 1     
        T-A 0.581 0.585 0.580 0.909 
        C-A 0.271 0.265 0.273 0.857 
        C-G 0.146 0.142 0.147 0.894 
    Block 2     
        C-A-G 0.420 0.414 0.438 0.630 
        C-A-T 0.432 0.393 0.430 0.445 
        A-G-G 0.140 0.185 0.124 0.076 
    Block 3     
        T-G-A-C-G-G-C-C 0.386 0.436 0.368 0.158 
        G-G-G-T-A-A-T-T 0.308 0.250 0.329 0.083 
        T-T-A-T-A-A-C-C 0.241 0.271 0.230 0.333 
Haplotype blocks 1, 2, and 3 were based on Figure 4.2. Haplotypes with frequencies <5% were not included.  
 
 
4.5 Chapter conclusion   
The present prospective study revealed that ADIPOQ polymorphisms rs2241766 (+45T>G), 
rs1063537, rs2241767, and rs2082940 were associated with the progression of albuminuria over a 
six-year follow-up period in male but not in female Taiwanese patients with type 2 diabetes. 
Patients with albuminuria, and female patients, tended to have higher concentrations of plasma 
adiponectin, although the difference between DN and non-DN did not reach statistical significance. 
ADIPOQ polymorphisms did not regulate circulating adiponectin in this cohort of diabetic patients. 
Our results suggest that there may be gender differences in ADIPOQ genetic risk for the 
progression of albuminuria in the Taiwanese population. Larger ethnically-matched longitudinal 
studies are needed to clarify this association in other Asian and Chinese populations.  
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Chapter 5: Association of dietary patterns with albuminuria and kidney 
dysfunction in Taiwanese patients with type 2 diabetes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been submitted to Journal of Nutrition.  
 
  
Chung HF, Hsu CC, Mamun A, Long K, Huang YF, Shin SJ, Hwang SJ, Huang MC. Association 
of dietary patterns with albuminuria and kidney function in Taiwanese patients with type 2 diabetes. 
J Nutr (submitted on 14 Dec 2014). 
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5.1 Chapter introduction 
Study objectives 
Primary:  
1. To generate major dietary patterns in Taiwanese adults with type 2 diabetes at each time 
point 
2. To examine the association of dietary patterns with albuminuria and kidney dysfunction in 
the diabetic population using repeated measures data 
Secondary: 
3. To evaluate the identified dietary patterns with nutrient biomarkers (erythrocyte fatty acids) 
using cross-sectional data from 2008 
4. To examine the correlations between dietary patterns and inflammatory biomarkers using 
cross-sectional data from 2008 
 
Outline of the study 
 
 
 
 
 
 
 
 
 Study design: a three-year follow-up cohort study from 2008 to 2010, n=929  
 Exclusion criteria: patients who reported an implausible energy intake (<500 or >5000 kcal/day) 
 Statistical analysis:  
1) factor analysis  
2) generalized estimating equation (GEE) model 
 
 
 
 
 
 
2008, 2009, 2010
0 
 2008, 2009, 2010 
2008 2008 
2008, 2009, 2010 
Dietary patterns  
(unhealthy, healthy) 
 
Albuminuria 
(ACR≥30) 
Kidney dysfunction 
(creatinine, eGFR<60)  
 
 
Inflammation 
(adiponectin, IL-6, CRP) 
 
Fatty acids  
(SFA, PUFA) 
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5.2 Submitted manuscript  
Background & Objective: A Western diet has been linked with an increased risk of kidney disease 
in the Western general population. However, little is known about the association between dietary 
patterns and kidney disease among the Chinese population with type 2 diabetes.  
Methods: A cohort of 929 Taiwanese adults with type 2 diabetes was followed up in 2008, 2009, 
and 2010 surveys. Albuminuria (albumin-to-creatinine ratio, ACR ≥30 mg/g) and kidney 
dysfunction (elevated creatinine ≥1.5 for men or ≥1.2 mg/dL women or decreased estimated 
glomerular filtration rate, eGFR <60 ml/min/1.73m
2
) were defined at each year. Using factor 
analysis, three major dietary patterns were identified across surveys: the high fat-meat pattern, 
traditional Chinese food-snack pattern, and fish-vegetable pattern. Factor scores for each pattern 
were categorized into quartiles. Generalized estimating equation (GEE) models for repeated 
measures were performed to analyse the associations. Erythrocyte fatty acid was measured as a 
nutrient biomarker in the 2008 survey.  
Results: In 2008, 36.0% of these diabetic patients had albuminuria, and 13.8% had decreased 
eGFR. Patients consuming the highest quartile (Q4) of fish-vegetable pattern were found to have a 
significantly reduced risk of elevated creatinine (adjusted OR=0.76, 95% CI:0.60-0.98, p-
trend=0.004) and decreased eGFR (OR=0.75, 95% CI:0.58-0.97, p-trend=0.04) compared to those 
whose consumption was in the lowest quartile (Q1) of this dietary pattern. No association was 
observed for albuminuria. Those in the highest quartile also had highest levels of erythrocyte n-3 
polyunsaturated fatty acids (PUFAs) (Q4:11.48% vs. Q1:10.26%, p<0.001). The high fat-meat and 
traditional Chinese food-snack patterns, on the other hand, were not associated with any of the renal 
outcomes after adjustments.  
Conclusions: Fish-vegetable dietary pattern had a beneficial effect on kidney dysfunction in 
Taiwanese patients with type 2 diabetes, but not on albuminuria. The greater erythrocyte n-3 PUFA 
status among patients adhering to fish-vegetable diets suggests that this dietary pattern could be 
evaluated by nutrient biomarker to elaborate the disease risk. 
 
Key words: albuminuria; dietary pattern; kidney dysfunction; n-3 fatty acid; type 2 diabetes  
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Introduction  
Chronic kidney disease (CKD) is the leading cause of kidney failure and cardiovascular disease 
(CVD) (1). It is clinically characterized by kidney damage (measured by albuminuria) and kidney 
dysfunction (decreased estimated glomerular filtration rate, eGFR). Patients with type 2 diabetes 
have a faster renal function decline rate than individuals without diabetes, even when albuminuria is 
not present (2). With the expected increases in the prevalence of type 2 diabetes and hypertension, 
the two most common leading causes of CKD, the prevalence of CKD is projected to rise 
dramatically over the next two decades (3). Therefore, identifying modifiable lifestyle factors, such 
as diet, that might prevent or delay the progression of CKD has become increasingly important, 
especially among diabetic patients.  
 
Many studies have investigated the association of specific foods and nutrients, including protein (4, 
5), fat (6), and micronutrients (7, 8), with the risk of kidney disease. Recently, dietary pattern 
analysis has become a complementary approach to examine the diet-disease association because it 
can generate food intake patterns based on actual foods consumed within a particular population 
without a priori hypothesis (9). The Western-style diet increases the risk of albuminuria and 
impaired kidney function (10, 11), while the Dietary Approach to Stop Hypertension (DASH) diet 
(10) and Mediterranean diet (12) improve kidney function. Findings from studies investigating 
these diets are limited to healthy populations or Caucasian women. To date, it remains unclear how 
dietary patterns affect the risk of CKD in patients who have been diagnosed with type 2 diabetes, 
and who therefore may have already changed, or be planning to change their diets. Moreover, 
Asian-style diets (e.g. Chinese and Japanese diets), rich in plant foods (vegetables and soy products) 
and white rice, are quite different from the Western-style diet. Thus, this study aimed to investigate 
the association of dietary patterns with albuminuria and kidney dysfunction in a cohort of 
Taiwanese patients with type 2 diabetes using three years of repeated measures of dietary and renal 
data. We also evaluated the erythrocyte fatty acid content of these dietary patterns as erythrocyte 
fatty acid has been widely used as a nutrient biomarker to reflect long-term intake of dietary fats 
and long-term changes in food compositions (13).   
 
Materials and Methods  
Study population 
Our study cohort included type 2 diabetic patients aged 30-70 years who had participated in the 
Diabetes Management through an Integrated Delivery System (DMIDS) project in Taiwan. Patients 
were a representative sample recruited from five medical centres and 36 clinics in northern, middle, 
and southern Taiwan. Details of the study design and inclusion criteria for original cohort have been 
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previously published (14). Briefly, 1209 patients were enrolled during the baseline recruitment 
period from 2003 to 2005. The first dietary data were collected in 2008, so the present study is 
limited to participants with complete sets of dietary and renal data obtained from the 2008, 2009, or 
2010 examinations (n=846, 867, and 798, respectively). Spot urine and fasting (≥8 hours) venous 
blood samples were collected for each of these examinations. We excluded patients who reported 
implausible energy intakes (<500 or >5000 kcal/day) (n=8, 40, 13 in each year), leaving us with a 
total of 929 patients who had completed at least one examination (n=838, 827, 785 in each year) 
over the three-year follow-up period. Patients who did not complete examinations tended to be 
older, had poorer glycemic control, and more advanced kidney disease (all p<0.05, data not shown) 
compared to those who did complete the examinations. This could result in an underestimation of 
our renal outcomes. The protocol for the present project was approved by the ethics committees of 
the National Health Research Institutes and Kaohsiung Medical University Hospital, Taiwan. All 
participants provided written informed consent. 
 
Dietary assessment  
Diet was assessed using a short semi-quantitative food frequency questionnaire (FFQ). The FFQ, 
which was developed for use with Chinese adults in Taiwan, has 45 questions on the consumption 
of foods belonging to various groups, serving sizes, and eating habits. Since very few dietary 
assessments are currently available for Chinese or Asian populations, the food groups and items 
used in the FFQ to assess dietary intakes for Chinese adults are shown in Table 5.1. Details of the 
dietary assessment have been previously reported (15). Briefly, we assessed specific food groups 
frequently consumed in a Chinese population including soy products, processed wheat/gluten 
products, pickled vegetables, Chinese staple, low nitrogen staple, and starchy foods etc. Participants 
were asked to report their average frequency of consumption of food groups over the previous 12 
months, with six frequency options ranging from “almost never” to “one or more times per day” for 
most food groups. Some food groups (e.g. eggs, milk and yogurt, fresh fruit, Chinese staple, and 
bread etc.) were recorded as usual portion sizes consumed per day. For the dietary pattern analysis, 
frequency of consumption of each food group was converted to weekly equivalents (e.g. times or 
portions per week).    
 
Assessment of nutrient biomarker  
Erythrocyte lipids were extracted in 2008 (n=805) according to a modified Bligh and Dyer method 
(16) and were derivatized to fatty acid methyl esters (FAMEs) using boron trifluoride-methanol. 
Details on the measurement of fatty acids have been previously published (17). Briefly, the FAMEs 
were extracted by hexane and then analysed using a Hewlett-Packard 6890N gas chromatography-
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flame ionization detector, GC-FID (Agilent Technologies, Santa Clara, CA, USA) equipped with a 
DB-225 capillary column (30m × 0.25mm inner diameter × 0.25μm film) and with N2 as the carrier 
gas. An equal weight FAME mixture (68A; Nu-Chek-Prep, Elysian, MN, USA) was used to 
generate response factors. The C17:0 was added as an internal standard to calculate quantitative 
profiles of erythrocyte fatty acids. Fatty acid levels were expressed as weight % of total fatty acids.  
 
Measurement of albuminuria and kidney dysfunction 
Urinary creatinine was determined by the Jaffe reaction method, and urinary albumin was measured 
by immunoturbidimetry using the Hitachi 7060 analyzer (Hitachi High Technologies, Tokyo, 
Japan). A urinary albumin-to-creatinine ratio (ACR) ≥30 mg/g was used to define albuminuria.1 
Serum creatinine was analyzed using the Jaffe reaction. GFR was estimated by the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) equation, which is calculated based on serum 
creatinine, age, sex and a four-level race variable (Black, Asian, Hispanic and Native American, or 
White and other) (18). A decreased eGFR of <60 mL/min/1.73m
2
 was used to define kidney 
dysfunction.
1 
We also defined an elevated serum creatinine of ≥1.5 mg/dL for men or ≥1.2 mg/dL 
for women as clinically significant kidney insufficiency or impairment (19, 20). These gender-
specific cut-off points for creatinine have been described as being equivalent to an insulin clearance 
of <60 mL/min (20).  
 
Assessment of covariates 
Age, sex, diabetic duration, and education level (≤6y, >6y) were assessed at the first examination. 
At each follow-up examination, lifestyle factors including smoking, alcohol consumption, and 
exercise were assessed using self-reported questionnaires. Patients were asked whether they were 
currently smoking cigarettes (yes, no), drinking alcohol at least once a week during the previous six 
months (yes, no), and getting exercise within the last two weeks (yes, no). Weight, height, and three 
blood pressure measures were taken by trained research personnel. Body mass index (BMI) and 
average blood pressure were calculated. Hypertension was defined as systolic blood pressure ≥140 
mmHg or diastolic blood pressure ≥90 mmHg, or self-reported use of antihypertensive medications. 
Hemoglobin A1C (HbA1C) was assessed using high-performance liquid chromatography (G7; 
Tosoh, Kobe, Japan), and triglycerides were assessed using an auto-analyser (LX20; Beckman 
Coulter, Fullerton, CA, USA). Additionally, for each food group, the average serving sizes of foods 
consumed per day by the patient were determined, and daily energy intakes were calculated.    
 
Statistical analysis   
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Pearson chi-squared tests and student t-tests were used to compare differences between groups. 
Factor analysis (posteriori method) was chosen to identify dietary patterns since there is no clear 
pre-existing evidence of how dietary patterns among diabetic or Asian population may influence the 
risk of kidney disease. We previously identified three dietary patterns using the data from the 2008 
FFQ (15), and labelled them as high fat-meat pattern, traditional Chinese food-snack pattern, and 
fish-vegetable pattern. For the present factor analysis, we used principal component extraction and 
varimax rotation to generate uncorrelated factors, which we called dietary patterns. Food items with 
a loading of ≥0.3 were considered important contributors to the dietary pattern. A factor score for 
each identified pattern for each patient was calculated by multiplying food items with their 
corresponding factor loadings and summing these values. The factor scores were then categorized 
into quartiles to rank individuals by degree of adherence to the patterns, and the lowest quartile was 
used as the reference group. ANOVA and post-hoc tests (LSD) were performed to evaluate 
associations between identified dietary patterns (factor score quartiles) and erythrocyte fatty acids 
measured in 2008. The correlation between individual food groups (e.g. marine fish and freshwater 
fish) and fatty acids were tested by Spearman’s correlation.   
 
Generalised estimating equation (GEE) models (logit link function) were used to examine the 
association between dietary pattern quartiles and kidney disease due to its ability to handle repeated 
measures data and to reduce some degree of misclassification. This model takes into account the 
dependency (correlation) of observations within each subject by specifying a working correlation 
structure (21). We applied the exchangeable correlation structure in the current analysis. The GEE 
model also makes better use of all available data, and handles missing values and time-dependent 
(time-varying) covariates, so it generally produces a more powerful and efficient estimate. 
Multivariable models were adjusted for a range of time-varying covariates including age, energy 
intake, diabetes duration, time points, lifestyle factors (current smoker, drinking habit, exercise 
habit, and BMI), and biological mediators (hypertension, HbA1c, and triglycerides). Sex and 
education were the only time-independent covariates. We further used nptrend (an extension of the 
Wilcoxon rank-sum test in Stata) to test for trend across the dietary pattern quartiles. A two-sided p-
value <0.05 was considered significant. Statistical operations were performed using SPSS (version 
22.0, SPSS Inc., Chicago, IL, USA).  
 
 
Results 
Baseline characteristics  
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Characteristics of the 838 diabetic patients in 2008 are shown in Table 5.2. The mean age was 59.5 
years, average diabetes duration was 8.9 years, and 47.5% of the subjects were male. Median ACR 
was 14.0 mg/g and the mean eGFR was 87.5 mL/min/1.73m
2
. The subjects with albuminuria had 
longer durations of diabetes and were more likely to have higher blood pressure, a higher BMI, and 
be taking anti-hypertensive medication (all p<0.01). They also had higher concentrations of HbA1C 
and triglycerides and lower levels of eGFR (p<0.001). Similarly, those with kidney dysfunction had 
longer durations of diabetes, were more likely to be hypertensive, and had higher serum 
triglycerides concentrations (all p<0.05); however, there were no differences in BMI. We also 
observed that they were older, less educated, and had higher ACRs (all p<0.05).   
 
Identification of dietary patterns 
The factor loading matrix for each dietary pattern is shown in Supplemental Table 5.5. Three 
dietary patterns were identified in each survey, and were similar to the patterns identified in our 
previous study (15). The high fat-meat pattern was characterized by high consumption of white and 
red meats, fatty meats and skin, fried foods, seafood, processed meats, eggs, canned meats, and 
frequent eating out. The traditional Chinese food-snack pattern was characterized by frequent intake 
of soy products, processed wheat/gluten products, low nitrogen staple foods, low calorie desserts, 
seeds and nuts, root vegetables, starchy/thickened soup and foods, pickled vegetables, and tea. The 
fish-vegetable pattern was characterized by high intake of light- and dark-coloured vegetables, 
freshwater aquaculture fish, and marine fish. These three patterns explained 25.9%, 24.9%, and 
24.7% of variance in 2008, 2009, and 2010, respectively.  
 
Dietary patterns and albuminuria  
In our study population, 36.0% (n=302) of patients had albuminuria in 2008, 40.1% (n=334) in 
2009, and 43.0% (n=339) in 2010. No significant association between dietary patterns and 
albuminuria was noted (Table 5.3). There was a marginally significant multivariable-adjusted 
association between the highest quartile of traditional Chinese food-snack pattern and lower risk of 
albuminuria, but this did not remain significant in the trend analysis.   
 
Dietary patterns and kidney dysfunction 
There were 13.8% (n=116) patients with eGFR<60 ml/min/1.73m
2
 in 2008, 16.2% (n=135) in 2009, 
and 15.0% (n=118) in 2010. The odds ratios for the associations between dietary patterns and 
kidney dysfunction are shown in Table 5.4. The high fat-meat pattern was not associated with any 
renal function outcomes. In the age- and energy intake-adjusted model, the traditional Chinese 
food-snack pattern was marginally associated with a lower risk of elevated creatinine (OR=0.79, 
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95% CI=0.62-1.02, p=0.07) and decreased eGFR (OR=0.80, 95% CI=0.62-1.03, p=0.08) when 
comparing the highest quartile (Q4) with the lowest quartile (Q1) of patients following this food 
pattern. The inverse effect on kidney dysfunction disappeared after multivariable adjustment.  
The fish-vegetable pattern was significantly associated with reduced risk of elevated creatinine and 
decreased eGFR. In the age-and energy intake-adjusted model, the ORs for elevated creatinine for 
Q1 to Q4 were 1.00, 1.01 (0.81-1.25), 0.76 (0.61-0.95), and 0.77 (0.61-0.97) (p-trend=0.003), and 
ORs for decreased eGFR for each of the quartiles (Q1-Q4) were 1.00, 0.81 (0.65-1.00), 0.81 (0.66-
1.00), and 0.76 (0.60-0.97) (p-trend=0.03). After adjusting for various potential confounders, 
including biological mediators, the fish-vegetable pattern remained significantly associated with 
better renal status, characterized by a lower risk of elevated creatinine (OR=0.76, 95% CI=0.60-
0.98, p-trend=0.004) and decreased eGFR (OR=0.75, 95% CI=0.58-0.97, p-trend=0.04), when 
comparing Q4 with Q1.    
 
Evaluation of dietary patterns  
We used erythrocyte n-3 PUFAs as a nutrient biomarker to evaluate the fish-vegetable pattern 
identified in this population (Fig. 5.1). We found that the highest quartile of fish-vegetable pattern 
scores had significantly higher levels of erythrocyte eicosapentaenoic acid (EPA), docosahexaenoic 
acid (DHA), total n-3 PUFA, as well as a higher n-3/n-6 PUFA ratio (Q4 vs. Q1, all p<0.001), but 
had a lower SFA/n-3 PUFA ratio (p<0.001). The results remained the same after controlling for age 
and energy intake. Correlations were higher between marine fish and n-3 PUFA than between 
freshwater fish and n-3 PUFA (r=0.47 vs.0.34, both p<0.001).  
 
Discussion  
This cohort study provides empirical evidence of an association between dietary pattern and the risk 
of kidney disease among an Asian population with type 2 diabetes. The results confirm the findings 
from our previously reported cross-sectional study (15), which found an association between dietary 
patterns and renal function indicators, using repeated measures data over three years. For patients 
with diabetes, adherence to the fish-vegetable dietary pattern was associated with a reduced risk of 
kidney dysfunction, but not with albuminuria. However, the high fat-meat pattern and the traditional 
Chinese food-snack pattern were not found to be associated with renal outcomes in this diabetic 
population after adjustments. This study provides clinically practical information regarding cut-off 
points for eGFR <60 mL/min/1.73m
2
, the most common manifestation of kidney dysfunction in 
clinical settings. We also found that patients with higher intake of fish, or fish-vegetable pattern, 
had greater levels of erythrocyte total n-3 PUFA and a higher n-3/n-6 PUFA ratio but a lower 
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SFA/n-3 PUFA ratio, suggesting that this fish-vegetable dietary pattern can be evaluated by nutrient 
biomarkers.  
 
The renoprotective effect of the fish-vegetable pattern found in this diabetic cohort is supported by 
a number of intervention trials studying diabetic patients (22-25). Clinical trials have reported that 
fish oil supplements improved albuminuria (22), renal function (23), and kidney injury (24), while a 
predominantly vegetarian diet reduced albumin excretion rate in diabetic patients (25). One trial 
also reported that adhering to a Mediterranean diet (rich in vegetables, fruit, fish, olive oil, and 
moderate red wine consumption) improved kidney function in subjects at high risk of CVD (>50% 
with type 2 diabetes) (26). Additional observational studies of diabetic patients suggest that higher 
daily fish intake (27), a reduced protein intake from animal sources, and an increased lipid intake 
from vegetable sources (28) would reduce the risk of albuminuria. Long chain n-3 PUFAs found in 
fish, and antioxidant vitamins and folic acid found in vegetables, might be important contributors to 
this pattern’s renoprotecive benefits (29).  
 
The biological mechanisms may be partially explained by the anti-inflammatory and anti-oxidative 
effects of n-3 PUFAs observed in animal models (30, 31). Treating early stage type 2 diabetic mice 
with EPA has been reported to improve their urinary ACR and attenuate mesangial matrix 
accumulation and tubulointerstitial fibrosis by mitigating renal inflammation, oxidative stress, and 
transforming growth factor beta (TGF-β) expression (30). In a chronic renal failure rat model, it was 
reported that n-3 PUFA supplementation reduced upregulation of pro-oxidant (NAD(P)H oxidase), 
pro-inflammatory (NF-κB activation, MCP-1), and pro-fibrotic (TGF-β) pathways, and resulted in 
the attenuation of tubulointerstitial injury and fibrosis in the remnant kidney (31). Our patients with 
higher intakes of fish or fish-vegetable pattern had higher levels of EPA, DHA, as well as total n-3 
PUFAs. Our previous study found that high n-3 PUFA concentrations attenuated the risk of renal 
function decline and modified the pro-inflammatory IL-6 effect on renal risk in type 2 diabetes (17). 
A moderate dose of n-3 PUFAs was also found to decrease IL-6 levels and its gene expression 
among patients at the later stages of CKD (32). It is important for future studies to investigate the 
relationship between vegetable-related nutrient biomarkers, such as folate and carotenoids (29), and 
disease to explore their roles as possible mechanisms.  
 
Prior studies have shown other healthy diets to be associated with a reduced risk of kidney disease, 
but those findings are limited to non-diabetic populations in Western countries (10, 12, 33). Healthy 
dietary patterns, such as the Mediterranean diet (12) and DASH diet (10) (characterized by a greater 
intake of vegetables, fruit, whole grains, low-fat dairy products, and low sodium), have been shown 
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to protect against kidney function decline among the general population. It should be noted that two 
large observational studies did not find a fish-vegetable pattern (33) or a prudent dietary pattern 
(10) to have a protective effect on either eGFR decline or albuminuria. Their findings, however, 
were found among the general population or older Caucasian women and so may not be 
generalizable to diabetic patients or non-Caucasian populations. Clinical trails or prospective 
studies with longer follow-up peroids are needed to confirm the protective effect of fish and 
vegetable intake on kidney disease in other Asian populations with or without diabetes.     
 
The high fat-meat dietary pattern was not significantly associated with any renal outcomes in this 
diabetic cohort. This pattern, rich in fat and meats, is comparable to a Western-style diet, which 
increases the risk of kidney disease (10, 11) and CVD (34). Our study enrolled diabetic patients 
who had participated in the DMIDS project where they had received nutritional education advising 
them to consume less saturated fats, salt, and sugar etc. for better glycemic control. In general, a 
Western-style diet induces dyslipidemia, oxidative stress, inflammation, hormonal disturbances, and 
fibrosis in the pathogenesis of CKD (11). Inflammation may be an important pathophysiologic link 
between poor diet and kidney disease (10). Two large-scale studies reported that diets high in fat 
and processed meat (e.g. a Western-style dietary pattern) were positively associated with IL-6 and 
CRP in non-diabetic populations (35, 36). Our results found that a high fat-meat (Western-style) 
pattern was not significantly associated with pro-inflammatory IL-6 (Q4 vs. Q1: 1.56 vs. 1.37 
pg/mL, p=0.252) and CRP (0.43 vs. 0.27 mg/dL, p=0.1). The lack of significance might be due to 
diet modifications, greater variations of inflammatory status, or disease complexities in diabetes.  
 
The traditional Chinese food-snack pattern was marginally associated with better renal function 
status, but the beneficial effect diminished after adjustment. This traditional Chinese pattern 
consists of foods primarily with plant protein (e.g. soy products and seeds), and foods high in 
carbohydrates (e.g. rice, porridge, low-nitrogen staple, and starchy soup). Evidence from previous 
studies has suggested that substitution of plant protein for animal protein may delay the 
development of kidney damage in diabetic patients (37). However, these traditional foods and 
snacks, often sold in street and night markets, contain high amounts of refined carbohydrates, which 
may worsen glycemic status. Further studies with longer follow-up durations are needed to evaluate 
the impact of this traditional food pattern on glycemic control and kidney dysfunction in Asian 
adults with diabetes.  
 
A limitation of the study was that GFR was not directly measured from creatinine clearance rate, 
but estimated from the CKD-EPI equation with a four-level race variable. This equation provides a 
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more accurate estimation of GFR than the Modification of Diet in Renal Disease (MDRD) equation 
that is widely used, especially when eGFR is ≥60 mL/min/1.73m2 (18). A large variation of ACR 
was observed in this diabetic population. The lack of repeated urine albumin measures within days 
could be a limitation due to day-to-day variability in urinary albumin excretion.
1
 Another limitation 
was the self-reported nature of the FFQ, which could result in errors associated with recall bias. The 
dietary patterns identified using self-reported FFQ were evaluated by nutrient biomarkers.  
 
In conclusion, a fish and vegetable dietary pattern may protect or improve kidney function in 
Taiwanese adults with type 2 diabetes. In this study, patients consuming more fish or a fish-
vegetable pattern had higher concentrations of erythrocyte n-3 PUFAs, which suggests that 
erythrocyte fatty acids may serve as a valuable nutrient marker for the effect of this dietary pattern 
on kidney risk. Future clinical trails, or prospective studies with longer follow-up periods, are 
needed to investigate the causal assocation between dietary patterns and albuminuria and kidney 
dysfunction in other Asian populations with or without diabetes. Such studies would also provide an 
opportunity to explore biological mechanisms linking diet and kidney disease in diabetes.       
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Table 5.1 The foods or food groups used in the food frequency questionnaire to assess dietary 
intakes for the Chinese population 
Foods or food groups Food items (listed examples) from the food frequency questionnaire  
Fatty meats and skin  Pork belly, chicken skin, fish skin, duck skin 
Fried foods Fried pork/chicken cutlet, fried salty chicken, fried fish/tofu, donuts 
Eggs Chicken, duck, bird eggs 
Seafood  Prawn, pipi, calamari, crab, oyster, squid 
Marine fish  Spanish mackerel, mackerel pike, salmon, ribbon fish, tilapia, snapper 
Freshwater aquaculture fish  Milk fish/white mullet, tilapia, eel 
Red meats  Pork, beef, lamb 
White meats  Chicken, duck, goose 
Canned meats  Canned tuna, eel, seasoned meat 
Processed meats  Ham, sausage, preserved meat, bacon, hot dog, salty pork, smoked meat 
Milk and yogurt  Cow milk, goat milk, yogurt drinks 
Processed dairy products Cheese slices, panna cotta, ice cream 
Soy products  Dried tofu, fresh tofu, soy pudding, soy milk, bean curd 
Processed wheat/gluten products  Fried/roasted gluten, gluten flour, vegetable protein or products 
Light-coloured vegetables  Cabbage, Chinese cabbage, Chinese radish, winter melon, loofah 
Dark-coloured vegetables  Broccoli, spinach, mushroom, Chinese green vegetables, carrot 
Pickled vegetables  Pickled or preserved salty cucumber or winter melon, dried bamboo        
shoot or radish, kimchi, other pickles 
Fresh fruit Fresh fruit 
Sweetened fruit juice  Bottled juice or fresh juice with sugar, condensed juice, coconut water 
Sugar-containing beverages Coffee and tea with sugar, milk tea, soy milk with sugar, energy drink, 
soft drink, yakult, fruit vinegar beverage 
Tea  Tea without sugar: oolong tea, black tea, puerh tea, green tea  
Chinese staple foods Rice, porridge, noodle, rice noodle, steamed bun 
Bread Toast, soft roll, croissant, sweet bun, red bean bun 
Root vegetables  Sweet potato, potato, taro, water caltrop, lotus root, Chinese yam 
Low nitrogen staple food s Rice noodle, bean noodle, pearl sago/tapioca, tapioca starch 
Starchy/thickened soup and foods Dextrinized starch: porridge, thickened soup with cornflour or tapioca 
flour, curry, rice and peanut milk 
Cakes and cookies  Pineapple cake, walnut cookie, cookie 
Seeds and nuts  Peanut, pumpkin seeds, pistachio, almond, walnut, cashew nut, sesame 
Eating out  Dine in or takeaway 
Sugar substitute use  Zero coke, sugar-free candy or chewing gum, sorbitol, oligofrutose 
Low calorie desserts and snacks  Konjac, gelatin, white fungus, agar dessert, seaweed nori 
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Table 5.2 Demographic and clinical characteristics of participants in 2008 stratified by renal status 
1
 
 
All 
Urine ACR (mg/g)  eGFR (mL/min/1.73m
2
)  
<30 ≥30 p-value ≥60 <60 p-value 
n 838 536 (64.0) 302 (36.0)   722 (86.2) 116 (13.8)  
Age  (years) 59.5±8.5 59.3±8.4 60.0±8.5 0.25 58.9±8.4 63.3±7.8 <0.001 
Diabetes duration (years) 8.9±5.7 8.5±5.6 9.7±5.8 0.003 8.8±5.7 10.0±5.8 0.03 
Male (%) 398 (47.5) 245 (45.7) 153 (50.7) 0.17 339 (47.0) 59 (50.9) 0.43 
Education ≤6y (%) 457 (54.5) 285 (53.2) 172 (57.0) 0.31 383 (53.0) 74 (63.8) 0.03 
Hypertension medication (%) 422 (50.4) 247 (46.1) 175 (57.9) 0.001 346 (47.9) 76 (65.5) <0.001 
Systolic BP (mmHg) 136.6±19.4 132.7±17.5 143.6±20.7 <0.001 136.0±19.2 140.5±20.7 0.02 
Diastolic BP (mmHg) 79.6±11.0 78.1±10.2 82.4±11.8 <0.001 79.7±10.7 79.0±12.6 0.58 
BMI (kg/m
2
) 26.1±3.8 25.8±3.6 26.6±4.1 0.007 26.0±3.8 26.5±3.5 0.22 
Current smoker (%) 175 (20.9) 103 (19.2) 72 (23.8) 0.13 150 (20.8) 25 (21.6) 0.85 
Alcohol (%) 107 (12.8) 65 (12.1) 42 (13.9) 0.46 96 (13.3) 11 (9.5) 0.25 
Exercise (%) 550 (65.6) 365 (68.1) 185 (61.3) 0.05 475 (65.8) 75 (64.7) 0.81 
HbA1C (%) 8.0±1.5 7.8±1.4 8.2±1.5 <0.001 8.0±1.5 7.7±1.3 0.02 
Triglycerides (mg/dL) 159.5±102.2 141.7±89.3 191.1±115.3 <0.001 152.7±97.9 201.7±117.3 <0.001 
Urinary ACR (mg/g)  14.0 (5.5, 67.7) 7.2 (4.1, 13.1) 122.7 (57.3, 526.2) <0.001 11.8 (5.0, 44.5) 89.5 (17.1, 1203.0) <0.001 
Creatinine (mg/dL) 0.98±0.76 0.84±0.24 1.23±1.19 <0.001 0.81±0.19 2.04±1.64 <0.001 
eGFR (mL/min/1.73m
2
) 87.5±23.9 92.8±18.5 78.1±29.1 <0.001 94.8±15.6 42.0±15.1 <0.001 
1
 Values are mean ± SD or number (%), or median (IQRs). BP, blood pressure; HbA1C, haemoglobin A1C; ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular filtration 
rate.  
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Table 5.3 Odds ratios for the associations of dietary patterns with albuminuria using repeated measures data in 2008, 2009, and 2010 
1
 
 Quartile Q4 vs Q1  
  Q1 (low) Q2 Q3 Q4 (high) p-value p-trend 
Albuminuria (ACR ≥ 30 mg/g)       
    High fat-meat pattern       
        Age and energy intake adjusted 1.00 1.09 (0.92-1.29) 1.02 (0.85-1.21) 1.13 (0.92-1.38) 0.24 0.39 
        Multivariate adjusted 
2
 1.00 1.06 (0.89-1.27) 0.95 (0.79-1.15) 1.02 (0.82-1.26) 0.85 0.86 
    Traditional Chinese food-snack pattern       
        Age and energy intake adjusted 1.00 0.91 (0.78-1.08) 0.91 (0.76-1.08) 0.86 (0.71-1.04) 0.11 0.14 
        Multivariate adjusted 
2
 1.00 0.88 (0.74-1.05) 0.92 (0.76-1.10) 0.83 (0.68-1.02) 0.07 0.13 
    Fish-vegetable pattern        
        Age and energy intake adjusted 1.00 0.96 (0.81-1.12) 0.91 (0.77-1.08) 0.91 (0.75-1.10) 0.31 0.26 
        Multivariate adjusted 
2
 1.00 0.97 (0.82-1.16) 0.91 (0.76-1.09) 0.92 (0.75-1.13) 0.42 0.32 
1
 Values are OR (95% CI). ACR, albumin-to-creatinine ratio; Q, quartile.  
2 Adjusted for age, energy intake, sex, diabetes duration, education (≤6y, >6y), current smoker (yes, no), alcohol (yes, no), exercise (yes, no), BMI, hypertension (blood pressure 
≥140/90 mmHg or taking anti-hypertensive medication), HbA1C, triglycerides, and time points (2008, 2009, and 2010).  
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Table 5.4 Odds ratios for the associations of dietary patterns with kidney dysfunction using repeated measures data in 2008, 2009, and 2010 
1
 
 Quartile Q4 vs Q1  
  Q1 (low) Q2 Q3 Q4 (high) p-value p-trend 
Elevated serum creatinine (≥1.5 or ≥1.2 mg/dL)       
    High fat-meat pattern       
        Age and energy intake adjusted 1.00 1.12 (0.94-1.34) 0.99 (0.82-1.19) 1.11 (0.85-1.45) 0.45 0.66 
        Multivariate adjusted
 2
 1.00 1.11 (0.91-1.35) 0.95 (0.77-1.16) 1.06 (0.80-1.42) 0.68 0.97 
    Traditional Chinese food-snack pattern       
        Age and energy intake adjusted 1.00 0.77 (0.63-0.95) 0.78 (0.63-0.95) 0.79 (0.62-1.02) 0.07 0.06 
        Multivariate adjusted 
2
 1.00 0.78 (0.63-0.96) 0.80 (0.65-0.99) 0.81 (0.63-1.06) 0.12 0.12 
    Fish-vegetable pattern        
        Age and energy intake adjusted 1.00 1.01 (0.81-1.25) 0.76 (0.61-0.95) 0.77 (0.61-0.97) 0.03 0.003 
        Multivariate adjusted 
2
 1.00 1.01 (0.80-1.27) 0.73 (0.58-0.93) 0.76 (0.60-0.98) 0.03 0.004 
Decreased eGFR (<60 mL/min/1.73m
2
)       
    High fat-meat pattern       
        Age and energy intake adjusted 1.00 0.96 (0.81-1.15) 0.94 (0.76-1.16) 1.00 (0.76-1.32) 0.99 0.83 
        Multivariate adjusted 
2
 1.00 0.97 (0.80-1.17) 0.90 (0.72-1.13) 0.98 (0.73-1.31) 0.89 0.65 
    Traditional Chinese food-snack pattern       
        Age and energy intake adjusted 1.00 0.78 (0.63-0.97) 0.72 (0.57-0.89) 0.80 (0.62-1.03) 0.08 0.04 
        Multivariate adjusted 
2
 1.00 0.79 (0.63-0.98) 0.73 (0.58-0.92) 0.79 (0.61-1.03) 0.08 0.04 
    Fish-vegetable pattern       
        Age and energy intake adjusted 1.00 0.81 (0.65-1.00) 0.81 (0.66-1.00) 0.76 (0.60-0.97) 0.03 0.03 
        Multivariate adjusted 
2
 1.00 0.80 (0.64-1.00) 0.82 (0.66-1.01) 0.75 (0.58-0.97) 0.03 0.04 
1
 Values are OR (95% CI). eGFR, estimated glomerular filtration rate; Q, quartile.  
2 Adjusted for age, energy intake, sex, diabetes duration, education (≤6y, >6y), current smoker (yes, no), alcohol (yes, no), exercise (yes, no), BMI, hypertension (blood pressure 
≥140/90 mmHg or taking anti-hypertensive medication), HbA1C, triglycerides, and time points (2008, 2009, and 2010).  
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Figure 5.1 Association between fish and vegetable factor score quartiles and erythrocyte fatty acids 
in the 2008 examination 
Five fatty acids were examined including (A) eicosapentaenoic acid (EPA) (B) docosahexaenoic 
acid (DHA) (C) total n-3 polyunsaturated fatty acid (PUFA) (D) n-3 to n-6 PUFA ratio (E) saturated 
fatty acid (SFA) to n-3 PUFA ratio. Total n-3 PUFA was the sum of α-linolenic acid (C18:3 n3), 
EPA (C20:5 n3), docosapentaenoic acid (C22:5 n3), and DHA (C22:6 n3). The differences of 
concentrations of erythrocyte fatty acids among factor score quartiles were tested by ANOVA and 
post hoc analysis. * p<0.001, Q1 as reference.  
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5.3 Supplementary materials for online publication 
Table 5.5 Factor loading matrix for the three major dietary patterns identified from the food 
frequency questionnaires in 2008, 2009, and 2010 
1
 
 Dietary pattern  
  
Food groups 
High fat-meat  
pattern 
Traditional Chinese 
food-snack pattern 
Fish-vegetable  
pattern 
 2008 2009 2010 2008 2009 2010 2008 2009 2010 
White meats 0.64 0.60 0.25    0.23  0.22 
Red meats 0.62 0.48 0.22     0.22 0.24 
Fatty meats and skin 0.61 0.55 0.42   0.29  0.35  
Fried foods  0.57 0.58 0.60 0.23  0.25    
Seafood 0.51 0.47 0.46     0.38  
Processed meats 0.49 0.52 0.46   0.22    
Eating out 0.47 0.51 0.52    -0.24   
Eggs 0.35 0.36 0.23   0.24    
Canned meats 0.32 0.22 0.34  0.27     
Chinese staple foods 0.28 0.30 0.42       
Sweetened drinks 0.21 0.29 0.36    -0.21   
Sweetened fruit juice 0.20 0.23 0.29       
Soy products  0.21 0.21 0.57 0.52 0.41    
Processed wheat/gluten products   0.37 0.50 0.47 0.22  -0.26  
Low nitrogen staple foods  0.32  0.49 0.24 0.25    
Low calorie desserts and snacks  0.26 0.28 0.46 0.28 0.57    
Seeds and nuts 0.23   0.43 0.36 0.51    
Root vegetables    0.42 0.37 0.34    
Starchy/thickened soup and foods 0.32  0.43 0.42 0.46     
Sugar substitute use  0.24  0.35  0.41    
Pickled vegetables   0.42 0.33 0.42     
Tea 0.28 0.30  0.33  0.31    
Cakes and cookies    0.28 0.30 0.30    
Processed dairy products    0.27  0.39    
Milk and yogurt   -0.23  0.23 0.20 0.25   
Freshwater aquaculture fish   0.30 -0.32   0.61 0.71 0.52 
Marine fish 0.30   -0.24   0.56 0.76 0.59 
Light-coloured vegetables       0.74 036 0.73 
Dark-coloured vegetables       0.71 0.34 0.74 
Fresh fruit      0.50  0.30  
Variance explained (%) 13.0 13.7 13.4 7.1 5.8 6.0 5.8 5.4 5.4 
1
 Foods with a factor loading < ±0.2 are not shown. 
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5.4 Additional analyses 
Characteristics of each dietary pattern 
The demographic and clinical characteristics stratified by the quartiles of dietary pattern scores are 
shown in Tables 5.6-5.8. The results were consistent with our previous study including a sub-
sample of 635 patients in 2008.
25
 High fat-meat pattern consumers tended to be younger males, 
more educated, had a shorter duration of diabetes, were more likely to have unhealthy lifestyle 
(smoking, drinking alcohol, high BMI). They had a higher diastolic blood pressure but better renal 
function (higher eGFR). High traditional Chinese food-snack pattern consumers were also younger, 
more educated, and had a shorter duration of diabetes. They had higher levels of diastolic blood 
pressure and HbA1C but better renal function. Patients adhering to the fish-vegetable diet pattern 
were found to be older and were more likely to have healthy lifestyle (exercise, non-smoking, low 
BMI). They also had a lower triglycerides and a higher eGFR. The association between high fat-
meat pattern and better renal function may be confounded by age, because the association 
disappeared after adjusting for age. Lifestyle may also be important confounders for the association 
between dietary pattern and CKD. However, the effects remained unchanged in our multivariate 
model after adjusting for current smoking, drinking habit, exercise habit, and BMI, although the 
assessments of these lifestyle factors were only from a simple declarative statement (yes, no).    
 
As shown in Table 5.9, we compared the consumption frequencies of the 30 food items and the 
actual intakes of macronutrients/energy according to the lowest and the highest quartile of dietary 
scores at the 2008 survey. Patients adhering to a high fat-meat pattern had the highest intakes of 
carbohydrate, protein, and fat, as well as highest energy intake. Patients adhering to a traditional 
Chinese food-snack pattern had the lowest intakes of protein and energy. They had the highest 
consumption of plant protein, such as soy, nuts, and gluten products, but the lowest consumption of 
fish. Patients adhering to a fish-vegetable pattern had the lowest intake of carbohydrate. 
 
In the present study, diet was assessed using a short FFQ. We assessed patients’ overall 
consumption frequency of Chinese staples, which include rice, porridge, noodle, rice noodle and 
steamed bun, rather than assessing rice consumption alone. It is noted that Chinese staple 
contributed a high factor loading to the fat-meat pattern rather than to the traditional Chinese food-
snack pattern (Table 5.5). Although a high consumption frequency of Chinese staple was also found 
in the traditional Chinese food-snack pattern, there was no significant difference between Q4 and 
Q1 (Table 5.9). Another possible explanation why Chinese staples are part of the high fat-meat 
pattern but not part of the traditional Chinese pattern could be that fat-meat pattern consumers were 
more likely to be young males. Young males generally consume more fat, meats, and also staples.     
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Table 5.6 Demographic and clinical characteristics of 838 patients in 2008 according to quartiles of high fat-meat pattern scores  
  High fat-meat pattern score quartiles   
 All Q1 Q2 Q3 Q4 p-value p-trend 
n 838 207 207 208 207   
Age  (years) 59.5±8.5 62.7±7.4 60.9±8.1 59.0±8.3 55.7±8.5 <0.001 <0.001 
Diabetes duration (years) 8.9±5.7 9.8±7.2 9.2±5.6 9.0±5.3 7.7±4.1 <0.001 <0.001 
Male (%) 398 (47.5) 55 (26.6) 94 (45.4) 107 (51.4) 136 (65.7) <0.001 <0.001 
Education ≤6y (%) 457 (54.5) 135 (65.2) 127 (61.4) 108 (51.9) 83 (40.1) <0.001 <0.001 
Hypertension medication (%) 422 (50.4) 105 (50.7) 106 (51.2) 111 (53.4) 93 (44.9) 0.357 0.328 
SBP (mmHg) 136.6±19.4 135.5±20.9 137.0±19.9 137.4±18.6 136.5±18.6 0.788 0.571 
DBP (mmHg) 79.6±11.0 76.8±10.3 78.6±10.9 80.2±10.7 82.6±11.1 <0.001 <0.001 
BMI (kg/m
2
) 26.1±3.8 25.6±3.8 26.1±3.6 26.0±3.8 26.7±4.0 0.038 0.009 
Current smoker (%) 175 (20.9) 11 (5.3) 39 (18.8) 50 (24.0) 71 (34.3) <0.001 <0.001 
Drinking habit (%) 107 (12.8) 4 (1.9) 29 (14.0) 23 (11.1) 49 (23.7) <0.001 <0.001 
Exercise habit (%) 550 (65.6) 143 (69.1) 138 (66.7) 135 (64.9) 128 (61.8) 0.464 0.112 
HbA1C (%) 8.0±1.5 7.9±1.5 8.0±1.5 8.0±1.5 8.0±1.4 0.674 0.285 
Triglycerides (mg/dL) 159.5±102.2 162.9±109.1 151.7±88.2 161.8±117.0 161.3±93.1 0.659 0.869 
Urinary ACR (mg/g)  14.0 [5.5, 67.7] 13.3 [5.2, 54.7] 19.5 [5.9, 89.2] 10.5 [5.6, 55.0] 13.5 [5.2, 74.0] 0.886 0.705 
Creatinine (mg/dL) 0.98±0.76 0.99±0.71 1.02±0.90 0.93±0.78 0.98±0.66 0.662 0.597 
eGFR (mL/min/1.73m
2
) 87.5±23.9 82.3±25.5 85.0±24.2 90.6±21.2 92.1±23.5 <0.001 <0.001 
Data are presented as mean ± standard deviation or number (% yes), or median [25th, 75th percentile]. Abbreviation: SBP, systolic blood pressure; DBP, diastolic blood pressure; 
BMI, body mass index; HbA1C, haemoglobin A1C; ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate. 
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Table 5.7 Demographic and clinical characteristics of 838 patients in 2008 according to quartiles of traditional Chinese food-snack pattern scores  
  Traditional Chinese food-snack pattern score quartiles   
 All Q1 Q2 Q3 Q4 p-value p-trend 
n 838 207 207 208 207   
Age  (years) 59.5±8.5 61.9±8.2 59.7±7.6 58.9±8.3 57.7±9.2 <0.001 <0.001 
Diabetes duration (years) 8.9±5.7 9.9±6.8 9.5±6.1 8.6±5.0 7.9±4.6 0.001 0.001 
Male (%) 398 (47.5) 104 (50.2) 97 (46.9) 101 (48.6) 90 (43.5) 0.556 0.231 
Education ≤6y (%) 457 (54.5) 147 (71.0) 115 (55.6) 94 (45.2) 97 (46.9) <0.001 <0.001 
Hypertension medication (%) 422 (50.4) 102 (49.3) 113 (54.6) 111 (53.4) 89 (43.0) 0.079 0.197 
SBP (mmHg) 136.6±19.4 136.3±19.7 136.1±21.9 136.2±17.2 137.9±19.1 0.754 0.413 
DBP (mmHg) 79.6±11.0 77.7±11.2 79.7±11.4 79.2±10.3 81.5±10.6 0.005 0.001 
BMI (kg/m
2
) 26.1±3.8 26.3±3.4 25.7±3.6 25.8±3.8 26.5±4.3 0.080 0.507 
Current smoker (%) 175 (20.9) 53 (25.6) 42 (20.3) 32 (15.4) 44 (21.3) 0.083 0.154 
Drinking habit (%) 107 (12.8) 24 (11.6) 31 (15.0) 28 (13.5) 22 (10.6) 0.550 0.670 
Exercise habit (%) 550 (65.6) 133 (64.3) 130 (62.8) 139 (66.8) 142 (68.6) 0.604 0.248 
HbA1C (%) 8.0±1.5 7.8±1.4  7.9±1.4 7.9±1.3 8.3±1.7 0.017 0.002 
Triglycerides (mg/dL) 159.5±102.2 153.3±80.9 154.9±94.2 164.2±117.1 165.2±113.6 0.509 0.158 
Urinary ACR (mg/g)  14.0 [5.5, 67.7] 17.0 [5.5, 88.0] 13.0 [5.6, 55.0] 11.2 [5.0, 60.7] 14.5 [6.3, 55.8] 0.979 0.753 
Creatinine (mg/dL) 0.98±0.76 1.00±0.47 1.03±0.72 1.04±1.21 0.85±0.36 <0.001 0.082 
eGFR (mL/min/1.73m
2
) 87.5±23.9 81.9±23.1 85.0±25.4 89.7±23.9 93.4±21.6 <0.001 <0.001 
Data are presented as mean ± standard deviation or number (% yes), or median [25th, 75th percentile]. Abbreviation: SBP, systolic blood pressure; DBP, diastolic blood pressure; 
BMI, body mass index; HbA1C, haemoglobin A1C; ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate. 
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Table 5.8 Demographic and clinical characteristics of 838 patients in 2008 according to quartiles of fish-vegetable pattern scores  
  Fish-vegetable pattern score quartiles   
 All Q1 Q2 Q3 Q4 p-value p-trend 
n 838 207 207 208 207   
Age  (years) 59.5±8.5 58.8±8.7 59.5±8.5 59.5±8.1 60.5±8.6 0.216 0.044 
Diabetes duration (years) 8.9±5.7 8.9±6.6 8.4±4.9 9.0±5.5 9.5±5.7 0.273 0.210 
Male (%) 398 (47.5) 92 (44.4) 96 (46.4) 101 (48.6) 103 (49.8) 0.710 0.243 
Education ≤6y (%) 457 (54.5) 122 (58.9) 100 (48.3) 112 (53.8) 119 (57.5) 0.132 0.939 
Hypertension medication (%) 422 (50.4) 103 (49.8) 101 (48.8) 102 (49.0) 109 (52.7) 0.853 0.565 
SBP (mmHg) 136.6±19.4 136.2±19.8 137.6±18.8 136.5±19.7 136.2±19.7 0.861 0.860 
DBP (mmHg) 79.6±11.0 80.0±10.3 79.6±10.4 79.9±11.7 78.7±11.3 0.609 0.283 
BMI (kg/m
2
) 26.1±3.8 26.6±3.8 26.0±3.5 26.0±3.7 25.8±4.1 0.149 0.037 
Current smoker (%) 175 (20.9) 49 (23.7) 50 (24.2) 33 (15.9) 39 (18.8) 0.110 0.070 
Drinking habit (%) 107 (12.8) 22 (10.6) 25 (12.1) 27 (13.0) 31 (15.0) 0.602 0.178 
Exercise habit (%) 550 (65.6) 115 (55.6) 135 (65.2) 140 (67.3) 154 (74.4) 0.001 <0.001 
HbA1C (%) 8.0±1.5 8.0±1.5 7.8±1.3 8.1±1.5 8.0±1.6 0.264 0.328 
Triglycerides (mg/dL) 159.5±102.2 163.1±87.7 172.0±117.2 159.5±96.0 143.1±105.2 0.055 0.023 
Urinary ACR (mg/g)  14.0 [5.5, 67.7] 17.6 [5.8, 93.6] 11.8 [4.8, 53.7] 13.3 [5.9, 49.4] 14.9 [5.2, 66.4] 0.306 0.143 
Creatinine (mg/dL) 0.98±0.76 1.02±0.71 1.02±1.07 0.96±0.66 0.91±0.52 0.425 0.120 
eGFR (mL/min/1.73m
2
) 87.5±23.9 84.7±25.2 87.6±24.8 87.6±23.6 90.1±21.9 0.146 0.028 
Data are presented as mean ± standard deviation or number (% yes), or median [25th, 75th percentile]. Abbreviation: SBP, systolic blood pressure; DBP, diastolic blood pressure; 
BMI, body mass index; HbA1C, haemoglobin A1C; ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate. 
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Table 5.9 Food consumption frequencies/intakes according to quartiles of dietary pattern of 2008 
Mean  
High fat-meat  
pattern 
Traditional Chinese 
food-snack pattern 
Fish-vegetable  
pattern 
 Q1 Q4 Q1 Q4 Q1 Q4 
White meats (times/wk) 0.52 2.32 1.48 1.34 1.12 1.82 
Red meats (times/wk) 0.70 3.31 1.99 2.09 1.67 2.22 
Fatty meats and skin (times/wk) 0.17 2.11 0.64 1.13 1.05 0.68 
Fried foods (times/wk) 0.17 1.20 0.34 0.83 0.61 0.54 
Seafood (times/wk) 0.25 1.17 0.54 0.69 0.48 0.83 
Processed meats (times/wk) 0.08 0.80 0.28 0.55 0.37 0.45 
Eating out (times/wk) 1.00 7.32 3.21 3.85 5.56 2.28 
Eggs (portions/wk) 1.42 3.38 1.79 2.60 2.27 2.34 
Canned meats (times/wk) 0.05 0.57 0.14 0.43 0.35 0.27 
Chinese staple foods (portions/wk) 12.29 16.06 14.32 15.08 14.20 14.19 
Sweetened drinks (portions/wk) 0.53 1.58 0.71 1.66 1.79 0.57 
Sweetened fruit juice (times/wk) 0.16 0.59 0.25 0.53 0.41 0.24 
Soy products (times/wk) 1.36 1.82 0.56 2.82 1.29 1.66 
Processed wheat/gluten products (times/wk) 0.48 0.52 0.16 1.03 0.56 0.39 
Low nitrogen staple foods (times/wk) 0.43 0.58 0.18 0.94 0.41 0.55 
Low calorie desserts and snacks (times/wk) 0.35 0.50 0.11 0.89 0.34 0.55 
Seeds and nuts (times/wk) 0.41 1.09 0.29 1.48 0.61 0.93 
Root vegetables (portions/wk) 0.35 0.50 0.12 0.87 0.38 0.53 
Starchy/thickened soup and foods (times/wk) 0.32 1.26 0.32 1.46 0.85 0.72 
Sugar substitute use (times/wk) 0.26 0.19 0.04 0.63 0.13 0.37 
Pickled vegetables (times/wk) 0.38 0.80 0.18 1.07 0.65 0.43 
Tea (portions/wk) 2.86 7.06 2.72 7.43 5.07 4.50 
Cakes and cookies (times/wk) 0.39 0.75 0.18 0.93 0.64 0.41 
Processed dairy products (portions/wk) 0.14 0.35 0.07 0.48 0.28 0.19 
Milk and yogurt (portions/wk) 3.23 1.89 1.86 3.09 1.50 3.64 
Freshwater aquaculture fish (times/wk) 1.14 2.05 3.12 1.22 0.81 3.71 
Marine fish (times/wk)  1.51 3.34 3.53 2.03 1.29 4.73 
Light-coloured vegetables (times/wk) 3.98 3.79 3.52 4.31 2.20 4.89 
Dark-coloured vegetables (times/wk) 4.25 3.89 3.73 4.47 2.54 4.92 
Fresh fruit (portions/wk) 8.08 9.72 7.56 9.77 7.46 9.71 
Carbohydrate (g/day) 150 191 162 187 168 176 
Protein (g/day) 35 75 47 59 44 71 
Fat (g/day) 39 113 75 77 59 100 
Energy (Kcal/day) 1089 2079 1540 1678 1377 1890 
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Dietary patterns and nutrient biomarkers 
Table 5.10 shows the partial correlation between dietary patterns and nutrient biomarkers including 
erythrocyte fatty acids and serum ferritin. The three dietary patterns derived from factor analysis 
were uncorrelated patterns. After controlling for age and energy intakes, high fat-meat pattern 
scores were correlated negatively with the scores of traditional Chinese food-snack pattern (r= -
0.14, p<0.001) and fish-vegetable pattern (r= -0.23, p<0.001). There was no association between 
traditional Chinese food-snack pattern and fish-vegetable pattern (p=0.793). Patients adhering to the 
high fat-meat pattern had a high consumption of fat, meats, and marine fish. We observed that high 
fat-meat pattern scores were correlated significantly with increased serum ferritin (r=0.10, 
p=0.004), total SFAs (r=0.10, p=0.006), and n-3 PUFAs (r=0.11, p=0.002), but with decreased n-6 
PUFAs (r= -0.11, p=0.001). The traditional Chinese food-snack pattern, which is characterised by 
high intakes of plant sources, especially seeds, but low intakes of fish, was significantly correlated 
with increased n-6 PUFAs (r=0.32, p<0.001) but with decreased n-3 PUFAs (r= -0.33, p<0.001). 
The fish-vegetable pattern was found to be correlated with increased n-3 PUFAs (r=0.18, p<0.001), 
especially EPA (r=0.16, p<0.001) and DHA (r=0.18, p<0.001), but with decreased n-6 PUFAs (r= -
0.13, p<0.001). As mentioned before in the Chapter 5.2, when we examined individual food items, 
there were stronger correlations between marine/freshwater fish and n-3 PUFA (r=0.3~0.5).  
 
There are many ways to validate an FFQ. Most validation studies compared an FFQ against other 
dietary assessment methods such as a weighted dietary record or 24h recalls; few studies compared 
an FFQ to a biomarker. Although the FFQ used in the present study is not directly validated against 
another dietary measurement method, we did evaluate the dietary patterns and some specific food 
items (e.g. fish) using nutrient biomarkers such as serum ferritin and erythrocyte fatty acids.  
 
Dietary patterns and inflammatory biomarkers  
The correlation between dietary patterns and inflammatory biomarkers is shown in Table 5.11. 
Based on studies conducted in the general population, we hypothesized unhealthy dietary patterns 
(e.g. high intake of fat and meats) may associate positively with CRP and pro-inflammatory IL-6 
and negatively with anti-inflammatory adiponectin; while the inverse association may be seen in 
healthy dietary patterns (e.g. high intake of fish and vegetables). However, in this type 2 diabetic 
population, we did not observe an association of any dietary patterns with CRP, IL-6, or 
adiponectin. The clinical complexities of diabetes and kidney disease associated with inflammation 
may partly explain the lack of association between dietary patterns and inflammatory biomarkers.    
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Table 5.10 Partial correlation between dietary pattern scores and nutrient biomarkers (n=801) 
 High fat-meat  
pattern 
Traditional Chinese 
food-snack pattern 
Fish-vegetable  
pattern 
 r p-value r p-value r p-value 
High fat-meat pattern 1.00 - -0.14 <0.001 -0.23 <0.001 
Traditional Chinese food-snack pattern -0.14 <0.001 1.00 - -0.01 0.793 
Fish-vegetable pattern -0.23 <0.001 -0.01 0.793 1.00 - 
Erythrocyte fatty acids       
Total SFAs (%) 0.10 0.006 -0.01 0.765 -0.02 0.559 
        C16:0 (PA) (%) 0.00 0.896 -0.01 0.843 0.03 0.393 
        C18:0 (SA) (%) 0.08 0.025 0.00 0.913 -0.05 0.201 
Total PUFAs (%)  -0.04 0.233 0.08 0.022 0.03 0.432 
        n-6 PUFAs (%) -0.11 0.001 0.32 <0.001 -0.13 <0.001 
            C18:2n6 (LA) (%) -0.13 <0.001 0.26 <0.001 -0.07 0.041 
            C20:4n6 (ARA) (%) 0.06 0.074 -0.01 0.755 -0.04 0.285 
        n-3 PUFAs (%) 0.11 0.002 -0.33 <0.001 0.18 <0.001 
            C18:3n3 (ALA) (%)  -0.13 <0.001 0.09 0.011 -0.03 0.393 
            C20:5n3 (EPA) (%)  0.04 0.309 -0.28 <0.001 0.16 <0.001 
            C22:5n3 (DPA) (%) 0.04 0.214 -0.12 0.001 0.05 0.201 
            C22:6n3 (DHA) (%) 0.13 <0.001 -0.34 <0.001 0.18 <0.001 
        n-3 to n-6 PUFA ratio  0.09 0.009 -0.33 <0.001 0.17  <0.001 
        SFA to PUFA ratio 0.08 0.026 -0.06 0.070 -0.03 0.409 
        SFA to n-6 PUFA ratio 0.11  0.003 -0.27 <0.001 0.11 0.002 
        SFA to n-3 PUFA ratio -0.17  <0.001 0.35 <0.001 -0.17 <0.001 
Serum ferritin  0.10 0.004 -0.03 0.453 -0.07 0.051 
Data are presented as correlation coefficient r. P-values were based on partial correlation controlling for age and energy 
intakes. Abbreviations: SFA, saturated fatty acid; PA, palmitic acid; SA, stearic acid; LA, linoleic acid; ARA, 
arachidonic acid;  ALA, α-Linolenic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA,  
docosahexaenoic acid;  PUFA, polyunsaturated fatty acid. 
 
 
Table 5.11 Partial correlation between dietary pattern scores and inflammatory biomarkers (n=743) 
 High fat-meat  
pattern 
Traditional Chinese 
food-snack pattern 
Fish-vegetable  
pattern 
 r p-value r p-value r p-value 
CRP -0.004 0.922 0.029 0.422 0.025 0.495 
IL-6 0.003 0.937 -0.002 0.965 0.028 0.446 
Adiponectin  -0.009 0.797 0.005 0.895 0.031 0.392 
Data are presented as correlation coefficient r. P-values were based on partial correlation controlling for age and energy 
intakes. Abbreviations: CRP: C reactive protein; IL-6: interlukin-6. 
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5.5 Chapter conclusion   
This study found that adhering to a fish-vegetable dietary pattern protected against kidney 
dysfunction, but not albuminuria, in Taiwanese adults with type 2 diabetes. In this study, higher 
consumption of fish or fish-vegetable pattern was associated with higher concentrations of 
erythrocyte n-3 fatty acids. This indicates that dietary patterns identified in this diabetic population 
can be evaluated with erythrocyte fatty acids to further explore disease risk. However, we did not 
observe an association between dietary patterns and inflammatory biomarkers in our type 2 diabetic 
patients. Future clinical trails or prospective studies with longer follow-up peroids are needed to 
investigate the causal assocation between dietary patterns and kidney diseasae in other Asian 
populations with or without diabetes and to explore underlying mechanisms in diabetes.       
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Chapter 6: Association of n-3 polyunsaturated fatty acids and inflammatory 
indicators with renal function decline in type 2 diabetes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been published online in Clinical Nutrition. 
 
Chung HF, Long K, Hsu CC, Mamun A, Jhang HR, Shin SJ, Hwang SJ, Huang MC. Association 
of n-3 polyunsaturated fatty acids and inflammatory indicators with renal function decline in type 2 
diabetes. Clin Nutr. 2015;34(2):229-234. 
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6.1 Chapter introduction  
Study objectives 
Primary: 
1. To examine the association of fatty acids with albuminuria and kidney dysfunction in 
patients with type 2 diabetes  
2. To examine the association of inflammatory biomarkers with albuminuria and kidney 
dysfunction in patients with type 2 diabetes  
Secondary:  
3. To examine whether anti-inflammatory PUFAs modify the effect of pro-inflammatory 
biomarkers on the risk of renal function decline   
 
Outline of the study 
 
 
 
 
 
 
 
 
 Study design: a four-year follow-up cohort study from 2008 to 2012, n=676  
 Exclusion criteria: patients who did not have complete data on fatty acids and inflammatory 
biomarkers in 2008 and eGFR in both 2008 and 2012, patients who had eGFR<15 in 2008 
 Statistical analysis:  
1) logistic regression analysis  
2) PUFA effect stratification 
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Background & aims: The n-3 polyunsaturated fatty acids (PUFAs) and the inflammatory indicator,
interleukin-6 (IL-6), have been implied in the development of renal dysfunction. This longitudinal study
examined the effect of n-3 PUFAs and IL-6 on the risk of renal function decline and explored whether n-3
PUFAs modify the effect of inflammatory indicators on renal dysfunction risk in type 2 diabetes.
Methods: Studying 676 type 2 diabetic patients, we analyzed erythrocyte fatty acids and inflammatory
markers in 2008 and estimated glomerular filtration rate (eGFR) in 2008 and 2012. Renal function
decline was defined as an eGFR decline of 25% over a 4-year period.
Results: Multivariable logistic regression revealed erythrocyte total PUFAs, n-3 PUFAs, and n-3/n-6 PUFA
ratio correlated negatively with risk of renal function decline (OR ¼ 0.75, 0.78, and 0.61, respectively, all
p < 0.01), while n-6 PUFAs did not. IL-6 independently predicted risk of renal dysfunction (OR ¼ 1.18,
p ¼ 0.015). Stratifying erythrocyte PUFAs into low (<50th percentile) or high group (50th percentile), we
found a positive association between IL-6 and risk of renal dysfunction only in the low n-3 PUFA
(OR ¼ 1.27, p ¼ 0.035), low n-3/n-6 PUFA (OR ¼ 1.27, p ¼ 0.034), and low total PUFA groups (OR ¼ 1.36,
p ¼ 0.005), but not in the high groups.
Conclusions: High PUFA concentrations, especially n-3 or higher n-3/n-6 PUFA ratio, may exert protective
effects against renal function impairment in type 2 diabetic patients. Whether the effect is mediated via
modification of inflammatory biomarker such as IL-6 by high n-3 PUFA status warrants further
investigation.
 2014 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.-EPI, chronic kidney disease
CVD, cardiovascular disease;
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for Clinical Nutrition and Metabol1. Introduction
Chronic kidney disease (CKD), an emerging public health issue,
leads to end stage renal disease (ESRD) and increased cardiovascular
mortality.1 It is common but often goes unrecognized among dia-
betic patients. Diabetes is the primary cause of ESRD accounting for
43.9% of the incidence of ESRD in the United States in 2007.2 Around
forty percent of type 2 diabetic patients develop diabetic kidney
disease, a disease clinically characterized by presence of albumin-
uria or decreased estimated glomerular filtration rate (eGFR).3 Di-
etary fat is thought to be an important contributing factor for the
development of renal disease in general and diabetic populations.4
Omega-3 polyunsaturated fatty acids (PUFAs) reduce the risk of
cardiovascular disease (CVD),5 the primary cause of death inism. All rights reserved.
H.-F. Chung et al. / Clinical Nutrition 34 (2015) 229e234230patients with diabetic kidney disease.6 Review studies suggest that
PUFAs may attenuate albuminuria in diabetes, but there is insuffi-
cient evidence supporting the protective effect on glomerular
dysfunction.6e8 To our knowledge, only one longitudinal study has
been conducted in older adults, and that study found that high
plasma PUFAs reduced age-associated decline of renal function.9 In
animal models, omega-3 supplements have been found to protect
against renal inflammation, fibrosis and oxidative stress.10 The ef-
fects of PUFAs are pleiotropic and act directly on endothelium
function and on the production of cytokine mediators due to their
properties of interfering with the synthesis of inflammatory
markers and responses.11
Interleukin (IL)-6, a well-known pro-inflammatory cytokine
correlated with a reduced renal function,12 is the major stimulus of
the acute-phase inflammatory response.13 Omega-3 PUFAs have
anti-inflammatory properties. Thus, PUFAs may attenuate renal
dysfunction by down-regulating pro-inflammatory markers and
also up-regulating anti-inflammatory markers.11,14 To date, the
mechanisms underlying the modifying effect of PUFAs on associa-
tion between inflammatory markers and renal function are not
very well understood in diabetic patients.
The aim of this study was to investigate the relationship of
erythrocyte PUFAs and inflammatory markers with renal function
decline in type 2 diabetic patients over 4 years and to examine
whether PUFAs modify the effect of inflammatory indicators on the
risk of renal dysfunction.
2. Materials and methods
2.1. Study population
This study enrolled type 2 diabetic patients who participated in
a study on diabetes management through an integrated delivery
system (DMIDS) (ClinicalTrials.gov NCT00288678) conducted in
Taiwan. DMIDS baseline recruitment took place from August 2003
to December 2005 (n ¼ 1209), and diabetic patients were followed
until the end of 2012. Full details on the study design and inclusion/
exclusion criteria for DMIDS study have been previously reported in
a sub-study following up patients from 2003 to 2009.15 In this
study, we included participants whose eGFR were estimated in
both 2008 and 2012, and those whose fatty acids and inflammatory
biomarkers were analyzed in 2008. Patients were excluded if they
were CKD stage 5 (eGFR <15 ml/min/1.73 m2) in 2008. After
applying these criteria, 676 of the remaining patients had eGFR
change data for analysis. The protocol for this study was approved
by the Ethics Committee of the National Health Research Institutes
and Kaohsiung Medical University Hospital, Taiwan. All partici-
pants provided written informed consent.
2.2. Clinical assessments
Anthropometric measures and fasting (8 h) venous blood sam-
ples were collected at 6-month intervals. All samples were kept in 2e
8 C, delivered to a certified laboratory (Union Clinical Laboratory,
Taipei, Taiwan), and measured within 8 h. Hemoglobin A1c (HbA1c)
was performed using high-performance liquid chromatography
(Tosoh G7, Tosoh, Kobe, Japan). Fasting glucose, triglyceride, choles-
terol, low-density lipoprotein cholesterol (LDL-C), high-density lipo-
protein cholesterol (HDL-C), bloodureanitrogen (BUN)and creatinine
were measured using an auto-analyser (Beckman LX20, Beckman
Coulter, Fullerton, CA, USA). Insulin was measured by a chemilumi-
nescent immunometric assay (Immulite 1000, Diagnostic Products,
Los Angeles, CA, USA) and urinary albumin by immunoturbidmetry
(Hitachi 7060, Hitachi High Technologies, Tokyo, Japan). Insulin
resistance was then assessed using the homeostatic model: HOMA-IR ¼ insulin (mU/ml)  fasting plasma glucose (mmol/L)/22.5. Micro-
albuminuria was categorized as urinary albumin-to-creatinine ratio
30 mg/g. Erythrocyte and plasma samples collected in 2008 were
stored at 80 C until further analyses.
2.3. Assessment of renal function decline
Serum creatinine was measured using the Jaffe method, with
the calibration procedures based on the US National Institute of
Standards and Technology (NIST) standard. Estimated GFR was
calculated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation, which is based on creatinine,
age, sex and a four-level variable for race (Black, Asian, Hispanic
and Native American, and white and other)16. The CKD-EPI
equation is more accurate than the Modification of Diet in Renal
Disease (MDRD) equation that is widely used, especially when
eGFR is 60 ml/min/1.73 m2.16 Renal function decline (renal
dysfunction) was defined as an eGFR decline of 25% between
2008 and 2012, as previously described in type 2 diabetes studies
with different follow-up periods17,18. Estimated GFR decline rate
was calculated by
2012 eGFR  2008 eGFRð Þ
2008 eGFR
 100%
2.4. Fatty acid analysis
Erythrocyte lipids were extracted using a modification of the
Bligh and Dyermethod,19 and derivatized to fatty acidmethyl esters
(FAMEs) using boron trifluoride-methanol. The methylated fatty
acids were quantified using gas chromatography (Agilent 6890 N,
Agilent Technologies, Santa Clara, CA, USA) equipped with a
capillary column (30 m  0.250 mm inner diameter  0.25 mm
film). N2 was used as the carrier gas. The C17:0 (Sigma, St Louis, MO,
USA) was added as internal standard, and 20 individual fatty acids
were identified by comparing findings with known standards. The
concentration of each fatty acid was quantified as a percentage of
total area under the peaks (weight %). We also performed fatty acid
analysis using the plasma samples. Four hundred eighty-six par-
ticipants had complete plasma fatty acid measurements. We found
moderate to strong correlations between erythrocyte and plasma
fatty acids (r ¼ 0.53e0.85, all p < 0.001).
2.5. Determination of inflammatory markers
The concentrations of IL-6 were measured in plasma samples
using a high sensitivity enzyme-linked immunosorbent assay kit
(ELISA) (R&D systems, Minneapolis, MN, USA) with a minimal
detectable concentration of 0.156 pg/mL. This assay is designed to
measure human circulating IL-6 in the presence of an IL-6-specific
antibody. We also measured the concentrations of an anti-
inflammatory adipokine adiponectin and a systemic inflamma-
tory marker C-reactive protein (CRP). Adiponectin was quantitated
by a commercial ELISA kit (R&D systems, Minneapolis, MN, USA).
The detection range of adiponectin is 3.9e250 ng/mL. Duplicates
and intra- and inter-assay coefficient of variation less than 10%
were used for sample quality control. High-sensitivity CRP was
analyzed using an immunoturbidimetric method (Cobas Integra
800, Roche, Mannheim, Germany).
2.6. Statistical analysis
The student’s t-test was used to compare continuous variables
between case and non-case groups, and chi-squared test was used
Table 1
Demographical and clinical characteristics of type 2 diabetic patients in year 2008.a
eGFR decline
25%
eGFR decline
<25%
P-valueb
n 68 608
Age (year) 62.3  6.9 58.7  8.6 <0.001
Diabetes duration (year) 12.2  7.9 8.5  5.3 <0.001
Male (%) 36 (52.9) 281 (46.2) 0.292
Education, 6 years (%) 44 (64.7) 302 (49.7) 0.019
Smoker (%) 23 (33.8) 172 (29.1) 0.414
Alcohol drinker (%) 8 (11.8) 82 (13.9) 0.635
Physical activity (%) 40 (58.8) 398 (67.2) 0.165
Cardiovascular disease (%) 15 (22.1) 79 (13.3) 0.051
Hypertension (%) 55 (80.9) 379 (64.2) 0.006
Microalbuminuria (%)c 46 (68.7) 184 (31.0) <0.001
Lowering lipid medication use (%) 47 (69.1) 429 (70.6) 0.805
Body mass index (kg/m2) 26.2  3.5 26.1  3.9 0.786
HbA1c (%) 8.1  1.4 7.9  1.5 0.248
HOMA-IR 2.76  2.18 2.93  4.02 0.857
Triglyceride (mg/dL) 202.1  115.5 153.7  101.0 <0.001
Cholesterol (mg/dL) 200.9  42.1 191.5  35.4 0.071
LDL-C (mg/dL) 120.4  35.3 120.0  32.3 0.934
HDL-C (mg/dL) 37.1  11.2 38.9  10.7 0.113
BUN (mg/dL) 18.1  6.7 15.0  5.9 <0.001
Creatinine (mg/dL) in 2008 1.17  0.55 0.85  0.30 <0.001
Creatinine (mg/dL) in 2012 2.08  1.57 0.82  0.29 <0.001
eGFR (mL/min/1.73 m2) in 2008 70.8  23.5 92.3  20.3 <0.001
eGFR (mL/min/1.73 m2) in 2012 41.4  18.7 91.7  19.8 <0.001
Erythrocyte PUFAs
Total PUFA (%) 42.9  1.3 43.7  1.4 <0.001
n-6 PUFA (%) 33.0  2.7 33.0  2.3 0.849
C18:2n6 (LA) (%) 14.3  2.4 14.1  2.1 0.614
C20:4n6 (ARA) (%) 13.5  1.3 13.8  1.3 0.088
n-3 PUFA (%) 9.9  2.3 10.6  1.8 0.012
C18:3n3 (ALA) (%) 0.25  0.09 0.22  0.08 0.022
C20:5n3 (EPA) (%) 0.83  0.46 0.97  0.47 0.002
C22:6n3 (DHA) (%) 6.7  1.8 7.3  1.3 0.018
n-3/n-6 PUFA ratio 0.31  0.09 0.33  0.07 0.045
Inflammatory indicators
hsCRP (mg/dL) 0.28  0.31 0.28  0.57 0.289
IL-6 (pg/mL) 1.8  1.6 1.3  1.5 <0.001
Adiponectin (mg/mL) 9.0  11.8 6.9  6.6 0.059
Abbreviation: eGFR: estimated glomerular filtration rate; HOMA-IR: homeostasis
model assessment-insulin resistance; PUFA: polyunsaturated fatty acid; LA: linoleic
acid; ARA: arachidonic acid; ALA: linolenic acid; EPA: eicosapentaenoic acid; DHA:
docosahexaenoic acid; hsCRP: high-sensitivity C-reactive protein; IL-6: interleukin-
6.
a Data are presented as mean  SD or n (%).
b Pearson chi-squared test or student t-test were used to compare the differences
between decline and non-decline groups.
c Microalbuminuria was categorized as urinary albumin-to-creatinine ratio
30 mg/g.
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was performed to test normality of the distribution, and a log-
transformation was used to normalize the skewed continuous
variables.
The associations of erythrocyte PUFAs and inflammatory
markers with an eGFR decline 25% were examined using logistic
regression models. Models were further adjusted for sex, age, dia-
betes duration, education (6/>6 y), hypertension (yes/no), and
triglyceride in year 2008. Hypertensionwas categorized as having a
blood pressure 140/90 mmHg or anti-hypertensive medication
use. BMI and other lifestyle covariates including smoking (yes/no),
alcohol (yes/no), physical activity (yes/no) were also considered in
the adjusted model but did not change the effects on eGFR decline,
and were therefore not included in the final model. We further
divided total PUFAs, n-3 PUFAs and n-3/n-6 PUFA ratio into quar-
tiles. The linear trends to compare an eGFR decline between 2008
and 2012 across quartiles were tested using multivariate linear
regression models, applying the same adjustment procedures
described above.
We then tested the modifying effect of erythrocyte PUFAs on the
association between inflammatory markers and risk of eGFR
decline. Levels of total PUFA and n-3 PUFA as well as n-3/n-6 PUFA
ratio were dichotomized into low (<50th percentile) or high group
(50th percentile), and then used to stratify the analysis of asso-
ciations between the inflammatory cytokine IL-6 and a 25%
decline in eGFR in the multivariate logistic regression model.
Stratification analyses were also performed using plasma PUFAs
(n ¼ 486, supplementary data) in an attempt to replicate the re-
sults. All statistical operations were performed using SPSS (version
21.0, SPSS Inc., Chicago, IL, USA). A two-sided p-value <0.05 was
considered significant.
3. Results
3.1. Study participants and renal function decline
Of our sample of 676 diabetic patients, 317 (46.9%) were males,
average age 59.0  8.5 years, and average diabetes duration was
8.8  5.7 years. In 2008, 407 (60.2%), 199 (29.4%), 64 (9.5%) and 6
(0.9%) patients were found to be in eGFR of90, 60e89, 30e59 and
15e29 ml/min/1.73 m2, respectively. Over the 4-year follow-up
period, 68 (10.1%) patients had an eGFR decline of 25% (Table 1).
These patients were older and less educated, and had longer dia-
betes duration, higher frequencies of hypertension and micro-
albuminuria, and higher concentrations of triglyceride in 2008 (all
p < 0.05) as well as marginally higher proportion of CVD
(p ¼ 0.051). CVD was defined by self-reported cardiovascular
medication use. They also had higher concentrations of plasma IL-6
(p < 0.001) and adiponectin (p ¼ 0.059) but lower erythrocyte total
PUFA and n-3 PUFA levels (p < 0.05).
3.2. Erythrocyte PUFAs and renal function decline
The associations between erythrocyte PUFAs and renal function
decline are shown in Table 2. After adjusting for covariates, we
found erythrocytes total PUFAs (OR¼ 0.75, 95% CI¼ 0.61e0.92), n-3
PUFAs (OR¼ 0.78, 95% CI¼ 0.68e0.90), eicosapentaenoic acid (EPA)
(OR ¼ 0.35, 95% CI ¼ 0.17e0.71), docosahexaenoic acid (DHA)
(OR ¼ 0.74, 95% CI ¼ 0.62e0.89) and n-3/n-6 PUFA ratio (OR ¼ 0.61,
95% CI ¼ 0.43e0.87) in 2008 to be independently associated with a
lower risk of renal function decline (all p < 0.01). However, no such
negative correlations were observed between n-6 PUFAs and eGFR
decline. We further divided total PUFAs, n-3 PUFAs and n-3/n-6
PUFA ratio into quartiles, and found the risk of eGFR decline to
consistently decrease across quartiles (Fig. 1). From the lowest tothe highest quartile of n-3 PUFA, the adjusted OR for eGFR decline
was 1.00, 0.46, 0.49 and 0.29 (p-trend¼ 0.003). The ORs across n-3/
n-6 PUFA quartiles were also linear (OR ¼ 1.00, 0.61, 0.43 and 0.30,
p-trend ¼ 0.002), indicating a dose-dependent effect. A similar
linear trend was also observed in total PUFA quartiles (OR ¼ 1.00,
0.87, 0.57 and 0.37, p-trend ¼ 0.022).
3.3. Effect of inflammatory indicators on renal function decline
modified by PUFA status
IL-6 correlated with an increased risk of eGFR decline after
adjusting for confounders (OR ¼ 1.18, 95% CI ¼ 1.03-1.35, p ¼ 0.015,
Table 2).With IL-6 levels categorized into quartiles, therewas a 2.61
fold risk of decline (95% CI ¼ 1.19-5.71, p ¼ 0.016) for quartile 4
compared to quartile 1. Furthermore, the ORs of renal function
decline across IL-6 quartiles were linear (p-trend¼ 0.001) (data not
shown). Adiponectinwas positively associatedwith eGFR decline in
the crude model (OR ¼ 1.03, 95% CI ¼ 1.00e1.05), but not after
Table 2
Association of erythrocyte polyunsaturated fatty acids and inflammatory indicators
with an eGFR decline 25%.a
Crude model Adjusted modelb
OR (95% CI) P-value OR (95% CI) P-value
Erythrocyte PUFAs
Total PUFA (%) 0.68 (0.58e0.81) <0.001 0.75 (0.61e0.92) 0.005
n-6 PUFA (%) 0.99 (0.89e1.10) 0.848 1.07 (0.96e1.20) 0.210
C18:2n6 (LA) (%) 1.03 (0.92e1.16) 0.614 1.06 (0.94e1.19) 0.366
C20:4n6 (ARA) (%) 0.85 (0.71e1.02) 0.089 0.95 (0.78e1.17) 0.647
n-3 PUFA (%) 0.82 (0.71e0.93) 0.002 0.78 (0.68e0.90) 0.001
C18:3n3 (ALA)
(%)  10
1.34 (1.04e1.73) 0.024 1.22 (0.92e1.62) 0.168
C20:5n3 (EPA) (%) 0.44 (0.23e0.85) 0.014 0.35 (0.17e0.71) 0.004
C22:6n3 (DHA) (%) 0.77 (0.65e0.92) 0.003 0.74 (0.62e0.89) 0.001
n-3/n-6 PUFA
ratio  10
0.71 (0.50e0.99) 0.045 0.61 (0.43e0.87) 0.006
Inflammatory indicators
hsCRP (mg/dL) 1.01 (0.64e1.59) 0.979 1.12 (0.69e1.82) 0.644
IL-6 (pg/mL) 1.16 (1.03e1.31) 0.017 1.18 (1.03e1.35) 0.015
Adiponectin (ng/mL) 1.03 (1.00e1.05) 0.038 1.02 (1.00e1.05) 0.094
Abbreviation: PUFA: polyunsaturated fatty acid; LA: linoleic acid; ARA: arachidonic
acid; ALA: linolenic acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid;
hsCRP: high-sensitivity C-reactive protein; IL-6: interleukin-6.
a Data are presented as OR (95% CI). P-values were based on multivariate logistic
regression.
b Adjusted model was adjusted for sex, age, diabetes duration, education (6/
>6 y), hypertension (yes/no), and triglyceride in year 2008.
Fig. 1. Odds ratios with 95% CIs for multivariate adjusted association of erythrocyte
total PUFA (A), n-3 PUFA (B) and n-3/n-6 PUFA (C) quartiles with an eGFR decline 25%
over a 4-year follow-up period. Multiple linear regression was used to examine a trend
of eGFR decline across PUFA quartiles, with adjustment for sex, age, diabetes duration,
education (6/>6 y), hypertension (yes/no), and triglyceride in year 2008.
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associated with eGFR decline.
We performed a stratified analysis to test whether the positive
correlation between IL-6 and renal function decline was modified
by low or high PUFA status using multivariate logistic regression
analyses (Table 3). IL-6 was significantly associated with higher risk
of renal dysfunction in subjects with low n-3 PUFA (OR ¼ 1.27, 95%
CI ¼ 1.02-1.59, p ¼ 0.035), low n-3/n-6 PUFA (OR ¼ 1.27, 95%
CI ¼ 1.02-1.59, p ¼ 0.034) as well as low total PUFA (OR ¼ 1.36, 95%
CI ¼ 1.10-1.69, p ¼ 0.005), but not with renal dysfunction in those
with high n-3 PUFA, n-3/n-6, and total PUFA levels (p ¼ 0.139-
0.863). These results suggest that n-3, n-3/n-6 PUFAs, and total
PUFAs may play some roles in modifying the positive association
between IL-6 and renal dysfunction, although the interaction terms
did not reach significance (p for interaction¼ 0.266, 0.227, and 0.09,
respectively). This could be due to a smaller number of cases being
defined in our study. As observed in erythrocyte PUFAs, plasma n-3
PUFA as well as total PUFA (n ¼ 486) also modified the positive
association between IL-6 and renal function decline (Supplemental
Table 1). IL-6 correlated positively with eGFR decline in patients
with low n-3 PUFA levels (OR¼ 1.39, p¼ 0.025), but this association
was insignificant in thosewith high n-3 PUFA (OR¼ 1.13, p¼ 0.268)
(p-interaction ¼ 0.243).
In addition to the finalmodel, we also adjusted for HOMA-IR and
CVD in our multivariable model. The results remained unchanged.
A positive association between IL-6 and risk of renal dysfunction
was only found in the low n-3 PUFA (OR ¼ 1.30, 95% CI ¼ 1.00-1.70,
p ¼ 0.049), low n-3/n-6 PUFA (OR ¼ 1.33, 95% CI ¼ 1.01-1.75,
p ¼ 0.039), and low total PUFA groups (OR ¼ 1.41, 95% CI ¼ 1.05-
1.89, p ¼ 0.024), but not in the high n-3, n-3/n-6, and total PUFA
groups (p ¼ 0.895-0.959) (only 443 subjects with available data for
this analysis, data not shown).4. Discussion
In this diabetic cohort study, patients with high erythrocyte n-3
PUFAs, n-3/n-6 PUFA ratio as well as total PUFAs had a lower risk of
renal function decline over the 4-year follow-up period, while n-6PUFAs did not. IL-6 was found to independently predict eGFR
decline. The positive association between IL-6 and renal function
declinewas attenuated in subjects with high erythrocyte n-3 and n-
3/n-6 PUFA levels.
Ourmain finding is consistent with a longitudinal observation of
older adults which reported that higher concentrations of plasma
n-3 PUFAs may have attenuated the age-associated decline in renal
function measured by creatinine clearance over a 3-year follow-
up.9 A diet rich in long-chain n-3 PUFAs and fish was associated
Table 3
Association of IL-6 with an eGFR decline 25%, in strata of low or high erythrocyte
polyunsaturated fatty acid status.a
IL-6 PUFA status Crude model Adjusted modelb
OR (95% CI) P-value OR (95% CI) P-value
Total PUFA
Lowc 1.34 (1.11e1.62) 0.003 1.36 (1.10e1.69) 0.005
High 1.03 (0.81e1.31) 0.822 1.03 (0.76e1.39) 0.863
n-3 PUFA
Lowc 1.29 (1.05e1.58) 0.016 1.27 (1.02e1.59) 0.035
High 1.11 (0.95e1.30) 0.182 1.15 (0.95e1.40) 0.139
n-3/n-6 PUFA ratio
Lowc 1.30 (1.06e1.59) 0.012 1.27 (1.02e1.59) 0.034
High 1.11 (0.95e1.30) 0.201 1.15 (0.95e1.39) 0.152
Abbreviation: PUFA: polyunsaturated fatty acid.
a Data are presented as OR (95% CI). P-values were based on multivariate logistic
regression.
b Adjusted model was adjusted for sex, age, diabetes duration, education (6/
>6 y), hypertension (yes/no), and triglyceride in year 2008.
c Low PUFA status was defined as less than 50th percentile.
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large-scale population-based study.20 In type 2 diabetic patients,
the beneficial effect of fish oil supplements on renal function has
been demonstrated in a 12-week randomized controlled trail.21 Its
biological mechanism can be explained in animal model of diabetic
nephropathy. N-3 PUFA supplements can reduce glomerular and
tubulointerstitial inflammatory infiltrate and mesangial activation,
inhibiting production of CeC motif chemokine 2 (CCL2), trans-
forming growth factor b (TGF-b) and reactive oxygen species
(ROS).6 These effects then attenuate glomerulosclerosis leading to
eGFR decline.6 The results of one meta-analysis pooling the data
from 12 clinical trials of patients with different types of kidney
disease show that n-3 long chain PUFA supplements did not
significantly reduce the decline in GFR, though the decline rate in
the intervention groups was slower.8 However, the small numbers
of participants involved in the intervention trails and different
methods to estimate GFR, according to the authors, limited the
power of the pooled result reported.8 Thus, larger scale longitudinal
studies and clinical trials are needed to further elucidate the
renoprotective effect of PUFAs on renal function.
The pro-inflammatory IL-6 was associated with a higher risk of
renal function decline in the type 2 diabetic patients in this study.
This relationship has also been found in patients with predialytic
chronic renal failure.12 IL-6 is the major inflammatory mediator
promoting the production of positive acute-phase reactants (i.e.
CRP and fibrinogen) and inhibiting the production of negative
acute-phase reactants (i.e. albumin and fetuin A).13 Inflammation
plays a critical role in the pathogenesis of vascular damage in the
uremic milieu.22 Studies have also shown IL-6 to be one of the most
reliable predictors of all-cause mortality in ESRD.22,23 Other in-
flammatory markers including CRP and tumor necrosis factor
(TNF)-a have also been shown to predict mortality in patients not
only with ESRD but also with CKD.22 Considered together, these
findings suggest that pro-inflammatory IL-6 may serve as an
important contributor to endothelial dysfunction in renal diseases.
This study found that the positive association between pro-
inflammatory IL-6 and renal function impairment remained sig-
nificant in low n-3 and n-3/n-6 PUFA groups, but this association
disappeared at high n-3 and n-3/n-6 PUFA levels. Similarly, the
effect of IL-6 on renal dysfunction risk modified by high total PUFAs
was also found. Two large-scale human observational studies have
shown dietary intake of long-chain n-3 PUFAs and fish and plasma
n-3 PUFAs concentrations to be both inversely associated with
plasma IL-6 and other inflammatory markers in general pop-
ulations, reflecting a reduced level of inflammation and endothelialactivation.14,24 Rats fed a coconut oil (saturated fatty acid) diet for
four weeks were reported by one study to have the highest IL-6
release from adipocytes, sunflower oil (PUFA) diet moderate
amount of IL-6, and an olive oil (monounsaturated fatty acid) diet
the least amount of IL-6 release in vivo.25 However, in vitro studies
show that IL-6 mRNA and protein levels can be induced by treating
3T3-L1 adipocytes with palmitic acid (C16:0), while no effect was
observed when treating these cells with DHA.26 The abilities of n-3
PUFAs tomodulate the expression and synthesis of IL-6 are not fully
clear at this point. Very few studies address the interactions be-
tween fatty acids and IL-6 concentrations (or genetic variations) as
well as their impacts on metabolic/chronic diseases.27 To the best
our knowledge, this current study represents the first human study
clearly showing that n-3 PUFAs may modify the effect of IL-6 on
renal dysfunction in type 2 diabetic patients.
Erythrocyte n-3 fatty acids have been found to be suitable
biomarkers of long-term n-3 fatty acid intake28. Our finding
suggests that higher erythrocyte n-3 PUFAs status may be asso-
ciated with slower renal dysfunction development. According to
the 2007 Kidney Disease Outcomes Quality Initiative (KDOQI)
clinical practice guideline,29 dietary fat <30% and saturated fat
<10% of total energy are recommended for CKD patients (stage
1e4) with or without diabetes. Adequate intake of alpha-
linolenic acid (n-3 PUFA) is suggested as 1.6g/day for men and
1.1g/day for women. Up to 10% of the n-3 PUFA amounts can be
substituted by EPA and/or DHA. Therefore, one serving of cold-
water fish (i.e. tuna, sardines, salmon, mackerel and herring) in
diet 3 times per week is recommended.29 However, taking >3 g
of EPA and DHA from supplements might cause excessive
bleeding and other adverse outcomes in some individuals.30
Omega-3 PUFA may have renoprotective effects in general and
among diabetic populations, but it is important to avoid exces-
sive intake of fish oil supplements.
The strength of this study is its longitudinal prospective study
design. Additionally, very few studies have included a group of type
2 diabetic patients at their early stage of kidney disease. In fact,
approximately 90% of study participants had an eGFR 60 ml/min/
1.73 m2 in 2008. When stratified by PUFA status, the effect of IL-6
on renal dysfunction was disappeared in higher strata of n-3
PUFA, though the interaction between n-3 PUFA and IL-6 was not
found to be statistically significant. It may be due to the limitation
of this study that a relatively smaller percentage of patients were
defined as development of renal function impairment over a 4-year
period of follow-up. Therefore, a longer follow-up duration may be
needed to include more patients with a decline in renal function.
In conclusion, this study clearly indicates that high PUFA con-
centrations, especially n-3 and n-3/n-6 PUFA ratio, may protect
against renal function decline in type 2 diabetic patients. The
positive association between IL-6 and renal function decline may
be attenuated by high concentrations of n-3 and n-3/n-6 PUFAs as
well as total PUFAs. Further large-scale longitudinal studies and
clinical trials are needed to confirm the beneficial effect of n-3
PUFAs on renal function in type 2 diabetes, and provide enough
evidence to suggest n-3 PUFA supplements for diabetic patients.
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6.3 Supplementary materials for online publication 
Table 6.1 Association of IL-6 with an eGFR decline ≥25%, in strata of low- or high-plasma PUFA 
status (n=486) 
a 
  
Crude Model
  
Adjusted Model 
b 
IL-6  PUFA status OR (95% CI) p-value  OR (95% CI) p-value 
 
Total PUFAs      
 
  Low 
c
 1.41 (1.10-1.80) 0.007  1.42 (1.08-1.86) 0.012 
 
  High  1.00 (0.78-1.29) 0.973  0.98 (0.71-1.36) 0.917 
 
n-3 PUFAs      
 
  Low 
c
 1.32 (1.02-1.71) 0.038  1.39 (1.04-1.84) 0.025 
 
  High  1.09 (0.91-1.31) 0.339  1.13 (0.91-1.40) 0.268 
 
n-3/n-6 PUFA ratio      
 
  Low 
c
 1.13 (0.92-1.39) 0.251  1.05 (0.83-1.32) 0.686 
 
  High  1.14 (0.95-1.36) 0.154  1.22 (1.00-1.49) 0.049 
Abbreviation: PUFA: polyunsaturated fatty acid.  
a
 Data are presented as OR (95% CI). P-values were based on multivariate logistic regression. 
b
 Adjusted model was adjusted for sex, age, diabetes duration, education (≤6/>6y), hypertension (yes/no), and 
triglycerides in year 2008.  
c
 Low PUFA status was defined as less than 50
th
 percentile.  
 
 
6.4 Additional analyses 
Saturated fatty acids and kidney function decline  
In this diabetic population, we observed that patients with an eGFR decline ≥25% over the four-
year follow-up had a higher erythrocyte concentration of palmitic acid but a lower concentration of 
stearic acid in 2008 (both p<0.001) (Table 6.2). There was no difference in concentrations of total 
saturated fatty acids (SFAs) between the decline and non-decline groups. After adjusting for 
covariates, we found erythrocyte palmitic acid in 2008 to be independently associated with a higher 
risk of renal function decline (OR=1.44, 95% CI=1.13-1.83, p=0.03), while stearic acid was 
associated with a lower risk of eGFR decline (OR= 0.64, 95% CI=0.51-0.80, p<0.001) (Table 6.3).  
    
Palmitate (C16:0) is the predominant circulating saturated fatty acid.
171
 In animal models, it induces 
insulin resistance by reducing insulin signalling and insulin-stimulated glucose transport (glucose 
utilization).
246,247
 In human cells, it directly blocks insulin-stimulated glucose uptake in podocytes 
(an epithelial cell of the visceral layer of a renal glomerulus).
171
 In our diabetic subjects, we found a 
significant positive correlation between palmitic acid and homeostatic model assessment for insulin 
resistance (HOMA-IR) (r=0.12, p=0.009), but no correlation between stearic acid and HOMA-IR 
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(r= -0.06, p=0.227). Also, higher concentrations of palmitic acid were independently associated 
with an increased risk of renal function decline. Thus, we suggest that saturated palmitic acid may 
play a role in linking insulin resistance and the development of kidney disease in type 2 diabetes.   
 
Table 6.2 Comparison of erythrocyte saturated fatty acids measured in 2008 in type 2 diabetic 
patients with and without renal function decline over a four-year follow-up period 
a
  
 GFR decline≥25% GFR decline<25%  
n 68 608 p-value 
b
 
Erythrocyte SFAs    
    Total SFAs (%) 39.2±0.8 39.4±0.9 0.180 
        C16:0 (PA) (%) 22.5±1.1 21.9±1.1 <0.001 
        C18:0 (SA) (%) 15.9±1.3 16.5±1.1 <0.001 
Abbreviation: eGFR: estimated glomerular filtration rate; SFA: saturated fatty acid; PA: palmitic acid; SA: stearic acid. 
a
 Data are presented as mean±SD.  
b
 Pearson chi-squared tests or student t-tests were used to compare the differences between decline and non-decline 
groups.     
 
 
Table 6.3 Association between erythrocyte saturated fatty acids and an eGFR decline ≥25% a 
              Crude Model  Adjusted Model b 
 OR (95% CI) p-value  OR (95% CI) p-value 
Erythrocyte SFAs      
    Total SFAs (%) 0.83 (0.63-1.09) 0.173  0.82 (0.61-1.09) 0.175 
        C16:0 (PA) (%) 1.54 (1.24-1.91) <0.001  1.44 (1.13-1.83) 0.003 
        C18:0 (SA) (%) 0.61 (0.50-0.75) <0.001  0.64 (0.51-0.80) <0.001 
Abbreviation: eGFR: estimated glomerular filtration rate; SFA: saturated fatty acid; PA: palmitic acid; SA: stearic acid. 
a
 Data are presented as OR (95% CI). P-values were based on multivariate logistic regression. 
b
 Adjusted model was adjusted for sex, age, diabetes duration, education (≤6/>6y), hypertension (yes/no), and 
triglycerides in year 2008.  
 
 
Fatty acids, inflammatory biomarkers, and albuminuria  
We also examined the association of erythrocyte fatty acids and inflammatory biomarkers measured 
in 2008 with albuminuria defined in 2012 (Table 6.4). A total of 308 (45.8%) patients had an 
albumin-to-creatinine ratio (ACR) <30 mg/g and were thus classified as having albuminuria. In the 
crude model, palmitic acid (OR=1.24, p=0.002) and linolenic acid (OR=1.23, p=0.028) were 
associated positively with albuminuria, while stearic acid and total PUFAs
 
were associated 
negatively with albuminuria (OR=0.83, p=0.007 and OR=0.84, p=0.002, respectively). However, 
these effects became insignificant after multivariable adjustment. Additionally, we did not observe 
any association between inflammatory biomarkers and albuminuria. We concluded that erythrocyte 
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fatty acids and inflammatory biomarkers did not predict the risk of albuminuria over a four-year 
follow-up period.  
 
Table 6.4 Association of erythrocyte fatty acids and inflammatory indicators with albuminuria 
(ACR ≥30 mg/g) in 2012 (cases=308) a 
              Crude Model  Adjusted Model b 
 OR (95% CI) P  OR (95% CI) P 
Erythrocyte SFAs      
    Total SFAs (%) 1.07 (0.90-1.27) 0.460  1.04 (0.86-1.25) 0.685 
        C16:0 (PA) (%) 1.24 (1.08-1.43) 0.002  1.14 (0.98-1.33) 0.100 
        C18:0 (SA) (%) 0.83 (0.73-0.95) 0.007  0.90 (0.77-1.04) 0.160 
Erythrocyte PUFAs      
    Total PUFAs (%) 0.84 (0.75-0.93) 0.002  0.94 (0.83-1.07) 0.339 
        n-6 PUFAs (%) 0.97 (0.91-1.04) 0.452  1.02 (0.95-1.10) 0.595 
            C18:2n6 (LA) (%) 0.98 (0.91-1.05) 0.512  0.98 (0.91-1.06) 0.624 
            C20:4n6 (ARA) (%) 0.95 (0.84-1.06) 0.335  1.20 (0.87-1.66) 0.270 
        n-3 PUFAs (%) 0.94 (0.87-1.02) 0.146  0.94 (0.86-1.03) 0.185 
            C18:3n3 (ALA) (%) ×10 1.23 (1.02-1.49) 0.028  1.13 (0.93-1.39) 0.222 
            C20:5n3 (EPA) (%) 0.74 (0.53-1.03) 0.074  0.73 (0.51-1.05) 0.088 
            C22:6n3 (DHA) (%) 0.94 (0.84-1.05) 0.260  0.94 (0.83-1.06) 0.301 
        n-3/n-6 PUFA ratio ×10 0.91 (0.75-1.12) 0.374  0.88 (0.71-1.09) 0.245 
Inflammatory indicators      
    hsCRP (mg/dL) 0.98 (0.74-1.30) 0.872  1.00 (0.75-1.34) 0.979 
    IL-6 (pg/mL) 1.07 (0.96-1.19) 0.211  1.07 (0.96-1.19) 0.228 
    Adiponectin (ng/mL) 1.01 (0.99-1.03) 0.402  1.01 (0.99-1.03) 0.487 
Abbreviation: SFA: saturated fatty acid; PA: palmitic acid; SA: stearic acid; PUFA: polyunsaturated fatty acid; LA: 
linoleic acid; ARA: arachidonic acid; ALA: linolenic acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; 
hsCRP: high-sensitivity C-reactive protein; IL-6: interleukin-6.    
a
 Data are presented as OR (95% CI). P-values were based on multivariate logistic regression. 
b 
Adjusted model was adjusted for sex, age, diabetes duration, education (≤6/>6y), hypertension (yes/no), and 
triglycerides in year 2008.  
 
 
Fatty acids and inflammatory biomarkers  
We also examined the correlations between fatty acids and inflammatory biomarkers using cross-
sectional data from 2008 (n=773) (Table 6.5). As expected, the systemic inflammatory marker CRP 
was positively correlated with pro-inflammatory marker IL-6 (r=0.44, p<0.001), while negatively 
correlated with anti-inflammatory marker adiponectin (r=-0.16, p<0.001). There was no direct 
correlation between IL-6 and adiponectin (r=0.04, p=0.231). We observed that total SFAs were 
associated significantly with higher concentrations of CRP (r=0.09, p=0.013) and IL-6 (r=0.09, 
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p=0.011), but not with adiponectin. Anti-inflammatory PUFAs, however, had an inverse effect. 
They were associated significantly with lower CRP (r=-0.10, p=0.005) and IL-6 (r=-0.11, p=0.002) 
but with higher adiponectin (r=0.10, p=0.004). These findings are consistent with studies conducted 
in the general population.
188,191
 
 
Table 6.5 The correlation between fatty acids and inflammatory biomarkers using cross-sectional 
data in 2008 (n=773) 
a
 
 CRP (mg/dL) IL-6 (pg/mL) Adiponectin (ng/dL) 
 r p-value r p-value r p-value 
CRP (mg/dL) 1.00 - 0.44 <0.001 -0.16 <0.001 
IL-6 (pg/mL) 0.44 <0.001 1.00 - 0.04 0.231 
Adiponectin (ng/dL) -0.16 <0.001 0.04 0.231 1.00 - 
Total SFAs (%) 0.09  0.013 0.09 0.011 0.03 0.495 
Total PUFAs (%) -0.10 0.005 -0.11 0.002 0.10 0.004 
Abbreviation: CRP: C reactive protein; IL-6: interlukin-6; SFA: saturated fatty acid; PUFA: polyunsaturated fatty acid. 
a
 Data are presented as correlation coefficient r. P-values were based on Spearman’s correlation. 
 
 
Different levels of eGFR decline  
We applied different cut-off points for eGFR decline in the regression analyses to minimise 
misclassification. When using cut-points of 15% (cases=117) and 20% (cases=90), the results were 
quite similar to those observed when a cut-off point of ≥25% was used, but the modifying effects of 
total PUFAs on the association between IL-6 and eGFR decline were weaker (Fig. 6.1). A decline 
of ≥30% resulted in an attenuated and insignificant effect of pro-inflammatory IL-6 on renal 
dysfunction because of the smaller numbers of cases defined (n=52). Similar results were obtained 
when stratifying by low and high n-3 PUFAs. Accordingly, an eGFR decline of ≥25% seems to 
provide a meaningful and clear outcome of interest in this short period of follow-up.            
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Figure 6.1 Odds ratios with 95% CIs for multivariate-adjusted associations of IL-6 with different 
levels of eGFR decline, in strata of low or high levels of erythrocyte total PUFAs and n-3 PUFAs 
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6.5 Chapter conclusion   
This study clearly indicates that high PUFA concentrations, especially n-3 PUFAs, protected 
against the risk of renal function decline in type 2 diabetic patients over a four-year follow-up, 
while high concentrations of SFAs (palmitate) increased the risk. However, no association was 
found with albuminuria. Pro-inflammatory IL-6 was a strong predictor of renal function decline but 
not albuminuria. High anti-inflammatory n-3 PUFAs could attenuate the effect of IL-6 on renal 
function decline. Further large-scale longitudinal studies and clinical trials are needed to confirm 
the beneficial effect of n-3 PUFAs on renal function in type 2 diabetes, and to provide enough 
evidence to suggest n-3 PUFA supplements for diabetic patients.  
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Chapter 7: Association of obesity and weight change with inflammatory 
biomarkers and chronic kidney disease in Taiwanese patients with type 2 
diabetes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been submitted to International Journal of Obesity.  
 
  
Chung HF, Mamun A, Huang MC, Long K, Huang YF, Shin SJ, Hwang SJ, Hsu CC. Association 
of obesity and weight change with inflammatory biomarkers and chronic kidney disease in 
Taiwanese patients with type 2 diabetes. Int J Obes (submitted on 10 Jan 2015). 
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7.1 Chapter introduction 
Study objectives 
Primary: 
1. To examine the association of body mass index (BMI) with albuminuria and kidney 
dysfunction in patients with type 2 diabetes using repeated measure data 
2. To examine the association of weight and BMI change over time with albuminuria and 
kidney dysfunction in patients with type 2 diabetes  
Secondary:  
3. To examine whether the obesity effect is gender specific  
4. To examine the association of baseline BMI and weight change with inflammatory 
adipocytokines 
 
Outline of the project 
 
 
 
 
 
 
 
 
 Study design: a seven-year follow-up cohort study from baseline to 2010, n=1,199  
 Exclusion criteria: subjects who did not have complete BMI and creatinine data at baseline 
 Statistical analysis:  
1) generalized estimating equation (GEE) model analysis for repeated measures BMI and renal 
outcomes 
2) logistic regression analysis for weight and BMI change over time and renal outcomes in 
2010 
3) analyses stratified by gender   
 
 
 
2008 
Baseline, 2008, 2009, 2010 
Baseline, 2008, 2009, 2010 
Obesity, ∆weight 
(BMI, weight change)  
 
Albuminuria 
(ACR≥30) 
Kidney dysfunction 
(CKD: eGFR<60) 
 
Inflammation  
(IL-6, adiponectin, CRP) 
 
gender difference? 
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7.2 Submitted manuscript  
Abstract  
Background/Objectives: Obesity has been linked to chronic kidney disease (CKD) in the general 
population. However, little is known about how obesity and weight change are associated with 
CKD in Asian diabetic populations, and what inflammatory mechanisms may underlie such 
relationships.  
Subjects/Methods: A cohort of 1199 Taiwanese adults with type 2 diabetes was followed from 
baseline (2003-2005) to 2010. Overweight and obesity were defined using Asian BMI cut-off points 
(23 and 27.5 kg/m
2
, respectively) at baseline and in 2008, 2009, and 2010. Relative changes in 
weight (%) between baseline and 2010 were categorized (<-10, <-5 to -10, ±5, >+5 to +10, and 
>+10%). CKD was defined as estimated glomerular filtration rate <60 mL/min/1.73m
2
 at each time 
point. Generalized estimating equation and logistic regression were used for repeated measures of 
BMI and CKD, and for weight change and CKD outcomes in 2010, respectively. Plasma IL-6 and 
CRP were measured as inflammatory biomarkers in 2008. 
Results: Obesity (adjusted OR=1.67, 95% CI:1.11-2.51, p=0.013) and weight gain >10% 
(OR=3.80, 95% CI:1.89-7.62, p<0.001) were associated with an increased risk of CKD over the 
seven-year follow-up compared to normal BMI and stable weight categories, respectively. Weight 
loss of 5-10% was associated with reduced risk of CKD (OR=0.48, 95% CI:0.23-1.00, p=0.050); 
however, weight loss >10% was not associated with lower risk (OR=0.98, p=0.965). Patients who 
gained weight >10% had the highest concentrations of IL-6, and those who lost 5-10% of their body 
weight had the lowest concentrations; while those who lost weight >10% had increased, rather than 
reduced, IL-6 (p=0.016). 
Conclusions: Obesity and weight gain were associated significantly with the risk of CKD among 
type 2 diabetic patients in Taiwan. Modest weight loss of 5-10% may help reduce the risk of CKD, 
while weight loss >10% may not. Pro-inflammatory IL-6 may be an underlying mechanism 
mediating this association.   
 
Key words: inflammation, kidney disease, obesity, type 2 diabetes, weight change
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Introduction  
Chronic kidney disease (CKD) is increasingly recognised as a global public health issue that occurs 
as a consequence of diabetes and hypertension.
1
 The prevalence of CKD is projected to increase 
dramatically, particularly in elderly populations, following the increased prevalence of diabetes and 
hypertension that has occurred among middle-aged adults in many parts of the world.
1
 CKD leads 
to cardiovascular disease (CVD) and kidney failure with high medical costs and poor outcomes.
2
 
Consequently, identifying and reducing risk factors for CKD has become a vital public health 
priority.  
 
Obesity has been associated with increased risk of CKD, kidney cancer, and end stage renal disease 
(ESRD) in general populations, and also found to contribute to the decline in renal function in 
patients with kidney-related disease.
3
 These adverse kidney outcomes may be partly because obese 
individuals are at far greater risk of developing hypertension and type 2 diabetes.
4
 Weight loss may 
occur in a patient after being diagnosed with type 2 diabetes as a consequence of lifestyle 
modifications in which more attention is paid to diet and physical activity.
5
 Excess weight, 
however, appears to be paradoxically associated with better survival among hemodialysis patients
6
 
and individuals with heart failure.
7
 This relationship is known as the “obesity paradox.”  
 
Obesity physically compresses the kidneys, stimulates sodium reabsorption, and causes arteriolar 
hypertension and compensatory glomerular hyperfiltration, ultimately leading to 
glomerulosclerosis.
8
 Inflammation, oxidative stress, endothelial dysfunction, and hormonal factors 
are the main pathogenic mechanisms involved in the progression to kidney disease in obese 
patients.
9
 In obesity, adipose tissues increase producing inflammatory adipocytokines such as leptin 
and interleukin-6 (IL-6).
10
 Adipocytokines may be a link between obesity and renal damage 
resulting from their effects on insulin resistance and vascular damage.
9,10
 However, the impact of 
obesity and long-term weight change on inflammatory adipocytokines in diabetes is not fully clear.  
 
To date, it remains unclear how obesity and longitudinal weight change affect the risk of CKD in 
patients with type 2 diabetes, and whether the association is independent of the precursors of CKD 
including hyperglycemia, dyslipidaemia, and hypertension. Although obesity is less prevalent in 
Asian populations than in Western populations, Asians are at a greater risk of type 2 diabetes and 
CVD at lower BMI cut-off points than those established by World Health Organisation (WHO) 
(overweight: ≥25 kg/m2; obesity: ≥30 kg/m2).11 Thus, the WHO has recommended using cut-off 
points of 23 and 27.5 kg/m
2 
for disease risk among Asian populations.
11
 We investigated the 
association of obesity and weight change over seven years with the risk of CKD in Taiwanese 
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patients with type 2 diabetes using the Asian BMI cut-off points of the WHO, and explored the 
possible inflammatory mechanisms underlying the association.    
 
Materials and Methods  
Study participants   
Study participants were type 2 diabetic patients aged 30-70 years who had participated in the 
Diabetes Management through an Integrated Delivery System (DMIDS) cohort in Taiwan. Details 
of the study design and methods for original cohort have been previously published.
12
 Briefly, 1209 
patients who had no major diabetic complications (e.g. uremia, receiving dialysis, or foot 
amputations) or other systemic illnesses (e.g. myocardial infarction, stroke, or cancer) were 
recruited at baseline (from 2003 to 2005). We excluded patients who did not have complete BMI 
and serum creatinine data at baseline (n=10), leaving us with 1199 subjects for the current analysis. 
Demographic information, anthropometric measurements (including weight, height, and blood 
pressure), lifestyle behaviours, and biomedical measurements were assessed by trained research 
personnel at baseline and in follow-up visits in 2008, 2009 and 2010. Fasting (≥8 h) venous blood 
samples were collected at each follow-up examination. The protocol for the present project was 
approved by the Ethics Committees of the National Health Research Institutes and Kaohsiung 
Medical University Hospital, Taiwan. All participants provided written informed consent. 
 
Assessment of obesity and weight change 
Anthropometric measurements were taken at baseline and in 2008, 2009, and 2010. Body weight (in 
light clothes and no shoes) was measured to the nearest 0.1 kg on standardised digital weight scales. 
Height without shoes was measured to the nearest 0.5 cm on standardised, wall-mounted height 
boards. Measurements were used to calculate BMI (body weight in kilograms divided by height in 
meters squared; kg/m
2
). BMI was constructed as a continuous term (kg/m
2
) and also as a categorical 
variable using the World Health Organisation (WHO) cut-off points for Asian populations 
(underweight: <18.5; normal: 18.5 to 22.9; overweight: 23.0 to 27.4; obese: ≥27.5 kg/m2).11 At 
baseline, only 12 diabetic patients (1%) had a BMI <18.5 kg/m
2
, so we categorized those subjects as 
belonging to the normal BMI group (<23 kg/m
2
). We also evaluated weight change between 
baseline and 2010. A relative weight change over seven years was calculated as: (2010 weight – 
baseline weight) / baseline weight × 100%. We then categorised weight change (%) into large 
weight loss (< -10%), modest weight loss (< -5% to -10%), stable weight change (-5% to +5%), 
modest weight gain (> +5% to +10%), and large weight gain (> +10%). Changes in BMI over time 
(%) were calculated similarly.   
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Measurement of inflammatory biomarkers  
Plasma concentrations of high-sensitivity C-reactive protein (Hs-CRP) and IL-6 were measured 
using available blood specimens collected in 2008 (n=844). Hs-CRP was analysed using an 
immunoturbidimetric method (Cobas Integra 800, Roche, Mannheim, Germany). Commercial 
enzyme-linked immunosorbent assay kit (ELISA) (R&D systems, Minneapolis, MN, USA) was 
used to measure human circulating IL-6 in the presence of an antibody specific for IL-6. The 
plasma concentrations of IL-6 were measured using a high sensitivity ELISA kit with a minimal 
detectable concentration of 0.156 pg/mL. Duplicates and intra- and inter-assay coefficients of 
variation less than 10% were used for sample quality control.  
 
Assessment of chronic kidney disease  
Serum creatinine was measured by the Jaffe reaction, with the calibration procedures based on the 
US National Institute of Standards and Technology (NIST) standards. The primary outcome of this 
study was CKD, defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m
2
.
13
 
GFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
equation, which is calculated based on serum creatinine, age, sex and a four-level race variable 
(Black, Asian, Hispanic and Native American, or White and other).
14
  
 
Assessment of covariates  
Age, sex, duration of diabetes, and education level data were collected at baseline. At each follow-
up time point, data on smoking status (never, past, current) and alcohol consumption (at least once a 
week during the previous six months) (yes, no) were collected by self-reported questionnaires. Data 
on physical activity (getting exercise within the last two weeks) and energy intake were only 
collected from the 2008, 2009, 2010 examinations. Hemoglobin A1C (HbA1C) was assessed using 
high-performance liquid chromatography (G7; Tosoh, Kobe, Japan), and triglycerides were 
assessed using an auto-analyser (LX20; Beckman Coulter, Fullerton, CA, USA). Hypertension was 
defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg, or self-
reported use of antihypertensive medications. 
 
Statistical analysis  
Pearson chi-squared tests and ANOVA were used to compare demographic and clinical 
characteristics among the three BMI categories at baseline. Generalised estimating equation (GEE) 
models were performed to examine the association between BMI and the risk of CKD due to its 
ability to handle the repeated measure data from the baseline, 2008, 2009, and 2010 sampling 
points. This type of modelling makes better use of all available data, so it generally produces a more 
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powerful estimate. It also takes into account the correlations within each subject by specifying a 
working correlation structure.
15
 We used the exchangeable correlation structure in this analysis.  
Moreover, the GEE model can handle time-dependent (time-varying) covariates. In the final 
multivariable model (model 2), we adjusted for various time-dependent covariates including age, 
diabetes duration, smoking (never, past, current), drinking alcohol (yes, no), time (baseline, 2008, 
2009, and 2010), as well as important biological mediators including HbA1c, triglycerides, and 
hypertension (yes, no). Sex and education were the only time-independent covariates. We also 
considered exercise, energy intake, and dietary pattern scores in the adjusted model, but the 
inclusion of these additional variables in the analysis did not change the BMI effects on CKD. 
Because the data on physical activity and diet were not available at baseline, we did not include 
these covariates in our final model. We also tested effect modification of gender by including 
interaction terms between obesity and gender. 
 
To examine the association between weight change over the seven-year follow-up and the risk of 
CKD, we first performed ANCOVA and post-hoc tests to compare the adjusted mean eGFR among 
the five weight change categories, and performed linear regression when weight change was 
constructed as a continuous term. We then used logistic regression models where the outcome CKD 
was defined as eGFR <60 mL/min/1.73m
2
. The association between the outcome and BMI change 
was also examined to confirm the results.  
 
The relationship between weight changes (from baseline to 2008) and inflammatory biomarkers was 
assessed using the markers measured in 2008. ANCOVA, adjusting for age and post-hoc test 
results, were performed to compare the differences among the five weight change categories. A 
two-sided p-value <0.05 was considered significant. All statistical operations were performed using 
SPSS (version 22.0, SPSS Inc., Chicago, IL, USA).  
 
Results 
Baseline patient characteristics  
Baseline characteristics of 1199 type 2 diabetic patients stratified by three BMI categories are 
shown in Table 7.1. At baseline, nearly half (49.4%) of subjects were overweight (BMI: 23-27.4 
kg/m
2) and nearly 30% were obese (BMI ≥27.5 kg/m2) when applying the Asian BMI cut-off 
points. In this population, there were more overweight men, but more obese women (p=0.002). 
Compared to patients with a normal BMI, obese patients tended to be younger (54.1 vs 56.6 years, 
p<0.001) and had a shorter duration of diabetes (4.0 vs. 6.5 years, p<0.001). As expected, blood 
pressure and triglycerides increased and eGFR decreased with increasing BMI. However, normal 
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BMI patients had a higher level of HbA1C than obese patients (9.0±2.2 vs. 8.2±1.8 mg/dL, 
p<0.001). This could be partly explained by a long duration of diabetes. Nearly 30% of normal BMI 
patients had diabetes for more than 10 years, compared with only 12% of obese patients who had it 
for that length of time (p<0.001).  
 
Obesity and chronic kidney disease  
The association between BMI and CKD was examined using repeated measures data (Table 7.2). 
The prevalence of CKD was 5.4% at baseline, and increased to 15.5% over seven years. In the age- 
and multivariate-adjusted GEE models, higher BMI was associated significantly with increased risk 
of CKD. Age-adjusted ORs for CKD were 1.32 (0.94-1.84, p=0.108) for the overweight category 
and 1.87 (1.26-2.77, p=0.002) for the obese category compared with the normal BMI category. This 
positive association was also observed when BMI was expressed as a continuous variable 
(OR=1.07, 95% CI=1.03-1.11, p<0.001). The effect of obesity on the risk of CKD remained 
statistically significant, although slightly diminished, after further adjustment for important time-
dependent mediators including HbA1C, triglycerides and blood pressure (OR=1.67, 95% CI=1.11-
2.51, p=0.013).   
 
Weight change and chronic kidney disease  
After a seven-year follow-up, the overall prevalence of overweigh (47.1%) and obesity (33.8%) 
remained similar to that observed at baseline, but approximately 40% of diabetic patients had a 
weight change greater than ±5% over time. In the ANCOVA model, age-adjusted mean eGFR in 
2010 ranged from 76.2 to 90.5 mL/min/1.73m
2 
across the five weight change categories (Table 7.3). 
After multivariate adjustment (model 2), patients with a modest weight loss of 5-10% had an 
improved eGFR (90.6 vs. 85.3 mL/min/1.73m
2
,
 
p=0.015) compared with patients who remained 
within a ±5% range of their baseline weight, while those with a large weight gain >10% had a low 
level of eGFR (78.0 vs. 85.3 mL/min/1.73m
2
,
 
p=0.013). A large weight loss >10% was not 
associated with improved renal function (86.7 vs. 85.3 mL/min/1.73m
2
, p=0.668). Weight change 
was also examined as a continuous term; each 1% gain in weight, on average, was associated with a 
decrease in eGFR of 0.43 mL/min/1.73m
2
 (p<0.001). Similar findings were observed with BMI 
changes.    
 
The odds ratios for the risk of CKD (eGFR <60 mL/min/1.73m
2
) according to weight and BMI 
change over time are shown in Table 7.4. In the multivariate adjusted model (model 2), weight gain 
>10% was strongly associated with an increased risk of CKD (OR=3.80, 95% CI=1.89-7.62, 
p<0.001) when compared with stable weight (change within ±5%); while a modest weight loss of 5 
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to 10% was associated with a reduced risk of CKD (OR=0.48, 95 % CI=0.23-1.00, p=0.050). 
However, a large weight loss >10% was not associated with a lower risk of CKD (OR=0.98, 95% 
CI=0.40-2.39, p=0.965). We also observed a similar J-shaped association with BMI change.  
 
Weight change, inflammation, and eGFR  
As expected, patients who were overweight or obese at baseline tended to have higher 
concentrations of pro-inflammatory cytokine IL-6 (p-trend<0.001) and systemic inflammatory 
marker CRP (p-trend=0.035) measured in 2008 compared to those with normal BMI (data not 
shown). Figure 7.1 shows the relationship between weight change, inflammatroy biomarkers, and 
eGFR over a five-year follow-up period (baseline to 2008). The concentrations of IL-6 increased 
significantly with increasing weight gain (p=0.016), accompanied by decreasing eGFR. Patients 
who gained weight >10% over the study period had lowest levels of eGFR and highest 
concentrations of IL-6, compared to those whose weight remained stable. Patients who lost 5-10% 
of their body weight had the highest levels of eGFR and the lowest concentrations of IL-6, while 
those who lost >10% of their body weight had increased, rather than decreased, IL-6. No 
association was observed for CRP.  
 
Discussion  
In this cohort study of Taiwanese patients with type 2 diabetes, there were significant associations 
between obesity and weight change and the development of CKD, and these associations were 
independent of biological mediators including hyperglycemia, dyslipidemia, and hypertension. 
Obese patients with a BMI ≥27.5 kg/m2 had a significant 1.7-fold increased likelihood that they 
would develop CKD compared to normal BMI patients. For diabetic patients who gained >10% of 
their baseline body weight over the seven-year follow-up, the risk of developing CKD was 3.8 fold 
greater compared to those who remained within a ±5% range of their baseline weight. Conversely, a 
modest weight loss of 5-10% was associated with a reduced risk of CKD, but weight loss >10% 
was not associated with a lower risk, indicating a J-shaped association. A similar J-shaped 
association was also found with pro-inflammatory cytokine IL-6.  
 
Few meta-analyses of cohort studies have evaluated obesity as a risk factor in the development of 
kidney disease in the general population.
3,16
 Recent prospective studies have also showed that 
weight gain over time, even among individuals with normal BMI, significantly predicted the risk of 
CKD in healthy populations.
17,18
 However, some interesting but conflicting results have been found 
in studies conducted among diabetic populations.
19-21
 High waist circumference but low BMI 
independently has predicted new onset of CKD over a follow-up of five years in Chinese patients 
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with type 2 diabetes.
19
 Raised BMI was reported to have no effect on the rate of progression to 
CKD in diabetic patients over a short follow-up period of 31 months.
20
 Therefore, we suggest that 
further studies are needed to assess long-term consequences of obesity on CKD and kidney failure 
in type 2 diabetes. It is interesting to note that studies conducted in Asian populations, such as 
Japanese
22
 and Malay adults,
23
 have reported a gender-specific association confined to men but not 
women. Our results showed that obese men had a higher risk of CKD than obese women after 
adjustment (OR=1.95, p=0.020 vs. OR=1.49, p=0.178), but the gender interaction did not reach 
significance (p=0.788). We did not observe significant gender differences with weight change either 
(Supplementary Tables 7.5 & 7.6), though insufficient power to detect the interaction effect may be 
one possibility for this lack of difference.   
 
Meta-analyses have reported that in general overweight and obese CKD patients, short-term non-
surgical weight loss interventions reduce proteinuria
24,25
 and blood pressure and prevent further 
decline in eGFR;
24
 while in morbidly obese individuals (BMI >40 kg/m
2
) with glomerular 
hyperfiltration, surgical interventions such as bariatric surgery normalise eGFR and ameliorate 
microalbuminuria and hypertension.
24
 The American Diabetes Association (ADA)
26
 and the 
National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-KDOQI)
2
 clinical 
guidelines have recommended overweight and obese individuals with diabetes (BMI ≥25 kg/m2)  
lose 10% of their body weight within one year to improve risk factors. However, there are limited 
studies providing evidence to support this recommendation for type 2 diabetic patients. Our findings 
suggest that 5-10% weight loss would reduce the risk of development of CKD in an Asian 
population. This benefit is supported by the Look AHEAD (Action for Health in Diabetes) study 
which recently carried out an intensive lifestyle intervention (reduced caloric consumption and 
increased physical activity) for overweight and obese adults with type 2 diabetes.
27,28
 One of their 
studies found that modest weight loss of 5-10% at one year was associated with significant 
improvements in blood pressure, glycemic status, and lipid profile.
27
 After an eight-year follow-up, 
another of their studies reported the incidence of very-high-risk CKD to be lower in the intervention 
group, suggesting a long-term beneficial effect of weight loss interventions on diabetic 
complications.
28
 However, prospective studies have reported that individuals with low BMI levels
29
 
or larger weight loss
17
 are at higher risk of kidney disease rather than a reduced risk. In the current 
study, no significant benefit was observed in patients who lost >10% of their body weight over a 
long-term period of follow-up. Overall, whether improvements in clinical outcomes such as blood 
pressure and blood sugar after weight loss actually translate to attenuated risk of CKD, or delay the 
rate of progression, is yet to be fully determined, particularly among Asian diabetic patients.  
 
 Page | 137  
  
The pathogenic mechanisms by which weight change is associated with the risk of CKD in type 2 
diabetes may be partially explained by pro-inflammatory IL-6. After five years of follow-up in 
2008, we observed that weight gain >10% was associated with the highest concentrations of IL-6, 
accompanied by a significant reduction in eGFR. A 5-10% weight loss was associated with the 
lowest concentrations, but weight loss >10% was associated with increased, rather than decreased, 
levels of IL-6. Obesity and diabetes both promote low-grade inflammation and macrophage 
infiltration into the kidneys.
30
 The infiltrated macrophages increase the release of pro-inflammatory 
mediators such as tumor necrosis factor-α (TNF-α), IL-6, and CRP, locally within adipose tissue 
and systemically.
30,31
 Both human and mouse models provide evidence that IL-6 is a key cytokine 
functioning downstream of angiotensin II signalling the induction of hypertension.
32
 IL-6 also 
directly contributes to the induction of fibrotic gene expression and endothelin 1 gene expression in 
the kidneys.
32
 One clinical trial suggested that weight loss treatment was significantly associated 
with reduced IL-6, and this improvement remained at 24 months regardless of participants regained 
their weight.
33
 We conclude that IL-6, in its role as a pro-inflammatory mediator, is a potent 
biological mechanism underlying the association between weight change and CKD in type 2 
diabetes.  
 
The effects of obesity on mortality in the general population and dialysis patients are controversial. 
One meta-analysis has reported obesity to be associated with higher all-cause mortality and 
overweight to be associated with lower mortality in the general poulation.
34
 Paradoxically, in 
patients receiving dialysis, obesity and weight gain appear to be associated with higher survival 
rates,
6,35,36
 and the survival advantage associated with obesity is more likely for patient receiving 
hemodialysis rather than peritoneal dialysis.
36
 Future studies need to consider these competing risks 
when investigating whether obesity modifies the association between ESRD and mortality.
37
 The 
effect of obesity of modifying this association is difficult to elucidate due to the competing risk of 
non-ESRD mortality occurring before ESRD is reached.
37
 Therefore, more prospective studies are 
needed to study its modification of this association. 
 
The strengths of this study are its use of longitudinal analysis with weight change over a relatively 
long period of time in an Asian diabetic population in the early stages of CKD, its use of the GEE 
models for repeated measures data, and its adjustments for a wide range of time-dependent 
mediators including HbA1C, lipids, and hypertension. Still, this study has some limitations. First, 
GFR was not measured directly from creatinine clearance rate but was estimated from the CKD-EPI 
equation. The CKD-EPI equation has been shown to be an accurate predictor of GFR, in particular 
for GFR <60 ml/min/1.73m
2
, and this four-level race equation reduced biases in Asian poulations.
14
 
 Page | 138  
  
Second, residual confounding and medication treatments remain a possible alternative explanation 
for our results. Third, we could not identify patients with un-intentional weight loss and exclude 
them from analyses. Un-intentional weight loss in the elderly and sick patients can be difficult to 
evaluate since many non-dieting and non-exercising factors are involved (e.g. medication side 
effect, psychiatric disorder, loss of appetite).
38 
Accurate evaluations are essential in future studies.  
 
In conclusion, obesity and weight gain over the seven-year follow-up were associated with 
increased risk of CKD in Taiwanese patients with type 2 diabetes. A modest weight loss (5-10% of 
initial body weight) may be beneficial to reduce the risk of CKD if patients are overweight or obese 
initially, but the advantages of weight loss >10% remain uncertain. Pro-inflammatory cytokine IL-6 
may be a pathogenic link between weight change and diabetes-related glomerulopathy. These 
analyses provide evidence that can be used to guide the prevention and management of CKD in 
Asian diabetic patients. Larger, long-term studies are needed to analysis the impact of obesity and 
weight change on the development of ESRD or mortality in diabetic patients with later stages of 
CKD.    
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Table 7.1 Baseline characteristics of 1199 type 2 diabetic patients according to baseline BMI 
categories    
 Body mass index (kg/m
2
)  
 Normal 
<23 
Overweight 
23-27.4 
Obese 
≥27.5 
p-value 
N (%) 252 (21.0) 592 (49.4) 355 (29.6)  
Male (%) 110 (19.2) 314 (54.7) 150 (26.1) 0.002 
Female (%) 142 (22.7) 278 (44.5) 205 (32.8)  
Age (years) 56.6±8.4 56.7±8.5 54.1±8.7 <0.001 
Diabetes duration (years)  6.5±6.1 5.0±5.3 4.0±5.4 <0.001 
    ≥10 years (%) 73 (29.3) 112 (19.0) 43 (12.2) <0.001 
BMI (kg/m
2
) 21.3±1.5 25.1±1.3 30.4±2.7 <0.001 
Education ≤6 years (%) 149 (59.1) 327 (55.2) 204 (57.5) 0.547 
Smoking (%)    0.263 
Never 181 (72.1) 385 (65.0) 249 (70.1)  
Past  24 (9.6) 73 (12.3) 35 (9.9)  
Current  46 (18.3) 134 (22.6) 71 (20.0)  
Drinking alcohol (%) 30 (12.0) 104 (17.6) 49 (13.8) 0.077 
SBP (mm Hg) 126.4±15.7 130.0±17.3 132.3±15.5 <0.001 
DBP (mmHg) 77.7±8.2 80.2±9.5 83.6±10.2 <0.001 
HbA1C (%) 9.0±2.2 8.4±1.9 8.2±1.8 <0.001 
Triglycerides (mg/dL) 170.6±232.6 172.1±129.1 199.9±198.6 0.058 
ACR (mg/g) 11.5 (4.0, 41.8) 11.0 (4.0, 36.0) 11.0 (4.0, 61.0) 0.381 
eGFR (mL/min/1.73m
2
)  102.4±21.9 96.9±21.7 99.5±20.7 0.003 
Age-adjusted eGFR  103.3 (101.0-105.6) 98.0 (96.5-99.5) 97.2 (95.2-99.1) <0.001 
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1C, 
haemoglobin A1C; ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate. Data are presented as 
number (%), mean ± standard deviation, median (IQR), or adjusted mean (95% CI). P-values for continuous variables 
are from ANOVA and for categorical variables from chi-square test. 
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Table 7.2 Age- and multivariate-adjusted ORs and 95% CIs for CKD (eGFR <60 mL/min/1.73m
2
) according to continuous BMI measurement and 
BMI category using repeated measures data from baseline, 2008, 2009, and 2010 
BMI  Age-adjusted p-value Model 1
a
 p-value Model 2 
b
 p-value 
    Continuous  (kg/m
2
) 1.07 (1.03-1.11) <0.001 1.06 (1.02-1.10) 0.003 1.05 (1.01-1.09) 0.018 
    Category       
        Normal (<23) 1.00  1.00  1.00  
        Overweight (23-27.4) 1.32 (0.94-1.84) 0.108 1.38 (0.99-1.92) 0.057 1.33 (0.95-1.86) 0.102 
        Obese (≥27.5) 1.87 (1.26-2.77) 0.002 1.83 (1.23-2.71) 0.003 1.67 (1.11-2.51) 0.013 
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; BMI, body mass index. Data are presented as OR (95% CI). Generalized estimating 
equation (GEE) models were performed using repeated measures data. 
a
 Model 1: adjusted for age, gender, diabetes duration, education (≤6y, >6y), smoking (never, past, current 
smoker), alcohol consumption (yes, no), and time (baseline, 2008, 2009, 2010). 
b
 Model 2: adjusted for all covariates in model 1 plus HbA1C, triglycerides, and hypertension 
(systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or self-reported antihypertensive medication use).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Page | 144  
  
Table 7.3 Age- and multivariate-adjusted means and 95% CIs for eGFR (mL/min/1.73m
2
) in 2010 according to weight and BMI change over the 
seven-year follow-up 
 Age-adjusted p-value Model 1 p-value Model 2 p-value 
Weight change        
    Continuous (%) -0.49 (0.10) <0.001 -0.47 (0.10) <0.001 -0.43 (0.10) <0.001 
    Category       
        < -10 87.8 (81.9-93.7) 0.481 87.0 (81.2-92.9) 0.598 86.7 (80.9-92.4) 0.668 
        < -5 to -10 90.5 (86.6-94.4) 0.029 91.0 (87.1-94.8) 0.012 90.6 (86.8-94.4) 0.015 
        -5 to +5 85.6 (83.6-87.6) - 85.4 (83.4-87.4) - 85.3 (83.4-87.3) - 
        > +5 to +10  80.5 (76.1-84.9) 0.041 80.8 (76.4-85.2) 0.063 81.0 (76.7-85.3) 0.074 
        > +10  76.2 (70.7-81.8) 0.002 77.2 (71.6-82.7) 0.007 78.0 (72.6-83.4) 0.013 
BMI change        
    Continuous (%) -0.40 (0.10) <0.001 -0.38 (0.10) <0.001 -0.34 (0.10) <0.001 
    Category       
        < -10 87.5 (81.3-93.6) 0.556 86.8 (80.7-92.8) 0.665 87.0 (81.0-92.9) 0.595 
        < -5 to -10 91.1 (87.1-95.0) 0.016 91.3 (87.4-95.2) 0.009 91.1 (87.2-94.9) 0.009 
        -5 to +5 85.5 (83.4-87.6) - 85.3 (83.3-87.4) - 85.3 (83.2-87.3) - 
        > +5 to +10  81.5 (77.5-85.5) 0.082 81.4 (77.3-85.4) 0.084 81.2 (77.2-85.1) 0.073 
        > +10  77.9 (73.0-82.7) 0.004 79.0 (74.2-83.9) 0.019 80.0 (75.3-84.8) 0.047 
Abbreviations: eGFR, estimated glomerular filtration rate; BMI, body mass index. Data are presented as beta (standard error) or adjusted mean (95% CI). Multiple linear regression 
and ANCOVA were performed. 
a
 Model 1: adjusted for age, gender, diabetes duration, education (≤6y, >6y), smoking (never, past, current smoker), alcohol consumption (yes, no) at 
baseline. 
b
 Model 2: adjusted for all covariates in model 1 plus HbA1C, triglycerides, and hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg 
or self-reported antihypertensive medication use) in 2010.  
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Table 7.4 Age- and multivariate-adjusted ORs and 95% CIs for CKD (eGFR <60 mL/min/1.73m
2
) in 2010 according to weight and BMI change over 
the seven-year follow-up 
 Age-adjusted p-value Model 1
 a
 p-value Model 2
 b
 p-value 
Weight change        
    Continuous (%) 1.07 (1.04-1.10) <0.001 1.07 (1.04-1.10) <0.001 1.07 (1.04-1.10) <0.001 
    Category        
        < -10 0.88 (0.37-2.08) 0.777 0.92 (0.38-2.21) 0.847 0.98 (0.40-2.39) 0.965 
        < -5 to -10 0.52 (0.26-1.06) 0.071 0.48 (0.23-0.99) 0.048 0.48 (0.23-1.00) 0.050 
        -5 to +5 1.00  1.00  1.00  
        > +5 to +10  1.86 (1.05-3.29) 0.034 1.82 (1.02-3.27) 0.044 1.81 (0.99-3.28) 0.052 
        > +10  3.86 (2.03-7.35) <0.001 3.83 (1.96-7.46) <0.001 3.80 (1.89-7.62) <0.001 
BMI change        
    Continuous (%) 1.06 (1.03-1.09) <0.001 1.06 (1.03-1.09) <0.001 1.06 (1.03-1.09) <0.001 
    Category       
        < -10 0.79 (0.32-1.97) 0.612 0.79 (0.31-2.02) 0.624 0.77 (0.30-1.97) 0.581 
        < -5 to -10 0.56 (0.28-1.16) 0.119 0.53 (0.25-1.09) 0.085 0.52 (0.25-1.09) 0.084 
        -5 to +5 1.00  1.00  1.00  
        > +5 to +10  1.70 (0.99-2.92) 0.054 1.77 (1.01-3.09) 0.045 1.76 (0.99-3.12) 0.055 
        > +10  3.08 (1.72-5.52) <0.001 2.98 (1.63-5.43) <0.001 2.79 (1.49-5.22) 0.001 
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; BMI, body mass index. Data are presented as OR (95% CI). Multivariable logistic 
regression models were performed. 
a
 Model 1: adjusted for age, gender, diabetes duration, education (≤6y, >6y), smoking (never, past, current smoker), alcohol consumption (yes, 
no) at baseline. 
b
 Model 2: adjusted for all covariates in model 1 plus HbA1C, triglycerides, and hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 
mmHg or self-reported antihypertensive medication use) in 2010.  
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Figure 7.1 Relationship between weight change (from baseline to 2008), renal function, and 
inflammatory biomarkers  meausred in 2008 (n=844)  
Three markers were examined: (A) eGFR (B) IL-6 (C) CRP. The mean differences in biomarkers 
among the five weight change categories were tested by ANCOVA adjusting for age and post-hoc 
analysis. * indictaes significant difference p<0.05, and # indicates p<0.1, weight change ±5% as 
reference. 
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7.3 Supplementary materials for online publication  
Table 7.5 Gender-stratified analysis of age- and multivariate-adjusted ORs and 95% CIs for CKD (eGFR <60 mL/min/1.73m
2
) according to 
continuous BMI measurement and BMI category using repeated measures data from baseline, 2008, 2009, and 2010 
BMI  Age-adjusted p-value Model 1
a
 p-value Model 2
 b
 p-value 
Men       
    Continuous  (kg/m
2
) 1.10 (1.05-1.17) <0.001 1.09 (1.04-1.15) 0.001 1.08 (1.02-1.14) 0.004 
    Category       
        Normal (<23) 1.00  1.00  1.00  
        Overweight (23-27.4) 1.26 (0.79-1.99) 0.337 1.44 (0.91-2.28) 0.122 1.38 (0.88-2.17) 0.165 
        Obese (≥27.5) 1.99 (1.13-3.51) 0.017 2.12 (1.21-3.73) 0.009 1.95 (1.11-3.42) 0.020 
Women       
    Continuous  (kg/m
2
) 1.05 (1.00-1.10) 0.054 1.04 (0.98-1.09) 0.173 1.03 (0.97-1.09) 0.355 
    Category       
        Normal (<23) 1.00  1.00  1.00  
        Overweight (23-27.4) 1.35 (0.83-2.19) 0.223 1.36 (0.84-2.21) 0.217 1.29 (0.78-2.15) 0.320 
        Obese (≥27.5) 1.78 (1.03-3.10) 0.040 1.63 (0.93-2.84) 0.086 1.49 (0.83-2.66) 0.178 
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; BMI, body mass index. Data are presented as OR (95% CI). Generalized estimating 
equation (GEE) models were performed using repeated measures data. 
a
 Model 1: adjusted for age, diabetes duration, education (≤6y, >6y), smoking (never, past, current smoker), 
alcohol consumption (yes, no), and time (baseline, 2008, 2009, 2010). 
b
 Model 2: adjusted for all covariates in model 1 plus HbA1C, triglycerides, and hypertension (systolic blood 
pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or self-reported antihypertensive medication use).  
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Table 7.6 Gender-stratified analysis of age- and multivariate-adjusted ORs and 95% CIs for CKD (eGFR <60 mL/min/1.73m
2
) in 2010 according to 
BMI change over the seven-year follow-up 
BMI change  Age-adjusted p-value Model 1
a
 p-value Model 2
 b
 p-value 
Men        
    Continuous (%) 1.09 (1.04-1.14) <0.001 1.09 (1.04-1.14) <0.001 1.09 (1.04-1.14) <0.001 
    Category       
        < -10 0.29 (0.04-2.37) 0.247 0.27 (0.03-2.31) 0.231 0.36 (0.04-3.08) 0.348 
        < -5 to -10 0.43 (0.15-1.19) 0.104 0.39 (0.14-1.13) 0.083 0.39 (0.13-1.15) 0.088 
        -5 to +5 1.00  1.00  1.00  
        > +5 to +10  1.59 (0.72-3.50) 0.247 1.64 (0.71-3.82) 0.250 1.82 (0.77-4.33) 0.173 
        > +10  3.21 (1.31-7.90) 0.011 2.86 (1.12-7.31) 0.028 2.87 (1.10-7.46) 0.030 
Women        
    Continuous (%) 1.05 (1.01-1.08) 0.006 1.05 (1.02-1.09) 0.004 1.04 (1.01-1.08) 0.014 
    Category        
        < -10 1.26 (0.44-3.61) 0.669 1.11 (0.38-3.25) 0.850 0.82 (0.27-2.47) 0.718 
        < -5 to -10 0.72 (0.26-1.98) 0.518 0.60 (0.21-1.73) 0.347 0.60 (0.20-1.79) 0.364 
        -5 to +5 1.00  1.00  1.00  
        > +5 to +10  1.85 (0.87-3.92) 0.108 2.00 (0.94-4.29) 0.073 1.76 (0.79-3.91) 0.167 
        > +10  3.28 (1.50-7.18) 0.003 3.16 (1.39-7.15) 0.006 2.61 (1.08-6.29) 0.033 
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; BMI, body mass index. Data are presented as OR (95% CI). Multivariable logistic 
regression models were performed. 
a
 Model 1: adjusted for age, diabetes duration, education (≤6y, >6y), smoking (never, past, current smoker), alcohol consumption (yes, no) at 
baseline. 
b
 Model 2: adjusted for all covariates in model 1 plus HbA1C, triglycerides, and hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg 
or self-reported antihypertensive medication use) in 2010.  
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7.4 Additional analyses 
Relationship between baseline BMI, weight change and adiponectin  
Table 7.7 shows the relationship between baseline BMI, inflammatory biomarkers, and eGFR. This 
table supports the findings in the results section of chapter 7.2 (data not shown). Since IL-6 and 
CRP have been reported in the submitted manuscript, we only present the relationship with 
adiponectin here. As expected, patients who were overweight or obese at baseline tended to have 
lower concentrations of anti-inflammatory adiponectin (p-trend=0.002) over the five-year follow-up 
period compared with those with normal BMI. However, increased adiponectin, accompanied with 
decline in renal function, was observed in our patients who gained weight over time (Fig. 7.2).  
 
Table 7.7 Age-adjusted kidney function and inflammatory markers in the 2008 examination 
according to baseline BMI  
Baseline BMI (kg/m
2
) 
eGFR 
(mL/min/1.73m
2
) 
IL-6 
(pg/mL) 
Adiponectin 
(ng/mL) 
CRP 
(mg/dL) 
<23 90.4 (87.1-93.8) 1.00 (0.76-1.23) 9.21 (8.25-10.16) 0.20 (0.11-0.29) 
23-27.4 87.5 (85.4-89.6) 1.42 (1.27-1.57) 6.46 (5.86-7.07) 0.31 (0.25-0.36) 
≥27.5 86.6 (84.0-89.2) 1.64 (1.46-1.82) 6.92 (6.18-7.66) 0.33 (0.26-0.40) 
    p-trend 0.096 <0.001 0.002 0.035 
 
 
Figure 7.2 Relationship between weight change (from baseline to 2008) and adiponectin meausred 
in 2008 (n=844) 
The mean differences among the weight change categories were tested by ANCOVA adjusting for 
age and post-hoc analysis. * indicates p<0.05, weight change ±5% as reference. 
 Page | 150  
  
Interrelationship between baseline BMI, BMI change, and inflammatory biomarkers  
Figure 7.5 shows the interrelationship between baseline BMI, BMI change, and eGFR or 
inflammatory markers. The effect of weight gain on eGFR was stronger for patients who were 
overweight or obese at baseline than for those who were normal weight (p-trend=0.002 vs. p-
trend=0.025). Patients who were overweight or obese at baseline and who increased their baseline 
BMI by >10% were found to have the lowest levels of eGFR and highest concentrations of IL-6.  
 
 
 
Figure 7.3 Interrelationship between baseline BMI, BMI change (between baseline and 2008), and 
(A) eGFR (B) IL-6 (C) adiponectin (D) CRP in the 2008 examination  
The p-trend across the BMI change categories was stratified by baseline BMI and tested by linear 
regression.  
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Obesity, weight change, and albuminuria  
Table 7.1 shows that the levels of ACR were similar among three BMI categories at baseline 
(p=0.381). We then categorised patients with an ACR ≥30 mg/g as having albuminuria. In the age- 
adjusted GEE model, higher BMI was associated with increased risk of albuminuria (OR=1.03, 
95% CI=1.00-1.06, p=0.024) (Table 7.8). The positive effect became marginally significant after 
multivariable adjustment (OR=1.03, 95% CI=1.00-1.05, p=0.069). However, this positive 
association was not observed when BMI was treated as a categorical variable (normal, overweight, 
and obese groups).  
 
The odds ratios for albuminuria according to changes in weight and BMI are shown in Table 7.9. 
Although the association between weight change and albuminuria was not statistically significant, 
ORs for albuminuria were above one for both modest weight gain (5-10%) and large weight gain 
(>10%) groups, and their estimated effects on albuminuria were similar after adjustment. We 
further combined these two weight gain groups and compared it with stable weight group. We 
obtained a narrower confidence interval with a greater sample power, but the increased ORs for 
albuminuria did not reach statistical significance for both weight gain (OR=1.26, 95% CI: 0.84-
1.87) and BMI gain (OR=1.16, 95% CI:0.80-1.69) (Table 7.9). In summary, we observed obese 
group and weight gain group had slightly increased odds of albuminuria, but the associations were 
not statistically significant.  
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Table 7.8 Age- and multivariate-adjusted ORs and 95% Cis for albuminuria (ACR ≥30 mg/g) according to continuous BMI measurement and BMI 
category using repeated measures data from baseline, 2008, 2009, and 2010  
BMI  Age-adjusted p-value Model 1 p-value Model 2 p-value 
Continuous  (kg/m
2
) 1.03 (1.00-1.06) 0.024 1.03 (1.00-1.06) 0.032 1.03 (1.00-1.05) 0.069 
Category       
        Normal (<23) 1.00  1.00  1.00  
        Overweight (23-27.4) 0.89 (0.73-1.08) 0.226 0.93 (0.76-1.12) 0.435 0.88 (0.71-1.08) 0.228 
        Obese (≥27.5) 1.15 (0.91-1.44) 0.241 1.18 (0.93-1.49) 0.164 1.10 (0.86-1.41) 0.436 
Data are presented as OR (95% CI). Generalized estimating equation (GEE) models were performed using repeated measures data. Model 1: adjusted for age, gender, diabetes 
duration, education (≤6y, >6y), smoking (never, past, current smoker), alcohol consumption (yes, no), and time (baseline, 2008, 2009, 2010). Model 2: adjusted for all covariates in 
model 1 plus HbA1C, triglycerides, and hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or self-reported antihypertensive medication use).  
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Table 7.9 Age- and multivariate-adjusted ORs and 95% Cis for albuminuria (ACR ≥30 mg/g) in 2010 according to weight and BMI change between 
baseline and 2010  
 Age-adjusted p-value Model 1 p-value Model 2 p-value 
Weight change  1.01 (0.99-1.03) 0.188 1.01 (0.99-1.03) 0.217 1.01 (0.99-1.03) 0.440 
Continuous (%)       
Category        
        < -10 0.85 (0.48-1.51) 0.575 0.88 (0.49-1.60) 0.681 0.91 (0.48-1.73) 0.778 
        < -5 to -10 0.93 (0.62-1.39) 0.723 0.86 (0.57-1.30) 0.473 0.86 (0.55-1.35) 0.512 
        -5 to +5 1.00  1.00  1.00  
        > +5 to +10  1.35 (0.87-2.09) 0.187 1.31 (0.84-2.05) 0.241 1.35 (0.84-2.18) 0.216 
        > +10  1.35 (0.79-2.31) 0.277 1.24 (0.71-2.15) 0.445 1.12 (0.62-2.02) 0.714 
       weight gain combined 1.35 (0.94-1.94) 0.110 1.28 (0.88-1.86) 0.192 1.26 (0.84-1.87) 0.259 
BMI change        
Continuous (%) 1.01 (0.99-1.02) 0.477 1.01 (0.99-1.02) 0.567 1.00 (0.98-1.02) 0.884 
Category       
        < -10 1.00 (0.55-1.81) 0.990 1.05 (0.57-1.92) 0.879 0.92 (0.48-1.76) 0.794 
        < -5 to -10 1.18 (0.78-1.77) 0.433 1.13 (0.75-1.71) 0.567 1.15 (0.74-1.81) 0.533 
        -5 to +5 1.00  1.00  1.00  
        > +5 to +10  1.14 (0.75-1.72) 0.548 1.18 (0.77-1.80) 0.451 1.15 (0.73-1.81) 0.555 
        > +10  1.39 (0.86-2.23) 0.180 1.27 (0.78-2.07) 0.342 1.18 (0.70-2.01) 0.534 
       BMI gain combined 1.23 (0.88-1.73) 0.227 1.21 (0.86-1.72) 0.276 1.16 (0.80-1.69) 0.433 
Data are presented as OR (95% CI). Multivariable logistic regression models were performed. Model 1: adjusted for age, gender, diabetes duration, education (≤6y, >6y), smoking 
(never, past, current smoker), alcohol consumption (yes, no) at baseline. Model 2: adjusted for all covariates in model 1 plus HbA1C, triglycerides, and hypertension (systolic blood 
pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or self-reported antihypertensive medication use) in 2010.  
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7.5 Chapter conclusion   
In conclusion, a high BMI (≥27.5 kg/m2) was associated significantly with a higher risk for kidney 
dysfunction (CKD) in Taiwanese patients with type 2 diabetes. We observed a J-shaped association 
between weight change and CKD. Weight gain (particularly weight gain >10%) increased the risk 
for CKD. A modest weight loss of 5 to 10% had a reduced risk of CKD, but a larger weight loss 
>10% did not have a lower risk. However, we were unable to differentiate between intentional and 
un-intentional weight loss in this study. It was found that the effect of obesity on CKD was stronger 
among in men than women, although there was no significant interaction. The J-shaped association 
was also found with the pro-inflammatory marker IL-6 such that a 5-10% weight loss was 
associated with reduced IL-6, while weight loss >10% was associated with increased IL-6. IL-6 
may be an important mediator linking obesity and kidney disease in type 2 diabetes. Additionally, 
obesity was associated with lower adiponectin. Weight gain over time, accompanied with kidney 
damage, was associated with higher levels of adiponectin. In this diabetic population, we did not 
observe significant association between obesity, weight change and albuminuria. Our findings 
provide clinical evidence for guiding the development of long-term weight management strategies 
in the prevention of CKD in Asian diabetic patients. Un-intentional weight loss, especially in 
elderly or ESRD patients, needs to be carefully evaluated in future studies. 
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Chapter 8: General discussion  
Given the high prevalence of risk factors for chronic kidney disease (CKD) (e.g. obesity, type 2 
diabetes, and hypertension), the increasing prevalence of kidney disease worldwide is not 
surprising.
1
 With the presence of CKD leading to multiple adverse health outcomes including 
cardiovascular disease (CVD), kidney failure, cognitive impairment, and death,
1
 there is growing 
interest in more effective prevention and management strategies for kidney disease, particularly in 
middle-aged and elderly populations with co-morbidities.  
 
Cohort study designs might be optimal to study the development of diabetic kidney disease (DKD) 
since diabetic patients may change their behaviours over time. Chapter 2 (literature review) found 
relatively few cohort studies that examine genetic and lifestyle factors related to DKD. In the last 
decade, case-control study designs have been commonly used for genetic-epidemiologic studies.
248
 
Recently, an increasing number of cohort studies have been carried out because case-cohort or 
nested case-control studies can effectively determine causality.
 254,255 
Accordingly, new statistical 
models have been developed to analyse survival data and longitudinal data. For example, Kaplan-
Meier curves and Cox hazard models have been used to analyse disease progression using censored 
time-to-event data.
248,249
 Generalized estimating equations (GEE) models, which control for the 
inherent correlation of observations within each subject, have been increasingly used to analyse 
longitudinal data (or repeated measures data) when the population-average effect is of interest.
250
  
 
The studies described in this PhD thesis were conducted using a diabetic cohort followed over a 10-
year period. Additional laboratory experiments (including ADIPOQ genotype determination, fatty 
acid extraction and analysis, and circulating adiponectin and IL-6 measurements) were performed 
as part of this research to identify mechanisms underlying the progression of DKD (Chapter 3). The 
previous four chapters presented the risk factors for the development of DKD including ADIPOQ 
genetic variations (Chapter 4), dietary patterns (Chapter 5), erythrocyte fatty acids (Chapter 6), and 
obesity/weight change (Chapter 7). This chapter provides a brief summary of the major findings in 
each chapter. I only provide an overview of the main findings in this chapter given the in-depth 
discussions provided in each of the previous chapters. I also discuss the gender-specific effects and 
gene-environment interactions. I then discuss the clinical implications for prevention and 
management of DKD and suggest a direction for future research.  
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8.1 Major findings 
At the end of the 10-year follow-up period, the average age of diabetic patients was 63.0 years, and 
the average duration of diabetes was 12.7 years. The overall incidence of diabetic nephropathy (DN; 
albuminuria) for the Diabetes Management through Integrated Delivery System (DMIDS) cohort 
was 6.7/100 person-years, and the prevalence was as high as 65%. For this PhD research, the 
primary aim was to examine whether each of the risk factors identified were associated with the 
development of kidney disease in Taiwanese patients with type 2 diabetes, and the secondary aim 
was to explore which inflammatory markers, if any, underlie such relationships.  
  
Chapter 4: ADIPOQ genetic variations and DN (albuminuria) 
1) The genotype frequencies of 18 ADIPOQ single nucleotide polymorphisms (SNPs) 
determined in this Taiwanese diabetic population were generally comparable with the 
HapMap Chinese reference population.   
2) Male patients carrying ADIPOQ SNP rs2241766 (+45T/G) TT, rs1063537 CC, rs2241767 
AA, and rs2082940 CC recessive homozygotes had an increased hazard of albuminuria over 
a six-year follow-up, but no association was found in female patients, indicating a gender-
specific effect.   
3) The ADIPOQ genetic variations were not associated with circulating adiponectin in this 
diabetic cohort. Patients with albuminuria tended to have higher, rather than lower, 
adiponectin, although the difference did not reach significance.  
4) Women tended to have higher concentrations of adiponectin than men regardless of kidney 
disease status.  
 
Chapter 5: Dietary patterns and DKD 
1) Three major dietary patterns were identified in this population across surveys: high fat-meat 
dietary pattern, traditional Chinese food-snack dietary pattern, and fish-vegetable dietary 
pattern. 
2) The fish-vegetable pattern was associated with a reduced risk of kidney dysfunction, while 
there was no association for the high fat-meat pattern or Chinese food-snack pattern. 
3) A higher intake of fish, or adherence to the fish-vegetable pattern, was associated with 
higher concentrations of erythrocyte n-3 polyunsaturated fatty acids (PUFAs) (including 
eicosapentaenoic acid, EPA and docosahexaenoic acid, DHA), indicating this pattern can be 
evaluated by nutrient biomarkers. 
4) Dietary patterns were not directly associated with inflammatory biomarkers or albuminuria 
in this diabetic population. 
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Chapter 6: Fatty acids, inflammatory biomarkers, and DKD 
1) Higher concentrations of erythrocyte PUFAs, particularly n-3 PUFAs, were associated with 
a reduced risk of renal function decline over time. 
2) IL-6 was a significant independent predictor of renal function decline over time.    
3) High inflammatory n-3 PUFAs attenuated the pro-inflammatory effect of IL-6 on renal risk. 
4) Fatty acids and inflammatory biomarkers were not associated with albuminuria in this study. 
 
Chapter 7: Obesity, weight change, and DKD 
1) High body mass index (BMI), in particular obesity (BMI ≥27.5 kg/m2), was associated with 
an increased risk of kidney dysfunction (CKD).  
2) Obese men had a slightly higher risk of CKD than obese women, although there was no 
statistically significant interaction.  
3) Weight gain, particularly a weight gain >10% of baseline body weight, was significantly 
associated with an increased risk of CKD. A modest weight loss 5-10 % was associated with 
a reduced risk of CKD, but a larger weight loss >10% was not associated with a lower risk, 
indicating a J-shaped association. A similar J-shaped association was observed with BMI 
change.    
4) A J-shaped association was also found between weight change and the pro-inflammatory 
cytokine IL-6 plasma concentrations. A large weight loss >10% was associated with higher, 
rather than lower, concentration of IL-6. Moreover, patients who were overweight or obese 
at baseline and gained >10% of their initial body weight had the lowest levels of estimated 
glomerular filtration rate (eGFR) and highest concentrations of IL-6.  
5) High baseline BMI was associated with lower concentrations of adiponectin, while weight 
gain was associated with increased adiponectin along with decreased kidney function. 
6) There was no association found between obesity, weight/BMI change, and albuminuria in 
this diabetic cohort. 
 
In the summary figure of main findings (Fig. 8.1), ADIPOQ genetic variations were associated with 
the progression to albuminuria only in men. Lifestyle factors were significantly associated with the 
development of kidney dysfunction but not with albuminuria. Obesity and weight gain were 
associated with an increased risk of kidney dysfunction; however, a modest weight loss of 5-10% of 
initial body weight, higher intake of a fish-vegetable diet, as well as higher erythrocyte n-3 PUFAs, 
appeared to reduce the risk. The beneficial effects of high n-3 PUFA and weight loss might be 
partly due to the attenuation of the pro-inflammatory IL-6 response. However, a large weight loss 
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>10% did not have significant benefits, which suggests a J-shaped association. It is clear that 
patients with kidney disease tended to have higher concentrations of IL-6 but also adiponectin. An 
increase in anti-inflammatory adiponectin could be partly due to a negative feedback regulation to 
reduce vascular damage. We concluded that IL-6 is a potent inflammatory mediator that links diet 
and obesity to kidney dysfunction in type 2 diabetes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1 Summary of major findings presented in this PhD thesis   
Abbreviations: RBC, red blood cell (erythrocyte); PUFAs, polyunsaturated fatty acids; EPA, 
eicosapentaenoic acid; DHA, docosahexaenoic acid; IL-6, interlukin-6; eGFR, estimated glomerular 
filtration rate; NS, non-significant.     
 
 
8.2 Discussion 
Overview of risk factors for DKD 
Our findings not only enrich previous knowledge about the impact of genetic and lifestyle factors 
on kidney disease but also provide empirical evidence for the possible mechanisms underlying such 
complex relationships in Taiwanese patients with type 2 diabetes. In addition to ADIPOQ genetic 
variations, diet, and obesity, other important risk factors for DKD found in our previous studies 
include IL-6 genetic polymorphisms, iron overload (high ferritin), insulin resistance, and HbA1C 
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variability.
23,24,236,251
 An overview of all risk factors for DKD found in this Taiwanese diabetic 
cohort is shown in Figure 8.2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.2 Overview of risk factors for DKD in the DMIDS cohort   
Abbreviations: HbA1C, hemoglobin A1C; HOMA-IR, homeostasis model assessment for insulin 
resistance; RBC, red blood cell (erythrocyte); PUFAs, polyunsaturated fatty acids; EPA, 
eicosapentaenoic acid; DHA, docosahexaenoic acid; IL-6, interlukin-6; eGFR, estimated glomerular 
filtration rate; NS, non-significant.     
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In this cohort, we found that IL-6 rs1800796 (-634 C>G) GG and rs2069837 GG carriers had worse 
albuminuria-free survival rates and also had increased hazard of progression to albuminuria after 
multivariable adjustment, compared with rs1800796 CG+CC and rs2069837 AG+GG carriers, 
respectively (Fig. 8.2, data not shown, unpublished data). Both ADIPOQ and IL-6 genetic variants 
were not significantly associated with adiponectin or IL-6 plasma concentrations in this diabetic 
cohort. Patients with kidney disease tended to have higher concentrations of IL-6 but also higher 
adiponectin, but the variations in these inflammatory biomarkers are relatively large. Although 
adiponectin and IL-6 have high genetic heritability,
12,13,252
 the genetic mechanisms for mRNA 
expression and protein production remain unclear in patients with diabetes given low-grade 
systemic and adipose tissue inflammation found in type 2 diabetes. 
 
The increase in circulating adiponectin among patients with kidney disease could be explained 
primarily by alteration in body composition and metabolic profiles (such as serum leptin), which 
occurs with progression in renal insufficiency or as proteinuria worsens.
253
 Elevated adiponectin 
might be a physiological counter regulatory response to attenuate endothelial damage and vascular 
damage.
122
 However, this increase is not the result of up-regulating adiponectin expression since 
adiponectin gene expression is significantly down-regulated in patients with end stage renal disease 
(ESRD) compared with age-, gender-, and BMI-matched healthy patients.
254
 Marchlewska et.al 
(2004) concluded that a negative feedback mechanism down-regulates the gene expression of 
adiponectin because of increased levels of adiponectin caused by renal failure.
254
  
 
The findings from the Nutrition And Health Survey in Taiwan (NAHSIT) support the conclusion 
that a diet rich in fish, vegetables, lean meats, milk, and fruit, and some specific Chinese food items 
such as soybeans, mushrooms, and seaweed may have beneficial effects on metabolic syndrome.
143
 
However, total intake of fish in Taiwan reduced from 4.56 to 3.69 times per week from the 1993-
1996 survey to the 2005-2008 survey, although the intake of sea fish increased slightly (from 0.82 
to 1.30 times per week).
143
 The intake of certain healthy foods including dark-green vegetables, 
fruit, soybeans, and lean meats did not increase over time either.
143
 This will be a challenge for 
future nutritional strategies to promote general health. Participants in this diabetic population 
consumed fish, on average, 3-4 times per week, which is comparable with the Taiwan general 
population. The diabetic patients in this cohort were receiving nutritional recommendations 
regularly and may have improved their dietary habits to include healthier options.   
 
Inflammation has been suggested as the main underlying pathophysiologic mechanism for the 
relationship between unhealthy diet and kidney disease.
135
 In this population, a high fat-meat 
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(Western-style) pattern was not associated with either inflammatory biomarkers or renal outcomes. 
Lack of direct association may be partly explained by dietary modifications and complexities of 
disease conditions. However, our previous studies found that this dietary pattern was highly 
associated with ferritin (a nutrient biomarker of iron stores),
23
 and high ferritin was found to be an 
independent risk factor for insulin resistance and albuminuria (Fig. 8.2).
23,24
 Insulin resistance was 
also a strong predictor of albuminuria.
236
 These findings suggest another pathway through which the 
impact of high fat and high meat intake on kidney damage in diabetes may involve worsening of 
insulin sensitivity via the iron metabolic pathway.
255
 The relationship between iron and glucose 
metabolism appears to be bi-directional, and iron depletion has been found to be beneficial in 
endothelial dysfunction and coronary artery responses.
255
 Further studies are required to confirm 
this diet-ferritin-disease association. Moreover, individual variation in inflammatory markers was 
large in patients with type 2 diabetes given low-grade systemic inflammation and complexities or 
co-morbid conditions of diabetes. Estimating an average effect over repeated measures is suggested.   
 
Our previous seven-year prospective study also found that high variability of HbA1C was a 
significant predictor of the progression of microalbuminuria in type 2 diabetes (Fig. 8.2).
251
 Glucose 
fluctuations have been found to activate oxidative stress and cause endothelial dysfunction.
256,257
 
Patients with high HbA1C variability (poor glycemic control) often live unhealthier lifestyles, 
which may also aggravate their vulnerability to the progression of DKD.
251
 The results also provide 
useful guidance for clinical applications; a two-year estimate of HbA1C variability can be 
considered as a short-term monitoring indicator for the development of albuminuria.
251
  
 
Hyperglycemia, hypertension, and dyslipidemia are well-known key risk factors for DKD. 
Antihypertensive therapies such as angiotensin-converting enzyme inhibitor (ACEi) and lipid-
lowering treatments such as statins have demonstrated some anti-proteinuric effects in patients with 
type 2 diabetes.
258-260
 Hypertension is prevalent in this cohort, and the majority of hypertensive 
patients take some antihypertensive medications. However, history of medication use was self-
reported, and participants only reported whether they take antihypertensive or lipid-lowering 
medications or not (yes or no). One limitation is that we are unable to discuss the mechanisms of 
specific types of medications and medication adherence in the pathogenesis of DKD. We included 
medication use as a confounder in some of our adjusted models. Moreover, cigarette smoking, 
excessive alcohol consumption, and physical inactivity appear to be risk factors associated with 
kidney disease in both diabetic and non-diabetic patients.
261-265
 In this study, we did not find 
significant associations of these lifestyle factors with DKD, but we included them as covariates in 
multivariable models.  
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Gender differences  
We highlight here some gender differences in the associations between risk factors and the 
development of DKD. ADIPOQ polymorphisms were associated with the progression of 
albuminuria in males but not in females. A gene-gender specific effect was also found in European 
populations but among females.
19,20
 Females tended to have higher concentrations of adiponectin 
than males regardless of kidney disease status, revealing a sexual dimorphism. This could be 
explained by the fact that androgens and testosterone decrease circulating adiponectin,
243
 indicating 
that sexual hormones play a significant role in the production of adiponectin. Moreover, we 
observed that obese males had a slightly higher risk of CKD than obese females although there was 
no statistically significant gender interaction. Studies from Asian populations, including 
Japanese
197,198
 and Malay adults,
199
 also reported a gender-specific association confined to males 
but not females. However, in Western populations, obese females were at higher risk of kidney 
stones,
200
 kidney cancer,
201
 and renal cell carcinoma
202,203
 than obese males. The complex gene-
gender interaction, gender-related regulation, and biological mechanisms remain largely unknown. 
Differences in nephron number or renal mass, systemic or glomerular hemodynamics, dietary 
intake, body fat composition, and direct effect of sex hormones may explain the gender differences 
in kidney disease.
26,62,66
 We concluded that gender and race are critical proxy indicators for both 
genetic and environmental factors. Current studies are attempting to further clarify gender and 
ethnic disparities and to identify what biological mechanisms underlie gene-gender interactions.  
 
Gene-environment interactions 
The pathogenesis of DKD is multifactorial as a consequence of an intricate interplay between genes 
and environmental exposures such as toxins, and lifestyle factors such as drugs, diet, smoking, 
alcohol, and exercise.
266,267
 Genetic and environmental variations contribute significantly to DKD 
susceptibility and progressive loss of kidney function.
266
 The gene-environment interaction can be 
understood as genetic control of an individual’s response to environmental factors.268 In this PhD 
research, ADIPOQ genetic variations were associated with the progression of albuminuria only in 
men (n=263). We did not have enough statistical power to detect gene-diet or gene-nutrient 
interactions with DKD due to a small sample size. Current evidence has shown a gene-environment 
interaction in obesity,
269
 hypertension,
268
 type 2 diabetes,
270
 and metabolic syndrome,
271
 which are 
leading causes of CKD. Few studies have investigated whether ADIPOQ is one of the genes that 
can interact with diet (especially dietary fats) or nutrients to regulate insulin action, metabolism of 
glucose and lipids, and also the up-regulation of adiponectin.
12,15,16,272,273
 ADIPOQ polymorphism -
11377C/G can interact with saturated fatty acids (SFAs) to alter insulin sensitivity,
15
 and can also 
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interact with the percentage of energy derived from fat in the diet for the development of obesity.
16
 
One study found interaction effects between ADIPOQ polymorphisms (-11377C/G, +45T/G, 
+276G/T) and dietary monounsaturated fatty acid (MUFA) to SFA ratios on serum total cholesterol 
and low density lipoprotein (LDL) cholesterol.
273
 Moreover, ADIPOQ SNP +276G/T was found to 
interact with dietary fibre to affect circulating adiponectin,
272
 and -10066G/G to interact with 
dietary MUFAs to modify adiponectin concentrations with advancing age.
12
 To date, little is known 
about the gene-diet or gene-lifestyle interactions with the progression of DKD. Gene-environment 
interactions may be important in modulating susceptibility for the development of DKD, so studies 
using a large enough sample size to detect the interactions are required.  
15,16
 
 
8.3 Implications and future research  
Clinical implications for the management of DKD 
Our findings identify gender-specific ADIPOQ genetic effect on the progression to albuminuria in 
the Taiwanese population, and also provide empirical evidence that would inform the development 
of lifestyle management programs to prevent or delay the progression of DKD for Asian 
populations. Asians have different dietary habits and different overweight and obesity cut-off points 
compared to Caucasians. We suggest that higher intakes of omega-3 (e.g. fish and fish oil) and plant 
food sources (e.g. vegetables), and modest weight loss of 5-10% of initial body weight could be 
useful clinical recommendations for Asian adults to prevent or manage the progression of DKD. 
Our suggestions are supported by the latest American Diabetes Association (ADA) consensus 
conference 2014 report (Table 8.1).
274
 The nutritional recommendations in the report are based on 
the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) 2007 
clinical guideline for diabetes and CKD,
5
 the Kidney Disease: Improving Global Outcomes 
(KDIGO) 2012 clinical guideline for CKD,
275
 and the ADA 2014 guidelines for diabetes.
276,277
 
Several dietary and lifestyle recommendations are discussed below:   
 
Fatty acids  
Consistent with our suggestion, the KDOQI 2007 guideline recommends that DKD patients 
increase their intake of omega-3 (to 10% of total calories) and omega-9 fatty acids (to 10% of total 
calories), but consume less dietary fat (<30% of total calories) and saturated fat (<10% of total 
calories) (Tables 8.1, 8.2).
5
 Adequate intake of alpha-linolenic acid (ALA, omega-3 fatty acid) is 
suggested to be 1.6g/day for men and 1.1g/day for women.
5
 Up to 10% of the omega-3 amounts can 
be substituted by EPA and/or DHA.
5
 The guideline recommends one serving of marine fish (i.e. 
tuna, sardines, salmon, mackerel and herring) three times per week.
5,278
 The ADA 2014 nutritional 
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guidelines also recommend an increase of foods containing long-chain omega-3 fatty acids (EPA 
and DHA from fatty fish) and omega-3 ALA (Table 8.1).
276,277
 At least two servings of fish per 
week are recommended for diabetic patients and for the general public.
277
 More than three servings 
of marine fish would provide fish oil in excess of the 10% of adequate intake amounts and raise 
some concerns of mercury contaminants.
5
 In addition, taking EPA and DHA supplements >3g may 
cause excessive bleeding and other adverse health outcomes.
174
 In summary, the renoprotective 
effect of omega-3 fatty acids has been recommended to CKD patients with or without diabetes, but 
excessive intake of fish or fish oil supplements may cause heavy metal toxicity and adverse health 
outcomes.   
 
Other nutrients  
The guidelines also recommend limiting intakes of protein, carbohydrate, and sodium (Tables 8.1, 
8.2).
274
 The ADA suggests diabetic patients maintain a dietary protein intake of approximately 16-
18% of total calories.
277
 Low-protein intake of 0.8 g/kg per day (about 10% of total energy) is 
recommended for adults with DKD or CKD stages 1-4.
5,275
 CKD Patients need to avoid high 
protein diets of >1.3 g/kg/day
275
 or ≥20% of total energy intake.5 Specifically, the KDOQI guideline 
suggests changing the protein source to soy protein, lean poultry, fish, and vegetable protein, with 
50% of protein from fish rich in omega-3.
5
  
 
Recommendations also pertain to carbohydrate and sodium intake. Approximately 50~60% of daily 
calories should come from carbohydrates; predominantly from vegetables, fruits, and whole grains 
(40-45%).
5,277
 Sodium restriction is also critical. Dietary sodium reduction to <2.3g per day (100 
mmol per day) (based on the DASH diet) has been recommended for diabetic and DKD 
patients.
5,276,277,279
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Table 8.1 The ADA consensus conference 2014 report: macronutrient recommendations in DKD 
274
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Table 8.2 The KDOQI 2007 clinical guideline: a balanced diet for CKD patients with or without 
diabetes - macronutrients and minerals 
5
  
 
 
 
Dietary patterns  
Our study suggests that the fish-vegetable dietary pattern is beneficial in reducing the progression of 
kidney dysfunction in type 2 diabetes. The ADA recently suggested promoting a healthy diet that 
incorporates nutritional principles to manage DKD (Table 8.3).
274
 For instance, incorporating vegan 
protein sources into meals; de-emphasizing fatty animal protein sources; enriching the diet with 
olive oil, fish oil, and vegetarian sources of omega-3 fatty acids; and reducing salt use are important 
principles to incorporate with whole diets.
274
 The KDOQI also suggests limiting intake of saturated 
fats, cholesterol, and sodium, and controlling carbohydrate, protein, and caloric intake (Table 8.4). 
Current studies have demonstrated potential benefits of the Mediterranean
280
 and DASH
281
 diets, 
both of which are rich in whole-grains (unrefined), vegetables, fruits, and plant protein (nuts, seeds, 
and beans), for reducing CVD risk factors. A Mediterranean diet pattern also incorporates foods that 
contain relatively higher quantities of MUFAs and PUFAs such as olive oil, fish, and red wine.
274
 
Whether healthy dietary patterns will directly affect DKD progression and CVD risk remains 
unclear.
274
 Incorporating healthy diets with lifestyle modifications (including weight reduction, 
exercise, and smoking cessation) could be a progressive approach for management of DKD.
274
 
Therefore, it is very important that patients achieve and maintain adequate intakes of macronutrients 
and minerals as well as a normal BMI to prevent disease risk and promote overall health.
274
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Table 8.3 The ADA consensus conference 2014 report: approaches to incorporating diet patterns 
for management for DKD 
274
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Table 8.4 The KDOQI 2007 clinical guideline: goals for risk factor management in patients with 
diabetes 
5
 
 
 
 
Weight management  
A modest weight reduction of 10% is also suggested for risk factor management by the KDOQI 
guideline (Table 8.4).
5
 Since Asians are at a greater disease risk at lower BMI cut-off points, we 
suggest Asian diabetic patients maintain a normal BMI of 18.5 to 23 kg/m
2
, rather than 18.5 to 25 
kg/m
2
.
196
 A 5-10% loss of initial weight is beneficial for Asian patients to reduce their risk of DKD. 
Weight loss should be achieved by a well-balanced calorie-restricted diet, rather than by consuming 
a diet with the majority of calories from animal protein (patients with CKD should avoid a high 
protein diet where >20% of total calories come from protein sources).
5,274
 A weight management 
plan should include regular physical activities as well.
5,274
 However, the obesity paradox should be 
carefully assessed as overweight and obesity are associated with better survival in ESRD
28
 and 
among diabetic patients.
31
  
 
Control of key risk factors  
Although lifestyle modifications are important risk-reduction strategies for preventing DKD, patient 
outcomes are most improved with simultaneous intensive control of hyperglycemia, hypertension, 
and dyslipidemia (Table 8.5).
274
 The general recommendations for diabetes are: HbA1C <7%, blood 
pressure <140/80 mmHg, and LDL-C <100 mg/dL or a 30~40% of reduction from baseline. 
However, the goal is modified for DKD patients. Optimised HbA1C is <8% when GFR 
<60mL/min/1.73m
2
 as a result of increased risk of hypoglycaemia. The goal for blood pressure is 
<140/90 mmHg for DKD. Oral medications are generally prescribed to control these key risk 
factors, but reduced doses (e.g. of statins and insulin) are often recommended for patients with GFR 
<60mL/min/1.73m
2
. 
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Table 8.5 The ADA consensus conference 2014 report: recommendations for key risk factor 
management in DKD 
274
  
 
 
 
In summary, clinical management of DKD should be multidisciplinary. Lifestyle modifications 
including a healthy diet and weight management are important risk-reduction strategies with 
simultaneous control of key risk factors (hyperglycemia, hypertension, and dyslipidemia). Healthy 
lifestyle changes such as smoking cessation and exercise adherence are also strongly recommended. 
Our study provides empirical evidence in support of the current clinical guidelines for Asian 
patients with type 2 diabetes. Several important messages from our study are presented below. 
Generally, patients with type 2 diabetes should:    
1) Increase intake of fish and vegetable dietary pattern. 
2) Consume sufficient omega-3 fatty acids to support a renoprotective effect. 
3) Maintain a normal weight (BMI 18.5 to 23 kg/m2).   
4) Lose 5-10% of initial body weight if overweight or obese 
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Applications of dietary biomarkers  
A dietary biomarker can be understood as a biochemical indicator to reflect recent or long-term 
dietary intake/nutritional status.
282
 Due to the complexities of dietary exposure, there are some 
random and systematic measurement errors and biases for all types of dietary assessment methods 
(e.g. questionnaire, diary, and 24-hour recall).
170
 Thus, the main advantage of dietary biomarkers is 
that they are objective measures.
170
 Our findings support that erythrocyte n-3 PUFAs can be used as 
dietary biomarkers to reflect long-term intake of fish and fish oil,
41,169
 while serum ferritin can 
reflect meat intake (especially red meats) in clinical research.
283
 Recent studies have introduced 
serum folate, carotenoids, and vitamin C as biomarkers of vegetable and fruit intake or prudent 
dietary pattern.
160,169,170,284,285
 There are different types of dietary biomarkers including recovery, 
predictive, concentration, and replacement dietary biomarkers (Fig. 8.3).
170
 Erythrocyte/plasma 
fatty acids and serum ferritin measured in this cohort can be defined as concentration dietary 
biomarkers. This type of dietary biomarker can be used to make comparisons with estimates of 
dietary intakes. The biomarker concentrations are correlated with intake of corresponding food 
items/groups/nutrients, although the strength of the correlation is relatively low (r<0.6).
170
  
 
Concentration dietary biomarkers are commonly applied to estimate diet-disease risk 
associations,
286
 especially when used in prospective cohort studies or clinical intervention trials. 
This is because the nature of the study designs allows the observation of the effect of dietary 
exposure, or the evaluation of the effect of dietary treatment, on disease risk or progression.
170
 The 
use of such biomarkers can take into account the influence of absorption, metabolism, excretion, 
and interactions between nutrients. However, many other factors may affect the measurement and 
utility of a dietary biomarker to properly reflect dietary exposures including genetic variability, 
lifestyle or physiologic factors, biological samples, analytical methodology, and nutrient 
bioaccessibility/ bioavailability.
170
 All these factors make it very difficult to compare the 
concentrations of dietary biomarkers across studies because different racial populations are assessed 
and different biological samples and analytical methods are used. To enhance the application and 
interpretation of dietary biomarkers, methods to improve current use of dietary biomarkers and 
identification of new dietary biomarkers (e.g. nutritional metabonomics) are required (Fig. 8.3). 
Researchers need to enhance laboratory methods and have a better understanding of nutrient 
metabolism and gene-diet, gene-nutrient, or gene-gene interactions.
170
 Based on the current 
findings, we recommended that further studies use dietary biomarkers (e.g. folate and carotenoids) 
as additional or substitute estimates of vegetable intake to clarify risk factors for complex diseases 
such as DKD. The inclusion of repeated dietary assessments and dietary biomarker measurements 
are essential in future research to minimise variations due to the complexities of disease condition 
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and possible diet modifications that occur after being diagnosed with type 2 diabetes. This would 
allow the estimation of an average effect over time among diabetic populations. 
 
 
 
Figure 8.3 Different classes of dietary biomarkers and their application to the validation of dietary 
assessment methods, measurement errors, and effect on disease risk 170 
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Future research  
Overall, a potential interactive association between diet, lifestyle, genetics, and risk of chronic 
disease has been investigated increasingly over the last decade. Diet is one of the major factors that 
directly contributes to the risk of many chronic diseases including obesity, type 2 diabetes, CKD, 
and CVD. Dietary biomarkers are increasingly used as a substitute to assess dietary intake and 
nutrient status. However, genetic variability can lead to differences in digestion, absorption, 
transport, metabolism, biotransformation, and excretion of nutrients or food components.
170
 To date, 
genetic influence per se on dietary choice and food intake, and the effects of gene-diet/nutrient 
interactions or gene-gene interactions on dietary biomarkers to directly or indirectly affect disease 
risk, are largely unexplored (Fig. 8.4).
170
 Such studies would provide insight into whether dietary 
biomarkers are more effectively utilized to assess dietary exposure in different populations where 
there are differences in genetic background. Current studies of gene-diet/nutrients interactions are 
mostly carried out in North American or European populations. Future studies are needed for a 
better understanding of these complex interactions in different racial groups such as Asians. A 
future priority should be to explore the gene-diet-lifestyle-disease risk associations in different 
racial groups, integrating high quality dietary assessment, effective use of dietary and genetic 
biomarkers, and novel statistical methods.
170
 
 
 
 
Figure 8.4 Possible interactions between dietary intake and dietary biomarkers with genetic 
variability to affect disease risk 170   
 
 
 
 Page | 173  
  
ADIPOQ polymorphisms have been found to interact with diet/nutrients (especially fatty acids) to 
affect insulin resistance, obesity and lipid profiles,
15,16,273
 which are all important risk factors for the 
development of CKD and CVD. In this cohort, our sample size (prospective design n=566, 
male=263) lacked statistical power to detect the gene-diet/nutrient interaction with the risk of DKD 
due to gender differences in the ADIPOQ genetic effect. We are also unable to incorporate lifestyle 
factors such as smoking, alcohol, exercise, and BMI into these complex interactions with disease 
risk. Future studies need to increase the power of analyses for this complex disease by carrying out 
a larger prospective cohort or a nested case-control studies over a longer period of follow-up. It is of 
interest to explore whether ADIPOQ genetic polymorphisms can interact with dietary fat/fatty acids 
and lifestyles (e.g. smoking, BMI) to affect the progression of DKD or its risk factors (e.g. insulin 
resistance) in Asian populations. There is also a need for future studies to include gene-by-
environment interplay in clinical trials to understand how intervention impacts vary between 
individuals due to specific genetic variations.  
 
In addition to exploring potent genetic and environmental risk factors for DKD, assessing how well 
diabetes is controlled is another priority for future studies so that diabetic complications may be 
prevented. How diabetic patients modify their lifestyle behaviours (such as diet) over time, and 
whether they adhere to medications, are the key components of diabetes management. Future 
studies also need to examine how complex gene-lifestyle interactions affect an individual’s 
response to medications.   
 
 
 
 
 
 
 
 
 
 
 Page | 174  
  
References  
1. Stevens LA, Viswanathan G, Weiner DE. Chronic kidney disease and end-stage renal 
disease in the elderly population: current prevalence, future projections, and clinical 
significance. Adv Chronic Kidney Dis. 2010;17(4):293-301. 
2. Marshall SM. Recent advances in diabetic nephropathy. Postgrad Med J. 2004;80(949):624-
633. 
3. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic 
nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164-176. 
4. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality 
associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes 
mellitus. Arch Intern Med. 2000;160(8):1093-1100. 
5. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice 
Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(2 
Suppl 2):S12-154. 
6. Yokoyama H, Kanno S, Takahashi S, Yamada D, Itoh H, Saito K, et al. Determinants of 
decline in glomerular filtration rate in nonproteinuric subjects with or without diabetes and 
hypertension. Clin J Am Soc Nephrol. 2009;4(9):1432-1440. 
7. Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG. Prevalence and risk factors for 
microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. 
Kidney Int. 2006;69(11):2057-2063. 
8. US Renal Data System. USRDS 2009 Annual Data Report: Atlas of End-Stage Renal 
Disease in the United States. Available at: http://www.usrds.org/atlas09.aspx. Accessed 
September  2014. 
9. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney 
disease as a risk factor for development of cardiovascular disease: a statement from the 
American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood 
Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 
2003;42(5):1050-1065. 
10. Rachmani R, Ravid M. Risk factors for nephropathy in type 2 diabetes mellitus. Compr 
Ther. 1999;25(6-7):366-369. 
11. Heid IM, Henneman P, Hicks A, Coassin S, Winkler T, Aulchenko YS, et al. Clear 
detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-
 Page | 175  
  
wide association analyses including 4659 European individuals. Atherosclerosis. 
2010;208(2):412-420. 
12. AlSaleh A, O'Dell SD, Frost GS, Griffin BA, Lovegrove JA, Jebb SA, et al. Single 
nucleotide polymorphisms at the ADIPOQ gene locus interact with age and dietary intake of 
fat to determine serum adiponectin in subjects at risk of the metabolic syndrome. Am J Clin 
Nutr. 2011;94(1):262-269. 
13. Comuzzie AG, Funahashi T, Sonnenberg G, Martin LJ, Jacob HJ, Black AE, et al. The 
genetic basis of plasma variation in adiponectin, a global endophenotype for obesity and the 
metabolic syndrome. J Clin Endocrinol Metab. 2001;86(9):4321-4325. 
14. AlSaleh A, Sanders TA, O'Dell SD. Effect of interaction between PPARG, PPARA and 
ADIPOQ gene variants and dietary fatty acids on plasma lipid profile and adiponectin 
concentration in a large intervention study. Proc Nutr Soc. 2012;71(1):141-153. 
15. Ferguson JF, Phillips CM, Tierney AC, Perez-Martinez P, Defoort C, Helal O, et al. Gene-
nutrient interactions in the metabolic syndrome: single nucleotide polymorphisms in 
ADIPOQ and ADIPOR1 interact with plasma saturated fatty acids to modulate insulin 
resistance. Am J Clin Nutr. 2010;91(3):794-801. 
16. Santos JL, Boutin P, Verdich C, Holst C, Larsen LH, Toubro S, et al. Genotype-by-nutrient 
interactions assessed in European obese women. A case-only study. Eur J Nutr. 
2006;45(8):454-462. 
17. Yang WS, Chuang LM. Human genetics of adiponectin in the metabolic syndrome. J Mol 
Med (Berl). 2006;84(2):112-121. 
18. Gu HF. Biomarkers of adiponectin: plasma protein variation and genomic DNA 
polymorphisms. Biomark Insights. 2009;4:123-133. 
19. Zhang D, Efendic S, Brismar K, Gu HF. Effects of MCF2L2, ADIPOQ and SOX2 genetic 
polymorphisms on the development of nephropathy in type 1 Diabetes Mellitus. BMC Med 
Genet. 2010;11:116. 
20. Zhang D, Ma J, Brismar K, Efendic S, Gu HF. A single nucleotide polymorphism alters the 
sequence of SP1 binding site in the adiponectin promoter region and is associated with 
diabetic nephropathy among type 1 diabetic patients in the Genetics of Kidneys in Diabetes 
Study. J Diabetes Complications. 2009;23(4):265-272. 
21. Wu LS, Hsieh CH, Pei D, Hung YJ, Kuo SW, Lin E. Association and interaction analyses of 
genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic 
nephropathy in a Taiwanese population with type 2 diabetes. Nephrol Dial Transplant. 
2009;24(11):3360-3366. 
 Page | 176  
  
22. Vionnet N, Tregouet D, Kazeem G, Gut I, Groop PH, Tarnow L, et al. Analysis of 14 
candidate genes for diabetic nephropathy on chromosome 3q in European populations: 
strongest evidence for association with a variant in the promoter region of the adiponectin 
gene. Diabetes. 2006;55(11):3166-3174. 
23. Yu FJ, Huang MC, Chang WT, Chung HF, Wu CY, Shin SJ, et al. Increased ferritin 
concentrations correlate with insulin resistance in female type 2 diabetic patients. Ann Nutr 
Metab. 2012;61(1):32-40. 
24. Hsu YH, Huang MC, Chang HY, Shin SJ, Wahlqvist ML, Chang YL, et al. Association 
between serum ferritin and microalbuminuria in Type 2 diabetes in Taiwan. Diabet Med. 
2013;30(11):1367-1373. 
25. Hsu CC, Jhang HR, Chang WT, Lin CH, Shin SJ, Hwang SJ, et al. Associations between 
dietary patterns and kidney function indicators in type 2 diabetes. Clin Nutr. 2014;33(1):98-
105. 
26. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and 
kidney disease: a systematic review and meta-analysis. Kidney Int. 2008;73(1):19-33. 
27. Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S. Weight 
loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J 
Am Soc Nephrol. 2009;4(10):1565-1574. 
28. Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, McAllister CJ, Shinaberger CS, Gjertson 
DW, et al. Association of morbid obesity and weight change over time with cardiovascular 
survival in hemodialysis population. Am J Kidney Dis. 2005;46(3):489-500. 
29. Abbott KC, Glanton CW, Trespalacios FC, Oliver DK, Ortiz MI, Agodoa LY, et al. Body 
mass index, dialysis modality, and survival: analysis of the United States Renal Data System 
Dialysis Morbidity and Mortality Wave II Study. Kidney Int. 2004;65(2):597-605. 
30. Fleischmann E, Teal N, Dudley J, May W, Bower JD, Salahudeen AK. Influence of excess 
weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int. 
1999;55(4):1560-1567. 
31. Carnethon MR, Rasmussen-Torvik LJ, Palaniappan L. The obesity paradox in diabetes. 
Curr Cardiol Rep. 2014;16(2):446. 
32. Franz MJ. The dilemma of weight loss in Diabetes. Diabetes Spectrum. 2007;20(3):133-136. 
33. Iglesias P, Diez JJ. Adipose tissue in renal disease: clinical significance and prognostic 
implications. Nephrol Dial Transplant. 2010;25(7):2066-2077. 
34. Dinh QN, Drummond GR, Sobey CG, Chrissobolis S. Roles of inflammation, oxidative 
stress, and vascular dysfunction in hypertension. Biomed Res Int. 2014 July 20. doi: 
10.1155/2014/406960 [Epub ahead of print]. 
 Page | 177  
  
35. Garcia-Garcia PM, Getino-Melian MA, Dominguez-Pimentel V, Navarro-Gonzalez JF. 
Inflammation in diabetic kidney disease. World J Diabetes. 2014;5(4):431-443. 
36. Imig JD, Ryan MJ. Immune and inflammatory role in renal disease. Compr Physiol. 
2013;3(2):957-976. 
37. Wu J, Xia S, Kalionis B, Wan W, Sun T. The role of oxidative stress and inflammation in 
cardiovascular aging. Biomed Res Int. 2014 July 20. doi: 10.1155/2014/615312 [Epub ahead 
of print]. 
38. Brown AA, Hu FB. Dietary modulation of endothelial function: implications for 
cardiovascular disease. Am J Clin Nutr. 2001;73(4):673-686. 
39. Beddhu S. The body mass index paradox and an obesity, inflammation, and atherosclerosis 
syndrome in chronic kidney disease. Semin Dial. 2004;17(3):229-232. 
40. Hu F. Dietary pattern analysis: a new direction in nutritional epidemiology. Curr Opin 
Lipidol. 2002;13(1):3-9. 
41. Sun Q, Ma J, Campos H, Hankinson SE, Hu FB. Comparison between plasma and 
erythrocyte fatty acid content as biomarkers of fatty acid intake in US women. Am J Clin 
Nutr. 2007;86(1):74-81. 
42. Oller do Nascimento CM, Ribeiro EB, Oyama LM. Metabolism and secretory function of 
white adipose tissue: effect of dietary fat. An Acad Bras Cienc. 2009;81(3):453-466. 
43. Senior PA. Diabetes and chronic kidney disease: concern, confusion, clarity? Can J 
Diabetes.2014;38(5):287-289. 
44. World Health Organisation. Diabetes fact sheet 2013. Available at: 
http://www.who.int/features/factfiles/diabetes/en/. Accessed September 2014. 
45. Yokoyama H, Okudaira M, Otani T, Sato A, Miura J, Takaike H, et al. Higher incidence of 
diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. 
Kidney Int. 2000;58(1):302-311. 
46. Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N, et al. Decreasing incidence 
of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care. 2003;26(4):1258-
1264. 
47. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: 
the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. 
Endocr Rev. 2004;25(6):971-1010. 
48. American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes 
Care. 2011;34 Suppl 1:S11-61. 
49. Jerums G, Panagiotopoulos S, Premaratne E, MacIsaac RJ. Integrating albuminuria and 
GFR in the assessment of diabetic nephropathy. Nat Rev Nephrol. 2009;5(7):397-406. 
 Page | 178  
  
50. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with 
type 2 diabetes. N Engl J Med. 2002;346(15):1145-1151. 
51. Pickering J. Diabetes in NZ – new scary data 2013. Available at:  
https://100dialysis.wordpress.com/tag/chronic-kidney-disease/. Accessed September 2014. 
52. Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes 
mellitus. Arch Intern Med. 1999;159(16):1873-1880. 
53. Pelletier EM, Smith PJ, Boye KS, Misurski DA, Tunis SL, Minshall ME. Direct medical 
costs for type 2 diabetes mellitus complications in the US commercial payer setting: a 
resource for economic research. Appl Health Econ Health Policy. 2008;6(2-3):103-112. 
54. Nichols GA, Vupputuri S, Lau H. Medical care costs associated with progression of diabetic 
nephropathy. Diabetes Care. 2011;34(11):2374-2378. 
55. Young BA, Maynard C, Boyko EJ. Racial differences in diabetic nephropathy, 
cardiovascular disease, and mortality in a national population of veterans. Diabetes Care. 
2003;26(8):2392-2399. 
56. Wu AY, Kong NC, de Leon FA, Pan CY, Tai TY, Yeung VT, et al. An alarmingly high 
prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria 
Prevalence (MAP) Study. Diabetologia. 2005;48(1):17-26. 
57. Pavkov ME, Knowler WC, Hanson RL, Nelson RG. Diabetic nephropathy in American 
Indians, with a special emphasis on the Pima Indians. Curr Diab Rep. 2008;8(6):486-493. 
58. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and 
progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes 
Study (UKPDS 64). Kidney Int. 2003;63(1):225-232. 
59. Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in 
diabetic complications in an insured population. JAMA. 2002;287(19):2519-2527. 
60. Brancati FL, Whittle JC, Whelton PK, Seidler AJ, Klag MJ. The excess incidence of 
diabetic end-stage renal disease among blacks. A population-based study of potential 
explanatory factors. JAMA. 1992;268(21):3079-3084. 
61. Aaberg ML, Burch DM, Hud ZR, Zacharias MP. Gender differences in the onset of diabetic 
neuropathy. J Diabetes Complications. 2008;22(2):83-87. 
62. Iseki K. Gender differences in chronic kidney disease. Kidney Int. 2008;74(4):415-417. 
63. Gava AL, Freitas FP, Meyrelles SS, Silva IV, Graceli JB. Gender-dependent effects of aging 
on the kidney. Braz J Med Biol Res. 2011;44(9):905-913. 
64. Iseki K, Iseki C, Ikemiya Y, Fukiyama K. Risk of developing end-stage renal disease in a 
cohort of mass screening. Kidney Int. 1996;49(3):800-805. 
 Page | 179  
  
65. Halbesma N, Brantsma AH, Bakker SJ, Jansen DF, Stolk RP, De Zeeuw D, et al. Gender 
differences in predictors of the decline of renal function in the general population. Kidney 
Int. 2008;74(4):505-512. 
66. Silbiger S, Neugarten J. Gender and human chronic renal disease. Gend Med. 2008;5 Suppl 
A:S3-S10. 
67. Zdunek M, Silbiger S, Lei J, Neugarten J. Protein kinase CK2 mediates TGF-beta1-
stimulated type IV collagen gene transcription and its reversal by estradiol. Kidney Int. 
2001;60(6):2097-2108. 
68. Hayashi T, Yamada K, Esaki T, Mutoh E, Iguchi A. Effect of estrogen on isoforms of nitric 
oxide synthase: possible mechanism of anti-atherosclerotic effect of estrogen. Gerontology. 
1997;43 Suppl 1:24-34. 
69. Kuo H, Tsai S, Tiao M, Yang C. Epidemiological features of CKD in Taiwan. Am J Kidney 
Dis. 2007;49(1):46-55. 
70. Chang HY, Hsu CC, Pan WH, Liu WL, Cheng JY, Tseng CH, et al. Gender differences in 
trends in diabetes prevalence from 1993 to 2008 in Taiwan. Diabetes Res Clin Pract. 
2010;90(3):358-364. 
71. Department of Health, Taiwan. The leading cause of death in 2009. Available at: 
http://www.doh.gov.tw/CHT2006/DM/DM2_2.aspx?now_fod_list_no=11663. Accessed 
September 2012. 
72. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, et al. All-cause mortality 
attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in 
Taiwan. Lancet. 2008;371(9631):2173-2182. 
73. Hsu CC, Hwang SJ, Wen CP, Chang HY, Chen T, Shiu RS, et al. High prevalence and low 
awareness of CKD in Taiwan: a study on the relationship between serum creatinine and 
awareness from a a ationally representative survey. Am J Kidney Dis. 2006;48(5):727-738. 
74. Middleton R, Foley R, Hegarty J, Cheung CM, McElduff P, Gibson JM, et al. The 
unrecognized prevalence of chronic kidney disease in diabetes. Nephrol Dial Transplant. 
2006;21(1):88-92. 
75. Zelmanovitz T, Gerchman F, Balthazar AP, Thomazelli FC, Matos JD, Canani LH. Diabetic 
nephropathy. Diabetol Metab Syndr. 2009;1(1):10. 
76. D'Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int. 2003;63(3):809-825. 
77. Rowe DJ, Dawnay A, Watts GF. Microalbuminuria in diabetes mellitus: review and 
recommendations for the measurement of albumin in urine. Ann Clin Biochem. 1990;27(Pt 
4):297-312. 
 Page | 180  
  
78. Lane JT. Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes 
mellitus: a temporal perspective. Am J Physiol Renal Physiol. 2004;286(3):F442-450. 
79. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, et al. 
Nephropathy in diabetes. Diabetes Care. 2004;27 Suppl 1:S79-83. 
80. Levey A, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney 
Foundation practice guidelines for chronic kidney disease: evaluation, classification, and 
stratification. Ann Intern Med. 2003;139(2):137-147. 
81. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new 
equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612. 
82. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating 
glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 
2012;367(1):20-29. 
83. Stevens LA, Claybon MA, Schmid CH, Chen J, Horio M, Imai E, et al. Evaluation of the 
Chronic Kidney Disease Epidemiology Collaboration equation for estimating the glomerular 
filtration rate in multiple ethnicities. Kidney Int. 2011;79(5):555-562. 
84. Rudberg S, Persson B, Dahlquist G. Increased glomerular filtration rate as a predictor of 
diabetic nephropathy--an 8-year prospective study. Kidney Int. 1992;41(4):822-828. 
85. Macisaac RJ, Tsalamandris C, Thomas MC, Premaratne E, Panagiotopoulos S, Smith TJ, et 
al. The accuracy of cystatin C and commonly used creatinine-based methods for detecting 
moderate and mild chronic kidney disease in diabetes. Diabet Med. 2007;24(4):443-448. 
86. Fornoni A, Ijaz A, Tejada T, Lenz O. Role of inflammation in diabetic nephropathy. Curr 
Diabetes Rev. 2008;4(1):10-17. 
87. Mora C, Navarro JF. Inflammation and diabetic nephropathy. Curr Diab Rep. 
2006;6(6):463-468. 
88. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Garcia-Perez J. 
Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev 
Nephrol. 2011;7(6):327-340. 
89. Granier C, Makni K, Molina L, Jardin-Watelet B, Ayadi H, Jarraya F. Gene and protein 
markers of diabetic nephropathy. Nephrol Dial Transplant. 2008;23(3):792-799. 
90. Iyengar SK, Fox KA, Schachere M, Manzoor F, Slaughter ME, Covic AM, et al. Linkage 
analysis of candidate loci for end-stage renal disease due to diabetic nephropathy. J Am Soc 
Nephrol. 2003;14(7 Suppl 2):S195-201. 
91. Freedman BI, Bostrom M, Daeihagh P, Bowden DW. Genetic factors in diabetic 
nephropathy. Clin J Am Soc Nephrol. 2007;2(6):1306-1316. 
 Page | 181  
  
92. Bowden DW, Colicigno CJ, Langefeld CD, Sale MM, Williams A, Anderson PJ, et al. A 
genome scan for diabetic nephropathy in African Americans. Kidney Int. 2004;66(4):1517-
1526. 
93. Imperatore G, Knowler WC, Nelson RG, Hanson RL. Genetics of diabetic nephropathy in 
the Pima Indians. Curr Diab Rep. 2001;1(3):275-281. 
94. Iyengar SK, Abboud HE, Goddard KA, Saad MF, Adler SG, Arar NH, et al. Genome-wide 
scans for diabetic nephropathy and albuminuria in multiethnic populations: the family 
investigation of nephropathy and diabetes (FIND). Diabetes. 2007;56(6):1577-1585. 
95. Placha G, Poznik GD, Dunn J, Smiles A, Krolewski B, Glew T, et al. A genome-wide 
linkage scan for genes controlling variation in renal function estimated by serum cystatin C 
levels in extended families with type 2 diabetes. Diabetes. 2006;55(12):3358-3365. 
96. Vardarli I, Baier LJ, Hanson RL, Akkoyun I, Fischer C, Rohmeiss P, et al. Gene for 
susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3-23. Kidney Int. 
2002;62(6):2176-2183. 
97. Krolewski AS, Poznik GD, Placha G, Canani L, Dunn J, Walker W, et al. A genome-wide 
linkage scan for genes controlling variation in urinary albumin excretion in type II diabetes. 
Kidney Int. 2006;69(1):129-136. 
98. Moczulski DK, Rogus JJ, Antonellis A, Warram JH, Krolewski AS. Major susceptibility 
locus for nephropathy in type 1 diabetes on chromosome 3q: results of novel discordant sib-
pair analysis. Diabetes. 1998;47(7):1164-1169. 
99. Osterholm AM, He B, Pitkaniemi J, Albinsson L, Berg T, Sarti C, et al. Genome-wide scan 
for type 1 diabetic nephropathy in the Finnish population reveals suggestive linkage to a 
single locus on chromosome 3q. Kidney Int. 2007;71(2):140-145. 
100. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and 
association genetic mapping studies of complex traits. Bioinformatics. 2003;19(1):149-150. 
101. Yang Y, Zhang F, Ding R, Wang Y, Lei H, Hu D. Association of ADIPOQ gene 
polymorphisms and coronary artery disease risk: a meta-analysis based on 12 465 subjects. 
Thromb Res. 2012;130(1):58-64. 
102. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived 
hormone adiponectin reverses insulin resistance associated with both lipoatrophy and 
obesity. Nat Med. 2001;7(8):941-946. 
103. Jorsal A, Tarnow L, Frystyk J, Lajer M, Flyvbjerg A, Parving HH, et al. Serum adiponectin 
predicts all-cause mortality and end stage renal disease in patients with type I diabetes and 
diabetic nephropathy. Kidney Int. 2008;74(5):649-654. 
 Page | 182  
  
104. Bostrom MA, Freedman BI, Langefeld CD, Liu L, Hicks PJ, Bowden DW. Association of 
adiponectin gene polymorphisms with type 2 diabetes in an African American population 
enriched for nephropathy. Diabetes. 2009;58(2):499-504. 
105. Jaziri R, Aubert R, Roussel R, Emery N, Maimaitiming S, Bellili N, et al. Association of 
ADIPOQ genetic variants and plasma adiponectin isoforms with the risk of incident renal 
events in type 2 diabetes. Nephrol Dial Transplant. 2010;25(7):2231-2237. 
106. Vasseur F, Helbecque N, Dina C, Lobbens S, Delannoy V, Gaget S, et al. Single-nucleotide 
polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene 
modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk 
for type 2 diabetes in French Caucasians. Hum Mol Genet. 2002;11(21):2607-2614. 
107. Kyriakou T, Collins LJ, Spencer-Jones NJ, Malcolm C, Wang X, Snieder H, et al. 
Adiponectin gene ADIPOQ SNP associations with serum adiponectin in two female 
populations and effects of SNPs on promoter activity. J Hum Genet. 2008;53(8):718-727. 
108. Menzaghi C, De Cosmo S, Copetti M, Salvemini L, De Bonis C, Mangiacotti D, et al. 
Relationship between ADIPOQ gene, circulating high molecular weight adiponectin and 
albuminuria in individuals with normal kidney function: evidence from a family-based 
study. Diabetologia. 2011;54(4):812-818. 
109. Vasseur F, Helbecque N, Lobbens S, Vasseur-Delannoy V, Dina C, Clément K, et al. 
Hypoadiponectinaemia and high risk of type 2 diabetes are associated with adiponectin-
encoding (ACDC) gene promoter variants in morbid obesity: evidence for a role of ACDC 
in diabesity. Diabetologia. 2005;48(5):892-899. 
110. Heid IM, Wagner SA, Gohlke H, Iglseder B, Mueller JC, Cip P, et al. Genetic architecture 
of the APM1 gene and its influence on adiponectin plasma levels and parameters of the 
metabolic syndrome in 1,727 healthy Caucasians. Diabetes. 2006;55(2):375-384. 
111. Hara K, Boutin P, Mori Y, Tobe K, Dina C, Yasuda K, et al. Genetic variation in the gene 
encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese 
population. Diabetes. 2002;51(2):536-540. 
112. Menzaghi C, Trischitta V, Doria A. Genetic influences of adiponectin on insulin resistance, 
type 2 diabetes, and cardiovascular disease. Diabetes. 2007;56(5):1198-1209. 
113. Mojiminiyi OA, Abdella NA, Al Arouj M, Ben Nakhi A. Adiponectin, insulin resistance 
and clinical expression of the metabolic syndrome in patients with Type 2 diabetes. Int J 
Obes (Lond). 2007;31(2):213-220. 
114. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin 
and resistin levels in relation to metabolic factors, inflammatory markers, and vascular 
 Page | 183  
  
reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care. 
2004;27(10):2450-2457. 
115. Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB. Circulating adiponectin levels are 
associated with better glycemic control, more favorable lipid profile, and reduced 
inflammation in women with type 2 diabetes. J Clin Endocrinol Metab. 2005;90(8):4542-
4548. 
116. Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB. Relationship between adiponectin and 
glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. 
Diabetes Care. 2004;27(7):1680-1687. 
117. Nayak S, Soon SQ, Kunjal R, Ramadoo R, Baptiste O, Persad J, et al. Relationship between 
adiponectin, inflammatory markers and obesity in type 2 diabetic and non-diabetic 
Trinidadians. Arch Physiol Biochem. 2009;115(1):28-33. 
118. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, et al. 
Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-
stage renal disease. J Am Soc Nephrol. 2002;13(1):134-141. 
119. Shen YY, Charlesworth JA, Kelly JJ, Loi KW, Peake PW. Up-regulation of adiponectin, its 
isoforms and receptors in end-stage kidney disease. Nephrol Dial Transplant. 
2007;22(1):171-178. 
120. Kollerits B, Fliser D, Heid IM, Ritz E, Kronenberg F. Gender-specific association of 
adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate 
Kidney Disease Study. Kidney Int. 2007;71(12):1279-1286. 
121. Saraheimo M, Forsblom C, Fagerudd J, Teppo AM, Pettersson-Fernholm K, Frystyk J, et al. 
Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care. 
2005;28(6):1410-1414. 
122. Schalkwijk CG, Chaturvedi N, Schram MT, Fuller JH, Stehouwer CD. Adiponectin is 
inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab. 
2006;91(1):129-135. 
123. Looker HC, Krakoff J, Funahashi T, Matsuzawa Y, Tanaka S, Nelson RG, et al. 
Adiponectin concentrations are influenced by renal function and diabetes duration in Pima 
Indians with type 2 diabetes. J Clin Endocrinol Metab. 2004;89(8):4010-4017. 
124. Koshimura J, Fujita H, Narita T, Shimotomai T, Hosoba M, Yoshioka N, et al. Urinary 
adiponectin excretion is increased in patients with overt diabetic nephropathy. Biochem 
Biophys Res Commun. 2004;316(1):165-169. 
 Page | 184  
  
125. Fujita H, Morii T, Koshimura J, Ishikawa M, Kato M, Miura T, et al. Possible relationship 
between adiponectin and renal tubular injury in diabetic nephropathy. Endocr J. 
2006;53(6):745-752. 
126. Hadjadj S, Aubert R, Fumeron F, Pean F, Tichet J, Roussel R, et al. Increased plasma 
adiponectin concentrations are associated with microangiopathy in type 1 diabetic subjects. 
Diabetologia. 2005;48(6):1088-1092. 
127. von Eynatten M, Liu D, Hock C, Oikonomou D, Baumann M, Allolio B, et al. Urinary 
adiponectin excretion: a novel marker for vascular damage in type 2 diabetes. Diabetes. 
2009;58(9):2093-2099. 
128. Jacobs DR Jr, Steffen LM. Nutrients, foods, and dietary patterns as exposures in research: a 
framework for food synergy. Am J Clin Nutr. 2003;78(3 Suppl):508S-513S. 
129. Mizoue T, Yamaji T, Tabata S, Yamaguchi K, Ogawa S, Mineshita M, et al. Dietary 
patterns and glucose tolerance abnormalities in Japanese men.  J Nutr. 2006;136(5):1352-
1358. 
130. Michels KB, Schulze MB. Can dietary patterns help us detect diet–disease associations? 
Nutr Res Rev. 2005;18(2):241-248. 
131. Fung TT, Schulze M, Manson JE, Willett WC, Hu FB. Dietary patterns, meat intake, and the 
risk of type 2 diabetes in women. Arch Intern Med. 2004;164(20):2235-2240. 
132. Montonen J, Knekt P, Harkanen T, Jarvinen R, Heliovaara M, Aromaa A, et al. Dietary 
patterns and the incidence of type 2 diabetes. Am J Epidemiol. 2005;161(3):219-227. 
133. Williams DE, Prevost AT, Whichelow MJ, Cox BD, Day NE, Wareham NJ. A cross-
sectional study of dietary patterns with glucose intolerance and other features of the 
metabolic syndrome. Br J Nutr. 2000;83(3):257-266. 
134. Lopez-Garcia E, Schulze MB, Fung TT, Meigs JB, Rifai N, Manson JE, et al. Major dietary 
patterns are related to plasma concentrations of markers of inflammation and endothelial 
dysfunction. Am J Clin Nutr. 2004;80(4):1029-1035. 
135. Lin J, Fung TT, Hu FB, Curhan GC. Association of dietary patterns with albuminuria and 
kidney function decline in older white women: a subgroup analysis from the Nurses' Health 
Study. Am J Kidney Dis. 2011;57(2):245-254. 
136. Odermatt A. The Western-style diet: a major risk factor for impaired kidney function and 
chronic kidney disease. Am J Physiol Renal Physiol. 2011;301(5):F919-931. 
137. Esmaillzadeh A, Kimiagar M, Mehrabi Y, Azadbakht L, Hu FB, Willett WC. Dietary 
patterns, insulin resistance, and prevalence of the metabolic syndrome in women. Am J Clin 
Nutr. 2007;85(3):910-918. 
 Page | 185  
  
138. Denova-Gutierrez E, Castanon S, Talavera JO, Gallegos-Carrillo K, Flores M, Dosamantes-
Carrasco D, et al. Dietary patterns are associated with metabolic syndrome in an urban 
Mexican population. J Nutr. 2010;140(10):1855-1863. 
139. Ambrosini GL, Huang RC, Mori TA, Hands BP, O'Sullivan TA, de Klerk NH, et al. Dietary 
patterns and markers for the metabolic syndrome in Australian adolescents. Nutr Metab 
Cardiovasc Dis. 2009;20(4):274-283. 
140. Naja F, Nasreddine L, Itani L, Chamieh MC, Adra N, Sibai AM, et al. Dietary patterns and 
their association with obesity and sociodemographic factors in a national sample of 
Lebanese adults. Public Health Nutr. 2011;14(9):1570-1578. 
141. Cunha DB, de Almeida RM, Sichieri R, Pereira RA. Association of dietary patterns with 
BMI and waist circumference in a low-income neighbourhood in Brazil. Br J Nutr. 
2010;104(6):908-913. 
142. Riserus U, Willett WC, Hu FB. Dietary fats and prevention of type 2 diabetes. Prog Lipid 
Res. 2009;48(1):44-51. 
143. Yeh CJ, Chang HY, Pan WH. Time trend of obesity, the metabolic syndrome and related 
dietary pattern in Taiwan: from NAHSIT 1993-1996 to NAHSIT 2005-2008. Asia Pac J 
Clin Nutr. 2011;20(2):292-300. 
144. Odegaard AO, Koh WP, Butler LM, Duval S, Gross MD, Yu MC, et al. Dietary patterns and 
incident type 2 diabetes in chinese men and women: the singapore chinese health study. 
Diabetes Care. 2011;34(4):880-885. 
145. He Y, Ma G, Zhai F, Li Y, Hu Y, Feskens EJ, et al. Dietary patterns and glucose tolerance 
abnormalities in Chinese adults. Diabetes Care. 2009;32(11):1972-1976. 
146. Nettleton JA, Steffen LM, Palmas W, Burke GL, Jacobs DR Jr. Associations between 
microalbuminuria and animal foods, plant foods, and dietary patterns in the Multiethnic 
Study of Atherosclerosis. Am J Clin Nutr. 2008;87(6):1825-1836. 
147. Lin J, Hu FB, Curhan GC. Associations of diet with albuminuria and kidney function 
decline. Clin J Am Soc Nephrol. 2010;5(5):836-843. 
148. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of 
kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis 
of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N 
Engl J Med. 1982;307(11):652-659. 
149. Aguila MB, Mandarim-De-Lacerda CA. Effects of chronic high fat diets on renal function 
and cortical structure in rats. Exp Toxicol Pathol. 2003;55(2-3):187-195. 
150. Aparicio M. Protein intake and chronic kidney disease: literature review, 2003 to 2008. J 
Ren Nutr. 2009;19(5 Suppl):S5-S8. 
 Page | 186  
  
151. Pan Y, Guo LL, Jin HM. Low-protein diet for diabetic nephropathy: a meta-analysis of 
randomized controlled trials. Am J Clin Nutr. 2008;88(3):660-666. 
152. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein 
restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. 
Ann Intern Med. 1996;124(7):627-632. 
153. Sanders PW. Effect of salt intake on progression of chronic kidney disease. Curr Opin 
Nephrol Hypertens. 2006;15(1):54-60. 
154. Mekinova D, Chorvathova V, Volkovova K, Staruchova M, Grancicova E, Klvanova J, et al. 
Effect of intake of exogenous vitamins C, E and beta-carotene on the antioxidative status in 
kidneys of rats with streptozotocin-induced diabetes. Nahrung. 1995;39(4):257-261. 
155. Claris-Appiani A, Assael BM, Tirelli AS, Marra G, Cavanna G. Lack of glomerular 
hemodynamic stimulation after infusion of branched-chain amino acids. Kidney Int. 
1988;33(1):91-94. 
156. Riley MD, Dwyer T. Microalbuminuria is positively associated with usual dietary saturated 
fat intake and negatively associated with usual dietary protein intake in people with insulin-
dependent diabetes mellitus. Am J Clin Nutr. 1998;67(1):50-57. 
157. Nicholls SJ, Lundman P, Harmer JA, Cutri B, Griffiths KA, Rye KA, et al. Consumption of 
saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and 
endothelial function. J Am Coll Cardiol. 2006;48(4):715-720. 
158. De Caterina R, Liao JK, Libby P. Fatty acid modulation of endothelial activation. Am J Clin 
Nutr. 2000;71(1 Suppl):213S-223S. 
159. Schulze MB, Hoffmann K, Manson JE, Willett WC, Meigs JB, Weikert C, et al. Dietary 
pattern, inflammation, and incidence of type 2 diabetes in women. Am J Clin Nutr. 
2005;82(3):675-684; quiz 714-715. 
160. Fung TT, Rimm EB, Spiegelman D, Rifai N, Tofler GH, Willett WC, et al. Association 
between dietary patterns and plasma biomarkers of obesity and cardiovascular disease risk. 
Am J Clin Nutr. 2001;73(1):61-67. 
161. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute 
coronary syndromes. J Am Coll Cardiol. 2003;41(4 Suppl S):37S-42S. 
162. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr, et al. 
Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis 
and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) 
study. Circulation. 1997;96(12):4219-4225. 
 Page | 187  
  
163. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma 
concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial 
infarction in apparently healthy men. Lancet. 1998;351(9096):88-92. 
164. Hu FB, Manson JE, Willett WC. Types of dietary fat and risk of coronary heart disease: a 
critical review. J Am Coll Nutr. 2001;20(1):5-19. 
165. Lopez-Garcia E, Hu FB. Nutrition and the endothelium. Curr Diab Rep. 2004;4(4):253-259. 
166. Drevon CA. Fatty acids and expression of adipokines. Biochim Biophys Acta. 
2005;1740(2):287-292. 
167. Shapiro H, Theilla M, Attal-Singer J, Singer P. Effects of polyunsaturated fatty acid 
consumption in diabetic nephropathy. Nat Rev Nephrol. 2011;7(2):110-121. 
168. Chien KL, Lee MS, Tsai YT, Chen PR, Lin HJ, Hsu HC, et al. A Taiwanese food frequency 
questionnaire correlates with plasma docosahexaenoic acid but not with plasma 
eicosapentaenoic acid levels: questionnaires and plasma biomarkers. BMC Med Res 
Methodol. 2013;13:23. 
169. Crispim SP, Geelen A, Souverein OW, Hulshof PJ, Ruprich J, Dofkova M, et al. Biomarker-
based evaluation of two 24-h recalls for comparing usual fish, fruit and vegetable intakes 
across European centers in the EFCOVAL Study. Eur J Clin Nutr. 2011;65 Suppl 1:S38-47. 
170. Jenab M, Slimani N, Bictash M, Ferrari P, Bingham SA. Biomarkers in nutritional 
epidemiology: applications, needs and new horizons. Hum Genet. 2009;125(5-6):507-525. 
171. Lennon R, Pons D, Sabin MA, Wei C, Shield JP, Coward RJ, et al. Saturated fatty acids 
induce insulin resistance in human podocytes: implications for diabetic nephropathy. 
Nephrol Dial Transplant. 2009;24(11):3288-3296. 
172. Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E, et al. Renal insulin 
resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: 
the mild and moderate kidney disease study. J Am Soc Nephrol. 2005;16(4):1091-1098. 
173. Dogra GK, Herrmann S, Irish AB, Thomas MA, Watts GF. Insulin resistance, 
dyslipidaemia, inflammation and endothelial function in nephrotic syndrome. Nephrol Dial 
Transplant. 2002;17(12):2220-2225. 
174. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, 
and cardiovascular disease. Circulation. 2002;106(21):2747-2757. 
175. Garman JH, Mulroney S, Manigrasso M, Flynn E, Maric C. Omega-3 fatty acid rich diet 
prevents diabetic renal disease. Am J Physiol Renal Physiol. 2009;296(2):F306-316. 
176. Lee CC, Sharp SJ, Wexler DJ, Adler AI. Dietary intake of eicosapentaenoic and 
docosahexaenoic acid and diabetic nephropathy: cohort analysis of the diabetes control and 
complications trial. Diabetes Care. 2010;33(7):1454-1456. 
 Page | 188  
  
177. Lee CT, Adler AI, Forouhi NG, Luben R, Welch A, Khaw KT, et al. Cross-sectional 
association between fish consumption and albuminuria: the European Prospective 
Investigation of Cancer-Norfolk Study. Am J Kidney Dis. 2008;52(5):876-886. 
178. Mollsten AV, Dahlquist GG, Stattin EL, Rudberg S. Higher intakes of fish protein are 
related to a lower risk of microalbuminuria in young Swedish type 1 diabetic patients. 
Diabetes Care. 2001;24(5):805-810. 
179. Stryjecki C, Mutch DM. Fatty acid-gene interactions, adipokines and obesity. Eur J Clin 
Nutr. 2011;65(3):285-297. 
180. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-
cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker 
by multivariate modeling. J Am Soc Nephrol. 2005;16 Suppl 1:S83-88. 
181. Weiner DE, Tighiouart H, Elsayed EF, et al. Inflammation and cardiovascular events in 
individuals with and without chronic kidney disease. Kidney Int. 2008;73(12):1406-1412. 
182. Cantwell MM. Assessment of individual fatty acid intake. Proc Nutr Soc. 2000;59(2):187-
191. 
183. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll 
Nutr. 2002;21(6):495-505. 
184. Chait A, Kim F. Saturated fatty acids and inflammation: who pays the toll? Arterioscler 
Thromb Vasc Biol. 2010;30(4):692-693. 
185. Davis JE, Gabler NK, Walker-Daniels J, Spurlock ME. Tlr-4 deficiency selectively protects 
against obesity induced by diets high in saturated fat. Obesity (Silver Spring). 
2008;16(6):1248-1255. 
186. Garcia-Escobar E, Rodriguez-Pacheco F, Garcia-Serrano S, Gomez-Zumaquero JM, Haro-
Mora JJ, Soriguer F, et al. Nutritional regulation of interleukin-6 release from adipocytes. 
Int J Obes (Lond). 2010;34(8):1328-1332. 
187. He K, Liu K, Daviglus ML, Jenny NS, Mayer-Davis E, Jiang R, et al. Associations of 
dietary long-chain n-3 polyunsaturated fatty acids and fish with biomarkers of inflammation 
and endothelial activation (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J 
Cardiol. 2009;103(9):1238-1243. 
188. Ferrucci L, Cherubini A, Bandinelli S, Bartali B, Corsi A, Lauretani F, et al. Relationship of 
plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol 
Metab. 2006;91(2):439-446. 
189. Nagao K, Inoue N, Wang YM, Yanagita T. Conjugated linoleic acid enhances plasma 
adiponectin level and alleviates hyperinsulinemia and hypertension in Zucker diabetic fatty 
(fa/fa) rats. Biochem Biophys Res Commun. 2003;310(2):562-566. 
 Page | 189  
  
190. Flachs P, Mohamed-Ali V, Horakova O, Rossmeisl M, Hosseinzadeh-Attar MJ, Hensler M, 
et al. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat 
diet. Diabetologia. 2006;49(2):394-397. 
191. Fernandez-Real JM, Vendrell J, Ricart W. Circulating adiponectin and plasma fatty acid 
profile. Clin Chem. 2005;51(3):603-609. 
192. Enzenbach C, Kroger J, Zietemann V, Jansen EH, Fritsche A, Doring F, et al. Erythrocyte 
membrane phospholipid polyunsaturated fatty acids are related to plasma C-reactive protein 
and adiponectin in middle-aged German women and men. Eur J Nutr. 2011;50(8):625-636. 
193. Hall ME, do Carmo JM, da Silva AA, Juncos LA, Wang Z, Hall JE. Obesity, hypertension, 
and chronic kidney disease. Int J Nephrol Renovasc Dis. 2014;7:75-88. 
194. Srivastava T. Nondiabetic consequences of obesity on kidney. Pediatr Nephrol. 
2006;21(4):463-470. 
195. Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic 
syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc 
Nephrol. 2011;6(10):2364-2373. 
196. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its 
implications for policy and intervention strategies. Lancet. 2004;363(9403):157-163. 
197. Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of 
development of end-stage renal disease in a screened cohort. Kidney Int. 2004;65(5):1870-
1876. 
198. Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Influence of smoking and 
obesity on the development of proteinuria. Kidney Int. 2002;62(3):956-962. 
199. Shankar A, Leng C, Chia KS, Koh D, Tai ES, Saw SM, et al. Association between body 
mass index and chronic kidney disease in men and women: population-based study of Malay 
adults in Singapore. Nephrol Dial Transplant. 2008;23(6):1910-1918. 
200. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. 
JAMA. 2005;293(4):455-462. 
201. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality 
from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 
2003;348(17):1625-1638. 
202. Pischon T, Lahmann PH, Boeing H, Tjonneland A, Halkjaer J, Overvad K, et al. Body size 
and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and 
Nutrition (EPIC). Int J Cancer. 2006;118(3):728-738. 
 Page | 190  
  
203. Flaherty KT, Fuchs CS, Colditz GA, Stampfer MJ, Speizer FE, Willett WC, et al. A 
prospective study of body mass index, hypertension, and smoking and the risk of renal cell 
carcinoma (United States). Cancer Causes Control. 2005;16(9):1099-1106. 
204. Gretz N, Zeier M, Geberth S, Strauch M, Ritz E. Is gender a determinant for evolution of 
renal failure? A study in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 
1989;14(3):178-183. 
205. Sakemi T, Toyoshima H, Morito F. Testosterone eliminates the attenuating effect of 
castration on the progressive glomerular injury in hypercholesterolemic male Imai rats. 
Nephron. 1994;67(4):469-476. 
206. Hall JE, Henegar JR, Dwyer TM, Liu J, Da Silva AA, Kuo JJ, et al. Is obesity a major cause 
of chronic kidney disease? Adv Ren Replace Ther. 2004;11(1):41-54. 
207. Praga M, Hernandez E, Herrero JC, Morales E, Revilla Y, Diaz-Gonzalez R, et al. Influence 
of obesity on the appearance of proteinuria and renal insufficiency after unilateral 
nephrectomy. Kidney Int. 2000;58(5):2111-2118. 
208. Ryu S, Chang Y, Woo HY, Kim SG, Kim DI, Kim WS, et al. Changes in body weight 
predict CKD in healthy men. J Am Soc Nephrol. 2008;19(9):1798-1805. 
209. Gelber RP, Kurth T, Kausz AT, Manson JE, Buring JE, Levey AS, et al. Association 
between body mass index and CKD in apparently healthy men. Am J Kidney Dis. 
2005;46(5):871-880. 
210. Morales E, Valero MA, Leon M, Hernandez E, Praga M. Beneficial effects of weight loss in 
overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis. 
2003;41(2):319-327. 
211. Solerte SB, Fioravanti M, Schifino N, Ferrari E. Effects of diet-therapy on urinary protein 
excretion albuminuria and renal haemodynamic function in obese diabetic patients with 
overt nephropathy. Int J Obes. 1989;13(2):203-211. 
212. Saiki A, Nagayama D, Ohhira M, Endoh K, Ohtsuka M, Koide N, et al. Effect of weight 
loss using formula diet on renal function in obese patients with diabetic nephropathy. Int J 
Obes (Lond). 2005;29(9):1115-1120. 
213. Praga M, Hernandez E, Andres A, Leon M, Ruilope LM, Rodicio JL. Effects of body-
weight loss and captopril treatment on proteinuria associated with obesity. Nephron. 
1995;70(1):35-41. 
214. Palomar R, Fernandez-Fresnedo G, Dominguez-Diez A, Lopez-Deogracias M, Olmedo F, 
Martin de Francisco AL, et al. Effects of weight loss after biliopancreatic diversion on 
metabolism and cardiovascular profile. Obes Surg. 2005;15(6):794-798. 
 Page | 191  
  
215. Navarro-Diaz M, Serra A, Romero R, Bonet J, Bayes B, Homs M, et al. Effect of drastic 
weight loss after bariatric surgery on renal parameters in extremely obese patients: long-
term follow-up. J Am Soc Nephrol. 2006;17(12 Suppl 3):S213-217. 
216. Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y. The effects of weight loss on 
renal function in patients with severe obesity. J Am Soc Nephrol. Jun 2003;14(6):1480-1486. 
217. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of 
modest weight loss in improving cardiovascular risk factors in overweight and obese 
individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481-1486. 
218. Look AHEAD Research Group. Effect of a long-term behavioural weight loss intervention 
on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of 
the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2014;2(10):801-
809. 
219. Fung F, Sherrard DJ, Gillen DL, Wong C, Kestenbaum B, Seliger S, et al. Increased risk for 
cardiovascular mortality among malnourished end-stage renal disease patients. Am J Kidney 
Dis. 2002;40(2):307-314. 
220. Curtis JP, Selter JG, Wang Y, Rathore SS, Jovin IS, Jadbabaie F, et al. The obesity paradox: 
body mass index and outcomes in patients with heart failure. Arch Intern Med. 
2005;165(1):55-61. 
221. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH. The 
relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. 
2001;38(3):789-795. 
222. Wiggins KJ, Johnson DW. The influence of obesity on the development and survival 
outcomes of chronic kidney disease. Adv Chronic Kidney Dis. 2005;12(1):49-55. 
223. Garland JS. Elevated body mass index as a risk factor for chronic kidney disease: current 
perspectives. Diabetes Metab Syndr Obes. 2014;7:347-355. 
224. Navarro-Diaz M, Serra A, Lopez D, Granada M, Bayes B, Romero R. Obesity, 
inflammation, and kidney disease. Kidney Int Suppl. 2008(111):S15-18. 
225. Maric-Bilkan C. Obesity and diabetic kidney disease. Med Clin North Am. 2013;97(1):59-
74. 
226. Serra A, Granada ML, Romero R, Bayes B, Canton A, Bonet J, et al. The effect of bariatric 
surgery on adipocytokines, renal parameters and other cardiovascular risk factors in severe 
and very severe obesity: 1-year follow-up. Clin Nutr. 2006;25(3):400-408. 
227. Ambeba EJ, Styn MA, Kuller LH, Brooks MM, Evans RW, Burke LE. Longitudinal effects 
of weight loss and regain on cytokine concentration of obese adults. Metabolism. 
2013;62(9):1218-1222. 
 Page | 192  
  
228. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, 
and imbalanced coagulation in development of diabetes and its complications. J Clin 
Endocrinol Metab. 2009;94(9):3171-3182. 
229. Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A. Inflammatory 
process in type 2 diabetes: The role of cytokines. Ann N Y Acad Sci. 2006;1084:89-117. 
230. Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic 
nephropathy. J Am Soc Nephrol. 2008;19(3):433-442. 
231. Stenvinkel P, Barany P, Heimburger O, Pecoits-Filho R, Lindholm B. Mortality, 
malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int 
Suppl. 2002;(80):S103-108. 
232. American Diabetes Association. Report of the expert committee on the diagnosis and 
classification of diabetes mellitus. Diabetes Care. 1997;20(7):1183-1197. 
233. Li Y, Yang Y, Shi L, Li X, Zhang Y, Yao Y. The association studies of ADIPOQ with type 
2 diabetes mellitus in Chinese populations. Diabetes Metab Res Rev. 2012;28(7):551-559. 
234. Tsai MH, Lin KM, Hsiao MC, Shen WW, Lu ML, Tang HS, et al. Genetic polymorphisms 
of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and 
treatment response. Pharmacogenomics. 2010;11(4):537-546. 
235. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J 
Biochem Physiol. 1959;37(8):911-917. 
236. Hsu CC, Chang HY, Huang MC, Hwang SJ, Yang YC, Tai TY, et al. Association between 
insulin resistance and development of microalbuminuria in type 2 diabetes: a prospective 
cohort study. Diabetes care. 2011;34(4):982-987. 
237. Jurkovitz CT, Abramson JL, Vaccarino LV, Weintraub WS, McClellan WM. Association of 
high serum creatinine and anemia increases the risk of coronary events: results from the 
prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc 
Nephrol. 2003;14(11):2919-2925. 
238. Couchoud C, Pozet N, Labeeuw M, Pouteil-Noble C. Screening early renal failure: cut-off 
values for serum creatinine as an indicator of renal impairment. Kidney Int. 
1999;55(5):1878-1884. 
239. Stevens LA, Schmid CH, Greene T, Zhang YL, Beck GJ, Froissart M, et al. Comparative 
performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of 
Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 
mL/min/1.73 m
2
. Am J Kidney Dis. 2010;56(3):486-495. 
240. Lin J, Hu FB, Mantzoros C, Curhan GC. Lipid and inflammatory biomarkers and kidney 
function decline in type 2 diabetes. Diabetologia. 2010;53(2):263-267. 
 Page | 193  
  
241. Miyazawa I, Araki S, Obata T, Yoshizaki T, Morino K, Kadota A, et al. Association 
between serum soluble TNFalpha receptors and renal dysfunction in type 2 diabetic patients 
without proteinuria. Diabetes Res Clin Pract. 2011;92(2):174-180. 
242. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. Relationship of 
adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for 
independent roles of age and sex. Diabetologia. 2003;46(4):459-469. 
243. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, et al. 
Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. 
Diabetes. 2002;51(9):2734-2741. 
244. Perez-Martinez P, Lopez-Miranda J, Cruz-Teno C, Delgado-Lista J, Jimenez-Gomez Y, 
Fernandez JM, et al. Adiponectin gene variants are associated with insulin sensitivity in 
response to dietary fat consumption in Caucasian men. J Nutr. 2008;138(9):1609-1614. 
245. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure 
of haplotype blocks in the human genome. Science. 2002;296(5576):2225-2229. 
246. Dimopoulos N, Watson M, Sakamoto K, Hundal HS. Differential effects of palmitate and 
palmitoleate on insulin action and glucose utilization in rat L6 skeletal muscle cells. 
Biochem J. 2006;399(3):473-481. 
247. Hunnicutt JW, Hardy RW, Williford J, McDonald JM. Saturated fatty acid-induced insulin 
resistance in rat adipocytes. Diabetes. 1994;43(4):540-545. 
248. Sahebi L, Dastgiri S, Ansarin K, Sahebi R, Mohammadi SA. Study designs in genetic 
epidemiology. ISRN Genetics. 2013;2013:8 pages. 
249. Liu CY, Maity A, Lin X, Wright RO, Christiani DC. Design and analysis issues in gene and 
environment studies. Environ Health. 2012;11:93. 
250. Hanley JA, Negassa A, Edwardes MD, Forrester JE. Statistical analysis of correlated data 
using generalized estimating equations: an orientation. Am J Epidemiol. 2003;157(4):364-
375. 
251. Hsu CC, Chang HY, Huang MC, Hwang SJ, Yang YC, Lee YS, et al. HbA1c variability is 
associated with microalbuminuria development in type 2 diabetes: a 7-year prospective 
cohort study. Diabetologia. 2012;55(12):3163-3172. 
252. Shah T, Zabaneh D, Gaunt T, Swerdlow DI, Shah S, Talmud PJ, et al. Gene-centric analysis 
identifies variants associated with interleukin-6 levels and shared pathways with other 
inflammation markers. Circ Cardiovasc Genet. 2013;6(2):163-170. 
253. Guebre-Egziabher F, Drai J, Fouque D. Adiponectin and chronic kidney disease. J Ren Nutr. 
2007;17(1):9-12. 
 Page | 194  
  
254. Marchlewska A, Stenvinkel P, Lindholm B, Danielsson A, Pecoits-Filho R, Lönnqvist F, et 
al. Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal 
disease. Kidney Int. 2004;66(1):46-50. 
255. Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Cross-talk between iron metabolism and 
diabetes. Diabetes. 2002;51(8):2348-2354. 
256. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative 
stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in 
patients with type 2 diabetes. JAMA. 2006;295(14):1681-1687. 
257. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, et al. Oscillating glucose is 
more deleterious to endothelial function and oxidative stress than mean glucose in normal 
and type 2 diabetic patients. Diabetes. 2008;57(5):1349-1354. 
258. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH. Aliskiren in 
combination with losartan reduces albuminuria independent of baseline blood pressure in 
patients with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol. 2011;6(5):1025-
1031. 
259. Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G. Impact of blood pressure 
control and angiotensin-converting enzyme inhibitor therapy on new-onset 
microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc 
Nephrol. 2006;17(12):3472-3481. 
260. Kowalski A, Krikorian A, Lerma EV. Diabetic nephropathy for the primary care provider: 
new understandings on early detection and treatment. Ochsner J. 2014;14(3):369-379. 
261. Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M. Smoking is 
associated with progression of diabetic nephropathy. Diabetes Care. 1994;17(2):126-131. 
262. Chuahirun T, Khanna A, Kimball K, Wesson DE. Cigarette smoking and increased urine 
albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes. 
Am J Kidney Dis. 2003;41(1):13-21. 
263. Christiansen JS. Cigarette smoking and prevalence of microangiopathy in juvenile-onset 
insulin-dependent diabetes mellitus. Diabetes Care. 1978;1(3):146-149. 
264. Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of 
nephropathy in type 2 diabetic patients. Kidney Int. 2004;66(4):1596-1605. 
265. Kazancioglu R. Risk factors for chronic kidney disease: an update. Kidney Int Suppl. 
2013;3(4):368-371. 
266. Komorowsky CV, Brosius FC 3rd, Pennathur S, Kretzler M. Perspectives on systems 
biology applications in diabetic kidney disease. J Cardiovasc Transl Res. 2012;5(4):491-
508. 
 Page | 195  
  
267. Hunter DJ. Gene-environment interactions in human diseases. Nat Rev Genet. 
2005;6(4):287-298. 
268. Pausova Z, Tremblay J, Hamet P. Gene-environment interactions in hypertension. Curr 
Hypertens Rep. 1999;1(1):42-50. 
269. Andreasen CH, Andersen G. Gene-environment interactions and obesity--further aspects of 
genomewide association studies. Nutrition. 2009;25(10):998-1003. 
270. Grarup N, Andersen G. Gene-environment interactions in the pathogenesis of type 2 
diabetes and metabolism. Curr Opin Clin Nutr Metab Care. 2007;10(4):420-426. 
271. Ordovas JM, Shen J. Gene-environment interactions and susceptibility to metabolic 
syndrome and other chronic diseases. J Periodontol. 2008;79(8 Suppl):1508-1513. 
272. Ntalla I, Dedoussis G, Yannakoulia M, Smart MC, Louizou E, Sakka SD, et al. ADIPOQ 
gene polymorphism rs1501299 interacts with fibre intake to affect adiponectin concentration 
in children: the GENe-Diet Attica Investigation on childhood obesity. Eur J Nutr. 
2009;48(8):493-497. 
273. Park JY, Lee HJ, Jang HB, Hwang JY, Kang JH, Han BG,
 
et al. Interactions between 
ADIPOQ gene variants and dietary monounsaturated: saturated fatty acid ratio on serum 
lipid levels in Korean children. Nutr Metab Cardiovasc Dis. 2014;24(1):83-90. 
274. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic 
kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 
2014;64(4):510-533. 
275. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 
clinical practice guideline for the evaluation and management of chronic kidney disease. 
Kidney Int Suppl. 2013;3:1-150. 
276. American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes 
Care. 2014;37 Suppl 1:S14-80. 
277. Evert AB, Boucher JL, Cypress M, Dunbar SA, Franz MJ, Mayer-Davis EJ, et al. Nutrition 
therapy recommendations for the management of adults with diabetes. Diabetes Care. 
2014;37 Suppl 1:S120-143. 
278. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in 
dialysis patients. Am J Kidney Dis. 2005;45(4 Suppl 3):S1-153. 
279. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood 
pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension 
(DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344(1):3-
10. 
 Page | 196  
  
280. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, et al. Primary prevention 
of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14):1279-
1290. 
281. Sacks FM, Obarzanek E, Windhauser MM, Svetkey LP, Vollmer WM, McCullough M, et al. 
Rationale and design of the Dietary Approaches to Stop Hypertension trial (DASH). A 
multicenter controlled-feeding study of dietary patterns to lower blood pressure. Ann 
Epidemiol. 1995;5(2):108-118. 
282. Potischman N, Freudenheim JL. Biomarkers of nutritional exposure and nutritional status: 
an overview. J Nutr. 2003;133 Suppl 3:873S-874S. 
283. Ley SH, Sun Q, Willett WC, Eliassen AH, Wu K, Pan A, et al. Associations between red 
meat intake and biomarkers of inflammation and glucose metabolism in women. Am J Clin 
Nutr. 2014;99(2):352-360. 
284. Brevik A, Vollset SE, Tell GS, Refsum H, Ueland PM, Loeken EB, et al. Plasma 
concentration of folate as a biomarker for the intake of fruit and vegetables: the Hordaland 
Homocysteine Study. Am J Clin Nutr. 2005;81(2):434-439. 
285. Campbell DR, Gross MD, Martini MC, Grandits GA, Slavin JL, Potter JD. Plasma 
carotenoids as biomarkers of vegetable and fruit intake. Cancer Epidemiol Biomarkers Prev. 
1994;3(6):493-500. 
286. Potischman N. Biologic and methodologic issues for nutritional biomarkers. J Nutr. 
2003;133 Suppl 3:875S-880S. 
 
 
 Page | 197  
  
Appendices  
Appendix 1 Ethics approval for the DMIDS cohort study (2003-2007), from Taiwan NHRI 
 
 
 Page | 198  
  
Appendix 2 Ethics approval for the DN cohort study (2008-2012), from Taiwan NHRI 
 
  
 Page | 199  
  
Appendix 3 Ethics approvals for the PhD thesis, from School of Population Health, UQ 
 
 
 
